
人é¡ã«å¯Ÿããäžççãªã¯ãŒãã¿ãŒ
11æ7æ¥ã«ä»¥äžã®ãã¹ããè¡ã£ãã®ã§ããã
2022åºçã¯PDFã§ããããä»ã¯å šæHPã§èªããããã«ãªã£ãŠããŸããåœæèªåãPDFå šèš³ããäžæžããšããŠnoteã«æ®ã£ãŠããŸãããå 容ã¯äœåºŠãæŽæ°ãããŠããã®ã§ããã¡ããèªãã æ¹ãè¯ããšæããŸãã
â ãããã²ããŸâ ¡ð (@akahiguma_ii) November 7, 2025
19äžæåã§ãð
äžççãªã³ãã屿©ã人é¡ã«å¯Ÿããäžççã¯ãŒãã¿ãŒãhttps://t.co/OIWRMqi9GE
ãªã³ã¯å ããããªããŸãã

èŠåãç¡èŠããŠç¶ãããæŒããšãªã³ã¯å ã«é£ã¶ã®ã§ãããæ°äººããèªããªããšDMãããã£ãã®ã§ãæ¢ããŠnoteã«åŒçšã¡ã¢ããŠãããŸãã
2022幎ã«ãPDFã玹ä»ããã®ã§ãããåœåã®PDFã¯æ¥æ¬èªãšããŠåèš³ããã«ã¯äžæéãããç¶æ³ã ã£ãã®ã§ãè±èªã§ãã®ãŸãŸèªãã人以å€ã¯èªãã§ããæ¹ãå°ãªããšæããŸãã
ãã®å 容ãéèŠãªã®ã¯ã2020幎ã«å§ãŸã£ãæ°åã³ãããŠã€ã«ã¹è©æ¬ºã®èæ¯ããã以åã®äºåã«è¡ã£ãŠãããã¹ãïŒè±ã€ã³ãã«çâŠïŒãå«ãã倧ããªæµãã倧æ ã§èããããšãã§ããèªåã®é ã§å€æããã«ã¯ãçµ¶å¥œã®ææã«ãªãããã§ãã
èªåã¯2022幎ã«ãã®å
容ãåèš³ããªãããã£ãããšèªã¿èããŠããŸããã
ããã¯ç®±åºå»çæŽè³ã«å®å
šã«é¥ã£ãŠãã人ãå€ãæ¥æ¬äººã«ãšã£ãŠã¯ãããããå€ã«åºãããã«ãšãŠãéèŠãªå
容ãªã®ã§ãäžå¿åèš³ãå
¬éããŠãè¯ããïŒãšã¢ãåã£ã段éã§ãåœæã¯ãæ¥æ¬èªèš³ãããæ¬ãçºå£²ãããŠããã®ã§ããã¡ããé²ããŠæ¬²ãããšããã·ã§ã«ã»ãã§ã¹ããã¹ããŒããã®çŽæ¥ã®ã¡ãŒã«ãããã ãæ§ããŠçŸåšã«è³ã£ãŠããã®ã§ãããäžèšã«è¿°ã¹ããèªããªãããšã®DMãšãæ¹ããŠHPãèŠããšãã«ã以äžã®å
容ã確èªããã®ã§ã¡ã¢ããããšã«ããŸããã

å 責äºé ïŒæ¬èšäºã®å 容ã¯èè ïŒãã¡ïŒã®åç¬ã®è²¬ä»»ã«ãããã®ã§ããã°ããŒãã«åç ç©¶ã»ã³ã¿ãŒã¯ãæ¬èšäºã«ãããäžæ£ç¢ºãŸãã¯èª€ã£ãèšè¿°ã«ã€ããŠäžåã®è²¬ä»»ãè² ããŸãããã°ããŒãã«åç ç©¶ã»ã³ã¿ãŒã¯ãåºå žãšèäœæš©ãæèšãããã€å ã®ã°ããŒãã«ãªãµãŒãèšäºãžã®ãã€ããŒãªã³ã¯ãæ·»ä»ããããšãæ¡ä»¶ã«ãã³ãã¥ããã£ã€ã³ã¿ãŒããããµã€ããžã®ã°ããŒãã«ãªãµãŒãèšäºã®è»¢èŒãèš±å¯ããŸããå°å·ç©ã忥ã€ã³ã¿ãŒããããµã€ããå«ããã®ä»ã®åªäœã§ã®ã°ããŒãã«ãªãµãŒãèšäºæ²èŒã«ã€ããŠã¯ã以äžãŸã§ãåãåãããã ããïŒpublications@globalresearch.ca
www.globalresearch.ca ã¯èäœæš©ã§ä¿è·ãããçŽ æãå«ãã§ããããã®äœ¿çšãèäœæš©è ã«ãã£ãŠåžžã«æç€ºçã«èš±å¯ãããŠããããã§ã¯ãããŸãããåœãµã€ãã¯ãæ¿æ²»ã»çµæžã»ç€ŸäŒåé¡ãžã®çè§£ä¿é²ãç®çãšããŠãããã§ã¢ãŠãŒã¹ãèŠå®ã«åºã¥ãåœè©²çŽ æãèªè ã«æäŸããŠããŸããæ¬ãµã€ãã®çŽ æã¯ãç ç©¶ã»æè²ç®çã§ã®åé ãåžæããè ã«å¯Ÿããå¶å©ç®çãªãé åžãããŸããããã§ã¢ãŠãŒã¹ã以å€ã®ç®çã§èäœæš©çŽ æãå©çšããå Žåã¯ãèäœæš©ææè ããèš±å¯ãåŸãå¿ èŠããããŸãã
ã¡ãã£ã¢ãåãåããå ïŒpublications@globalresearch.ca
ãã®èšäºå šãŠãäºå®ã ãšã¯èšããªããã©ã倧ããªæµããçè§£ããã«ã¯å€§åãªå 容ã§ãã
ãŸãèªãæã«ã¯æã ãŠã€ã«ã¹ãè¯å®ããéšåãåºãŠããŸããããç åãšäŒãããå šãŠã®ãŠã€ã«ã¹ã¯ååšããªããããšã念é ã«ãããŠèªã¿é²ããŠãããšãããçè§£ãæ·±ãŸããšæããŸãã
以äžã«å€§äºãªæµããšç¹ãããç¥ããç®±åºå»çæŽè³ãèµ·ããã人é¡ã«å¯Ÿããã¯ãŒãã¿ãŒãçè§£ããããã«ã¯ã倧äºãªèšäºãã¡ã¢ããŠãããŸãã
äžççãªã³ãã屿©ã人é¡ã«å¯Ÿããäžççã¯ãŒãã¿ãŒ
ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒ
ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒã¯ããã®é°éºãªèšç»ãã©ã®ããã«ã人ã ã®ç掻ãç Žå£ããã®ãããè©³çŽ°ã«æ€èšŒããã圌ã¯ããã®ããã³ãããã¯ãã«ã€ããŠç¥ã£ãŠããã¹ãããšãã¹ãŠãå æ¬çã«åæãããå»åŠçåŽé¢ããçµæžçã»ç€ŸäŒç圱é¿ãæ¿æ²»çèæ¯ããããŠç²Ÿç¥çã»å¿çç圱é¿ãŸã§ã
äœå®¶ãšããŠã®ç§ã®ç®æšã¯ãäžçäžã®äººã ã«æ å ±ãäŒããåœå®¶å šäœã®çµæžã»ç€ŸäŒæ§é ãäžå®å®åããããã®åŸãèŽæ»çãªãCOVID-19ãã¯ã¯ãã³ããæŒãä»ããããã®æ£åœåãšããŠå©çšãããŠããå ¬åŒèŠè§£ãåé§ããããšã§ãããã®å±æ©ã¯äººé¡å šäœãã€ãŸãçŽ80å人ã«åœ±é¿ãåãŒããŠããŸããç§ãã¡ã¯äžçäžã®ä»²éã®äººéããããŠåäŸãã¡ãšé£åž¯ããŸããçå®ã¯ååŒ·ãææ®µã§ãã
ã¬ãã¥ãŒ
ããã¯ãããåºãèŠç¹ããçè§£ãæ·±ããããšèããŠãã人ã«ãšã£ãŠãéåžžã«è峿·±ã詳现ãªãªãœãŒã¹ã§ããèè ã¯å°æ¿åŠã«ã€ããŠéåžžã«ç¥èãè±å¯ã§ããããããã³ããã®æèåã®ä»æ¹ã«è¡šããŠããŸãããã€ã¯ã»ã€ã§ãŒãã³å士
ç§ãã¡ãä»çŽé¢ããŠãã人é¡ã«å¯ŸããæŠäºãèªç±ãšäººã ã®åè¯ãã«å¯Ÿãããã®ç¹ç°ã§äžèŠåãã€å€§èŠæš¡ãªæ»æã«ãããŠããã§ã¹ãœããã¹ããŒã®èæžã¯ç§ãã¡ã®æŠããæ¯ããããã®å²©ç³ã§ããâãšããã¥ãšã«ã»ã¬ã«ã·ã¢å士
15ç« ãããªãç°¡æœãªç§åŠã«åºã¥ãæ¬æžã§ããã·ã§ã«ã¯åœã®æ°åã³ãããŠã€ã«ã¹ææçãã³ãããã¯ã®è»è·¡ã蟿ããæå€§97%ã®åœéœæ§çãè£ä»ããPCRæ€æ»ãšã容赊ãªã24æéäœå¶ã®ææãã£ã³ããŒã³ãçžãŸã£ãŠãããã«ããŠäžççãªãããã¯ãåŒãèµ·ãããããã©ã³ãããã¯ããåŒãèµ·ãããã®ãã解説ããããããŠããã®ãã©ã³ãããã¯ã¯ãæªåé«ãDNAæ¹å€ããªã¡ã©ãŒãŒé£éåå¿æ€æ»ãªãã«ã¯èããããªãã£ãã§ãããããšãæããã«ããããã®æ€æ»ã¯ã仿¥ã«è³ããŸã§ãäœã®ç¥èããªã倧倿°ã®ç¡å®ã®äººã ã«æŒãä»ããããŠããããã·ã§ã«ã®çµè«ã¯ãèåãªç§åŠè ãã¡ã®èšŒèšã«ãã£ãŠè£ä»ããããŠããã- ããŒã¿ãŒã»ã±ãŒãã°
ãã§ã¹ãœããã¹ããŒææã¯ãããŠã€ã«ã¹ãšçµæžå€æ°ã®éã«å æé¢ä¿ã¯ãªãããšããçå®ãæããã«ããŠãããèšãæããã°ãäžççµæžã®åæ¢ãåŒãèµ·ãããã®ã¯COVID-19ã§ã¯ãªãããããéè«ççã§ç§åŠçæ ¹æ ã®ãªãããã¯ããŠã³ã®æå³çãªå®æœã ã£ãã®ã ã âãã€ãŽã£ããã»ã¹ã¯ãªããã¯
ãã§ã¹ãœããã¹ããŒã®èæžãèªããšããã°ã¬ãŒãã»ãªã»ããããšåŒã°ããäžççãªã¯ãŒãã¿ãŒãé²è¡äžã§ããããšããããŠäžçäžã®èªç±ãæãã人ã ããã®ã¯ãŒãã¿ãŒã«æµæãã黿¢ããªããã°ãããŸã æ³åãã§ããªããã£ã¹ããã¢çãªæªæ¥ã蚪ããããšãå æ¬çã«çè§£ã§ããŸããæé ãã«ãªãåã«ããã§ã¹ãœããã¹ããŒææããã®ãã®ç¡æã®ããããã²ãæã«ãšã£ãŠãã ãããããã»ã©è²Žéãªæ å ±ãšåæãäžãæã«éããããšã¯ãªãã§ãããã âãšãã¯ãŒãã»ã«ãŒãã£ã³
ä»çµãã ã³ãã屿©ïŒãäžçã®åæåããèããè ãã¡
2022幎11æ18æ¥ã«æ¥æ¬ð¯ðµã§ã¬ãã¥ãŒãããŸãã
çŽ æŽãããæ¬ãªã®ã§ããã²æ¥æ¬äžã®äººã«èªãã§ã»ããã§ããèªãã§ãããšãæç³»åã§èª¬æãããŠããæ§ã ãªåºæ¥äºããäžã€ã²ãšã€ã®çéãæèã«åãŸããçŸå®å³ã垯ã³ãŠããŠãæããããèªã¿é²ãããã¡ã«èžãããããããŠèŠãããªããŸãããæ°åã³ãããŠã€ã«ã¹ææçã®ãã³ãããã¯ãåŒãèµ·ããã人ã ã®åæã®è£åŽããç§ãã¡ã¯ãã£ãããšèŠæ¥µããªããã°ãªããŸãããç§ãã¡èã®æ ¹ã®äººéãšããŠãäœãã§ããã®ããé£ããåé¡ã§ãã
âŠãã®åŸã«æ¬æžãšãæç³»åã«èª¬æãããŠããæ§ã ãªåºæ¥äºããããšããšãå¿ã«èœã¡èŸŒãã§ãçŸå®å³ã«è¿«ã£ãŠããŸãããæããããŠãèªã¿é²ãããã¡ã«èžãããããèŠãããªããŸããã床ãæã¡ãŸããã§ããããã ããå çãšããåçŽãªè©±ã§ã¯ãããŸãããå人çã«ã¯ãæã£ã仲ã®ããåéãšã®è©±ã«æçµ¶ãæããŠããŸãããå€ãã®äººã ãæ®å¿µãæã£ãŠããŸãã
docsendã§ããŒãžã§ã³ãããŠã³ããŒã
ISBN: 978-0-9879389-3-0ã 幎: 2022ãPDFé»åæžç±ã ããŒãžæ°: 164ã15ç«
äŸ¡æ Œ: 11.50ãã« ç¡æã³ããŒïŒ ããïŒdocsendïŒãã¯ãªãã¯ããŠããŠã³ããŒãããŠãã ããã
以äžã®é»åæžç±ã®ãªã³ã©ã€ã³çã
ã°ããŒãã«ã»ãªãµãŒãã®DonorBoxãäžççãªã³ãã屿©ããã£ã³ããŒã³ããŒãžããå¯ä»ãããŠãé»åæžç±ãããžã§ã¯ããæ¯æŽããŠãã ãã ã
ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææ
ã°ããŒãã«ã»ãªãµãŒãã2025幎9æ10æ¥
ã°ããŒãã«ã»ãªãµãŒãã»ãããªãã·ã£ãŒãºçºè¡ã®é»åæžç±ïŒ2022幎åºçïŒ
äžççãªã³ãã屿©
人é¡ã«å¯Ÿããäžççãªã¯ãŒãã¿ãŒ
人é¡ã«å¯Ÿããã¯ãŒãã¿ãŒ
åžæ°ç€ŸäŒã®ç Žå£ãä»çµãŸããçµæžäžæ³
èïŒãã·ã§ã«ã»ãã§ã¹ããã¹ããŒ
ã°ããŒãã«ãªãµãŒã

èè ã«ã€ããŠ

ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒã¯ãåè³æŽã®ããäœå®¶ã§ããããªã¿ã¯å€§åŠçµæžåŠéšææïŒåèªææïŒã§ãã
ãªã¿ã¯å€§åŠçµæžåŠéšææïŒåèªææïŒ
ã¢ã³ããªãªãŒã«ã»ã°ããŒããªãŒãŒã·ã§ã³ç ç©¶ã»ã³ã¿ãŒïŒCRGïŒåµèšè
å
Œæé·ã
ãã°ããŒãã«ã»ãªãµãŒããèªç·šéé·ã
ã©ãã³ã¢ã¡ãªã«ãã¢ãžã¢ãäžæ±ããµãã©ç æŒ ä»¥åã®å°åã§çŸå°èª¿æ»ã宿œã
ã©ãã³ã¢ã¡ãªã«ãã¢ãžã¢ãäžæ±ããµãã©ä»¥åã®ã¢ããªã«ã倪平æŽå°åã§çŸå°èª¿æ»ã宿œã
éäžåœã®çµæžã«ã€ããŠå¹
åºãå·çããŠããã
è²§å°ãšç€ŸäŒçäžå¹³çãäžå¿ãšããéäžåœçµæžã«ã€ããŠå¹
åºãå·çã
ãŸããä¿å¥çµæžåŠã®ç ç©¶ã«ãæºãã£ãŠããã
(åœé£ã©ãã³ã¢ã¡ãªã«ã»ã«ãªãæµ·çµæžå§å¡äŒïŒECLACïŒãUNFPA,
CIDAãWHOããããºãšã©æ¿åºãJohns Hopkins International Journal of Health Services (1979, 1983))
èæžã«ãè²§å°ã®ã°ããŒããªãŒãŒã·ã§ã³ãšæ°äžçç§©åºãïŒ2003幎ïŒãªã©13åããããã¢ã¡ãªã«ã®ããããšã®æŠäºããïŒ2005幎ïŒããæŠäºã®ã°ããŒãã«åãã¢ã¡ãªã«ã®äººé¡ã«å¯Ÿããé·ææŠäºãïŒHumanityïŒïŒ2015幎ïŒãããã
ããªã¿ãã«çŸç§äºå
žã®å¯çš¿è
ã§ãããã圌ã®èäœã¯20以äžã®èšèªã§åºçãããŠããã
2014幎ãèäœã«ããã»ã«ãã¢å
±ååœã®ååŽè³ïŒãŽãŒã«ãã¡ãã«ïŒãåè³ã
NATOã®ãŠãŒãŽã¹ã©ãã¢ãžã®äŸµç¥æŠäºã«é¢ããèäœã§ã2014幎ã«ã»ã«ãã¢å
±ååœååŽè³ãåè³ã圌ã®é£çµ¡å
ã¯ãcrgeditor@yahoo.com
äžççãªã³ãã屿©ã人é¡ã«å¯Ÿããã°ããŒãã«ã»ã¯ãŒãã¿ãŒ
by Michel Chossudovsky
© Michel Chossudovsky, 2022. All rights reserved - Global Research Publishers, Centre for Research on
ã°ããŒããªãŒãŒã·ã§ã³ç ç©¶ã»ã³ã¿ãŒïŒCRGïŒã
æ¬æžã®ãããªãéšåããæžé¢ã«ããåºç瀟ã®èš±å¯ãªãã«äœ¿çšãŸãã¯è€è£œããããšã¯ã§ããŸããã
åºçç€Ÿã®æžé¢ã«ããèš±å¯ãªããæ¬æžã®äžéšãŸãã¯å
šéšãè€è£œããããšãçŠããŸãã
ã°ããŒãã«ãªãµãŒããããªãã·ã£ãŒãºã¯ãã°ããŒããªãŒãŒã·ã§ã³ç ç©¶ã»ã³ã¿ãŒïŒCRGïŒã®äžéšéã§ãP.O. Box
55019, 11, rue Notre-Dame Ouest, Montréal, Québec, H2Y 4A7, Canadaã®äžéšéã§ãã
詳现ã«ã€ããŠã¯ãäžèšäœæã®åºç瀟ã«ãåãåããããã ãããåŒç€ŸãŠã§ããµã€ã
www.globalresearch.caã
æ¬æžã«èšèŒãããèŠè§£ã¯èè
ã®è²¬ä»»ã§ãããå¿
ãããã°ããŒããªãŒãŒã·ã§ã³ç ç©¶ã»ã³ã¿ãŒã®èŠè§£ãåæ ãããã®ã§ã¯ãããŸããã
æ¬æžã§è¿°ã¹ãããŠããèŠè§£ã¯ãèè
å人ã®è²¬ä»»ã§ãããå¿
ãããCentre for Research on Globalizationã®èŠè§£ãåæ ãããã®ã§ã¯ãããŸããã
åºç瀟ã¯ãæ¬æžã«å«ãŸããè³æãããã«é¢é£ããèšè¿°ãè±èœãäžæ£ç¢ºãã«ã€ããŠè²¬ä»»ãè² ããã®ã§ã¯ãããŸããã
æ¬æžã«èšèŒãããŠããå
容ããŸãã¯ããã«é¢é£ããèšè¿°ãçç¥ãäžæ£ç¢ºãã«ã€ããŠãåºç瀟ã¯äžåã®è²¬ä»»ãè² ããŸããã
ååéå®ç
衚çŽåç © fernando zhiminaicela/Pixabay
ã«ããã§å¶äœãããŸããã
ISBN 978-0-9879389-3-0 ïŒè±èªçã®ã¿
ã«ãã峿žé€šã»å
¬ææžé€šåºçç©ã«ã¿ãã°æ²èŒ
ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒïŒè
äžçã³ãã屿©ã人é¡ã«å¯Ÿããã°ããŒãã«ã¯ãŒãã¿ãŒ
ISBN 978-0-9879389-3-0 (pdf) é»åæžç±
ãã®æ¬ã¯ãç§ã®ç涯ã®ããŒãããŒã§ãããé£åž¯ããŠè¡åããŠãã
ãã·ã¥ã©ã³ã»ã©ãã¥ãŒãµãŒã«æ§ããŸãã
å
šäººé¡ã®æªæ¥ã®ããã«
è¬èŸ
æ¬æžã®ç·šéã»å¶äœã«ããããJezile Torculasæ°ã®ãµããŒããšã¢ããã€ã¹ã«æè¬ããŸãã
ãžã§ãºã£ãŒã«ã»ãã«ã¯ã©ã¹ã«æè¬ãããåçš¿ã®æ¥æ¬èªèš³ãçå
ããŠè¡ã£ãŠãããå®åéé倫ããã«æè¬ããŸãã
æ¥æ¬èªã«ç¿»èš³ããŠãããå®åéé倫ããã«æè¬ããŸãããŸããã¬ã€ã¢ãŠããšè¡šçŽã®ãã¶ã€ã³ã«ååããŠãããTeresa Balisacanã«æè¬ããŸãã
é·å¹Žã«ãããã€ã³ã¹ãã¬ãŒã·ã§ã³ã®æºã§ãã£ããã§ãªã·ãã£ã»ã¢ãŒãã¹ãããããããŠãç§ãæ¯ããŠãããåšã®ãã€ã«æè¬ã®æã衚ããŸãã
åšã®ãã€ã¯ãCOVID-19屿©ã®å£æ»
çãªåœ±é¿ã«ã€ããŠãç§ã«çè§£ãšæŽå¯ãäžããŠãããã
COVID-19ã®å±æ©ãè¥ãäžä»£ã«äžãã壿»
çãªåœ±é¿ã«ã€ããŠçè§£ãšæŽå¯ãäžããŠãããåšã®ãã€ããããªå¶äœã«æè¬ããã¢ãªãšã«ã»ããšã©ã»ãããªã²ã¹ããã€ã±ã«ã»ãŠã§ã«ãã«ã
ãã€ã±ã«ã»ãŠã§ã«ãã«ã¯ãåªããã°ããŒãã«ã»ãªãµãŒãã»ã©ãžãªçªçµãæäŸããŠããã£ãã
ãŸããããæ°å¹Žã®éã«ãã°ããŒãã«ã»ãªãµãŒãã®èè
ãå人ãã¡ãã以äžã®ãããªè²¢ç®ãããŠãããããšã«æè¬ããŸãã
ãã®æ°å¹Žéãäžçäžã®äººã
ã®ç掻ã«åœ±é¿ãåãŒããŠããã³ããã®å±æ©ã詳现ã«çè§£ããããã«è²¢ç®ããŠãããã°ããŒãã«ãªãµãŒãã®èè
ãå人ãã¡ã«ãæè¬ããŠããŸãã
ãã®æ°å¹Žéãäžçäžã®äººã
ã®ç掻ã«åœ±é¿ãåãŒããŠããã³ãã屿©ã®è©³çްãªçè§£ã«è²¢ç®ããŠããããã°ããŒãã«ã»ãªãµãŒãã®èè
ãå人ãã¡ã«æè¬ããŸãã
Peter Koenig, Manlio Dinucci, David Skripac, Dr. Denis Rancourt, Dr. Stephen Frost, F. William Engdahlã«æè¬ããŸãã
William Engdahl, Christine Massey, Dr. Rudolf Haensel, Edward Curtin, Richard Gale, Dr. Gary Null,
ã³ãªã³ã»ããããã³ã¿ãŒããã€ã±ã«ã»ãã€ããããŒãã¢ã³ãœããŒã»Jã»ããŒã«ææããã¹ã«ã«ã»ãµã¯ã¬å士ãã©ã€ããŒã»ããšã«ãããå士ãããŒã«ã»ã¯ã¬ã€ã°ã»ãããŒãå士
ããŒã«ã»ã¯ã¬ã€ã°ã»ãããŒããã©ãŠã«ã»ãã¬ã¬ã¹ææãã·ã§ãŒã³ã»ã¯ã€ã³ãã¹ãã£ãŒãã³ã»ã¬ã³ããã³ãããŒã¯ã»ã¿ãªãããžã£ãã¯å士
ããŠãšã«ã¹å士 ã¯ã©ãŠãã£ã¢ã»ãã©ã³ã»ãŽã§ã«ããå士 ã³ã€ã ã®ã³ã»ãªã»ã¯ããã£ãã€ã³å士 ã«ãŒã©ã»ã¹ãã¢å士 ãããŒã»ãã©ãŒã¯ããŒå士 ãã£ã¢ã·ãŒå士
A. ã°ãºãã³ ãããŒãã»ãããŠãº ã²ã€ãªãŒã»Gã»ã³ãŒã«ãº ãã³ãŒã«ã»ãã¬ããŒã ãªãã£ãŒãã»ãã«ã¬ã ãšããã¥ãšã«
Mathias Chang, Stephen Sefton, Chandra Muzzafar, 圌ãã®èäœããµããŒããå±ãŸãã«æè¬ããŸãã
ãããŠå±ãŸãã«æè¬ããŸãã
ãŸããæ
ãã²ã«ã»ãã¹ã³ãã»ãããã¯ãã³ç¥ç¶ã«ã¯ãç§ã«æ¹è©çãªçè§£ãäžããŠãããããšã«æè¬ã®å¿µãæ±ããŠããã
ãäžããŠãããæ
ãã²ã«ã»ãã¹ã³ãã»ãããã¯ãã³ç¥ç¶ã«æè¬ããŸãã
-ç®æ¬¡
åºæ
第1ç«
ã¯ããã«ãåžæ°ç€ŸäŒã®ç Žå£ãææãã£ã³ããŒã³
第2ç«
ã³ããã¿ã€ã ã©ã€ã³
第3ç«
COVID-19ãSARS-CoV-2ãšã¯äœãïŒã©ã®ããã«æ€æ»ããã®ãïŒã©ã®ããã«æž¬å®ããã®ãïŒ
第4ç«
人工çãªçµæžäžæ³
第5ç«
è¶
å¯è£å±€ã®å¯ã®å¢å€§ãå¯ã®æšªé ãšååé
第6ç«
ã¡ã³ã¿ã«ãã«ã¹ãžã®åœ±é¿
第7ç«
è
æããç§åŠïŒãæ²»çæ³ã¯ãªãããå®äŸ¡ã§å¹æçãªè¬ãããããã·ã¯ãããã³ïŒHCQïŒã®æå¶
第8ç«
倧æè£œè¬äŒç€Ÿã®COVIDãã¯ã¯ãã³ã
第9ç«
2009幎ã®H1N1è±ã€ã³ãã«ãšã³ã¶ã®å€§æµè¡ãããã¯ãªããŒãµã«ã ã£ãã®ãïŒ
第10ç«
衚çŸã®èªç±ãæè°éåããå瀟äŒçãµã€ã³ãã¹ããšåé¡ãã
第11ç«
äžççãªCOVaxäœæŠãšãã¥ã«ã³ãã«ã¯ç¶±é ã人éã«å¯Ÿãã眪ããžã§ããµã€ã
第12ç«
ãäžçã¯ãŒãã¿ãŒããšãã°ã¬ãŒãã»ãªã»ããããäžçåµåãšæ°èªç±äž»çŸ©ã®ãã·ã§ãã¯çæ³ã
第13ç«
ãããžã¿ã«å°å¶ããšQRã³ãŒã
第14ç«
COVID-19ã®çµå±ïŒåªçåŠãšäººå£åæžèšç»
第15ç«
ä»åŸã®éçïŒãã³ããã®æŽæ¿ãã«å¯Ÿæããäžççãªéåã®æ§ç¯
-----åç¥------
"å°çã¯ç©ºã£ãœã§ãæªéã¯ã¿ããªããã«ãã" - ãŠã£ãªã¢ã ã»ã·ã§ã€ã¯ã¹ãã¢ããã³ãã¹ãã1610幎
COVID-19ã®å±æ©ã¯ã人ã
ã®ç掻ãç Žå£ããŠãããèè
ãšããŠã®ç§ã®è²¬ä»»ã¯ãçå®ãæããã«ããããšã§ããã
ã¡ãã£ã¢ã®åœæ
å ±ã®æµããæã¡åããäžçäžã®ã§ããã ãå€ãã®äººã
ã«äŒããããšã§ãã
ç§ãã¡ã¯ãéåžžã«è€éãªããã»ã¹ãæ±ã£ãŠããã
ãã®2幎åãç§ã¯ã»ãŒæ¯æ¥ãCOVID-19ã®å±æ©ã®æç³»åãšæšç§»ãåæããŠããã
2020幎1æã®åœåãããäžçäžã®äººã
ããæ¥éã«é²è¡ããŠããCOVID-19ã®ååšãä¿¡ããåãå
¥ããããã«ä»åããããã
æ¥éã«é²è¡ããå±éºãªç«ç
ã®ååšãä¿¡ããããåãå
¥ãããããã¡ãã£ã¢ã®åœæ
å ±ã¯COVID-19ã®ã·ããªãªãç¶æããã®ã«åœ¹ç«ã£ãã
æ¬çš¿å·çæç¹ã§ã¯ã倿°ã®åœã§æè°éåãåçºããŠãããå°çå
šäœã
çµæžçã瀟äŒçæ··ä¹±ã«é¥ã£ãŠãããäžççãªé£ç³§ãšèŸ²æ¥ã®å±æ©ãé²è¡äžã§ããã
äžçã®äž»èŠãªå°åã§é£¢é¥ãçºçããŠããïŒç¬¬IVç« åç
§ïŒã
2020幎1æã®åœåãããç§åŠçãªåãšèåœããCOVã®æ£åœæ§ãç¶æããããã«äœ¿ãããŠããã
ããã¯ããŠã³ããã§ã€ã¹ãã¹ã¯ã®è£
çãªã©ãCOVID-19ã®æ¿çã®æ£åœæ§ãç¶æããããã«ãç§åŠçãªåãåœãã䜿ãããŠããã
瀟äŒçè·é¢ã眮ãããšãåºæ¬çäººæš©ã®æå§ãªã©ã§ããã
æææ±ºå®ããã»ã¹ã¯ãéèæ©é¢ã«ãã£ãŠã³ã³ãããŒã«ãããŠãããã°ããŒãã«ã»ã¬ããã³ã¹ãã®æ§é
æ°äž»äž»çŸ©ãšåžæ°ç€ŸäŒã®å¶åºŠã匱äœåããããã°ããŒãã«ã»ã¬ããã³ã¹ãã®æ§é ãå±éãããŠããããããŠããã®æç€ºã¯
åãæç€ºããå€ãã®åœã®è
æããæ¿æ²»å®¶ã«åæã«äŒéãããŠããã
åãæç€ºããå€ãã®åœã®è
æããæ¿æ²»å®¶ã«ãåæã«éãããŠãããåœé£ã·ã¹ãã ããŸãããã®æ¥µæªééãªè©Šã¿ã®éè¡ã«å æ
ããŠããã
ãã³ãããã¯ã¯2020幎3æ11æ¥ã«çºè¡šãããã忥ãããã¯ããŠã³ã®æç€ºã¯
åœé£å çåœ193ã«åœã«ãåŽååã®éã蟌ããšãééãã矩åã¥ããæç€ºæžãéãããã
åŽååã®éã蟌ããçµæžçã»ç€ŸäŒçæ¯èгã®ãééããããŠã€ã«ã¹å¯Ÿçãã®ææ®µãšããŠèŠæ±ããŠããã
ããŠã€ã«ã¹ãšã®æŠã ãã§ããã
äžçäžã®70å人以äžã®äººã
ããçŽæ¥ãŸãã¯éæ¥çã«ã³ãã屿©ã®åœ±é¿ãåããŠããã
ã¢ã©ã«ã«æ¬ ããååœæ¿åºã宿œããç Žå£çãªåœä»€ã«ãã£ãŠãçŽæ¥ãŸãã¯éæ¥çã«åœ±é¿ãåããŠããŸãã
mRNAã¯ã¯ãã³
2020幎åŸåãããäžçäžã®äººã
ã¯ãããã°ãã¡ãŒãã®COVID-19ã¯ã¯ãã³æ³šå°ãã解決çãã§ãããšä¿¡ã蟌ãŸãããããã«ãªããŸããã
泚å°ãã解決çãã§ãããšä¿¡ã蟌ãŸãããŸããããããŠãçŽ80å人ã®å°ç人é¡ãå
šå¡æ¥çš®ãããã°ããæ°ããæ£åžžãªç¶æ
ããå埩ããããšä¿¡ã蟌ãŸãããŸããã
æ°åã®SARS-CoV-2ãŠã€ã«ã¹ã®ã¯ã¯ãã³ãã®mRNAã¯ãéåžžã®æ¡ä»¶äžã§ã¯äœå¹Žããããã¯ããªã®ã«ãã©ãããŠããã«éçºãããã®ã ããã
倧æè£œè¬äŒç€Ÿãçºè¡šãããã¯ã¯ãã³ãã¯ããã¡ã€ã¶ãŒããªãŒãããŠããããå®éšçãªéºäŒåç·šémRNAæè¡ãããŒã¹ã«ããŠããã
1.éºäŒåç·šémRNAæè¡ã«åºã¥ããã®ã§ãããã²ãã ã«é¢ä¿ãããã®ã§ããã
2.ããŠã¹ããã§ã¬ããã䜿ã£ãæšæºçãªåç©å®éšãè¡ãããã®ã ãããïŒ
ãããšãããã¡ã€ã¶ãŒç€Ÿã¯ããã®ãŸãŸäººéã® "ã¢ã«ã¢ãã "ã«ãããã®ã ãããïŒããã§ã®ãã¹ãã¯7æäžæ¬ãã8æäžæ¬ã«éå§ããã2020
3.ãæ°ããã¯ã¯ãã³ã®ãã¹ãã«3ã¶æãšããã®ã¯å代æªèã§ããæ°å¹Žãæ®éã ã

Large + JIPÃMã«ãããã®é¢šåºç»ã¯ãç§ãã¡ã®èŠå¢ã説æããŠããŸãã
ããŠã¹1å·ïŒãã¯ã¯ãã³ãæ¥çš®ããã€ããã§ããïŒã
ããŠã¹2å·ïŒãæ°ã§ãçã£ãã®ãããŸã 人éã§ã®ãã¹ããçµãã£ãŠããªããã ãã
mRNAã¯ã¯ãã³ãæ»äº¡çãšçœ¹æ£çãäžççã«äžæããããšãã蚌æ ã¯ååã«èšŒæãããŠããã
æ»äº¡çãšçœ¹æ£çã®äžæãããããããšããããšã§ãã
COVID-19ã¯ã¯ãã³ãæã
ã®åäŸãã¡ã殺ããŠããããšã確èªããå ±åããããè±åœã§ã¯ããå
šæ»äº¡ã®ç¹ã§ææªã®æ°åãåºããã
è±åœã§ã¯ããå
šåå æ»ã®ç¹ã§ææªã®æ°åã¯ãäºéã¯ã¯ãã³æ¥çš®ã®10代ã§ãããã4
æžç±ã®èª¬æãšæŠèŠ
åºç« ã§ã¯ãææã®ãã£ã³ããŒã³ãåžæ°ç€ŸäŒã®æå³çãªäžå®å®åãã¡ãã£ã¢ã®é°æ¹¿ãªåœ¹å²ã«çŠç¹ãåœãŠãã
ã¡ãã£ã¢ã»ãããã¬ã³ãã®é°æ¹¿ãªåœ¹å²ã«çŠç¹ãåœãŠãã
ã³ãã19屿©ã®æŽå²ã«ã€ããŠãäž»èŠãªåºæ¥äºã®æç³»åãæ€èšŒãã詳现ãªã¬ãã¥ãŒã第â
¡ç« ã«ããã
第â
¡ç« ã§ã¯ããã®æŠèŠã説æããã
第IIIç« ã§ã¯ãSARS-CoV-2ãŠã€ã«ã¹ã®æ§è³ªãšãSARS-CoV-2ãŠã€ã«ã¹ã®æ¬ é¥ã«çŠç¹ãããŠãŠããã
é転åããªã¡ã©ãŒãŒé£éåå¿(RT-PCR)ãã¹ãã¯ãåœåããååœæ¿åºããåœã®ãSARS-CoV-2ãŠã€ã«ã¹ãäœãåºãããã«éå°ã§ç€ŸäŒçã«æå§çãªæ¿çåœä»€ãæ£åœåããç®çã§ããåœã®ããŒã¿ããäœæããã
ãã®å±æ©ããããããåºç¯ãªçµæžçã»ç€ŸäŒç圱é¿ã¯ãäžççãªè²§å°åãšåé
åã®ããã»ã¹ãå«ãã
è¶
å¯è£å±€ãžã®å¯ã®ååé
ãå«ãããã®å±æ©ããããããåºç¯ãªçµæžçã»ç€ŸäŒç圱é¿ã«ã€ããŠã¯ã第IVç« ãšç¬¬Vç« ã§æ€èšããã
çµæžçæ··ä¹±ã¯ãäžçå²äžæãæ·±å»ãªäžççåµå屿©ã®åŒãéãšãªã£ãã
ç£çŠæ¿çã粟ç¥è¡çã«äžããç Žå£çãªåœ±é¿ïŒèªæ®ºãè¬ç©ä¹±çšã®å¢å ãªã©ïŒã«ã€ããŠã¯ã第Vç« ã§æ€èšŒããã
第VIç« ã§ã¯ãèªæ®ºãè¬ç©ä¹±çšã®å¢å ãªã©ã粟ç¥è¡çãžã®å£æ»
çãªåœ±é¿ãæ€èšãããŠããã
第VIIç« ã§ã¯ãå®äŸ¡ã§å¹æçãªè¬ã§ããããããã·ã¯ãããã³ïŒHCQïŒã®æå§ãæ€èšŒãããè¬ã§ããã
ããã°ãã¡ãŒãã®ã¯ã¯ãã³æ¥çš®ããã°ã©ã ã¯ãæ°åã³ãããŠã€ã«ã¹ã®çºçãçãããæ°ã«æåãããã§ã«æ³å®ãããŠããŸããã2019幎æ«ã«æŠæŒ¢ã§æ°åã³ãããŠã€ã«ã¹ãçºçãããšãããæ°ã¶æåããæ³å®ãããŠããã第VIIIç« ã§ã¯ããa best described as a ãã§ããããšãã¬ãã¥ãŒããŸãã
ãæ®ºäººã¯ã¯ãã³ãã§ãããæ¬ç« ã®åŸåã§ã¯ãID2020 ããžã¿ã«ã»ã¢ã€ãã³ãã£ãã£ã»ãããžã§ã¯ã ãšãããããã¯ã¯ãã³ãã¹ããŒãã®æŒãä»ãã«ã€ããŠã
第IXç« ã§ã¯ã2009幎ã®H1N1è±ã€ã³ãã«ãšã³ã¶ã®ãã³ãããã¯ã®ç¶æ³ãæ¯ãè¿ãããããè©æ¬ºã§ãã£ãããšã倿ããããæ¯ãè¿ããããã¯ãäºè¡æŒç¿ãã ã£ãã®ã ãããã
第10ç« ã¯ã衚çŸã®èªç±ã®å¥å¥ªãšæš©åšäž»çŸ©çãªåŒŸå§ã«çŠç¹ãåœãŠãã第10ç« ã§ã¯ã衚çŸã®èªç±ã®å¥å¥ªãšãæè°éåãæå§ãã瀟äŒçãªã³ã³ãã©ã€ã¢ã³ã¹ã確ä¿ããããã«çšããããæš©åšäž»çŸ©çãªæ¿çã«çŠç¹ãåœãŠãã
第XIç« ã¯ã人éã«å¯Ÿãã眪ãšãã¥ã«ã³ãã«ã¯ã»ã³ãŒãã«çŠç¹ãåœãŠãã
第12ç« ã§ã¯ãäžççµæžãã©ãŒã©ã ãææ¡ãããã°ã¬ãŒãã»ãªã»ããããåæãããã°ããŒãã«ã»ã¬ããã³ã¹ã確ç«ããçŠç¥åœå®¶ã廿¢ããå€§èŠæš¡ãªç·çž®è²¡æ¿ãè¡ããšãããã®ã§ããããã®å
容ã¯ãã°ããŒãã«ã»ã¬ããã³ã¹ã®ç¢ºç«ãçŠç¥åœå®¶ã®å»æ¢ãè²§å°ã«ããã人ã
ãžã®å€§èŠæš¡ãªç·çž®è²¡æ¿ã®æŒãã€ãã§ããããã°ã¬ãŒãã»ãªã»ãããã®å
¬åŒãšã³ãã¬ã WEFã®ã¯ãäœãææããã幞çŠã«ãªããã§ããã
ãããžã¿ã«å°å¶æ¿æ²»ããšé¡ããã第13ç« ã§ã¯ã80åäººèŠæš¡ã®ã°ããŒãã«ãªããžã¿ã«ããŒã¿ãã³ã¯ãæ§ç¯ããããã®åºç€ãšãªãäžçèŠæš¡ã®QRèªèšŒã³ãŒããããžã§ã¯ãã«çŠç¹ãåœãŠãŠããã
ããŒã¿ãŒã»ã±ãŒãããã¯ãQRã³ãŒãã ãå
šé»åID-åå人ã®ãããããã®ïŒå¥åº·ãéè¡ãå人ããã©ã€ããŒããªã©ã®èšé²ïŒã«ãªã³ã¯ãã ããšè¡šçŸããŠããã
XIVç« ã¯ãEugenics and Depopulation AgendaïŒåªçåŠãšäººå£æžå°ã¢ãžã§ã³ãïŒã«çŠç¹ãããŠãŠããã
第XVç« ã¯ããThe Road Ahead: ã³ããå°å¶æ¿æ²»ã«å察ããäžççãªéåã®æ§ç¯ ã³ããå°å¶æ¿æ²»ã«å察ããäžççãªéåã®èŒªéãæããŠãããéèãšãªãŒãã倧æè£œè¬äŒç€Ÿãªã©ã®æ£åœæ§ããããŠåœå®¶ã¬ãã«ã®è
æããæ¿æ²»çæš©åšã«ææŠããäžççãªéåã®èŒªéãæããæ¿æ²»çæš©åšã®è
æããæ§é ã«å¯ŸããŠãååŒ·ãææŠããäžççãªéåã®èŒªéãæããŠããŸãã
æ¹æ³è«ã«ã€ããŠäžèšãç§ãã¡ã®ç®çã¯ã以äžã®ãããªæ
éãªåæãéããŠãã倧ããªåããå蚌ããããšã§ãã
æ£ç¢ºãªããŒã¿ãæŠå¿µãå®çŸ©ãå«ãCOVID屿©ã®æŽå²çãªæŠèŠã
å ¬åŒææžãå°éå®¶ã«ããå ±åæžããã®åŒçšã倿°ã®åºå žãšåèæç®ã®æç€ºã®åŒçšã
ãå ¬åŒãããŒã¿ãæšå®å€ãå®çŸ©ã®ç§åŠçåæããã³è©³çްãªã¬ãã¥ãŒã
WHOã®ãã¬ã€ãã©ã€ã³ããšæ¿åºã®æ¿çãçµæžã瀟äŒãå ¬è¡è¡çã®å€æ°ã«äžãã圱é¿ã«ã€ããŠã®åæã圱é¿ãåæãããã®ã§ãã
ç§ã®èè ãšããŠã®ç®çã¯ãäžçäžã®äººã ã«æ å ±ãæäŸããåœå šäœã®çµæžçã»ç€ŸäŒçæ§é ãäžå®å®ã«ããå£å®ãæ£åœåãšããŠäœ¿ããããã®åŸãèŽåœçãªãCOVID-19ãã¯ã¯ãã³ããæŒãä»ããå ¬åŒã®ã·ããªãªã«åè«ããããšã§ããã
ãã®å±æ©ã¯ãã»ãŒ80å人ãšãã人é¡å šäœã«åœ±é¿ãåãŒããŠããŸãã
ç§ãã¡ã¯ãäžçäžã®åèãšåã©ããã¡ãšé£åž¯ããŠããŸãã
çå®ã¯åŒ·åãªéå ·ã§ããã
ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒ
ã°ããŒãã«ã»ãªãµãŒããã¢ã³ããªãªãŒã«ã2022幎8æ
å·»æ«è³æ
F. William Engdahl, November 15, 2020. ãã¡ã€ã¶ãŒã®ã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã«ã€ããŠèªãããŠããªãããšããããã®ã¢ã«ã¢ããïŒãhttps://www.globalresearch.ca/what-not-said-pfizer-coronavirus-vaccine/5729461
Ibid.
åäž
ãæŽé²ã2022幎7æ29æ¥å·ãã·ã§ããã³ã°ãªããšãè±åœæ¿åºãCOVIDã¯ã¯ãã³æ¥çš®ã®åäŸã¯éæ¥çš®ã®åäŸãã4423%æ»äº¡çãé«ããCOVID-19ã§æ»äº¡ããå¯èœæ§ã13633%é«ããšèªãã https://www.globalresearch.ca/printversion-of-covid-book/5780283.
4
--------------------第1ç« --------------------
ã¯ããã«
åžæ°ç€ŸäŒãç Žå£ãã ææã®ãã£ã³ããŒã³
飢é¥ãè²§å°ã倧é倱æ¥ã¯ãSARS-CoV-2ãããå€ãã®äººã
ã®åœã奪ããç Žå£ããããã ïŒãã®ãã¬ãã£ããªãã©ã³ã¹ç¶æ
ãéå£ãã¹ããªãŒããæãåºãæãæ¥ãã®ã ã- ãã¹ã«ã«ã»ãµã¯ã¬å士1
ãé¡ã®çºç¹ãçèææçãçŽ°èææçã®æ£è
ã蚺å¯ããŠããŸããã...2æãš3æïŒ2020幎ïŒã«ã¯ããã¹ã¯ãããªãããã«ãšèšãããŠããŸãããäœãå€ãã£ãã®ã§ããããïŒç§åŠã¯å€ãããªãã£ããæ¿æ²»ãå€ãã£ãã®ã§ããããã¯ã³ã³ãã©ã€ã¢ã³ã¹ã«ã€ããŠã§ããç§åŠã®è©±ã§ã¯ãªãã®ã§ãã
ãäžæŠãåãçå®ã«ãªããšãåŸæ»ãã¯ã§ããªããçæ°ãæ¯é
ãããäžçã¯ã²ã£ããè¿ããã -ããã·ã§ã«ã»ãã§ã¹ããã¹ããŒ
ãææçèŽæ»ç0.2%æªæºã§ããã¯ãªã³ãããŠããã -Dr.ãªãã£ãŒã Schabas3
ç§ãã¡ã¯ä»ãäžçå²äžæãæ·±å»ãªå±æ©ã®å²è·¯ã«ç«ããããŠãããç§ãã¡ã¯æŽå²ãçããŠããã®ã§ãããããã2020幎1æä»¥éã®äžé£ã®åºæ¥äºã«å¯Ÿããæã
ã®çè§£ã¯ææ§ãªãŸãŸã§ããäžççã« ã®åå ãçµæã«ã€ããŠãæ¿åºãã¡ãã£ã¢ã«æããããŠãããCOVID-19 "ãã³ããã㯠"ã®å£æ»
çãªçµæã«ã€ããŠãäžçäžã®äººã
ãæ¿åºãšã¡ãã£ã¢ã«ãã£ãŠèª€è§£ãããŠããã
èªãããããšã®ãªãçå®ã¯ããã®æ°åã³ãããŠã€ã«ã¹ããæš©åããéèé¢ä¿è
ãšè
æããæ¿æ²»å®¶ãã¡ã«ãå
šäžçã倧éã®å€±æ¥ãç Žç£ã極貧ãçµ¶æã®ã¹ãã€ã©ã«ã«é¥ããå£å®ãšæ£åœåããçç±ãæäŸããŠãããšããããšã§ããã
ããããä»èµ·ããŠããããšã®çå®ã®å§¿ã§ãããè€éãªæææ±ºå®ããã»ã¹ã®çµæãªã®ã ã
"ææå°é "ã¯ãåžæ°ã®èªç±ãš "çããæš©å© "ãžã®äŸµå®³ã§ããã
åœå®¶çµæžå
šäœã屿©ã«ãããããŠãããæå³ä»€ãçºä»€ãããåœãããã
äžå°è³æ¬ã¯æ·æ±°ãããäºå®ã§ãããå€§è³æ¬ãåªäœã«ç«ã€ã
äŒæ¥ã®å¯ã®å€§èŠæš¡ãªéäžãé²è¡ããŠããã
極æªééãªãæ°äžçç§©åºãã®èªçã§ããã
ã¬ãããŸãŒã³ããã§ã€ã¹ãã¹ã¯ã瀟äŒçè·é¢ãåŠæ ¡ã倧åŠã®ééãå®¶æå£ããã®çŠæ¢ãèªçæ¥ã®ãç¥ãã®çŠæ¢ãå®¶æå£ãããèªçæ¥ç¥ãã鳿¥œãèžè¡ãæåã€ãã³ãã®å»æ¢ãã¹ããŒãã€ãã³ãã®äžæ¢ãèµ€ç·å°åž¯ããã§ã€ã¹ãã¹ã¯ã瀟äŒççå€ãåŠæ ¡ã倧åŠééãæåã€ãã³ãã®å»æ¢ãã¹ããŒãã€ãã³ãã®å»æ¢ãæåçãªã€ãã³ããã¹ããŒãã€ãã³ãã®äžæ¢ãçµå©åŒã®äžæ¢ããæãšäººçãã®å
šé¢çãªçŠæ¢ã
ãããŠãããã€ãã®åœã§ã¯ãã¯ãªã¹ãã¹ãšæ°å¹Žã®å®¶æå£æ¬ïŒ2021-2022幎ïŒãéæ³ãšãããã
äžççµæžãééããããšãããŠã€ã«ã¹å¯Ÿçã®ææ®µãšããŠæç€ºãããŠãããããã 圌ãã¯ç§ãã¡ã«ä¿¡ããããããšããŠããã®ã§ããããåœæ°ãCOVID-19ããå£ç¯æ§ã€ã³ãã«ãšã³ã¶ã«äŒŒãŠããããšç¥ããããŠããã
ãããCOVID-19ããå£ç¯æ§ã€ã³ãã«ãšã³ã¶ã«äŒŒãŠããããšç¥ããããŠããããææã®ãã£ã³ããŒã³ã¯æ«æããŠããã ããã
5
2020幎3æ11æ¥ãWHOããã³ãããã¯ãå
¬åŒã«çºè¡šããåœé£å çåœ190ã«åœïŒ193ã«åœäžïŒã®çµæžãå°éãããããã®æç€ºã¯ããŠã©ãŒã«è¡ãäžççµæžãã©ãŒã©ã ïŒWEFïŒãåäžé·è
ã®è²¡å£ãªã©ãäžå±€éšããåºããããã®ã§ããã
2020幎3æ11æ¥ã®ãã³ãããã¯ã«å
ç«ã¡ãWHOã®ãåœéä¿å¥äžã®ç·æ¥äºæ
ïŒPHEICïŒããçºä»€ãããã2020幎1æ30æ¥ã®PHEICïŒPublic Health Emergency of International ConcernïŒããããŠ2020幎2æã®éèåžå Žã®äžå®å®åã«ç¶ããŠã2020幎3æ11æ¥ã®ãã³ãããã¯ãšãªã£ããéèåžå Žã®äžå®å®åã§ããã
äžã®åç»ã¯ã1幎以äžåãã¯ã¯ãã³çºå£²åã«Vimeoã§å
¬éããããã®ã§ããã¯ã¯ãã³ã®çºå£²åã«ã°ããŒãã«ã»ãªãµãŒã瀟ã«åããããæ€é²è¡çºãšããŠã2022幎3æ5æ¥ã«åé€ãããŸããããã¡ããã¯ãªãã¯ããŠã芧ãã ããã
To view the video on Bitchute and/or enter a comment, click here. (Screenshot from the video, copyright Global Research)
1æ30æ¥ãç·äººå£64å人ã®ãã¡ãäžåœåœå€ã®ãCOVID-19確å®çäŸãã¯83人ã§ãã£ãã2æã®éè屿©åã®æ°æ¥éã§ãäžåœåœå€ã®ãCOVID-19確èªçäŸãã¯1,076ä»¶ã§ãã£ãïŒç¬¬IIç« ã®åæåç §ïŒã

ä¹ããæ¬ é¥ã®ããæšå®å€ã«åºã¥ãããã®æ¥µæªééãªãããžã§ã¯ãã¯ãäŒæ¥ã¡ãã£ã¢ã«ãã£ãŠã人éçãåªåã§ãããšããããªã説æããããåœé瀟äŒãã¯ãä¿è·ãã責任ãïŒR2PïŒãè² ã£ãŠããã
ãã€ã¢ãã»ãžã§ã³ã¹ãã³ã®èšèãåããã°ãããã¯ãäžççãªå£å®ããªã®ã ãäžççµæžãã©ãŒã©ã ïŒWEFïŒã®åŸæŽã®ããšãéžæã§éžã°ããããã§ããªãã宿°ããŒãããŒã·ãããããå°çäžã®79åã®äººã ãæãããã«ãã£ãŠããã®ã§ãããåœé£å çåœ193ã«åœã®åœæ°çµæžã®ééã¯ãããŠã€ã«ã¹ã殺ããããã®ææ®µãšããŠæç€ºãããŠããã
6
ã°ãããŠããããã«èããããå°çäžã®å®äœçµæžãééããããšã¯ãã解決çãã§ã¯ãªãããããäžççãªäžå®å®åãšè²§å°åã®æ¥µæªééãªããã»ã¹ã®ãåå ãã§ããã
åœæ°çµæžã¯ãæ¿æ²»çã瀟äŒçãæåçãªå¶åºŠãšçµã¿åããã£ãŠãæåŸãéçšãçç£ã貿æãã€ã³ãã©ã瀟äŒãµãŒãã¹ãšãã£ããå®ç掻ã®åçç£ãã®åºç€ãšãªããã®ã§ããã
å°çã®çµæžãäžå®å®ã«ããããšã¯ããŠã€ã«ã¹ãšéãããã®ã解決çãã«ã¯ãªãåŸãªããããããããã¯åœŒããç§ãã¡ã«ä¿¡ããããããšããŠããæŒãä»ããããã解決çãã§ããããããŠãããããã圌ããè¡ã£ãŠããããšãªã®ã§ãã
ããã¯ã人ã
ã®ç掻ãç Žå£ããããšã§ããåžæ°ç€ŸäŒãäžå®å®ã«ããããšã ã
ãã®åã¯ã2幎å以äžã«ããã£ãŠ24æé365æ¥çµ¶ãéãªãç¹°ãè¿ããããCOVIDã¢ã©ãŒãããšããå€§èŠæš¡ãªã¡ãã£ã¢æ
å ±ãã£ã³ããŒã³ã«ãã£ãŠç¶æãããŠãããããã¯ç€ŸäŒå·¥åŠã®äžéçšã§ããã
圌ããæãã§ããã®ã¯ãç£çŠãæ£åœåããããã«æ°åãã€ãäžããããšã§ããCOVIDã®æ»äº¡çµ±èšã¯ãæé ãã§ããïŒç¬¬äžç« åç
§ïŒã
COVID-19ã¯ã殺人ãŠã€ã«ã¹ããšããŠæãããŠããã
åžæ°ç€ŸäŒãç Žå£ãã
人ã
ã¯æ¯ããå°æããŠãããããªã圌ãã¯ãããªããšãããã®ã ããïŒã
空ã£ãœã®åŠæ ¡ã空ã£ãœã®ç©ºæž¯ãåç£ãã飿ååºã
ãã©ã³ã¹ã§ã¯ããCOVID-19ã®çºçãããã£ãŠæäŒãã«ã©ã·ãã³ãã§è
ãããããïŒ2020幎4æïŒ4
éœåžã®ãµãŒãã¹çµæžå
šäœã屿©ã«çããŠãããååºãããŒãã¬ã¹ãã©ã³ã¯åç£ã«è¿œã蟌ãŸãããæµ·å€æ
è¡ãäŒæã¯äžæããããè¡è·¯ã¯ç©ºã£ãœã«ãªããããã€ãã®åœã§ã¯ãããŒãã¬ã¹ãã©ã³ã¯ãå¿
èŠã«å¿ããŠå¹æçãªé£çµ¡å
ã®è¿œè·¡ããµããŒãããããã«ãååãšé£çµ¡å
ã®æ
å ±ãåãããšãèŠæ±ãããŠããŸã5ã
æåçããã¯ããŠã³
åæã«ã2020幎3æãããäžççãªåœå®¶çµæžã®ééã¯ã鳿¥œãèžè¡ã€ãã³ãã«åœ±é¿ãäžããæåçããã¯ããŠã³ã䌎ããŸããã空ã®çŸè¡é€šããªãã©ããªããªããäº€é¿æ¥œå£ããªããªããã³ã³ãµãŒãããŒã«ãäžçäžã§ééããããããããããžã¿ã«ã»ã¹ãã€ã»ã¢ããã»ããŒã ã»ãã©ãããã©ãŒã ãæã¡åºããããã¢ã¡ãªã«ã§ã¯ããã¥ãŒãšãŒã¯ã»ã¡ããããªã¿ã³çŸè¡é€šãç®åãã«ã2020幎3æ12æ¥ã«çŸè¡é€šãééãçºè¡šããŸããããã©ã³ã¹ã§ã¯ãã«ãŒãã«çŸè¡é€šããã«ãµã€ãŠå®®æ®¿ããšããã§ã«å¡ããå°éãã2æ¥åŸã®2020幎3æ13æ¥ã«ééãããã
èšè«ã®èªç±ãæå§ããã
ããã¯ããŠã³ã®ã·ããªãªã¯ãã¡ãã£ã¢ã®åœæ
å ±ããããæ€é²ããœãŒã·ã£ã«ãšã³ãžãã¢ãªã³ã°ãææãã£ã³ããŒã³ã«ãã£ãŠæ¯ããããŠããã
å
¬åŒã®ã·ããªãªã«çåãåããå»åž«ã¯è
è¿«ãããã圌ãã¯è·ã倱ãã圌ãã®ãã£ãªã¢ã¯ç Žå£ããããæ¿åºã®ããã¯ããŠã³ã«å察ãã人ã
ã¯ããå瀟äŒç粟ç¥ç
質è
ãã«åé¡ãããã6
7
çŸåšãããã€ãã®åœã§ãæšæ¬èª¿æ»ã䜿ã£ãæ»èªä»ãã®å¿çåŠçãç ç©¶ããè¡ãããŠããã倧ããªåããåãå
¥ããã°ãããªãã¯ä»äººã®æ°æã¡ãçè§£ãããå
±æåããæã£ããè¯ã人ããšããã¿ã°ãä»ããããã
瀟äŒçè·é¢ã®åãæ¹ããã§ã€ã¹ãã¹ã¯ã®ççšãmRNAã¯ã¯ãã³ã«ã€ããŠé æ
®ã衚æããã°ãããªãã¯ïŒãç§åŠçèŠè§£ãã«åŸã£ãŠïŒãå·é
·ã§äººã欺ããµã€ã³ãã¹ãïŒç¬¬XIç« åç
§ïŒãšããã¿ã°ãä»ããããã
倧åŠãã«ã¬ããžã§ã¯ãæå¡ã¯COVIDã®å
¬åŒã·ããªãªã«æºæ ããæ¯æããããå§åããããããŠããããªã³ã©ã€ã³ã®ãæå®€ãã§ç£çŠãã¯ã¯ãã³ã®æ£åœæ§ã«çåãåãããšãè§£éãããå¯èœæ§ãããã
COVIDã®ã³ã³ã»ã³ãµã¹ãã¯ã¯ãã³ã«å察ããæ°å€ãã®å»åž«ãç§åŠè
ã鮿ãããŠããŸãã2020幎12æã«ã¯ãCOVID-19ã¯ã¯ãã³ã«å察ããŠããããšã§ç¥ãããåŒéããå€§åŠææããžã£ã³ïŒãã«ããŒã«ã»ãã«ãã£ã©ã³ãããè»ã®ææ®äžã®æ³å·è¡å®ã«ãã£ãŠé®æããããŠãŒã¹ã®ç²Ÿç¥ç
é¢ã«åŒ·å¶çã«ç¬æ¿ã«å
¥ããããŠããŸã£ããããã«ãã£ã©ã³ã¯ããå±éºãªã¢ãžã¥ãã³ãã䜿çšããã¯ã¯ãã³ã®é·å¹Žã®æ¹å€è
ããšããŠç¥ãããŠããŸããã.7
ã°ãŒã°ã«ããã§ã€ã¹ããã¯ããã€ãã¿ãŒ 倧åã®ããŒã±ãã£ã³ã°
ç£çŠããã§ã€ã¹ãã¹ã¯ã瀟äŒçè·é¢ã眮ãããšã«çåãåããèåãªç§åŠè ã®æèŠã¯ãã°ãŒã°ã«ã«ãã£ãŠãåãäžãããããã
WHOãååœã®ä¿å¥åœå±ããèªåãã¡ã®ããŒã¿ãæŠå¿µã«ççŸãããããšãèªããããäºå®ç¢ºèªããšç§°ããŠããã®ã§ããåæ§ã«ãTwitterã¯ãããäºé²æ¥çš®ãåããããšã«ããæªåœ±é¿ã圱é¿ããããããšã瀺åããæçš¿ã¯ãã¹ãŠåé€ãããããšã確èªããŠããŸãã»ã»ã»ã
Twitterã¯ãã¯ã¯ãã³ã«ã€ããŠãæå³çãªé°è¬ãåŒã³èµ·ããããŸãã¯ãæå®³ãèåœããŸãã¯èª€è§£ãæãç©èªãé²ãããæçš¿ããã¡ã¢ãªãŒããŒã«åããããšããã
8

2020幎3æ11æ¥ ä»çµãŸããçµæžææ ãäžççãªã¯ãŒãã¿ãŒãïŒ
193ã«åœã®åœæ°çµæžãäžæã«äžå®å®ã«ããã®ã¯ããçµæžæŠäºãè¡çºã§ããããã®æ¥µæªééãªèšç»ã¯ãåœæ°åœå®¶ã®äž»æš©ãèããäžçäžã®äººã
ãè²§å°ã«é¥ããããã«å»ºãŠã®äžççè² åµãæ¥å¢ãããã
ã°ããŒãã«è³æ¬äž»çŸ©ã®åŒ·åãªæ§é ãããã°ãããŒãšãã®æ
å ±æ©é¢ãè»äºæ©æ§ãåååã§ãããé«åºŠãªããžã¿ã«æè¡ãšéä¿¡æè¡ãé§äœ¿ããäžççµæžã®å°éãšçµæžçééã¯ãäžçå²äžåäŸã®ãªãããšã§ããã
çŽ193ã«åœãžã®åæä»å
¥ã¯ãæ°äž»äž»çŸ©ãèãã«ãããè»äºä»å
¥ãå¿
èŠãšãããäžçäžã®åœæ°åœå®¶ã®äž»æš©ãæãªããããã¯ããçµæžæŠäºãã®é«åºŠãªåœ¢æ
ã§ãããåŸæ¥ã®ïŒã€ã©ã¯åŒã®ïŒåå ŽåæŠäºãå«ãä»ã®åœ¢æ
ã®æŠäºãåé§ããŠããïŒç¬¬IVç« ãšç¬¬Vç« ãåç
§ïŒã
ãã°ããŒãã«ã»ã¬ããã³ã¹ãã®ã·ããªãª ãã¹ãCOVIDæä»£ã®äžçæ¿åºïŒ
2020幎3æ11æ¥ã®ããã¯ããŠã³ã»ãããžã§ã¯ãã¯ãæçµçã«ãã°ããŒãã«ã»ã¬ããã³ã¹ããšé¡ããäžçèŠæš¡ã®å šäœäž»çŸ©äœå¶ãïŒéžæã§éžã°ããã®ã§ã¯ãªã圹人ã«ãã£ãŠïŒæŒãä»ããããã«ãåãšæ¬ºçãçšãããã®ã§ãããããŒãããã»ããã¯ãã§ã©ãŒã®èšèãåããã°
9
ã...äžçã¯ä»ãããæŽç·Žãããäžçæ¿åºã«åãã£ãŠè¡é²ããæºåãæŽã£ãŠãããç¥çãšãªãŒããäžçã®éè¡å®¶ã«ããè¶ åœå®¶çãªäž»æš©ã¯ãé廿°äžçŽã«å®è·µãããåœå®¶ã®èªæ±ºããããã£ãšå¥œãŸããããšã ãããã(Aspen Times, August 15, 2011, emphasis added)9ããåŒçšããã

ã°ããŒãã«ã»ã¬ããã³ã¹ã®ã·ããªãªã¯ã瀟äŒå·¥åŠãšçµæžçã³ã³ãã©ã€ã¢ã³ã¹ãšããã¢ãžã§ã³ããæŒãä»ãããã®ã§ããã
ããã¯ãçºå±éäžåœãšå é²åœã®äž¡æ¹ã«èª²ãããæ°èªç±äž»çŸ©çãªæ¿çã®æ çµã¿ã®å»¶é·ãæ§æãããã®ã§ãããããã¯ããåœå®¶ã®èªæ±ºãã廿¢ããäž»èŠãªéèæ©é¢ãåäžé·è ããããŠåœŒãã®æ ååºéãããªããè¶ åœå®¶ç䞻暩ãïŒäžçæ¿åºïŒã«ãã£ãŠç®¡çãããèŠªç±³ä»£çæ¿æš©ã®äžççãªãã¯ãµã¹ãæ§ç¯ããããšã§ããïŒç¬¬XIIIç« åç §ïŒã
ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ ããã¯ãã§ã©ãŒç€Ÿã® "ããã¯ã¹ãããã»ã·ããªãª"
ããã¯ãã§ã©ãŒè²¡å£ã¯ããã°ããŒãã«ã»ã¬ããã³ã¹ããéè¡ããããã®ææ®µãšããŠããã·ããªãªã»ãã©ã³ãã³ã°ãã®æŽ»çšãææ¡ããŠãã10ã
ããã¯ãã§ã©ãŒè²¡å£ã2010幎ã«çºè¡šãããæè¡ãšåœééçºåéã®æªæ¥ãžã®ã·ããªãªãã§ã¯ãã°ããŒãã«ã»ã¬ããã³ã¹ã®ã·ããªãªãšäžççãªãã³ãããã¯ãçºçããå Žåã®å¯Ÿå¿ã«ã€ããŠèããããŠãã11ã
å
·äœçã«ã¯ãäžççãªåŒ·æ¯æ§ã€ã³ãã«ãšã³ã¶ãå«ãããã¯ã¹ãããã»ã·ããªãªã®ã·ãã¥ã¬ãŒã·ã§ã³ãæ³å®ãããŠããïŒp.18ïŒã
ãããã¯ã¹ããã ãã·ããªãªã¯ããæ¿åºã®ãããããŠã³ã«ããçµ±å¶ã匷åãããæš©åšäž»çŸ©çãªæå°åã匷ãŸããã€ãããŒã·ã§ã³ãå¶éãããåžæ°ã®åçºã匷ãŸãäžçããæããŠããã2012幎ãïŒã€ãŸãå ±åæžã®åºçãã2幎åŸïŒãïŒã·ãã¥ã¬ãŒã·ã§ã³ã®äžç°ãšããŠïŒéçã®ã¬ãã§ãŠã«ç±æ¥ãããæ¥µããŠæªæ§ã§èŽæ»æ§ã®ãã€ã³ãã«ãšã³ã¶ãäžçã屿ãããäžç人å£ã®20ïŒ ãææãããã7ã«æã§800äžäººïŒãã®å€§åã¯å¥åº·ãªè¥å¹Žå±€ïŒãæ»äº¡ããã(Helen Buyniski, February 2020)12ã
2010幎ã®ããã¯ãã§ã©ãŒã¬ããŒãã¯ã2009幎ã®H1N1è±ã€ã³ãã«ãšã³ã¶ã®å€§æµè¡ã®çŽåŸã«çºè¡šãããïŒIXç« åç §ïŒã
ã¯ã¬ãŒãXã®åäžã·ã¥ãã¬ãŒã·ã§ã³
2018幎5æ15æ¥ããã¯ã¬ãŒãXããšåä»ãããããã³ãããã¯ã®åäžã·ãã¥ã¬ãŒã·ã§ã³ãããžã§ã³ãºã»ãããã³ã¹å€§åŠ ãžã§ã³ãºã»ãããã³ã¹å¥åº·å®å
šä¿éã»ã³ã¿ãŒã®äž»å¬ã§è¡ãããã
ã¯ã¬ãŒãXã¯ããã®ç®çããç±³åœãšäžçã«ããã...ãã³ãããã¯ãé²ãããã®ãã€ã¬ãã«ãªæŠç¥ç決å®ã説æããããšãïŒåŒ·èª¿ïŒãšäž»å¬è
ã説æãã1æ¥ã®ãã³ãããã¯ã»ããŒãã«ãããæŒç¿ã§ããåœå®¶å®å
šä¿éãç«ç
察å¿ã®åéã§èåãªåäººãæŒãããŠãã13ã
ãã«ã»ã²ã€ãã¯äºèŠããŠãã
10
ãçç©åŠçè åšã®å Žåããã®ãããªåè¿«æãæ¬ ããŠãã...ãäžçã¯æŠäºã«åããã®ãšåãããã«ããã³ãããã¯ã«çå£ã«åããå¿ èŠããããã (ãã«ã»ã²ã€ããBusiness Insiderã2018幎4æ17æ¥ããåŒçš)
2019幎10æã® ãã€ãã³ã201ã
ã¯ã¬ãŒãXã«ç¶ããŠãã€ãã³ã201ãšé¡ãããå¥ã®åäžã·ãã¥ã¬ãŒã·ã§ã³ãè¡ãããïŒãããäž»å¬ã¯ Johns Hopkins Center for Health Securityã®äž»å¬ïŒ14ã
ã€ãã³ã201ã¯ãnCoV-2019ãšé¡ãããã³ãããŠã€ã«ã¹ã®æµè¡ã«é¢ãããã®ã§ãã£ããããã¯ã2020幎1æåæ¬ã«äžåœåœå±ã2019-nCoVïŒãã®åŸSARS-CoV-2ãšæ¹ç§°ïŒãšé¡ããæ°åã³ãããŠã€ã«ã¹ãçºè¡šãã3ã«æãåã®2019幎10æ18æ¥ã«éå¬ãããã
ãnCoV ããšåœç€Ÿã®ãã³ãããã¯æŒç¿ã«é¢ããã¹ããŒãã¡ã³ã
2020幎1æ24æ¥ - 2019幎10æããžã§ã³ãºã»ãããã³ã¹å¥åº·ã»ãã¥ãªãã£ã»ã³ã¿ãŒã¯ãããŒãããŒã§ããäžççµæžãã©ãŒã©ã ãšãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãšãšãã«ãã€ãã³ã201ãšãããã³ãããã¯åäžæŒç¿ãéå¬ãããæè¿ãå¥åº·å®å šä¿éã»ã³ã¿ãŒã«ã¯ããã®ãã³ãããã¯æŒç¿ãçŸåšäžåœã§çºçããŠããæ°åã³ãããŠã€ã«ã¹ã®çºçãäºæž¬ãããã©ããã«ã€ããŠã®è³ªåãå¯ããããŠããŸãã
ã¯ã£ãããããŠãããŸãããå¥åº·å®å šä¿éã»ã³ã¿ãŒãšããŒãããŒã¯ãåäžæŒç¿ã§äºæž¬ãããããã§ã¯ãããŸãããã·ããªãªã§ã¯ãæ¶ç©ºã®ã³ãããŠã€ã«ã¹ãã³ãããã¯ãã¢ãã«åããŸããããããã¯äºæž¬ã§ã¯ãªãããšãæç¢ºã«è¿°ã¹ãŸããããã®ä»£ããããã®æŒç¿ã§ã¯ãéåžžã«æ·±å»ãªãã³ãããã¯ã®éã«çºçããå¯èœæ§ã®é«ããæºåãšå¯Ÿå¿ã®èª²é¡ã匷調ãã圹å²ãæãããŸãããç§ãã¡ã¯ãnCoV-2019ã®å€§æµè¡ã§6,500äžäººãæ»äº¡ãããšäºæž¬ããŠããããã§ã¯ãããŸããã
æã ã®åäžæŒç¿ã«ã¯æš¡æ¬æ°åã³ãããŠã€ã«ã¹ãå«ãŸããŠãããããã®æ¶ç©ºã®ãŠã€ã«ã¹ã®æœåšç圱é¿ã®ã¢ããªã³ã°ã«çšããå ¥åã¯ãnCoV-2019ãšã¯äŒŒãŠããªã"(匷調)ã(匷調)15
2019幎10æ18æ¥ã®ã€ãã³ã201ãã³ãããã¯æŒç¿ã§ã¯ããœãŒã·ã£ã«ã¡ãã£ã¢ããããããèª€å ±ãã«ã©ã察åŠããããåãäžããããã
201ãã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ãã®å€ãã®ç¹åŸŽã¯ã2020幎1æ30æ¥ã«WHOäºåå±é·ãäžççãªå
¬è¡è¡çäžã®ç·æ¥äºæ
ãéå§ããéã«å®éã«èµ·ãã£ãããšã«å¯Ÿå¿ããŠããã®ã§ãã
ã€ãã³ã201ã®ã·ããªãªã§ã¯ãéèåžå Žã15ïŒ
厩å£ããããšããã·ãã¥ã¬ãŒã·ã§ã³ããããŠããããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãäžççµæžãã©ãŒã©ã ãå«ãã€ãã³ãã®äž»å¬è
ãšã¹ãã³ãµãŒã«ããã°ãããã¯ãäºæž¬ãããããã®ã§ã¯ãªã16ã
ã€ãã³ã201ã®ã¹ãã³ãµãŒïŒWEFãšã²ã€ã財å£ãå«ãïŒã¯ãRT-PCRãã¹ããããã¯ããŠã³æé ãããã³mRNAã¯ã¯ãã³ãå«ãCOVID-19é¢é£æ¿çã®èª¿æŽïŒããã³è³éïŒã«åœåããç©æ¥µçã«é¢äžããŠããããšã¯æ³šç®ã«å€ããããã®èšŒæ ã«ããããã®æ¿çã¯ãã£ãšæ©ãææããèšç»ãããæ³å®ãããŠããã
ã·ããªãª201ã®åå è
ãžã§ã³ãºã»ãããã³ã¹ã®åäžã·ããªãªã®201人ã®ããã¬ãŒã€ãŒãã®äžã«ã¯ãå€ãã®äžæ žçãªçµç¹ã§é¡§åãäžçŽè·ã«å°±ããŠããéèŠãªäººç©ãå«ãŸããŠããã3ãµæãçµããªããã¡ã«ããã®201人ã®ããã¬ãŒã€ãŒããã¡ã¯ãCOVID-19ã®ãã³ãããã¯ã«å¯Ÿããæ¿ç察å¿ã«ç©æ¥µçã«é¢ããããã«ãªã£ãã
11
ãã°ããŒãã«ããžãã¹ãæ¿åºãå ¬è¡è¡çãã以äžã®èå人ããã€ãã³ã201ãã³ãããã¯åäžæŒç¿ã§ãæ¶ç©ºã®çºçã·ããªãªã«å¯Ÿããæ¿ç察å¿ãäž»å°ãã圹å²ãæ ãæŒç¿ãã¬ãŒã€ãŒãšãªã£ãã17

ãã®ããã¬ã€ã€ãŒããçŽæ¥çã»éæ¥çã«ã代衚ãããå£äœã¯ãWHOããžã§ã³ãºã»ãããã³ã¹ãã¯ã¯ãã³ãšäºé²æ¥çš®ã«é¢ããäžçé£åïŒGAVIãDr. Timothy Grant EvansïŒãç±³åœæ
å ±æ©é¢ããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ïŒDr. Chris EliasïŒãCEPIïŒCoalition for Epidemic Preparedness Innovations, Chairman Jane HaltonïŒãäžççµæžãã©ãŒã©ã ïŒWEFïŒãåœé£è²¡å£ãç±³åœçŸç
察çäºé²ã»ã³ã¿ãŒïŒCDC, Stephen ReddïŒãäžåœçŸç
察çäºé²ã»ã³ã¿ãŒïŒCDCããã£ã¬ã¯ã¿ãŒ Dr. George Fu GaoïŒãããã°ãã¡ãŒãïŒAdrian ThomasïŒãäžçéè¡ãšã°ããŒãã«ãã³ãã³ã°ãèªç©ºæ¥çãšããã«æ¥çãåå ããŠããŸãã詳ããã¯ãã¡ããã芧ãã ããã
äžåœã®CDCé·å®ãžã§ãŒãžã»ããŒã»ã¬ãªå士ã¯ã2020幎åé ã«æŠæŒ¢ã§çºçããCOVID-19ã®ç£ç£ã«ãããŠããã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£ããžã§ã³ãºã»ãããã³ã¹ããã®ä»ãšç·å¯ã«é£çµ¡ãåããªããäžå¿ç圹å²ãæãããããšã¯ç¹çã«å€ããããŸãããŠã§ã«ã«ã ã»ãã©ã¹ãã®ãã§ããŒãæ°å¹ŽéåããŠããã
ã¹ãã£ãŒãã³ã»ã¬ãå士ïŒCDCïŒã¯ãç±³åœã«ããã2009幎ã®H1N1ã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã§éèŠãªåœ¹å²ãæãããããããã¯åœç©ã§ããããšã倿ããïŒIXç« åç
§ïŒã
nCoV-2019
WHOãåœåããžã§ã³ãºã»ãããã³ã¹ã®ãã³ãããã¯ã€ãã³ã201æŒç¿ïŒnCoV-2019ïŒãšåæ§ã®é åèªïŒã³ãããŠã€ã«ã¹ãæå®ããïŒãæ¡çšããããšã泚ç®ã«å€ããŸããã...æ°åãŠã€ã«ã¹ã¯åœåã[WHO]ã«ãã£ãŠ2019-nCoVãšåä»ãããã ã18ã
ã2020幎2æ11æ¥ãWHOã¯ã³ãããŠã€ã«ã¹ç 2019ïŒCOVID-19ïŒãšæ¹åããã忥ãåœéãŠã€ã«ã¹å§å¡äŒã®ã³ãããŠã€ã«ã¹ç ç©¶ã°ã«ãŒãïŒCSGïŒã¯
bioRxivã«åçš¿ãæçš¿ãããã®äžã§2019-nCoVãé¢é£ã³ãããŠã€ã«ã¹ã®ç³»çµ±è§£æã«åºã¥ããŠéçæ¥æ§åŒåžåšçå矀ã³ãããŠã€ã«ã¹2ïŒSARS-CoV-2ïŒã«æå®ããããšãææ¡ããŸãããããšãããŸãã(ã©ã³ã»ãã)19
12
SARS-CoV-2ãšããåç§°ã®éžå®ã«ã€ããŠã¯ãããããããã¹ãã³ã»ã¬ããŒããšã®é¢é£ã§ç¬¬IIIç« ã§èª¬æããã
ã€ã³ããªãžã§ã³ã¹ãš ãæ¬ºçã®èžè¡ã
COVID屿©ã¯ããã¯ãŒãšãªãŒãã®å·§åŠãªéå ·ã§ãããããã¯ããæ¬ºçãšå¯Ÿææ¬ºçããé§äœ¿ããŠåšå°ã«èšç»ãããè«å ±æŽ»åã®ç¹åŸŽããã¹ãŠåããŠãããã¬ãªã»ã¹ãã©ãŠã¹ã¯ãã€ã³ããªãžã§ã³ã¹ããæ¿çç«æ¡è ãæ¿çç®æšãéæããæ£åœåããããã®ææ®µã§ãã£ãŠãäžçã®çŸå®ãèšè¿°ããããã®ææ®µã§ã¯ãªãããšèããŠããããããŠãããããããCOVID-19ã«é¢é£ããŠåœŒããè¡ã£ãŠããããšãªã®ã§ããã20
ãã°ããŒãã«ãªå£å®ã
èåãªç§åŠè
ãã¡ããäžçä¿å¥æ©é¢ïŒWHOïŒãç±³åœçŸç
察çã»ã³ã¿ãŒïŒCDCïŒãªã©ã®å
¬çãªå
¬è¡è¡çæ©é¢ã«ãã£ãŠç¢ºèªãããŠããããã«ãCOVID-19ã¯å
¬è¡è¡çäžã®æžå¿µäºé
ã§ã¯ããããå±éºãªãŠã€ã«ã¹ãšããããã§ããªãã
COVID-19ã®å±æ©ã¯ãWHOã®æ¯æŽã®äžã§ã®å
¬è¡è¡çäžã®ãç·æ¥äºæ
ãã§ãããçµæžã瀟äŒãæ¿æ²»ã®åæ§ç¯ã®äžççããã»ã¹ãåŒãèµ·ããããã®å£å®ãæ£åœåãšããŠå©çšãããŠããããšãç¹åŸŽã§ããããã®åŸåã¯ãå
šäœäž»çŸ©çãªåœå®¶ãæŒãä»ããããšã«ããã
瀟äŒå·¥åŠãé©çšãããŠãããæ¿åºã¯ãçµæžçã»ç€ŸäŒçã«å£æ»
çãªåœ±é¿ãåãŒãã«ãããããããããã¯ããŠã³ãå»¶é·ããããå§åããããŠããã
å
¬è¡è¡çã®å±æ©ã解決ããææ®µãšããŠãäžççµæžã®ééã宿œããç§åŠçæ ¹æ ã¯ãªããã¡ãã£ã¢ãšæ¿åºã®äž¡æ¹ãåœæ
å ±ã®æ¡æ£ã«é¢äžããŠããã
ææãã£ã³ããŒã³ã«ã¯ç§åŠçæ ¹æ ããªããããªãæ¹æ¿åºã¯åãã€ããŠãããå®éã圌ãã¯èªåèªèº«ã«åãã€ããŠããã®ã ã
13
å·»æ«è³æ
1. ããµã«ã»ãµã¯ã¬å士ã2020幎8æ7æ¥ãCOVID-19: ããçå®ã«è¿ã¥ãïŒãã¹ããšå
ç«ã
https://www.globalresearch.ca/ covid-19-closer-to-the-truth-tests-and-immunity/5720160
2. ãžã§ã³ã»Cã»Aã»ãã³ãªãŒã2020幎10æ6æ¥ããã¹ã¯ççšã«ãããçŽ°èæ§èºçãå¢å ããŠããããšèŠåããå»åŠå士 https://www.globalresearch.ca/medical-doctor-warns-bacterial-pneumonias-rise-mask-wearing/5725848.
3. ãªãã£ãŒãã»ã·ã£ãã¹å士ã2021 幎 1 æ 19 æ¥ãç§ãã¡ã¯ææèŽæ»ç0.2%æªæºã§ããã¯ããŠã³ãããŠããïŒDr. Richard Schabasãããªã³ã¿ãªãªå·éŠçžDoug Fordãž
https://www.globalresearch.ca/were-being-locked-down-infection-fatality- rate-less-than-0-2/5734799
4. ã«ãŒã·ãŒã»ãŠã£ãªã¢ã ãœã³ã2020 幎 4 æ 22 æ¥ãã³ãããŠã€ã«ã¹ãCovid-19ã®çºçãããã£ãŠã«ã©ã·ãã³ãã§è
ãããæäŒ
https:// www.bbc.com/news/av/world-europe-52389953
5. WHOã2020 幎 9 æ 9 æ¥ãCOVID-19ã远跡ãããããžã¿ã«æä»£ã®ã³ã³ã¿ã¯ããã¬ãŒã¹
https://www.who.int/news-room/feature- stories/detail/tracking-covid-19-contact-tracing-in-the-digital-age
6. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020幎10æ6æ¥ãã¯ã¯ãã³æ¥çš®è
vs. éæ¥çš®è
ã
https://www.globalresearch.ca/collective-narcissism-and- the-dark-triad-those-who-protest-against-the-official-covid-19-narrative-are-categorized-as-psychopaths-is-it-a-witch-h hunt/5722151
7. ãžã£ã³ãã»ã¹ãããã2020幎12æ11æ¥ãCOVIDã®å
¬åŒã·ããªãªã«çåãåãã粟ç¥ç
é¢ã«æŸã蟌ãŸãã補è¬äŒç€Ÿã®çç·Žææãhttps://www.lifesitenews.com/news/accomplished-pharma-prof-thrown-in-psych-hospital-after-questioning-official- covid-narrative/ã
8. Youtube Help, n.d. COVID-19 medical misinformation policy. https://support.google.com/youtube/answer/9891785?hl=en.
9. ãŠã£ã«ã»ã±ã¹ã©ãŒã2011幎8æ15æ¥ãæ°äžçç§©åºã«æ³šæãããhttps://www.aspentimes.com/news/beware-new-world-order/
10. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020幎5æ1æ¥ãã°ããŒãã«è³æ¬äž»çŸ©ããäžçæ¿åºãããããŠã³ãã屿©
https:// www.globalresearch.ca/global-capitalism-world-government-and-the-corona-crisis/5712312.
11. ããã¯ãã§ã©ãŒè²¡å£ãšã°ããŒãã«ã»ããžãã¹ã»ãããã¯ãŒã¯ã2010 幎 5 æããã¯ãããžãŒãšåœééçºã®æªæ¥ãžã®ã·ããªãªã https://www.nommeraadio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf
12. ãã¬ã³ã»ãã€ãã¹ããŒã2020幎2æ5æ¥ãVIDEO: ããã¯ã»ã¹ããããã·ãã¥ã¬ãŒã·ã§ã³ã»ã·ããªãªïŒãèŠå¯åœå®¶çµ±å¶ã®ããªã¬ãŒãšãªãã³ãããŠã€ã«ã¹æ§ã®ãã³ãããã¯ã
https://www.globalresearch.ca/all-sectors-us-establishment-lock-step-deep- states-latest-bio-war/5702773.
13. Johns Hopkins Center for Health Security, n.d. CLADE X EXERCISE. https://www.centerforhealthsecurity.org/our-work/events/2018_clade_x_exercise/
14. Johns Hopkins Center for Health Security, n.d. Event 201. https://www.centerforhealthsecurity.org/event201/
15. Johns Hopkins Center for Health Security, January 24, 2020. nCov ãšæã
ã®ãã³ãããã¯æŒç¿ã«é¢ãã声æ
https://.www.centerforhealthsecurity.org/news/center-news/2020/2020-01-24-Statement-of-Clarification-Event201.html
16. Michel Chossudovsky ææã2020 幎 3 æ 1 æ¥ãCOVID-19ã³ãããŠã€ã«ã¹ãåœã®ãã³ãããã¯ïŒèª°ããã®èåŸã«ããã®ãïŒGlobal Economic, Social and Geopolitical Destabilization.
https://www.globalresearch.ca/covid-19-coronavirus-a-fake-pandemic- whos-behind-it-global-economic-and-geopolitical-destabilization/5705063
17. Johns Hopkins Center for Health Security, n.d. Event 201 Players. https://www.centerforhealthsecurity.org/event201/ players/
18. Shibo Jiang, Zhengli Shi, et al., February 19, 2020. æ°ããã³ãããŠã€ã«ã¹ã«ã¯æç¢ºãªåç§°ãå¿
èŠã§ãããhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30419-0/fulltext
19. Ibid.
20. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020幎11æ12æ¥ãã³ããããã³ãããã¯ãã人ã
ã®ç掻ãç Žå£ãããä»çµãŸããçµæžææ
ãäžççãªãã¯ãŒãã¿ãŒãïŒ
https://www.globalresearch.ca/the-second-wave-destroying-peoples-lives-global-coup-detat/5728207
14
--------------------第2ç« --------------------
ã³ããã®å¹Žè¡š
æ¬ç« ã§ã¯ã2019 幎 8 æããå§ãŸãã³ãã屿©ã®è©³çްãªå¹Žè¡šãšæŽå²ã玹ä»ããŸãã
2019幎8æ1æ¥ïŒã°ã©ã¯ãœã»ã¹ãã¹ã¯ã©ã€ã³ïŒGSKïŒãšãã¡ã€ã¶ãŒããã¯ã¯ãã³ãå«ãã³ã³ã·ã¥ãŒããŒãã«ã¹è£œåã«ãããäŒæ¥ææºã®æç«ãçºè¡šã
2019幎9æ19æ¥ïŒID2020ã¢ã©ã€ã¢ã³ã¹ã®äŒå
ID2020ã¢ã©ã€ã¢ã³ã¹ã¯ããRising to the Good ID Challengeããšé¡ãããµãããããã¥ãŒãšãŒã¯ã§éå¬ããŸãããGAVIïŒAlliance for Vaccine IdentityïŒã®æ¯æŽã®ããšãããžã¿ã«ãã¹ããŒããçµã¿èŸŒãã ã¯ã¯ãã³ã®ç¢ºç«ã«çŠç¹ãåœãŠãããŸããããã®ç®çã¯ãã°ããŒãã«ãªããžã¿ã«ããŒã¿ããŒã¹ãæ§ç¯ããããšã§ãããšè¿°ã¹ãããŠããŸãã1
ID2020ã®ãšã°ãŒã¯ãã£ããã£ã¬ã¯ã¿ãŒã§ããDakota Gruenerã¯ããããžã¿ã«IDã®å®çŸ©ãšå®è£
ã¯çŸåšé²è¡äžã§ãããIDã®ã£ãããè§£æ¶ããããã®è¿
éãªè¡åãéèŠã§ããããšãèªèããŠããŸãããšè¿°ã¹ãŠããŸãã
äºé²æ¥çš®ãããžã¿ã«IDã®ãã©ãããã©ãŒã ãšããŠæ©èœããæ©äŒãåŸãŠããã®ããã°ã©ã ã§ã¯ãæ¢åã®åºçç»é²ãšäºé²æ¥ç𮿥åãæŽ»çšããæ°çå ã«æºåž¯å¯èœã§æ°žç¶çãªãã€ãªã¡ããªãã¯ã«ãªã³ã¯ããããžã¿ã«IDãæäŸããŸãããšè¿°ã¹ãŠããŸãããŸãããã®ããã°ã©ã ã§ã¯ãåºçæããæ°žç¶çãªããžã¿ã«IDãæäŸããããã«ãããã€ãã®äž»èŠãªä¹³å çäœèªèšŒæè¡ã調æ»ã»è©äŸ¡ããäºå®ã§ãã
ãç§ãã¡ã¯ãæ¢åã®ã·ã¹ãã ãããã°ã©ã ãæŽ»çšããªããããå人ãèªèº«ã®å人æ å ±ãã³ã³ãããŒã«ã§ããããã«ãããããžã¿ã«ã¢ã€ãã³ãã£ãã£ãžã®ååããªã¢ãããŒãã宿œããŠããŸã ã2
2019幎10æ18æ¥ïŒã€ãã³ã201. 201幎ãã³ãããã¯ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã®æ§å
ã³ãããŠã€ã«ã¹ã¯åœåãWHOã«ãã£ãŠ2019-nCoVãšåœåãããŸããããããã¯ãžã§ã³ãºã»ãããã³ã¹å€§åŠãã«ãŒã ããŒã°ä¿å¥å€§åŠé¢ãããŒã¹ã»ãã¥ãªãã£ã»ã³ã¿ãŒäž»å¬ã®2019幎10æ18æ¥ã®201ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ïŒã²ã€ã財å£ãšäžççµæžãã©ãŒã©ã äž»å¬ã®ã€ãã³ãïŒã§æ¡çšãããåç§°ãšåãïŒæ¥ä»ã®é 眮ãé€ãïŒãã®ã§ããã€ãã³ã201
ã2019幎10æããžã§ã³ãºã»ãããã³ã¹å¥åº·å®å šä¿éã»ã³ã¿ãŒã¯ãããŒãããŒã§ããäžççµæžãã©ãŒã©ã ãšãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãšãšãã«ãã€ãã³ã201ãšãããã³ãããã¯åäžæŒç¿ãéå¬ããã... ã·ããªãªã¯ãæ¶ç©ºã®ã³ãããŠã€ã«ã¹ã®ãã³ãããã¯ãã¢ãã«åããŸããããäºæž¬ã§ã¯ãªãããšãæç€ºããŸãããã(匷調ã第äžç« åç §)3
2019幎12æ12æ¥ïŒæŠæŒ¢åžè¡çå§å¡äŒ
å§åããã®æ¥ãåå äžæã®ãŠã€ã«ã¹æ§èºçã®æ£è
59äººã®æãæ©ãæ¬æ¥ã®çºçæ¥ã§ãããšäž»åŒµãããšãã(æç³»åã»åæå¹Žè¡š)4
2019幎12æ31æ¥ïŒæ¹åçæŠæŒ¢åžã§åå äžæã®èºçã®æ£è
ãåããŠæ€åºãããWHOã«å ±åãããããåèš44äººã®æ£è
ãå ±åãããŸããã11人ãéçãæ®ã33人ã¯å®å®ããç¶æ
 ã5
15
2020幎1æ1æ¥ãäžåœã®ä¿å¥åœå±ã¯ãæŠæŒ¢ã®è¯åæµ·é®®åžå£²åžå Žã§è²©å£²ãããŠããéçåç©ããŠã€ã«ã¹ã®çºçæºã§ããå¯èœæ§ããããšããæ¬§ç±³ã¡ãã£ã¢ã®å ±éãåããååžå ŽãééããŸããããã®æåã®è©äŸ¡ã¯ããã®åŸãäžåœã®ç§åŠè
ã«ãã£ãŠåè«ãããŸããã
2020幎1æ7æ¥ãäžåœåœå±ã¯ïŒå ±éã«ããã°ïŒ2020幎1æ7æ¥ã«ãæ°åã®ãŠã€ã«ã¹ãç¹å®ãããåé¢ãããããŠã€ã«ã¹ã®åé¢éçšã«é¢ããå
·äœçãªå
å®¹ã¯æããã«ãããŠããªããç§åŠçãªå ±åã«ãããšããŠã€ã«ã¹ã®èº«å
確èªãšåé¢ã®ããã»ã¹ã¯è¡ãããŠããªãã£ãïŒè©³çްã¯ç¬¬IIIç« ãåç
§ïŒãçäŸæ°ã¯æ¥µããŠå°ãªããããŠã€ã«ã¹ç¹ç°çæ žé
žã15人ããããæ€åºãããªãã£ãã®ã«ã44人ã®èºçæ£è
ãçºçããããäžåœã§æµè¡ãå±éãããŠããããšã瀺ã蚌æ ã¯ãªãã6
2020幎1æ11æ¥ãæŠæŒ¢åžè¡çå§å¡äŒãã³ãããŠã€ã«ã¹ã«ããåã®æ»è
ãçºè¡šã
2020幎1æ22æ¥ WHO - WHOç·æ¥å§å¡äŒã®ã¡ã³ããŒã¯ãããã®äºè±¡ãPHEICïŒåœéçã«æžå¿µãããå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒãæ§æãããåŠãã«ã€ããŠãç°ãªãèŠè§£ã衚æããããå§å¡äŒã®äŒåã¯ãããã¹ã§éå¬ãããäžççµæžãã©ãŒã©ã ã®äŒè°ïŒ2020幎1æ21æ¥ïœ24æ¥ïŒãšéãªãã1æ23æ¥ã«åéããããäžåœã§ã®çäŸæ°ãå°ãªããããPHEIC ãæ£åœåããããšã¯ã§ããªãã£ãã7
åœéä¿å¥èŠåïŒIHRïŒã«åºã¥ãWHOäºåå±é·ãæéããç·æ¥å§å¡äŒã®äŒåïŒ2005幎ïŒã§ã¯ããã®äºè±¡ãPHEICã«è©²åœãããåŠãã«ã€ããŠãããŸããŸãªèŠè§£ã瀺ãããããã®æç¹ã§ã¯ãä»åã®äºè±¡ã¯PHEICã«è©²åœããªããšã®å©èšã§ãã£ãããå§å¡äŒã®ã¡ã³ããŒã¯äºæ ã®ç·æ¥æ§ã«åæããæ°æ¥äžã«å§å¡äŒãåéããŠäºæ ãããã«æ€èšããããææ¡ããã(WHOãæ°åã³ãããŠã€ã«ã¹(2019-nCoV)ã®çºçã«é¢ããåœéä¿å¥èŠå(2005)ç·æ¥å§å¡äŒã®äŒåã«é¢ããã¹ããŒãã¡ã³ã)8
2020幎1æ21æ¥ïœ24æ¥ äžççµæžãã©ãŒã©ã ïŒã¹ã€ã¹ã»ããã¹ïŒã«ãããåè°
ãã®åè°ã¯ãã¯ã¯ãã³ããã°ã©ã éçºã®ããã®Coalition for Epidemic Preparedness Innovations ïŒç«ç
察çã€ãããŒã·ã§ã³é£åïŒ(CEPI)ã®äž»å¬ã§éå¬ãããŸãããCEPIã¯ãWEF-Gatesã®ããŒãããŒã·ããã§ããCEPIããã®æ¯æŽã«ãããã·ã¢ãã«ã«æ ç¹ã眮ãModernaã¯ã2019-nCoVã«å¯ŸããmRNAã¯ã¯ãã³ã補é ããäºå®ã§ãã
ãNIHã®äžéšã§ããåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æïŒNIAIDïŒã®ã¯ã¯ãã³ç ç©¶ã»ã³ã¿ãŒïŒVRCïŒã¯ãModernaãšå ±åã§ã¯ã¯ãã³ã®èšèšãè¡ã£ãã9ã
ãã®èšŒæ ã«ã2019幎ã®nCoVã¯ã¯ãã³ãããžã§ã¯ãã¯ãã§ã«é²è¡ããŠããïŒç¬¬VIIIç« åç
§ïŒãäžåœåœå±ã«ãã2020幎1æ7æ¥ã®çºè¡šãã2é±éåŸã«ããã¹äŒè°ã§æ£åŒã«çºè¡šããã2020幎1æ30æ¥ã«WHOã®äžçå
¬è¡è¡çç·æ¥äºæ
ãæ£åŒã«éå§ããã1é±éåã«ãã£ãšçºè¡šãããã®ã§ããã
WEF-Gates-CEPIã®ã¯ã¯ãã³çºè¡šã¯ãWHOã®ãåœéçã«æžå¿µãããå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒPHEICïŒãã«å
è¡ããŠè¡ãããŸããWEFã®ãããªãã芧ãã ããã
WHOã®PHEICã®ç«ã¡äžãã«ã¯ãæ¯é
çãªéèå©çå£äœãåäžé·è
ã®è²¡å£ãåœééèæ©é¢ãéèŠãªåœ¹å²ãæãããŸããã
ãã®æŽå²çãªWHOã®æ±ºå®ã«å
ç«ã€1é±éãããã¹ã§éå¬ãããäžççµæžãã©ãŒã©ã ïŒWEFïŒã§ãPHEICã¯ãåè°ãã®å¯Ÿè±¡ãšãªã£ãïŒ1æ21æ¥ã24æ¥ïŒãããã¹äŒè°ã«ã¯ãWHOã®ãããã¹äºåå±é·ãåºåžããŠããããã®åè°ã¯ã1æ30æ¥ã®WHOã®æŽå²çãªæ±ºå®ã«åœ±é¿ãäžããã®ã ãããã
16
WHOã®å®çŸ©ããå©ççžåã¯ãã£ãã®ã ãããïŒWHOã®æå€§ã®å¯ä»è
ã¯ãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ã§ãWEFãCEPIãšãšãã«ã1æ30æ¥ã®æŽå²çãªPHEICã®ç«ã¡äžãã«å
ç«ã£ãŠãããã¹äŒè°ã§ãã§ã«COVID-19ã¯ã¯ãã³ã®éçºãçºè¡šããŠããã10
WHOäºåå±é·ã¯ããã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£ã倧æè£œè¬äŒç€Ÿãäžççµæžãã©ãŒã©ã ïŒWEFïŒã®æ¯æãåããŠããã®ã§ãããWHOãäžçä¿å¥äžã®ç·æ¥äºæ
ã宣èšããæ±ºå®ã¯ã1æ22æ¥ã«ãžã¥ããŒãã§éå¬ãããç·æ¥å§å¡äŒã®äŒè°ãšéãªããããã¹ã§éå¬ãããWEFã®åãã§è¡ãããïŒ1æ21æ¥ãã24æ¥ïŒããšã瀺åãããŠããã
2020幎1æ28æ¥ ç±³åœçŸç
察çã»ã³ã¿ãŒïŒCDCïŒã¯ãæ°åã³ãããŠã€ã«ã¹ãåé¢ãããããšãïŒç¢ºåºãã蚌æ ãªãã«ïŒç¢ºèªããïŒç¬¬IIIç« åç
§ïŒ11ã
2020幎1æ30æ¥ãWHOã®ãåœéçã«æžå¿µãããå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒPHEICïŒãã
ãã®å±æ©ã®ç¬¬äžæ®µéã¯ã1æ30æ¥ã«WHOã«ãã£ãŠéå§ããããå
¬åŒã«ã¯ããã³ãããã¯ãã«ã¯æå®ãããªãã£ãããããã§ãææãã£ã³ããŒã³ã®å
é£ãåãããšã«è²¢ç®ããã
åœåãããéœæ§ç¢ºèªäŸãã®æšå®ã¯ããæ°åã²ãŒã ãã®äžéšã§ãã£ãã
ããå Žåã«ã¯ãçµ±èšã¯åã«èšåãããããŸãããå Žåã«ã¯ããããã¯ãåŒãèµ·ãããšããç®çã§ãæ°åãéžæçã«èªåŒµãããã®ã§ããã
ã¡ãã£ã¢ã¯èšåããŠããªããããã®é å€§ãªæ±ºå®ãæ£åœåããããã«äœ¿ããã誀ã£ãæšå®ïŒRT-PCRïŒã«åºã¥ãã確å®çäŸãã®æ°ã¯ãã°ãã°ãããã»ã©å°ãªãã£ãã
äžåœä»¥å€ã®äžçã®äººå£ã¯64å人çšåºŠã§ããã2020幎1æ30æ¥ã®æç¹ã§ãäžåœä»¥å€ã®åœã«ã¯
ã18ã«åœã§83äººã®æ£è ãããããã®ãã¡äžåœãžã®æž¡èªæŽããªãã®ã¯7人ã ãã§ãããã (WHOã2020 幎 1 æ 30 æ¥ãåç §)12ã
PHEICçºå忥ã®2020幎1æ29æ¥ïŒWHOèšé²ïŒã«ã¯ãç±³åœã§5äŸãã«ããã§3äŸããã©ã³ã¹ã§4äŸããã€ãã§4äŸã§ãã£ã13ã
äžççãªå
¬è¡è¡çäžã®ç·æ¥äºæ
ã®ç«ã¡äžããæ£åœåãããç§åŠçæ ¹æ ãã¯ãªãã£ãã

17
ãã®äœãæ°åïŒã¡ãã£ã¢ã¯èšåããïŒã¯ãäžççãªææã®ãã£ã³ããŒã³ã®éå§ã劚ããªãã£ãã
2020幎1æ31æ¥ã®ããšããã©ã³ã倧統é ã«ããäžåœãšã®èªç©ºäŸ¿ã®å©çšåæ¢æ±ºå®
ç¿æ¥ïŒ2020幎1æ31æ¥ïŒããã©ã³ã倧統é ã¯ãéå»14æ¥éã«äžåœãæ è¡ãããäžåœäººããã³å€åœäººã®ç±³åœãžã®å ¥åœãæåŠãããšçºè¡šãããããã¯çŽã¡ã«ãèªç©ºæ è¡ãäº€éæ©é¢ãç±³äžè²¿æé¢ä¿ã ãã§ãªãã貚ç©ã»æµ·éååŒã«ã屿©çç¶æ³ãåŒãèµ·ãããã
WHOããïŒæž¡èªã貿æã®å¶éãïŒæšå¥šããªãã£ããã®ã«å¯Ÿããç±³åœã§ç¢ºèªããã5人ã®ãããããææè ãã¯ã2020幎1æ31æ¥ã«ãã©ã³ã倧統é ãäžåœãšã®èªç©ºæ è¡ã忢ããæ±ºå®ããæ£åœåãããã®ã«ååã§ãããåæã«è¥¿æ¬§è«žåœå šäœã§äžåœäººæ°æã«å¯Ÿãããã€ããã£ã³ããŒã³ãä¿ããã
ãã®æŽå²çãª1æ31æ¥ã®æ±ºå®ã¯ãåœéåå貿æã®æ··ä¹±ãšãäžççãªèªç©ºæž¡èªå¶éã®çºåãžã®éãéããããããŠã倧æèªç©ºäŒç€Ÿã®ç Žç¶»ã®å éãã€ããããšã«ãªã£ãã
ããã§ã€ã¯ã»ã¡ãã£ã¢ãã¯çŽã¡ã«å€§æãæ¯ã£ãŠåãåºãããäžåœãäžçäžã«ãæææ¡å€§ãã®è²¬ä»»ãè² ããããã
2020幎2æäžæ¬ãã³ãããŠã€ã«ã¹ã®ç¥ç§°ããnCoV-2019ïŒ10æã®ã€ãã³ã201ãžã§ã³ãºã»ãããã³ã¹ã»ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã§ã®åç§°ïŒãããSARS-CoV-2ã«å€æŽããããCOVID-19ã¯ãSARS-CoV-2ã«ãã£ãŠåŒãèµ·ããããç æ°ã瀺ãã
2020幎2æ20æ¥ãã21æ¥ã«ãããŠãäžåœä»¥å€ã®äžççãªCOVIDããŒã¿ãã¯ã«ãŒãºè¹ããã€ã€ã¢ã³ãã»ããªã³ã»ã¹ã
äžåœã¯COVID-19ã®ææè æ°ã75,567人ãšå ±åãããïŒ2æ20æ¥ïŒãäžåœä»¥å€ã®ç¢ºå®çäŸã¯ç°åžžã«å°ãªããããŠã€ã«ã¹ã®äžççæ¡å€§ãã確èªããããã«çšããRT-PCRæ€æ»ã«åºã¥ãçµ±èšã¯ãã¯ã£ããèšã£ãŠçããããã®ã§ãã£ããããããäžåœåœå ã®75,567äŸã®ãã¡ãããªãã®å²åãå埩ããŠããã®ã§ããããããŠãååŸ©ã®æ°å€ã¯ã¡ãã£ã¢ãèªããªãã£ãã
ãããã¹åå£«ã®æŽå²çãªèšè äŒèŠã®æ¥ïŒ2020幎2æ20æ¥ïŒãäžåœä»¥å€ã®ç¢ºå®æ£è æ°ã®èšé²ã¯1073人ã§ããã®ãã¡621人ã客è¹ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ïŒæ¥æ¬é æµ·ã«åº§ç€ïŒã®ä¹å®¢ã»ä¹å¡ã§ãã£ãã
çµ±èšåŠçã«èŠãŠãããäžççãªãŠã€ã«ã¹ã®æ¡æ£ãã®å¯èœæ§ãææããWHOã®å€æã¯æå³ããªããªãã£ãã
2æ20æ¥ã®æç¹ã§ãå šäžçã®COVID-19ã確å®çäŸãã®57.9ïŒ ããã€ã€ã¢ã³ãã»ããªã³ã»ã¹ããã®ãã®ã§ãããå šäžçã®ãçµ±èšçåŸåãã代衚ãããã®ãšã¯å°åºæããªãã®ã§ãããå ¬åŒçºè¡šã¯æ¬¡ã®ãããªãã®ã§ããã
- 1æ25æ¥ã«éŠæž¯ã§ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹ãäžè¹ããéŠæž¯åšäœã®ä¹å®¢ãèºçãçºçãã1æ30æ¥ã«æ°åã³ãããŠã€ã«ã¹ã®æ€æ»ã§éœæ§ãšå€å®ãããã
- 圌ã¯1æ10æ¥ã«äžåœæ¬åã®æ·±ã»ã³ïŒéŠæž¯ã®æ°é åã«æ¥ããïŒã«æž¡èªãããšå ±åãããŠããŸãã
- ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ã¯2æ3æ¥ã«æšªæµã«å°çãã¯ã«ãŒã¶ãŒã«æ€ç«ã課ããããNCBI study.ãåç §ã14
18
è¹å ãžã®éã蟌ãã«ãããå€ãã®ä¹å®¢ãäœèª¿ã厩ããã
ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ã®ä¹å®¢ã»ä¹å¡å šå¡ãPCRæ€æ»ãåããã
2æ23æ¥ãç¢ºå®æ£è æ°ã¯691人ã«å¢å ãã15ã

ããèªãã§ãã ãããäžççãªçµ±èšçåŸåãè©äŸ¡ããç«å Žãããããšããã®ããŒã¿ã¯è ã«èœã¡ãªãããã€ã€ã¢ã³ãã»ããªã³ã»ã¹ã®ããŒã¿ããªããã°ã2020幎2æ20æ¥ã®äžåœä»¥å€ã®äžçã®ãããã確å®çäŸã¯ã人å£64å人ã®ãã¡ã452人ã®ãªãŒããŒã§ããã
äžã®WHOã®ã°ã©ããæ€èšŒããŠã¿ãŸããããéè²ã¯ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ïŒ2020幎2æ3æ¥ã«æšªæµã«å°çããåœé茞éè¹ïŒã§ã®ç¢ºèªçäŸã§ããã®å€ãã2é±é以äžéšå±ã«éãããã£ãç 人ã§ããïŒæ¥æ¬ã課ããæ€ç«ïŒãä¹å®¢ã»ä¹å¡å šå¡ãRT-PCRæ€æ»ïŒSARS-CoV-2ã®æ€åºã»ç¹å®ã¯ã§ããªãïŒãåããã
ãã®ããããããŒã¿ãã2020幎2æã®1ã¶æéã®ææãã£ã³ããŒã³ãšéèåžå Žã®åŽ©å£ã®å éãšãªã£ãããšã¯èšããŸã§ããªãïŒç¬¬IVç« åç §ïŒã

19

2020幎2æ20æ¥ã®ããšã§ãããWHOäºåå±é·ãCOVID-19ã®ãã³ãããã¯ãè¿«ã£ãŠãããšäºå å·®ãè¿«ã
2æ20æ¥æšææ¥ååŸïŒCETïŒããžã¥ããŒãã§ã®èšè äŒèŠã§ãWHOäºåå±é·ã®ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å»åž«ã¯ã次ã®ããã«è¿°ã¹ãã
ãã³ãããŠã€ã«ã¹ã®çºçãé£ãæ¢ããæ©äŒã倱ããã€ã€ããããšãæžå¿µããŠããããšè¿°ã¹ãã
ãç§ã¯æ©äŒã®çªã¯ãŸã ãããšä¿¡ããŠãããããã®çªã¯çãŸã£ãŠããŠããã16ã
äžåœåœå€ã§ã®ææè ã¯1,076åã®ã¿ïŒãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å®¢è¹ãå«ãïŒã

泚ïŒ2020幎2æ20æ¥ã®ããŒã¿ã瀺ãäžèšã®WHOã®ã°ã©ãã§ã¯1,073ä»¶ãšãªã£ãŠããããWHOã®èšè äŒèŠã§ã¯1,076ä»¶ãšè¡šç€ºãããŠããã
20
ãããã®ãè¡æãšçæãã®çºèšã¯ãäžåœåœå€ã§ã®ç¢ºèªçäŸæ°ã極ããŠå°ãªãã«ãããããããææãã£ã³ããŒã³ãé«ããããšã«è²¢ç®ããã
2020幎2æ20æ¥ãã21æ¥ã¯ã2020幎éè屿©ã®å§ãŸãã§ããïŒç¬¬IVç« åç §ïŒã
ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹ãé€ããšãWHOã¯2æ20æ¥ã«ã64å人ã®äººå£ã«å¯ŸããŠãäžåœä»¥å€ã®äžçã§åèš452人ã®ãããããç¢ºå®æ£è ããèšé²ãã-ç±³åœã§15人ãã«ããã§8人ãè±åœã§9人ã§ããïŒäžã®è¡šåç §ïŒããã®æ°åã¯ããããã¹å士ã®ãçªã¯çãŸã£ãŠããããšããèŠåãæ£åœåããããã«äœ¿ããããã®ã§ããã
äžåœä»¥å€ã§ã¯ãéåœïŒWHOã«ãããš153ä»¶ïŒãšã€ã¿ãªã¢ïŒååœåœå±ãèšé²ïŒã§ããå€ãã®çäŸãèšé²ãããŠããã

ãããã¹å士ã®çºèšïŒæ¬ é¥ã®ããæŠå¿µãšçµ±èšã«åºã¥ãïŒã¯ã2æã®éèç Žç¶»ã®èå°ãšãªã£ãïŒç¬¬IVç« åç §ïŒã
2020幎2æ24æ¥ã®ããšãCEPIãæ¯æŽããModerna Inc.ã¯ãmRNA-1273ãšããŠç¥ãããå®éšçãªmRNA COVID-19ã¯ã¯ãã³ããã詊éšã®æºåãæŽã£ããšçºè¡šãã17ã
2020幎2æ28æ¥ãWHOäºåå±é·ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å士ã«ãããWHOã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ãçºè¡šãããŸããïŒ18
ãäžççã«20以äžã®ã¯ã¯ãã³ãéçºäžã§ãããããã€ãã®æ²»çè¬ãèšåºè©Šéšäžã§ãããæ°é±é以å ã«æåã®çµæãåºããã®ãšæãããŸããã
ã¯ã¯ãã³éçºãã£ã³ããŒã³ã¯ãWHOãäžççãªå
¬è¡è¡çäžã®ç·æ¥äºæ
ãéå§ããããšã決å®ããåã«éå§ãããããšã¯ç¹çã«äŸ¡ããŸããCEPIãããã¹ã§éå¬ãããWEFäŒè°ïŒ1æ21æ¥ã24æ¥ïŒã§åããŠçºè¡šãããã
2020幎3æäžæ¬ã®ããšãäžåœãææè
ã®50ïŒ
以äžãå埩ãåèš49,856äººã®æ£è
ãCOVID-19ããå埩ããäžåœåœå
ã®ç
é¢ããéé¢ããã
WHOã¯ã2020幎3æ3æ¥ã«äžåœã§ç¢ºèªãããææè
ã¯åèš80,304人ãšèšé²ããŠããŸãããããæå³ãããšããã¯ãäžåœã«ããããææç¢ºå®çäŸãã®ç·æ°ã30,448人ã§ãã£ããšããããšã§ãããããªãã¡ã80,304ãã49,856ãåŒãããã®ïŒ30,448ã§ãããäžåœã§ã®ãã³ãããã¯ã®èšŒæ ã¯ãªãã
ãããããå埩ãããããåãã¯ã欧米ã¡ãã£ã¢ã§ã¯å ±éãããªãã£ãã
2020幎3æ5æ¥ã®ããšã§ãããWHOäºåå±é·ã¯ãäžåœä»¥å€ã§ã¯33ã«åœã§2,055äººã®ææè
ãå ±åãããŠããããšã確èªããã®çŽ8å²ã3ã«åœïŒéåœãã€ã©ã³ãã€ã¿ãªã¢ïŒã®æ£è
ã§ãã£ã19ã
2020幎3æ7æ¥ ã¢ã¡ãªã« ç±³åœã§ã¯ã3æäžæ¬ã®ã確å®çäŸãïŒææã»å埩è
ïŒã¯430人å°ã§ãçŽ600人ã«å¢å ïŒ3æ8æ¥ïŒã3æã«å
¥ã£ãŠããCOVIDéœæ§è
ãæ¥å¢ããŠããã
ãããã®æ°åãã€ã³ãã«ãšã³ã¶BãŠã€ã«ã¹ã«ä¿ãæ°åãšæ¯èŒããŠã¿ãŸããããCDCã¯2019-2020幎ã®ïŒç±³åœã®ïŒæšå®å€ãšããŠããå°ãªããšã1500äžäººã®ãŠã€ã«ã¹æ§ã€ã³ãã«ãšã³ã¶ã®çºç
è
...ã14äžäººã®å
¥é¢ãš8,200äººã®æ»äº¡ãã(ã¶ã»ãã«)20
21
2020幎3æ7æ¥ äžåœã§ã®ãã³ãããã¯ã¯çºçãã äžåœã§ã®æ°èŠæ£è å ±åæ°ã¯2æ¡ã«æžå°ã3æ7æ¥ã«99äŸãèšé²ãæ¹åç以å€ã®æ°èŠçäŸã¯ãã¹ãŠãèŒžå ¥ææçãïŒå€åœããã®ææçïŒã«åé¡ããããããŒã¿ã®ä¿¡é Œæ§ã¯ãŸã 確ç«ãããŠããªãã
æ¹åçã§ã®74äŸãå«ã99äŸãæ°ãã«ç¢ºèªããã... æ°èŠææè ã®äžã«ã¯ãçç²çã§17人ãå京ã§3人ãäžæµ·ã§3人ãåºæ±çã§1人ã®èš24人ã®èŒžå ¥ææè ãå«ãŸããŠããŸã21ã
2020幎3æ11æ¥ æŽå²çãªCOVID-19ãã³ãããã¯ããã¯ããŠã³ãçŽ190ã®åœæ°çµæžåã®ãééãïŒç¬¬IVç« ïŒ
WHOäºåå±é·ã¯ã2æ21æ¥ã®èšè äŒèŠã§ããã§ã«ãã®èå°ãæŽããŠãã22ã
ãäžçã¯ã³ãããŠã€ã«ã¹ã®ãã³ãããã¯ã«ãã£ãšåããã¹ãã ããWHO㯠WHOã¯ååœã«ãæºåã®æ®µéãã«å ¥ãããåŒã³ãããŠããã
WHOãäžççãªãã³ãããã¯ãå ¬åŒã«å®£èšããã®ã¯ãå šäžçïŒäžåœãå«ãïŒã§ç¢ºèªãããæ£è æ°ã11äž8000äººãæ»äº¡è æ°ã4291人ã«ãªã£ãæç¹ã§ãã(2020幎3æ11æ¥ãèšè äŒèŠã«ããïŒ23 ãã®ãçµ±èšãã¯äœãç©èªã£ãŠããã®ã ãããã
äžåœïŒäººå£64å人ïŒä»¥å€ã§ã®ç¢ºå®æ£è æ°ã¯44,279äººãæ»äº¡è æ°ã¯1,440人ã®ãªãŒããŒã§ããïŒ3æ11æ¥ã«WHOãèšé²ãã3æ12æ¥ã®æ°åãå³è¡šåç §ïŒããã®æ°åã¯ãçŽ190ã®åœã®çµæžå°éãæ£åœåããããã«äœ¿ããããã®ã§ããã24
(ãããã¹æ°ã®èšè äŒèŠã§èšåãããäžåœä»¥å€ã®æ»è æ°ã¯4,291人ã§ããïŒã
2020幎3æ11æ¥ã«èšé²ãããç±³åœã§ã¯ããžã§ã³ãºã»ãããã³ã¹ã«ãããšã1,335人ã®ãæ£è ããš29äººã®æ»è ïŒãæšå®ãïŒPCR確èªïŒãåºãŠããã

2020幎3æ11æ¥ããã³ãããã¯ã®èšŒæ ãªãã
2020幎3æ11æ¥ã®WHOçºè¡šçŽåŸãããææãã£ã³ããŒã³ãæ¬æ Œåããã(çµæžçã»è²¡æ¿çãªåœ±é¿ã«ã€ããŠã¯ãç¬¬â £ç« ã§æ€èšããïŒã
2020幎3æ16æ¥ã®ããšã§ãããModerna mRNA-1273ã¯ãã¯ã·ã³ãã³å·ã·ã¢ãã«ã§45人ã®ãã©ã³ãã£ã¢ãå¯Ÿè±¡ã«æ°æ®µéã®ãã¹ãã宿œã2æäžæ¬ã«ã¯ã¯ãã³ããã°ã©ã ãéå§ãããã
ããã®ã¯ã¯ãã³ãå ç«åå¿ãåŒãèµ·ãããã©ããããŸãå®å šãã©ããã¯ããããŸãããã ãã詊éšãããŠããã®ã§ãããšãžã£ã¯ãœã³ã¯åŒ·èª¿ããããäžè¬åžæ°ã«æäžããããšãå¯èœãªæ®µéã§ããæ éã«ãªãã¹ã段éã§ããªã ããšã(APã2020幎3æ16æ¥)25
2020幎3æ18æ¥ ç±³åœã§ããã¯ããŠã³
2020幎11æ8æ¥ COVID-19 mRNAãã¯ã¯ãã³ããçºå£²ãããã(第VIIIç« )
22
2020幎12æäžæ¬ïœäžæ¬ mRNAã¯ã¯ãã³ããã°ã©ã ã®å
šäžçã§ã®å®æœã
2021幎1æïŒä»¥éïŒãã¯ã¯ãã³é¢é£ã®æ»äº¡ãæå®³äºè±¡ãå¢å åŸåã«ããããšããå
¬åŒããŒã¿ããã¡ã€ã¶ãŒç€Ÿã®æ©å¯å ±åæžïŒç¬¬VIIIç« åç
§ïŒã«ããèšé²ãããã
å
¬åŒããŒã¿ããã³ãã¡ã€ã¶ãŒç€Ÿã®ã³ã³ãã£ãã³ã·ã£ã«ã¬ããŒãïŒç¬¬VIIIç« åç
§ïŒã«ããå ±åãããã
2021幎3æ èŽæ»çãªãµã«ããã¯ã¹ãŠã€ã«ã¹ãã³ãããã¯ã®æ¶ç©ºæŒç¿ã·ããªãª
2021幎3æã®ãã¥ã³ãã³å®å
šä¿éäŒè°ã§ã¯ããç°åžžãªæ ªã®ãµã«ããã¯ã¹ãŠã€ã«ã¹ãå«ãæ¶ç©ºã®æŒç¿ã·ããªãªãã®åäžã·ãã¥ã¬ãŒã·ã§ã³ãçºè¡šããããæ žè
åšã€ãã·ã¢ããïŒNTIïŒã®ãé倧ãªçç©åŠçè
åšãäºé²ã察å¿ããããã®ã°ããŒãã«ã·ã¹ãã ã®åŒ·åãããã°ã©ã ïŒç¬¬XIIIç« åç
§ïŒãäž»å¬ãããã®ã§ããã
Johns Hopkins Event 201 October 2019 Tabletop Simulation of a novel coronavirusã®åå è
ã®ãã¡ã2åãåºåžãããäžåœCDCã®è²¬ä»»è
ã§ãããžã§ãŒãžã»ã¬ãªã»ããŒå士ãšãã²ã€ã財å£ã®ã°ããŒãã«éçºéšéãã¬ãžãã³ãã§ããã¯ãªã¹ã»ãšãªã¢ã¹å士ã§ãã26ã
2021幎5æãã6æã«ãããŠããã«ã¿å€çš®ãšã第4ã®æ³¢ããçºè¡šãããã
ãã«ã¿å€çš®ã®å±éºæ§ãææãããã¯ã¯ãã³æ¥çš®ããã°ã©ã ã®ã¹ããŒãã¢ãããšãã¯ã¯ãã³ãã¹ããŒãã®çºå¹ã«å©çšãããã
2021幎8æïœ9æã欧米æ°ã«åœã§ã®ã¯ã¯ãã³ã»ãã¹ããŒãã®æŒãã€ã
2021幎10æ æ
å ±å
¬éïŒFOIïŒã«åºã¥ããã¡ã€ã¶ãŒç€Ÿã®æ©å¯å ±åæžã®å
Ž
ãã®å ±åæžã¯ããã¡ã€ã¶ãŒ-ãã€ãªNTech瀟ã®mRNAã¯ã¯ãã³ã®åœ±é¿ïŒæ»äº¡ãšæå®³äºè±¡ïŒã確èªãããã®ã§ããïŒç¬¬VIIIç« åç
§ïŒã27
2021幎11æã®ããšã§ããããªãã¯ãã³ã®å€çš®ãåã¢ããªã«ã§æ€åºããããšããããææãã£ã³ããŒã³ã¯ãååååŒã®æ··ä¹±ãšçžãŸã£ãŠãç©ºã®æ
ã®å±æ©ãåã³åŒãèµ·ããã27ã
2021 幎 11 æïœ2022 幎 1 æïŒäžçäžã§æ°ååã® COVID æåãšå®¶åºç𿀿»ããããé
åžããããããããCOVID-19 確å®çäŸãã®æ°ã 6 ã¶æã®éã«åå¢ãããããšã«è²¢ç®ãããç±³åœã§ã¯10åå以äžã®å®¶åºçšã»æåæ€æ»ãã«ããã§ã¯2å9,100äžå28ã
2021幎12æ24æ¥ã®ããšãCOVID-19ã®ã¯ãªã¹ãã¹ãªãã¯ãã³å°é
ã¯ãªã¹ãã¹ã®å€§èŠæš¡ãªåçªäŒã®çŠæ¢ãèªå®
åŸ
æ©ã®çŸ©åä»ããããŒãã¬ã¹ãã©ã³ã®äžéšééïŒãããªãåç£ã«ã€ãªããïŒãã¹ããŒããæåã€ãã³ãã®äžæ¢ãæé»ã®ç®çã¯ã人éãå€ç«ãããããšãã€ãŸãã人ã
ã瀟亀çã«ãªã£ãããæãã人ãšäŒã£ããããã®ãé²ãããšã§ããã
2022幎1æïœ2æïŒéšåçãªããã¯ããŠã³ãã¯ã¯ãã³æªæ¥çš®è
ã«åããããå·®å¥çè¡çº
å€ãã®åœã§ãã¯ã¯ãã³æªæ¥çš®è
ã¯å®¶ã«éã蟌ããããæ
è¡ã劚ããããä»äºãè§£éãããåŠæ ¡ã倧åŠã«éãããšãã§ããªããªã£ãã圌ãã¯éæ¿æŽŸããµã€ã³ãã¹ã ãšéé£ãããã®ã§ãããããã瀟äŒçåè£ã¯ãå®¶æãå°å瀟äŒã®äžã§å¯Ÿç«ãçã¿ãæåéã瀟äŒç掻ã®åŽ©å£ãå©é·ããçµæžæŽ»åã«ã壿»
çãªåœ±é¿ãåãŒããŠããïŒç¬¬XIç« åç
§ïŒã
23
ã«ããã®ããªãŒãã ã³ã³ã〠2022幎
2022幎1æã2æäžæ¬ïŒã«ããã§ã¯ã¯ãã³çŸ©ååã«å察ããå€§èŠæš¡ãªæè°éåãèµ·ããã

2022幎3æ WHOãã³ãããã¯æ¡çŽã®ç«ã¡äžã
2022幎3æãWHOã¯ãA Pandemic Treatyãããªãã¡æ¡æãããã°WHOå çåœã®æš©åšãèŠãã°ããŒãã«ãã«ã¹çµ±æ²»äœã®åµèšãå§ä»»ãããæ¿åºéäº€æžæ©é¢ïŒINBïŒãç«ã¡äžããïŒç¬¬XIIIç« ãåç
§ïŒã
äžæµ·ã«èª²ãããäžåœã®COVIDãŒããã¬ã©ã³ã¹æä»€
2022幎3æ28æ¥ããã人å£2,600äžäººã®æž¯æ¹Ÿéœåžã§ããäžæµ·ã«COVID Zero Tolerance Mandateã課ãããã2022幎4æãã7æã«ãããŠãäžæµ·ãç®åãã«äžåœã®äž»èŠéœåžã«æ¡å€§ïŒç¬¬IVç« åç
§ïŒã
2022幎5æ13æ¥ïŒWHOããµã«çã®ã¢ãŠããã¬ã€ã¯ãçºè¡š
WHOã«ãããš
2022幎5æ13æ¥ä»¥éããµã«çãŠã€ã«ã¹ã®é¢šåç ã§ãªã12ã®å çåœããã3ã€ã®WHOå°åã«ããã£ãŠãµã«çã®çäŸãWHOã«å ±åãããŠããŸããç«åŠç調æ»ã¯ç¶ç¶äžã§ãã5æ21æ¥çŸåšãå®éšå®€ã§ç¢ºèªããã92äŸãšã調æ»äžã®28äŸã®ãµã«çã®çãäŸãã12ã®å çåœããWHOã«å ±åãããŠããŸãïŒç¬¬13ç« åç §ïŒã
2022幎6æïœ7æïŒç¬¬7æ³¢ããªãã¯ãã³BA-4ãBA-5äºçš®ã®ãå·®ãè¿«ã£ãå±éºæ§ããçãããã
2022幎7æ23æ¥ïŒãåœéçã«æžå¿µããããµã«çå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒPHEICïŒã
WHOäºåå±é·ã¯ããµã«çãŠã€ã«ã¹ã«ä¿ãåœéçãªæžå¿µã®ããå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒPHEICïŒã宣èšã
24
ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å士ã¯ãåœéä¿å¥èŠçŽïŒ2005幎ïŒïŒIHRïŒç·æ¥å§å¡äŒã®å€æ°æ±ºã«åããŠãäžæ¹çã«ãã®æ±ºå®ãäžããŸããã
ãç§ãã¡ã¯ãæ°ããæææ§åŒã«ãã£ãŠäžçäžã«æ¥éã«åºãã£ãŠããã¢ãŠããã¬ã€ã¯ãæ±ããŠããŸããç§ïŒãããã¹ïŒã¯åœéçã«æžå¿µãããå ¬è¡è¡çäžã®ç·æ¥äºæ ã宣èšããŠããããä»ã®ãšãããããã¯ç·æ§ãšã»ãã¯ã¹ããç·æ§ãç¹ã«è€æ°ã®æ§çããŒãããŒãæã€ç·æ§ã«éäžããŠããã¢ãŠããã¬ã€ã¯ã§ããã29 ïŒç¬¬XIIIç« åç §ïŒã
å·»æ«è³æ
1. PYMNTSã2019 幎 9 æ 18 æ¥ãHow To Build A Global Digital Identity Network.
https://www.pymnts.com/news/consumer- èªèšŒ/2019/how-to-build-a-global-digital-identity-network/ã
2. PYMNTSã2019 幎 9 æ 19 æ¥ãID2020ã¢ã©ã€ã¢ã³ã¹ã¯ããžã¿ã«IDããã°ã©ã ãå
¬éã
https://www.pymnts.com/news/ biometrics/2019/id2020-alliance-unveils-digital-id-program/
3. Johns Hopkins Center for Health Security, n.d. Event 201. https://www.centerforhealthsecurity.org/event201/
4. ã«ã€ãã³ã»ãªã¿ãŒã³ã2021 幎 9 æ 30 æ¥ãCovid-19ããã³ãããã¯ãã®ã¿ã€ã ã©ã€ã³ãšåæã®å¹Žè¡šãPCRã¢ãã»ã€ãšã·ãŒã±ã³ã¹ã
https://www.globalresearch.ca/early-chronology-covid-pcr-assay-sequencing/5757189
5. åäžã
6. åäž
7. WHOã2020幎1æ23æ¥ãæ°åã³ãããŠã€ã«ã¹ïŒ2019-nCoVïŒã®çºçã«é¢ããåœéä¿å¥èŠåïŒ2005ïŒç·æ¥å§å¡äŒã®åäŒåã«é¢ãã声æ https://www.who.int/news/item/23-01-2020- statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of- novel-coronavirus-(2019-ncov).
8. åäž
9. ç±³åœåœç«è¡çç ç©¶æã2020 幎 3 æ 16 æ¥ãCOVID-19 ã®æ²»éšçšã¯ã¯ãã³ã® NIH èšåºè©Šéšãéå§
https://.www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
10. WHOã2020 幎 1 æ 30 æ¥ãæ°åã³ãããŠã€ã«ã¹ïŒ2019-nCoVïŒã®çºçã«é¢ããåœéä¿å¥èŠåïŒ2005ïŒç·æ¥å§å¡äŒã®ç¬¬2åäŒåã«é¢ãã声æ https://www.who.int/news/item/30-01-2020-statement- on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-nov- coronavirus-(2019-ncov)
11. CDCã2020 幎 12 æ 29 æ¥ãCDCã«ãããSARS-CoV-2ãŠã€ã«ã¹å¹é€ https://www.cdc.gov/coronavirus/2019-ncov/lab/grows- virus-cell-culture.html
25
12. WHOã2020 幎 1 æ 30 æ¥ãæ°åã³ãããŠã€ã«ã¹ïŒ2019-nCoVïŒã®çºçã«é¢ããåœéä¿å¥èŠåïŒ2005ïŒç·æ¥å§å¡äŒã®ç¬¬2åäŒåã«é¢ãã声æ https://www.who.int/news/item/30-01-2020-statement- on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-nov- coronavirus-(2019-ncov).
13. WHOã2020幎1æ29æ¥ãæ°åã³ãããŠã€ã«ã¹ïŒ2019-nCoVïŒç¶æ³å ±å-9. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200129-sitrep-9-ncov-v2.pdf?sfvrsn=e2c8915_2
14. äžæŸ€è±èŒãäºéè£åº·ãä»ã2020 幎 3 æ 24 æ¥ã客è¹ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ã«ããã COVID-19 çäŸã®å¹Žè¡šãšå«ççèå¯: æ¥æ¬ããã®å ±å https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156812/.
15. åäž.
16. WHOã2020 幎 2 æ 20 æ¥ã2020 幎 2 æ 20 æ¥ã® COVID-19 ã«é¢ããã¡ãã£ã¢ããªãŒãã£ã³ã°ã§ã® WHO äºåå±é·ã®éäŒã®èŸ https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on- covid-19-on-20-february-2020.
17. WEFã2020 幎 2 æ 13 æ¥ãUpdate: Coronavirus (COVID-19) | DAVOS 2020.
https://www.weforum.org/videos/update- wuhan-coronavirus-covid-19-davos-2020.
18. WHOã2020 幎 2 æ 28 æ¥ãCOVID-19ã«é¢ããã¡ãã£ã¢ããªãŒãã£ã³ã°ã§ã®WHOäºåå±é·åé çºèš-2020幎2æ28æ¥ã
https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on- covid-19-28-february-2020.
19. WHOã2020 幎 3 æ 5 æ¥ãCOVID-19 ã«é¢ããã¡ãã£ã¢ããªãŒãã£ã³ã°ã§ã® WHO äºåå±é·ã®éäŒã®èŸ - 2020 幎 3 æ 5 æ¥ãhttps://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on- covid-19-5-march-2020
20. ãžã§ã»ãã»ã°ã¹ãã³ã2020 幎 1 æ 27 æ¥ãã³ãããŠã€ã«ã¹ã¯åºãã£ãŠãã - ããããã€ã³ãã«ãšã³ã¶ã¯ã¢ã¡ãªã«äººã«ãšã£ãŠãã倧ããªè
åšã§ãããhttps:// thehill.com/changing-america/well-being/longevity/480089-coronavirus-sparks-panic-as-flu-poses-greater-threat-to
21. Xinhua, March 7, 2020. Xinhua Headlines: äžåœã®æ°èŠ COVID-19 çäŸã1 æ 21 æ¥ä»¥é 2 æ¡ã®æ°å€ã«æžå°
http:// www.xinhuanet.com/english/2020-03/07/c_138853686.htm.
22.WHOã2020 幎 2 æ 21 æ¥ãã³ãããŠã€ã«ã¹ç
ïŒCOVID-19ïŒèšè
äŒèŠ. https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-full-press-conference-21feb2020-final.pdf?sfvrsn=954f8ec7_2
23. WHOã2020 幎 3 æ 11 æ¥ãCOVID-19 - 11 March 2020ã«é¢ããã¡ãã£ã¢ããªãŒãã£ã³ã°ã§ã®WHOäºåå±é·ã®éäŒã®èŸ
https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
24. WHOã2020 幎 3 æ 12 æ¥ãã³ãããŠã€ã«ã¹çŸæ£2019ïŒCOVID-19ïŒç¶æ³å ±å-52.
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf
25. APéä¿¡ã2020幎3æ16æ¥ãCOVID-19ã¯ã¯ãã³ãã¹ãéå§ããã©ã³ãã£ã¢æ£è
ã«1åç®ã®æ¥çš®ã宿œ
https://www.cbc.ca/news/health/coronavirus-vaccine-1.5499244
26. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022 幎 8 æ 4 æ¥ãäžççãªãµã«çå¥åº·å±æ©(PHEIC)ããã«ã»ã²ã€ãã«ãšã£ãŠã¯ããããŒããã¯ã¹ãã2021幎3æã«æ¶ç©ºã®ãµã«çãŠã€ã«ã¹ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ã宿œã2022幎5æã«æ¬çªçšŒå
https://www.globalresearch.ca/bill-gates-warns-smallpox-terror-attacks-urges-leaders-use-germ-games-prepare/5781195?utm_campaign=magnet&utm_source=article_page&utm_medium=related_articles
27. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022幎8æ13æ¥ãBombshell Document Dump on Pfizer Vaccine Data.
https://www.globalresearch.ca/bombshell-document-dump-pfizer-vaccine-data/5763397
28. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022幎7æ19æ¥ãäžçå²ã«ãããæå€§ã®åããã³ãããã¯ã¯ååšããªãã£ããããŒã¿ã»ããŒã¹ã«ã¯æ¬ é¥ããããThe Covid Mandates including the Vaccine are Invalid. https://www.globalresearch.ca/biggest-lie-in-world-history-the-data-base-is-flawed-there-never-was-a-pandemic-the-covid-mandates-including-the-vaccine-are-invalid/5772008
29. WHOã2022幎7æ23æ¥ã
https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022
26
----------------------第3ç« ---------------------
COVID-19ãSARS-CoV-2ãšã¯äœãïŒ
ã©ã®ããã«æ€æ»ãããã®ãïŒã©ã®ããã«æž¬å®ãããã®ãïŒ
ãPCRã¯ããã»ã¹ã§ãããããã¯ããªããç
æ°ã§ããããšãæããŠããããã®ã§ã¯ãããŸãããã -ããŒãã«è³åè³è
ã§RT-PCRã®çºæè
ã§ããã«ãªãŒã»ããªã¹å士ïŒ2019幎8æéå»ïŒã
ãã»ã»ã»ãããã®éœæ§ã®ãã¹ãŠãŸãã¯çžåœéšåã¯ãããããåœéœæ§æ€æ»ã«ãããã®ã§ããå¯èœæ§ããããŸããã-ãã€ã±ã«ã»ã€ã§ãŒãã³å士ãèåãªç§åŠè
ãå
ãã¡ã€ã¶ãŒç€Ÿå¯ç€Ÿé·å
Œæé«ç§åŠè²¬ä»»è
ããã®RT-PCRæè¡ã®èª€çšã¯ãå®éã®æ£è
æ°ã§ã¯ãªããRT-PCRæ€æ»ã®éœæ§æ°ã«åºã¥ããã³ãããã¯ãå£å®ã«ã...倿°ã®æ²æ³äžã®æš©å©ã®äŸµå®³ãªã©ã®éå°ãªæªçœ®ãæ£åœåããããã«ãäžéšã®æ¿åºã«ãã£ãŠå·æãã€æå³çãªæŠç¥ãšããŠé©çšãããŠããŸããã -ãã¹ã«ã«ã»ãµã¯ã¬å士ïŒãã«ã®ãŒãéçæ£è
ãå°éãšããå»åž«ãèåãªå
¬è¡è¡çã¢ããªã¹ãïŒã
ãç§ã¯ãçæ£è
ãè³åäžæ£è
ãªã©ãããããéåžžã®æ»äº¡è
ãCovidãšåœã£ãŠãCovidã«ããæ»äº¡æ°ãæå³çã«å¢å ãããããšããå€§èŠæš¡ãªåªåãèŠãŠããŸããããã®ããã«äœ¿ãããæ¹æ³ã¯å®å
šã«æ¬ é¥ããããäŸãã°PCRãã¹ãã¯ã誰ãã䟡å€ããªããšç¥ã£ãŠãã45åšæã§å®è¡ãããŸãããã人ã
ã¯ããã«åºã¥ããŠå®æ¥œæ»ãããããæã«ã¯èžéšXç·ã ãã«åºã¥ããŠå®æ¥œæ»ãããããããšããããŸããã-ãžã§ã³ã»ãªã«ãŒããŒãè¬åå±ããã«ãã³ã»ã±ã€ã³ãºãã€ã®ãªã¹
ã¯ããã«
ã¡ãã£ã¢ã®åãšãçµç¹çãã€åšå°ã«ä»çµãŸããææã®ãã£ã³ããŒã³ã¯ãäžçã®äž»èŠå°åã«å®¹èµŠãªãåºããæ®ºäººãŠã€ã«ã¹ã®ã€ã¡ãŒãžãæç¶ãããŠããã
190ã«åœä»¥äžã§æ°åå人ãCOVID-19ã®æ€æ»ãåããŠããïŒåæ€æ»ãå«ãïŒãæ¬çš¿å·çæç¹ã§ãäžçäžã§5å人以äžããCOVID-19確å®çäŸã
ãconfirmed casesãïŒã环ç©çäŸãïŒã«åé¡ãããŠããŸãã
ãã®ãã³ãããã¯ã¯ã580äžäººä»¥äžã®COVID-19é¢é£ã®æ»äº¡ãããããããšèšãããŠããŸãã
眹æ£çãšæ»äº¡çã®äž¡æ¹ã®æ°åãç¡å¹ã§ãããé«åºŠã«çµç¹åãããCOVIDæ€æ»æ©é¢ïŒãã®äžéšã¯åäžé·è
ã®è²¡å£ã«ãã£ãŠè³éæäŸãããŠããïŒã¯ããCOVID-19確å®çäŸãã®æ°ãå¢ããç®çã§èšç«ãããããã¯åºæ¬çäººæš©ã®æ€å»ãšçµã³ã€ãããã¯ã¯ãã³ããã¹ããŒããæŒãä»ããããã®æ£åœåãšããŠäœ¿ãããã®ã§ããã
2020幎1æã®ãã®å±æ©ã®å§ãŸãããããåœãæãææ®µããšããŠæ¯æãããåœæ°ã«æç€ºããããã¹ãŠã®é å€§ãªæ¿ç決å®ã¯ãæ¬ é¥ã®ããç¡å¹ãªRT-PCRéœæ§äŸã«åºã¥ããŠããã®ã§ãã
ãããã®ç¡å¹ãªCOVID-19ãæšå®å€ãã¯ãç£çŠã瀟äŒçè·é¢ããã§ã€ã¹ãã¹ã¯ã®ççšã瀟äŒçéäŒãæåã»ã¹ããŒãã€ãã³ãã®çŠæ¢ãçµæžæŽ»åã®ééããããŠ2020幎11æã«çºå£²ãããmRNAãã¯ã¯ãã³ãã®æœè¡ãæ£åœåããããã«äœ¿çšãããŠããŸããã
27
ãCOVID-19確å®çäŸããªããŠãã®ã¯ååšããªããç§åŠçèŠè§£ãšäžçä¿å¥æ©æ§ã®äž¡æ¹ããã£ãããšèªããŠããããã«ããŠã€ã«ã¹ïŒããã³ãã®äºçš®ïŒã®æ¡æ£ããæ€åºãããããã«çšããããRT-PCRãã¹ãã¯æ¬ é¥ãããã ãã§ãªããå®å
šã«ç¡å¹ã§ããã
ææã®ãã£ã³ããŒã³ã¯ãæ¿æ²»ççºèšãšã¡ãã£ã¢ã®åœæ
å ±ã«ãã£ãŠå·æã«å
å°ãããŠãããååœã®ä¿å¥åœå±ãçºè¡šããå
¬åŒå ±åæžãå°éå®¶ã®æ»èªãçµãè«æã詳ãã調ã¹ããšããŸã£ããç°ãªãå§¿ãæµ®ãã³äžãã£ãŠããã
ãã®ç« ã§ã¯ã次ã®ãããªåé¡ã«çŠç¹ãåœãŠãŸãã
SARS-CoV-2ãŠã€ã«ã¹ã®ç¹åŸŽïŒWHOãCDCãå°éå®¶ã«ããå ±åæžïŒãå±éºãªãŠã€ã«ã¹ãªã®ãïŒ
 SARS-CoV-2ã®ãæ€åº/åå®ãã«äœ¿çšãããé転åããªã¡ã©ãŒãŒé£éåå¿ïŒRT-PCRïŒãã¹ãã
COVID-19ææçæã«é¢ããæ»äº¡çã»çœ¹æ£çã®æšå®å€ã®ä¿¡é Œæ§ã
SARS-CoV-2ã®ç¹åŸŽ
äžäœçºã«ããåïŒã¡ãã£ã¢ã¯ããåºãåœæ°ãå®å¿ãããããšã«å€±æããã以äžã¯ãWHOã«ããCOVID-19ã®å ¬åŒå®çŸ©ãšCDCã®å®çŸ©ã§ããã
ã³ãããŠã€ã«ã¹ã¯ãåç©ã人éã«ç æ°ãåŒãèµ·ããå¯èœæ§ã®ãããŠã€ã«ã¹ã®å€§å®¶æã§ãããããã§ã¯ã颚éªããäžæ±åŒåžåšçå矀ïŒMERSïŒãéçæ¥æ§åŒåžåšçå矀ïŒSARSïŒãªã©ã®ããæ·±å»ãªçŸæ£ã«è³ããŸã§ãããã€ãã®ã³ãããŠã€ã«ã¹ãåŒåžåšææçãåŒãèµ·ããããšãç¥ãããŠããŸããæè¿çºèŠãããã³ãããŠã€ã«ã¹ã¯ãã³ãããŠã€ã«ã¹ææçCOVID-19ãåŒãèµ·ãããŸãã
ãCOVID-19 ãã®æãäžè¬çãªçç¶ã¯ãçºç±ã也ããå³ãç²åŽæã§ãã... ãããã®çç¶ã¯éåžžã軜床ã§ãããåŸã ã«å§ãŸããŸããäžã«ã¯ãææããŠããã軜ãçç¶ããåºãªã人ãããŸããã»ãšãã©ã®äººïŒçŽ80ïŒ ïŒã¯ãç é¢ã§ã®æ²»çãå¿ èŠãšããã«ç æ°ããå埩ããŸããCOVID-19ã«ææãã人ã®5人ã«1人çšåºŠãéçåããåŒåžå°é£ã«é¥ããŸãã1
CDCã«ãããšãã€ã³ãã«ãšã³ã¶ã«äŒŒãŠãã
COVID-19ãšã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹AåãBåïŒããã³ãã®äºåïŒã®æ¯èŒ
ã¡ãã£ã¢ãæ¿æ²»å®¶ãèšåããããšã¯ã»ãšãã©ãªããCDCïŒç±³åœæ¿åºæ©é¢ïŒã¯ãCOVID-19ãã€ã³ãã«ãšã³ã¶ã«é¡äŒŒããŠããããšã確èªããŠããŸãã
ãã€ã³ãã«ãšã³ã¶ïŒFluïŒãšCOVID-19ã¯ã©ã¡ããäŒææ§ã®åŒåžåšçŸæ£ã§ãããç°ãªããŠã€ã«ã¹ã«ãã£ãŠåŒãèµ·ããããŸããCOVID-19ã¯æ°åã³ãããŠã€ã«ã¹ïŒSARS-CoV-2ãšåŒã°ããïŒã®ææã«ãã£ãŠåŒãèµ·ããããã€ã³ãã«ãšã³ã¶ã¯ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®ææã«ãã£ãŠåŒãèµ·ããããã®ã§ããã€ã³ãã«ãšã³ã¶ãšCOVID-19ã¯çç¶ã䌌ãŠããéšåããããããçç¶ã ãã§ã¯èŠåããã€ããªãããšãããã蚺æã®ç¢ºå®ã«ã¯æ€æ»ãå¿ èŠãªå ŽåããããŸããã€ã³ãã«ãšã³ã¶ãšCOVID-19ã¯å€ãã®ç¹ã§å ±éããŠããŸãããäž¡è ã«ã¯ããã€ãã®éèŠãªéãããããŸãã2ã
28
ãããCOVIDããã€ã³ãã«ãšã³ã¶ã«äŒŒãŠããããšããããšãåœæ°ã«ç¥ãããå®å¿ãããŠããããææãã£ã³ããŒã³ã¯æ«æããŠããã ããã
åœæ°çµæžã®ããã¯ããŠã³ãšééã¯ãçã£åããåŠå®ãããããšã ããã
Wolfgang Wodargå士ã«ããã°ãèºçã¯ã宿çã«ã³ãããŠã€ã«ã¹ã«ãã£ãŠåŒãèµ·ããããããããã¯äŒŽãããã®ã§ãããšã®ããšã§ã3ã
å
ç«åŠè
ãCDCã®å®çŸ©ãåºã確èªããŠãããCOVID-19ã¯ãå£ç¯æ§ã€ã³ãã«ãšã³ã¶ãšèºçã®çµã¿åããã«äŒŒãç¹åŸŽãæã£ãŠããŸãã
ã¢ã³ãœããŒã»ãã¡ãŠãïŒNIAIDæé·ïŒãHã»ã¯ãªãã©ãŒãã»ã¬ãŒã³ããããŒãã»Rã»ã¬ãããã£ãŒã«ãïŒCDCæé·ïŒã¯ãNew England Journal of Medicineèªã«æ¬¡ã®ããã«æžããŠããŸãã
ãCovid-19ã®å šäœçãªèšåºçµæã¯ãSARSãMERSã®ãããªçŸæ£ã§ã¯ãªããéçå£ç¯æ§ã€ã³ãã«ãšã³ã¶ïŒèŽæ»ççŽ0.1ïŒ ïŒãŸãã¯ãã³ãããã¯ã€ã³ãã«ãšã³ã¶ïŒ1957幎ãš1968幎ã®ãã®ãšåæ§ïŒã«äŒŒãŠãããããããŸããã
ãªããšéœåãããããšããäžèšã®è«æã¯ã2020幎3æ16æ¥ã«ãã©ã³ã倧統é ãåœå®¶éåžžäºæ 宣èšãåºããŠããã¡ããã©10æ¥åŸã®3æ26æ¥ã«NEJMã«åããŠæ²èŒãããŸããããã®æš©åšããæ»èªæžã¿ã®æç« ãç±³åœæ°ã®ç®ã«çãŸã£ãŠããã°ãããã¯ããŠã³ã®çŸ©ååã¯é æ«ããŠããã ããã

Anthony Fauciå士ã¯èªåèªèº«ã«åãã€ããŠããã圌ã¯å
¬ã®å Žã§ãCOVIDã¯ãå£ç¯æ§ã€ã³ãã«ãšã³ã¶ã®10åæªãããšè¿°ã¹ãŠããŸã5ã
圌ã¯ãäžã§åŒçšããèªåã®æ»èªä»ãå ±åæžã«åè«ããŠããããã¡ãŠãã¯åœåãããã¢ã¡ãªã«å
šåã§ææãšãããã¯ã®ãã£ã³ããŒã³ãå±éããããšã«åãæ³šãã§ããã®ã§ã6ã
29
é転åããªã¡ã©ãŒãŒã»ãã§ãŒã³åå¿ïŒRT-PCRïŒæ€æ»ã«ã€ããŠ
WHOã®æå°ã®ããšã§é©çšãããŠããããŠã€ã«ã¹æ¡æ£ã®çããæ€åºããããã®æãäžã®æ¹æ³è«ã¯ã2020幎2æããäžçäžã§æ¥åžžçã«é©çšãããŠããé転åããªã¡ã©ãŒãŒé£éåå¿ïŒRT-PCRïŒãã¹ãã§ããã
RT-PCRãã¹ãã¯ãæ°çŸäžä»¶ã®èª€ã£ããCOVID-19確å®çäŸããçã¿åºãããã«äžçäžã§äœ¿çšãããŠããããã®çäŸã¯ãçæã®ãã³ãããã¯ãå®åšãããšããå¹»æ³ãæç¶ãããããã«äœ¿çšãããŠããŸãã
ãã®èª€ã£ãæ°åã«åºã¥ãè©äŸ¡ã¯ãéå»2幎åã®éã«ãææãã£ã³ããŒã³ã®å
é ã«ç«ã¡ããããç¶æããããã«å©çšãããŠããã
ãããŠã人ã
ã¯ä»ãCOVID-19ãã¯ã¯ãã³ããã解決çãã§ãããšä¿¡ããããã«ä»åããããŠããããããŠãå°çäžã®å
šäººå£ãã¯ã¯ãã³ãæ¥çš®ããã°ããæ£åžžãªç¶æ
ããå埩ããã®ã ãšã
ãç¢ºèªæžã¿ ãã¯èª€çšã§ãããã確å®ããRT-PCRéœæ§äŸãã¯ãCOVID-19確å®äŸããæå³ãããã®ã§ã¯ãããŸããã
RT-PCRéœæ§ã¯COVID-19ç ãšå矩ã§ã¯ãããŸãã! PCRã®å°éå®¶ã¯ãæ€æ»ã¯åžžã«æ€æ»å¯Ÿè±¡æ£è ã®èšåºèšé²ãæ£è ã®å¥åº·ç¶æ ãšæ¯èŒããŠããã®äŸ¡å€ïŒ»ä¿¡é Œæ§ïŒœã確èªããªããã°ãªããªãããšãæç¢ºã«ããŠããã(ãã¹ã«ã«ã»ãµã¯ã¬å士)7
åœã®ä¿å¥åœå±ãæ¡çšããŠããæé ã¯ããã¹ãŠã®RT-PCRéœæ§äŸããCOVID-19確å®äŸãïŒå»åŠç蚺æã®æç¡ã«ãããããïŒã«åé¡ããããšã§ããç®èãªããšã«ãã確å®çäŸããç¹å®ãããã®æ¥åžžçãªããã»ã¹ã¯ãCDCèªèº«ã®ã¬ã€ãã©ã€ã³ã«åããŠããã
ããŠã€ã«ã¹RNAã®æ€åºã¯ãæææ§ãŠã€ã«ã¹ã®ååšã2019-nCoVãèšåºçç¶ã®åå ç©è³ªã§ããããšã瀺ããªãå Žåããããããã®æ€æ»ã®æ§èœã¯ã2019-nCoVææçã®æ²»çã®ã¢ãã¿ãªã³ã°ã®ããã«ç¢ºç«ãããŠããŸããããã®æ€æ»ã¯ãä»ã®çްèãŸãã¯ãŠã€ã«ã¹æ§ç åäœã«ããçŸæ£ãé€å€ããããšã¯ã§ããŸããã8 ïŒåŒ·èª¿ïŒ
ãŠã€ã«ã¹ã®æ€åºã𿡿£ã®æšå®ã«äœ¿çšãããæ¹æ³è«ã¯ãæ¬ é¥ãããç¡å¹ã§ããã
åœéœæ§ïŒFalse PositivesïŒ
屿©ãå§ãŸã£ãåœåã¯ããåœéœæ§ ãã®åé¡ã«è°è«ãéäžããã
WHOãCDCãèªããŠããããã«ãRT-PCRæ€æ»ã¯é«ã確çã§åœéœæ§ãåºãããšãç¥ãããŠããŸããããã¹ã«ã«ã»ãµã¯ã¬å士ã«ããã°ãã仿¥ãåœå±ãããå€ãã®äººãæ€æ»ããããã«ãªã£ããã
ã仿¥ãåœå±ãããå€ãã®äººãæ€æ»ããã°ãããå€ãã®RT-PCRæ€æ»ãéœæ§ãšãªãã¯ãã§ããããã¯ãCOVID-19ãåæµè¡ããæµè¡ã«æ³¢ãããããšãæå³ãããã®ã§ã¯ãããŸãããæ€æ»ãåãã人ãå¢ãããããã ãã§ãã9ã
åœéœæ§ã«ã€ããŠã®è°è«ïŒä¿å¥åœå±ã¯èªããŠããïŒã¯ããããã誀ããææããŠããããå¿ ãããSARS-CoV-2ãŠã€ã«ã¹ã®æ¡æ£ãæ€åºããææ®µãšããŠã®RT-PCRæ€æ»ã®å šäœçãªæå¹æ§ãçåèŠããŠããããã§ã¯ãªãã
30
PCRãã¹ãã¯ãŠã€ã«ã¹ã®æ£äœãæ€åºããªã
PCRæ€æ»ã¯ãŠã€ã«ã¹ãç¹å®ã»æ€åºãããã®ã§ã¯ãããŸãããPCRæ€æ»ã§åå®ãããã®ã¯ã倿°ã®ãŠã€ã«ã¹ïŒã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹AåãBåã颚éªã®åŒãéãšãªãã³ãããŠã€ã«ã¹ãªã©ïŒã®éºäŒåæçã§ãã
RT-PCRæ€æ»ã®çµæã§ã¯ãæ€æ»ãåããå人ãSARS-CoV-2ã«ææããŠãããã©ãããã確èªãããããšã¯ã§ããªãã
以äžã®å³ã¯ãéœæ§äŸãšé°æ§äŸãèå¥ããããã»ã¹ããŸãšãããã®ã§ãããéœæ§ãã«åé¡ãããããã«å¿ èŠãªã®ã¯ãããŠã€ã«ã¹ã®éºäŒç©è³ªããååšããããšã§ããããã®æé ã§ã¯ãCOVID-19ãç¹å®ãããåé¢ãããããããšã¯ã§ããªããæ€æ»ã«çŸããã®ã¯ããŠã€ã«ã¹ã®æçã§ã10ã

31
æ€æ»ãéœæ§ã§ããããªãããŠã€ã«ã¹ãæã£ãŠããããããã¯ãŠã€ã«ã¹ãææãããå¯èœæ§ããããšããããšã§ã¯ãããŸããã
PCRæ³ã®çºæè
ã§ããKary Mulliså士ã«ããã°ããPCRæ³ã¯ããŠã€ã«ã¹èªäœã®äžéšã§ããæ žé
žã®éåžžã«å°ããªã»ã°ã¡ã³ããæ€åºããŸãã
ãPCRã¯ãŠã€ã«ã¹ã®äžéšã§ããæ žé žã®éåžžã«å°ããªã»ã°ã¡ã³ããæ€åºããŸããã

ã¹ã€ã¹ã®æåãªå ç«åŠè ã§ããB.ã¹ã¿ãã©ãŒå士ã«ããã°
ã§ããããå ç«ã®ãã人ã«PCRã³ããæ€æ»ãè¡ããšãæ€åºãããã®ã¯ãŠã€ã«ã¹ã§ã¯ãªãããŠã€ã«ã¹ã²ãã ã®å°ããªç²ç ãããéšåãªã®ã§ãããŠã€ã«ã¹ã®å°ããªç Žçãæ®ã£ãŠããéããæ€æ»ã¯éœæ§ãšãªãã®ã§ããææãããŠã€ã«ã¹ããšã£ãã«æ»ãã§ããŠããã³ããæ€æ»ã§éœæ§ãšãªãããšããããPCRæ³ã¯ããŠã€ã«ã¹ã®éºäŒç©è³ªã®ããäžéšã§ãååã«å¢æ®ãããããã ã
Pascal Sacré å士ã¯ãããããã®æ€æ»ã¯ããŠã€ã«ã¹å šäœã§ã¯ãªãããŠã€ã«ã¹ç²åãéºäŒåé åãæ€åºããŠããããšåæããŠãã12ã
ããŠã€ã«ã¹éãå®éåããããšãããšããããã®é åã¯ããšã©ãŒãæ» èãšã©ãŒãæ±æã®å¯èœæ§ããã倿°ã®è€éãªå·¥çšãçµãŠãæ°åå¢å¹ ããããã
WHOã® ãã«ã¹ã¿ãã€ãºããã ãRT-PCR COVID-19 ããã¹ãã
éèŠãã€é¢é£ãã2ã€ã®åé¡
PCRæ€æ»ã¯ãäžèšã®ããã«ãŠã€ã«ã¹ãç¹å®ãããã®ã§ã¯ãªããããã«ãWHOã¯ã2020幎1æã«ã¯ãæ°å2019-nCoVãŠã€ã«ã¹ã®åé¢ã»ç²Ÿè£œãµã³ãã«ãä¿æããŠããªãã£ãã
2020幎1æã«äºå®ãããŠããã®ã¯ãWHOã«ããPCRæ€æ»ã®ãã«ã¹ã¿ãã€ãºãã§ãã£ãã
ã·ã£ãªãç
é¢ãã«ãªã³ãŠã€ã«ã¹ç ç©¶æã®ç§åŠçæå°ã®äžã§ãWHOãè¡ã£ãPCRæ€æ»ã®ãã«ã¹ã¿ãã€ãºãã§ããã
ãã«ãªã³ãŠã€ã«ã¹ç ç©¶æã®Christian Drostenå士ãšãã®ååã¯ããDetection of 2019 novel coronV virusããšé¡ããç ç©¶ãè¡ã£ãã
ããªã¢ã«ã¿ã€ã RT-PCR ã«ãã 2019 幎æ°åã³ãããŠã€ã«ã¹ (2019-nCoV) ã®æ€åºã13ã

ãã«ãªã³ãŠã€ã«ã¹ç ç©¶æã®ç ç©¶ã¿ã€ãã«ã¯ãæãããªèª€èšã§ãããPCRæ€æ»ã§ã¯ã2019å¹Žã®æ°åã³ãããŠã€ã«ã¹ããæ€åºãããããšã¯ã§ããªãã(äžã«åŒçšããã«ãªãŒã»ããªã¹å士ãBã»ã·ã¥ã¿ãã©ãŒå士ããã¹ã«ã«ã»ãµã¯ã¬å士ãåç §ïŒã
ããã«ãEurosurveillanceãçºè¡šããç ç©¶ã§ã¯ãWHOãæ°å2019-nCoVãŠã€ã«ã¹ã®åé¢ã»ç²Ÿè£œãµã³ãã«ãä¿æããŠããªãããšãèªããŠããã
32
ãäžæ¹ã...ããã€ãã®ãŠã€ã«ã¹ã®ã²ãã é åãå ¬éãããŠãããã...æææ£è ããã®ãŠã€ã«ã¹åé¢ããµã³ãã«ïŒ2019-nCoVïŒã¯å ¥æã§ããªãã£ã...ã14
Drostenãã®ããŒã ã¯ãã®åŸã2019-nCoVãŠã€ã«ã¹ã®å颿 ªããªãå Žåãæ°åãŠã€ã«ã¹ã®ã代ç人ãïŒåç §ç¹ïŒãšããŠãé¡äŒŒãã2003幎ã®SARS-CoVã䜿çšããããWHOã«å§åããŸããã
ãã²ãã é åã¯ãéçæ¥æ§åŒåžåšçå矀ïŒSARSïŒé¢é£CoVãšåŒã°ãããŠã€ã«ã¹çš®ã®ã¡ã³ããŒã«å¯æ¥ã«é¢é£ãããŠã€ã«ã¹ã®ååšã瀺åããŠããã[3,4].
å©çšå¯èœãªãŠã€ã«ã¹å颿 ªãŸãã¯å ã®æ£è æ€äœãååšããªãå Žåã«èšèšãããã2019 nCoVã¹ã¯ãªãŒãã³ã°ãš [RT-PCRæ€æ»ã䜿çšãã] ç¹ç°ç確èªã®ããã®èšºæã¯ãŒã¯ãããŒã®ç¢ºç«ãšæ€èšŒã«ã€ããŠå ±åãããèšèšãšæ€èšŒã¯ã2003幎ã®SARS-CoVãšã®å¯æ¥ãªéºäŒçé¢é£æ§ã«ãã£ãŠå¯èœã«ãªããåææ žé žæè¡ã®äœ¿çšã«ãã£ãŠæ¯æŽããããâ(Eurosurveillanceã2020幎1æ23æ¥ã匷調ã远å ).15.
ãã®ææ§ãªèšè¿°ã瀺åããã®ã¯ã2019-nCoVã®åäžæ§ã¯èŠæ±ãããããCOVID-19確å®äŸãïŒ2019幎æ°åã³ãããŠã€ã«ã¹ã«èµ·å ããææçïŒã¯ãã2003 SARS-CoVã«è¿ãéºäŒçé¢é£æ§ ãã«ãã£ãŠæ€èšŒããããšããããšã§ããã
ãããæå³ãããšããã¯ã19幎åã«æ€åºãããã³ãããŠã€ã«ã¹ïŒ2003 SARS-CoVïŒãã2019幎12ææ«ã«äžåœã®æ¹åçã§åããŠæ€åºããããããããæ°åã³ãããŠã€ã«ã¹ãã®èº«å
ããæ€èšŒãããããã«äœ¿çšãããŠãããšããããšã§ãã
ãã®åŸãDrostenç ç©¶ã®å§åïŒã²ã€ã財å£ã®å¯å€§ãªæ¯æŽãšè³éæäŸïŒã¯WHOã«äŒéãããŸããããã®åŸãWHOã®äºåå±é·ã§ãããããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å士ã«ãã£ãŠæ¿èªãããŸããã
ããããWHOã¯ãŠã€ã«ã¹ã®åå®ã«å¿
èŠãªããŠã€ã«ã¹å颿 ªããä¿æããŠããªãã£ããæ°åã³ãããŠã€ã«ã¹ã®å颿 ªã¯å¿
èŠãªããšå€æãããã
RT-PCRæ€æ»ã®äžççãªäœ¿çšïŒWHOã®æå°ã®äžïŒã«ä¿ãDrosten, et al.ã®è«æã¯ã23人ã®åœéçãªãŠã€ã«ã¹åŠè
ã埮çç©åŠè
ãet al.ã®ã°ã«ãŒãã«ãã2020幎11æ27æ¥ã®ç ç©¶ã§ç°è°ãå±ããããŸããã
RT-PCR æ€æ»ã®äžççãªäœ¿çšã«ã€ããŠãPCRæ€æ»ã2003幎ã®SARS-CoVãŠã€ã«ã¹ããåºæºç¹ããšããŠäœ¿çšãããªãã°ãæ°èŠãŠã€ã«ã¹2019-nCoVïŒãã®åŸSARS-CoV-2ãšæ¹åïŒãŸãã¯ãã®å€çš®ã®COVID-19çäŸãã確èªããããªãã®ã¯åœç¶ã§ãããã
2019-nCoVã®æ£äœã¯ç¢ºèªãããã®ãïŒãã®ãŠã€ã«ã¹ã¯ååšããã®ãïŒ
WHO ã¯ãŠã€ã«ã¹ã®å颿 ªãä¿æããŠããŸããã§ãããã2019å¹Žçæ°åã³ãããŠã€ã«ã¹ããç
æ°ã®æ£è
ããæ¡åããæ··ãããã®ãªããµã³ãã«ãããåé¢ããããšããæå¹ã§ä¿¡é Œã§ãã蚌æ ãããã®ã§ãããã16ã
äžåœåœå±ã¯2020幎1æ7æ¥ããSARSãMERSã«é¢é£ãããã®ãšé¡äŒŒããããæ°åã®ãŠã€ã«ã¹ã確èªãããããšçºè¡šããïŒé¢é£å ±éãäžåœæ¿åºã®ãªãªãžãã«ãœãŒã¹ã§ã¯ãªãïŒãäžåœã®ç ç©¶ããŒã ãæ¡çšããæ ¹æ¬çãªæ¹æ³ã¯ã以äžã®éãã§ããã
33
ãªã¢ã«ã¿ã€ã RT-PCR ãšæ¬¡äžä»£ã·ãŒã±ã³ãµãŒã«ãããå®éšå®€ã§ 2019-nCoV ææã確èªãããæ£è ã®ããŒã¿ãååãã«åéããåæããã
ããŒã¿ã¯ãWHOãšInternational Severe Acute Respiratory and Emerging Infection Consortiumãå ±æããæšæºåãããããŒã¿åéãã©ãŒã ãçšããŠãé»åã«ã«ãããååŸããŸãã17ïŒåŒ·èª¿ïŒã
äžèšã®ç ç©¶ïŒäžèšã®åŒçšããã³åç §ããä»ã®ææžïŒã¯ãäžåœã®ä¿å¥åœå±ãæ£è ã®æ€äœã®åé¢/粟補ãè¡ããªãã£ãããšã瀺åããŠããããªã¢ã«ã¿ã€ã RT-PCRã«ããå®éšå®€ã§ç¢ºèªããã2019-nCoVææãïŒåœŒãã®ç ç©¶ã§åŒçšïŒã¯ãæãããªèª€çšã§ãããããªãã¡ãRT-PCRæ€æ»ã¯ãããªãç¶æ³ã§ããŠã€ã«ã¹ãç¹å®ããããã«äœ¿çšããããšã¯ã§ããªããäžåœåœå±ã«ãããŠã€ã«ã¹ã®åé¢ã¯æªç¢ºèªã§ãã18ã
SARS-CoV-2ã®å颿 ªã«é¢ããæ å ±å ¬éã«ã€ããŠ
ã¯ãªã¹ãã£ã³ã»ããã·ãŒã«ãã詳现ãªèª¿æ»ãããžã§ã¯ããFreedom of Information RequestsïŒæ å ±å ¬éè«æ±ïŒããChristine Masseyã«ãããFreedom of Information Requests: Health/ Science Institutions Worldwide "Have No Record" of SARS-COV-2 Isolation/Purificationããšé¡ãã詳现ãªèª¿æ»ãããžã§ã¯ãã§ã¯ããŠã€ã«ã¹ã®æ£äœã«é¢ããææžãæäŸããŠããã25ã«åœã127æ©é¢ããå¯ãããããããã®èŠè«ã«å¯Ÿããåçã¯ãSARS-CoV-2ã®åé¢ã»ç²Ÿè£œãã誰ã«ãã£ãŠãã©ãã§ããããŸã§ã«è¡ãããã®ãããšããèšé²ããªãããšã確èªãããã®ã§ãã£ã "19ã
éŸå€å¢å¹ ãµã€ã¯ã«ãWHOã¯ãRT-PCRããã¹ããã®çµæãå šãç¡å¹ã§ããããšãèªããŠããã
RT-PCRãã¹ãã¯ããã«ãªã³ã»ãŠã€ã«ã¹åŠç ç©¶ã°ã«ãŒãã®å§åïŒäžèšåŒçšïŒã«åŸãã2020幎1æ23æ¥ã«WHOãSARS- CoV-2ãŠã€ã«ã¹ã®æ€åºææ®µãšããŠæ¡çšãããã®ã§ããã
ã¡ããã©1幎åŸã®2021幎1æ20æ¥ãWHOã¯æ€åããã圌ãã¯ãç§ãã¡ã¯ééããç¯ããããšã¯èšããŸãããæ€åå
å®¹ã¯æ
éã«çå®ãããŠããïŒWHOã®åæã¯ãã¡ãïŒ20ã
äºç¹ã¯ãå¢å¹
éŸå€ãµã€ã¯ã«æ°ïŒCtïŒã«é¢ãããã®ã§ãããPieter Borger, et al.ã«ããã°ã以äžã®éãã§ããã
å¢å¹ ãµã€ã¯ã«æ°ã¯35以äžã§ããã¹ãã§ã25ã30ãµã€ã¯ã«ãæãŸããããŠã€ã«ã¹æ€åºã®å Žåã35ãµã€ã¯ã«ä»¥äžã§ã¯ã现èå¹é€ã§ã®åé¢ã«ãã£ãŠæ±ºå®ãããæææ§ãŠã€ã«ã¹ãšçžé¢ã®ãªãã·ã°ãã«ããæ€åºãããªã...ïŒDrosten Studyã®æ¹å€ïŒ21ã
äžçä¿å¥æ©é¢ïŒWHOïŒã¯1幎åŸã35ãµã€ã¯ã«å¢å¹
éŸå€ïŒCtïŒä»¥äžã§è¡ããããã¹ãŠã®PCRæ€æ»ã¯ç¡å¹ã§ããããšãé»èªããŠãããããããããã¯2020幎1æã«ãã«ãªã³ã®ã·ã£ãªãç
é¢ã®ãŠã€ã«ã¹åŠããŒã ãšåè°ããŠå§åãããã®ã§ãã
CtéŸå€35以äžïŒWHOãæšå¥šããïŒã§æ€æ»ããå ŽåãSARS-CoV-2ãŠã€ã«ã¹ã®éºäŒåã»ã°ã¡ã³ãã¯æ€åºã§ããªãã®ã§ãéå»2幎åã®éã«äžçäžã§éèšããããããããCOVID-19確å®äŸãã¯ãã¹ãŠç¡å¹ãšããããšã«ãªãã
Pieter BorgerãBobby Rajesh MalhotraãMichael Yeadonãã«ãããšãCt>35ã¯ããšãŒããããšã¢ã¡ãªã«ã®ã»ãšãã©ã®ç ç©¶æã§ãæšæºãšãªã£ãŠãã22ã
34
WHOã® "Mea Culpa
以äžã¯ãWHOãæ éã«çå®ãããæ€åãã§ããã
ãWHOã®ã¬ã€ãã³ã¹ SARS-CoV-2ã®èšºææ€æ»ã§ã¯ã匱ãéœæ§çµæãæ éã«è§£éããããšãå¿ èŠã§ãããšè¿°ã¹ãŠãã(1)ããŠã€ã«ã¹ãæ€åºããããã«å¿ èŠãªãµã€ã¯ã«éŸå€ïŒCtïŒã¯ãæ£è ã®ãŠã€ã«ã¹éã«åæ¯äŸããŠãããæ€æ»çµæãèšåºçç¶ãšäžèŽããªãå Žåã(PCRã§35ãšå€å®) æ°ããæ€äœãæ¡åããåããŸãã¯ç°ãªãNATæè¡ã䜿çšããŠåæ€æ»ããå¿ èŠãããã(匷調)
WHOã¯ãIVDã®äœ¿çšè ã«å¯ŸããçŸæ£ã®æç çãæ€æ»çµæã®äºæž¬å€ãå€åãããçŸæ£ã®æç çãäœäžãããšåœéœæ§ã®ãªã¹ã¯ãå¢å ããããšãåèµ·ããŠããŸã(2)ãã€ãŸããéœæ§ãšãªã£ã人ïŒSARS-CoV-2ãæ€åºããã人ïŒãæ¬åœã«SARS-CoV-2ã«ææããŠãã確çã¯ããã®ç¹ç°æ§ã«é¢ä¿ãªããæç çã®æžå°ã«äŒŽãæžå°ããã®ã§ããã23ã
ãç¡å¹ãªéœæ§ããšããæŠå¿µãæ ¹åºã«ãã
ããã¯ã匱ãéœæ§ãããåœéœæ§ãå¢å ãããªã¹ã¯ãã®åé¡ã§ã¯ãªããåé¡ãªã®ã¯ããCOVID-19確å®çäŸãã®ç¡å¹ãªæšå®ãå°ããæ¹æ³è«ã®æ¬ é¥ãã§ããã
ãã®WHOã®åçœã«ãã£ãŠç¢ºèªãããã®ã¯ãPCRæ€æ»ïŒå¢å¹
éŸå€ã35ãµã€ã¯ã«ä»¥äžïŒã«ããCOVIDéœæ§ã®æšå®å€ãç¡å¹ã§ãããšããããšã§ããããã®å ŽåãWHOã¯å詊éšãæšå¥šããŠããããæ°ããæ€äœãæ¡åããŠå詊éšãè¡ãã¹ãã§ãã...ãã
WHOããå詊éšããæ±ããã®ã¯ããæã
ã¯å€±æããããšèšãã«çããã
ãã®å§åã¯ãããã©ãŒããŒã§ããããããªããšã¯èµ·ãããªãããã§ã«äžçã§æ°åå人ã ã2020幎2æäžæ¬ããæ€æ»ãåããŠããã
åœåãããPCRæ€æ»ã¯35ãµã€ã¯ã«ä»¥äžã®Ctå¢å¹
éŸå€ã§æ¥åžžçã«é©çšãããŠããããã®ããšãæå³ããã®ã¯ãäžçäžã§é©çšãããŠããPCRã®æ¹æ³è«ããéå»2幎åã®éã«ã誀ã£ãã誀解ãæãCOVID-19æšå®å€ã®äœæã«ã€ãªãã£ããšããããšã§ãããWHOã«ãããšïŒ2021幎1æ20æ¥ïŒãããã¯ç¡å¹ãªæ¹æ³ã«åºã¥ããŠããã®ã§ããã
ãããŠãããã¯ãããããããã³ãããã¯ãã®é²è¡åºŠã枬ãããã«äœ¿ãããçµ±èšã§ããå¢å¹
åšæ35以äžã§ã¯ãæ€æ»ã§ãŠã€ã«ã¹ã®æçãæ€åºããããšã¯ã§ããŸããããããã£ãŠãå
¬åŒã®ãCOVIDæ°ãïŒCOVID-19確å®çäŸæ°ïŒã¯æå³ããªãã
ã€ãŸãããã³ãããã¯ã®ååšã確èªããç§åŠçæ ¹æ ã¯ãªãã瀟äŒçãããã¯ã倧éã®è²§å°ã倱æ¥ããããããããã¯ããŠã³ïŒçµæžå¯ŸçïŒãŠã€ã«ã¹ã®æ¡æ£ãæãããããšãããïŒã«ã¯äœã®æ£åœæ§ããªãããšã«ãªããç§åŠçèŠè§£ã«ããã°âŠ
ããã誰ããPCRã§35ãµã€ã¯ã«ä»¥äžã®éŸå€ã䜿çšããŠéœæ§ãšå€å®ãããå ŽåïŒãšãŒããããšã¢ã¡ãªã«ã®ã»ãšãã©ã®ç ç©¶æãããã§ããïŒããã®äººãå®éã«ææããŠãã確çã¯3ïŒ æªæºã§ããããã®çµæãåœéœæ§ã§ãã確çã¯97ïŒ ã§ããã
...
3. å¢å¹ ãµã€ã¯ã«æ°ïŒ35ãµã€ã¯ã«ä»¥äžã奜ãŸããã¯25ïœ30ãµã€ã¯ã«ïŒã
ãŠã€ã«ã¹æ€åºã®å Žåã35åãè¶ ãããšã现èå¹é€ã§ã®åé¢ã«ãã£ãŠæ±ºå®ãããæææ§ãŠã€ã«ã¹ãšçžé¢ããªãã·ã°ãã«ããæ€åºãããªã[2]ïŒãã誰ããPCRã§
35
35 ãµã€ã¯ã«ä»¥äžã®éŸå€ã䜿çšããå ŽåïŒæ¬§ç±³ã®ã»ãšãã©ã®ç ç©¶æãããã§ããïŒããã®äººãå®éã«ææããŠãã確ç㯠3%æªæºã§ããããã®çµæãåœéœæ§ã§ãã確ç㯠97%ãïŒåŒ·èª¿ïŒ24 ïŒPieter Borger, Bobby Rajesh Malhotra, Michael Yeadon, Clare Craig, Kevin McKernan, et al.
äžèšã®ããã«ããåœè©²çµæãåœéœæ§ã§ãã確çã¯97ïŒ
ãã§ãããã
äžèšã®ããã«ãåœéœæ§ã§ãã確çã¯97ïŒ
ãã§ããããšããã35ãµã€ã¯ã«ä»¥äžã®æ€åºãè¡ãããšã¯ããåœéœæ§ãã®æ°ããå¢å ããããããšã«äžå¯é¿çã«è²¢ç®ããããšã«ãªãã
WHOã¯ãCOVID-19 PCRæ³ã®é©çšãç¡æå³ã§ããããšãèªããã®ã§ããã
CDCã¯PCRãã¹ãã®æ€åãåœããã
WHOã®æŽå²çãªæ€åã«ç¶ããŠã6ã¶æåŸã«CDCã®ã¡ã¢ã«ã«ãïŒmea culpaïŒãçºè¡šãããŸããã2021幎7æ21æ¥ãç±³åœçŸç 察çã»ã³ã¿ãŒïŒCDCïŒã¯ãSARS-CoV-2ãæ€åºã»ç¹å®ããããã®æå¹ãªæ¹æ³ãšããŠãPCRæ€æ»ã®æ€åãæ±ããã
ã2021幎12æ31æ¥ä»¥éãCDCã¯ãSARS-CoV-2ã®ã¿ã®æ€åºã®ããã«2020幎2æã«åããŠå°å ¥ããã¢ãã»ã€ã§ããCDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panelã®ç·æ¥äœ¿çšæ¿èªïŒEUAïŒã®ããã®ç±³åœé£åå»è¬åå±ïŒFDAïŒãžã®èŠè«ãåãäžããŸããã
ãã®å€æŽã«åããCDCã¯ãCDC 2019-nCoV RT-PCRã¢ãã»ã€ã䜿çšããŠããèšåºæ€æ»å®€ããã³æ€æ»æœèšã¯ãå¥ã®FDAå ¬èªCOVID-19ãã¹ããéžæããç§»è¡ãéå§ããããšãæšå¥šããã
CDCã¯ãSARS-CoV-2ãšã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®æ€åºãšéå¥ã容æã«ããããšãã§ããå€éåæ³ã®æ¡çšãæ€èšããããæ€æ»å®€ã«å§ããŠããŸãã(匷調)25
ããèªãã§ã»ããããã®CDCæä»€ãé»èªããŠããã®ã¯ãPCRæ€æ»ããSARS-CoV-2ãšã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ãã广çã«åºå¥ã§ããªãããšã§ããããã®ããšã¯åœåããåãã£ãŠããããšã§ããã
2022幎1æ1æ¥ä»ã§ãCDCã¯ç±³åœã«ãããRT-PCRæ€æ»ã®æšå¥šãåãäžããã®ã§ãã
ãããCDCãšWHOã®äž¡æ¹ãäºåããŠããããã«PCRæ€æ»ãç¡å¹ã§ããã°ããã³ãããã¯ãšèšãããæµè¡ãå§ãŸã£ãŠããäžçäžã§åéã»éèšããã5å7400äžä»¥äžã®ãããããCOVID-19確å®äŸãïŒ2022幎7æïŒãš630äžä»¥äžã®COVIDé¢é£æ»äº¡ãšãããäŸïŒåïŒã¯å
šãç¡æå³ãªãã®ã«ãªã£ãŠããŸãã®ã ã
æ»äº¡èšºææžã®æ¹ãã
PCRæ€æ»ãç¡å¹ã§ãã以äžãSARS-CoV-2ã®äºçš®ã®æ€åºãå«ããCOVID-19確å®çäŸãã®æšå®å€ãå
šãç¡å¹ã§ããããšã«ãªãããã®ããšã¯ãäžçã®COVID-19é¢é£æ»äº¡ã®ç¢ºå®ã«é¢ããæ¹æ³è«ãç¡å¹ã§ããããšãæå³ããã
2020幎12æã®å ±åæžã§ãCDCã¯ãCOVIDã«èµ·å ããæ»äº¡ã®94%ã«ã䜵åçãïŒããªãã¡ä»ã®åå ã«ããæ»äº¡ïŒããããšå ±åããŠããããšã¯æ³šç®ã«å€ãã26ã
36
æ»äº¡äŸã®6ïŒ
ã«ãããŠãCOVID-19ãå¯äžã®åå ãšããŠèšåãããŠãããCOVID-19ã®ã»ãã«ç
æ
ãŸãã¯åå ããã£ãæ»äº¡è
ã«ã€ããŠã¯ãå¹³åããŠ1人åœãã2.6人ã®ç
æ
ãŸãã¯åå ã远å ãããŠãããåç
æ
ãåå ãæã€æ»äº¡è
æ°ã¯ãå
šæ»äº¡è
ã幎霢局å¥ã§ç€ºããã
ãã¥ãŒãšãŒã¯å·ã¹ã¿ãã³ã¢ã€ã©ã³ãã®è¬åå±Michael Lanzaã¯ãã圌ãã¯ãã¹ãŠã®æ»äº¡èšºææžã«COVIDãšæžããŠããããšè¿°ã¹ãŠããŸãã
ãè¬åå±ã¯ãã³ãããã¯ã«èµ·å ããæ»äº¡ã®æ£åœæ§ãçããæ°åã'æ°Žå¢ã'ãããŠããããšãæããŠããã(Project Veritas)27
ããã«ãCDCããMedical Examiners' and Coroners' Handbook on Death Registration and Fetal Death Reporting Revision 2003ïŒæ€æ»å®ã»æ€èŠå®ã«ããæ»äº¡ç»é²ãšèå æ»äº¡å ±åã«é¢ãããã³ããã㯠æ¹èš2003幎çïŒãã®åºæºãçšããŠããããæ¬¡ã®ãããªããšãèµ·ãã£ãŠããã ããã
ã... COVID-19ã®æ»äº¡æ°ã¯çŽ90.2%å°ãªãã£ãã ããã(H.Ealy, M.McEvoy, et al., August 09, 2020ãåç §) 28

COVID-19 æ»å ããšCDCã®ãMore Often Than Notãæ¡é
CDCã¯äœµåçŸæ£ã®åé¡ãèªããªããããæ»äº¡èšºææžã«é¢ããŠã¯å šãç¡å¹ãªæç€ºãå¶å®ããã
2020幎3æ11æ¥ã®æŽå²çãªããã¯ããŠã³ããããã1é±éåŸã«ãCDCããæ»äº¡èšºææžïŒãšå šç±³äººå£åæ çµ±èšã·ã¹ãã ïŒNVSSïŒã§ã®éèšïŒã«é¢ããå ·äœçãªã¬ã€ãã©ã€ã³ãå°å ¥ããã29ã
COVID-19ã¯æ»å ã®åºç€ãšãªããïŒãã®æŠå¿µã¯åºæ¬çãªãã®ã§ã30ã
æ»äº¡ã®æ ¹æ¬çãªåå ã¯ãWHOã«ãã£ãŠæ¬¡ã®ããã«å®çŸ©ãããŠããŸãã
æ»äº¡ã®æ ¹æ¬åå ãšã¯ããæ»ã«çŽæ¥ã€ãªããäžé£ã®äºè±¡ãéå§ãããçŸæ£ãŸãã¯å·å®³ããšWHOã¯å®çŸ©ããŠããŸãã
37
CDCãçµ±èšçãªã³ãŒãåãšåé¡ã«é¢ããŠæšå¥šããŠããã®ã¯ãCOVID-19ã "more often than not ( ããå€ãã®å Žå)"æ»äº¡ã®æ ¹æ¬åå ã§ãããšäºæ³ãããããšã§ãã
CDCã¯ãã®2ã€ã®åºæºãçµã¿åãããŠããŸãããåºç€ãšãªãæ»å ããšãããã§ãªãå Žåãããå€ããã§ãã
COVID-19ã¯æ»äº¡ã®æ ¹æ¬çãªåå ã«ãªãã®ã§ããããïŒ
ãåºç€ãšãªãæ»å ãã¯ãæ»äº¡èšºææžã®ã©ãã§ã©ã®ãããªç¶æ ãå ±åããããã«ãããŸããããããæ»å ã®ã³ãŒãã£ã³ã°ãšéžæã«é¢ããã«ãŒã«ã«ãããCOVID-19ãæ»å ãšãªãããšãããå€ããªããšäºæ³ããã31ã
äžèšã®æä»€ã¯ã«ããŽãªãŒå¥ã§ããã
CDCã®æŠå¿µãšæ£åœæ§
èªèšŒè ã¯ãç¹å®ã®èæ ªãç¹å®ããã«ã³ãããŠã€ã«ã¹ãå ±åããããšã¯èš±ãããªãããããŠãã¬ã€ãã©ã€ã³ã¯COVID-19ãåžžã«è¡šç€ºããªããã°ãªããªãããšãæšå¥šããŠããŸãã

èªèšŒè
ã¯CDCã®åºæºããå€ããããšã¯ã§ããªããCOVID-19ã課ããããCDCã®åºæºãããèªãã§ãã ãã32ã
æãéã¯ãªãã®ã§ãã
ãããã®CDCã®æç€ºã¯ãCOVID-19ãèšé²ããããæ»å ããšããŠåé¡ããããšã«å¯äžããŠãããå
šäœãéããŠãäºã€ã®åºæ¬çãªæŠå¿µãæ¯é
çã§ããã
1. ãæ ¹æ¬çãªæ»å ã
2. æ»å ãåœããMore Often than NotïŒããã§ãªãå Žåãããé »ç¹ã«ïŒãæ¡é
ãããŠããããã®åºæºã¯ãWHOãšCDCã®äž¡æ¹ãèªããŠããããã«ããæ»å ããè£ã¥ããããã«çšããããRT-PCRæ€æ»ã誀解ãæãçµæããããããšããäºå®ã«ããããããã課ããããŠããã®ã§ãã
å®éã«ã¯ãäžèšã®ããã«ãPCRæ€æ»ã®å®æœã忀ãè¡ãããšãªãããCOVID-19ã®å¯èœæ§ãé«ãããŸãã¯ãæšå®COVID-19ãããæ ¹æ¬çãªæ»å ããšã¿ãªãããããšã«ãªãã®ã§ãã
ç±³åœã«ããããåºç€çãæ»å ã®èšå®åºæºã¯ãCDCãå
šåœçã«å®ãããmore often than notãæ¡é
ïŒäžèšåç
§ïŒã«åºã¥ãã
38
ã«ãã æ»å ã® "æšå® "ã®æ¬ é¥
ã«ããã§ã¯ãå·ã«ãã£ãŠåºæºãç°ãªããã«ããã®ã±ããã¯å·ã«ãããæ»å ã®åé¡ã¯ãéå€§ãªæäœã®å¯Ÿè±¡ã«ãªã£ãŠãã33ã
ã±ããã¯å·ä¿å¥çã®æä»€ïŒ2020 幎 4 æïŒã«ããã°ã以äžã®éãã§ããã
ãæ»å ãCovid-19ãšæšå®ãããå ŽåïŒéœæ§åå¿ã®æç¡ã«ãããããïŒã忀ã¯é¿ããããæ»å ã¯Covid-19ãšæšå®ãããã¹ãã§ãããããŸãããæšå®æ»å ãã³ãã-19ã§ããæ»äº¡ã¯èªç¶æ»ãšã¿ãªãããæ€èŠå®ã«ããéç¥ã®å¯Ÿè±¡ãšã¯ãªããªããã (åæãã匷調)34
ãã®æä»€ã§ã¯ã䜵åçŸæ£ã®ã«ãŠã³ããèªããŠããªãã2020 幎 4 æ 16 æ¥ã«é©çšããããã®æä»€ã¯ãCOVID-19 ã«èµ·å ããæ»äº¡æ°ã®å³ææ¥å¢ãå©é·ãããã®ã§ãã£ãã
ã±ããã¯å·ã®ç·æ»äº¡è æ°ã®44.9ïŒ ãCOVID-19ã«èµ·å ããŠããïŒ2020幎4æ11æ¥ãã18æ¥ã®é±ïŒïŒäžã®è¡šåç §ïŒã
ã¢ã³ããªãªãŒã«ã®La Presseã«ãããšãã4æïŒ2020幎ïŒã¯æãæ»è
ã®å€ãæãã§ãã£ããããããLa Presseã¯ä¿å¥çã®æç€ºãåç
§ããã®ã ãããïŒ
以äžã¯ã2020幎4æ12æ¥ãã18æ¥ã®é±ïŒæ¿åºæä»€ã®çŽåŸïŒã«å¯Ÿå¿ããã±ããã¯å·ã®ïŒæ¯æ¥ã®ïŒæ»å ããä¿å¥çãåºããåºæºã«åŸã£ãŠèšæž¬ãããã®ã§ãã35ã 2020幎3æã«ã¯COVIDæ£è
ãæ»äº¡è
ãäºå®äžèšé²ãããŠããªãã
äžè¡šã®ãšãããæ»å ã1æ¥å¹³å

39
ãã®æ°åã¯ãããããèŽåœçãªãã³ãããã¯ã®çµæãªã®ã ãããïŒãããšãã誀ã£ãåºæºã«åºã¥ãååŽçã®ãæéãã®çµæãªã®ã ãããã
- COVIDã«ä¿ã "æšå® "çäŸ
- "éœæ§åå¿ã®æç¡"
- æ»å ã® "æšå® "äŸ
- COVID-19ã«ä¿ãã忀ãé¿ããã¹ããäºäŸ
- ãæ»å ãCOVID-19ã§ãããšæãããæ»ã¯èªç¶æ»ãšã¿ãªãããæ€èŠå®ãžã®éç¥ã®å¯Ÿè±¡ãšã¯ãªããªãã
ç 人ä¿è·åè°äŒïŒCPMïŒã®ããŒã«ã»Gã»ããªã¥ãæ°ã«ãããšã
æ»å ã¯COVIDã§ã¯ãªããè±æ°Žãæ é€å€±èª¿ãéºæ£ã§ããããšãããäžéšã®å»åž«ã®åçºã«ãã£ãŠæããã«ãªããŸããããšBrunetæ°ã¯åããã§ã¯ãCHSLDïŒé«éœ¢è ä»è·æœèšïŒãå人ã®äœå® ã«ããäœå人ãã®äººã ã¯ããæ¬åœã¯äœã®ããã«æ»ãã ã®ã ããããïŒLa PresseããåŒçšããã©ã³ã¹èªèš³ïŒ
ãã¹ãããã¹ãããã¹ãïŒç¡å¹ãªããŒã¿ãš "æ°åã²ãŒã "
人ã
ã¯æ¯ããŠãããPCRãã¹ããããããã«å§ããããåœéœæ§ã®æ°ãå¢ãããŠãããæ¿åºã¯ããããããCOVID-19確å®çäŸãã®æšå®å€ãèšããŸããç®çã§ãPCRæ€æ»ã®åæ°ãå¢ããããšã«é¢äžããŠããŸãã
ããã«ã2021幎åŸåãããå
šäžçã§æ°åååã®æåã»å®¶åºç𿀿»ããããé
åžããããç±³åœã§ã¯10åå以äžã®æ€æ»ããããé
åžãããŸããã
人å£3850äžäººã®ã«ããã§ã¯ãé£éŠæ¿åºã2å9100äžåã®COVID-19æååšå®
æ€æ»ãããã®çŽå
¥ãåœããïŒ2021幎æ«ã2022幎åãïŒããã®æ±ºå®ã¯ãææãã£ã³ããŒã³ã®å
é£ãåãããšã«è²¢ç®ããã ãã§ãªãã瀟äŒãæ··ä¹±ããç¶æ³ãäœãåºããŸãããããããã確å®çäŸãã®æ°ãæŒãäžããããšã«è²¢ç®ãã36 ããããã®æ€æ»ã¯ãæ¥åžžçã«æ£è
ã®å»åŠç蚺æã䌎ããã®ã§ã¯ãªãã
40
第IIIç« ä»å±æž
2021幎1æ20æ¥ä»ãWHOæä»€ã®å šæ37

ããªã¡ã©ãŒãŒé£éåå¿ïŒPCRïŒãå©çšããæ žé
žæ€æ»ïŒNATïŒæè¡ã§
SARS-CoV-2æ€åºã®ããã®ããªã¡ã©ãŒãŒé£éåå¿ïŒPCRïŒæè¡
補åã®çš®é¡ ããªã¡ã©ãŒãŒé£éåå¿ïŒPCRïŒãçšããæ žé
žæ€æ»ïŒNATïŒæè¡ã§
SARS-CoV-2æ€åºã®ããã®æ žé
žæ€æ»ïŒNATïŒæè¡
æ¥ä»ïŒ2021幎1æ13æ¥
WHO-èå¥åïŒ2020/5ãããŒãžã§ã³2
察象è
ïŒæ€æ»å®€å°éå®¶ããã³äœå€èšºæçšå»è¬åã®ãŠãŒã¶ãŒ
æ¬éç¥ã®ç®çïŒWHOã以åã«æäŸããæ
å ±ãæç¢ºã«ããããã®éç¥ã¯ã2020幎12æ14æ¥ã«çºè¡ãããWHOäœå€èšºæçšå»çæ©åšïŒIVDïŒãŠãŒã¶ãŒåãæ
å ±éç¥2020/05ããŒãžã§ã³1ã«åã£ãŠä»£ãããã®ã§ããã
åé¡ã®èª¬æïŒWHOã¯ãPCRæ³ãçšããŠæ€æ»ããæ€äœã®çµæãè§£éããéã«ã䜿çšèª¬ææžïŒIFUïŒã«åŸããããŠãŒã¶ãŒã«èŠè«ããã
IVDã®ãŠãŒã¶ãŒã¯ãPCRéœæ§éŸå€ã®æå調æŽã補é è
ã«ãã£ãŠæšå¥šãããŠãããã©ããã倿ããããã«ãIFUãæ³šææ·±ãèªã¿ãããã«åŸããªããã°ãªããªãã
WHOã¬ã€ãã³ã¹ SARS-CoV-2ã®èšºææ€æ»ã§ã¯ã匱ãéœæ§ã®çµæãæ
éã«è§£éããå¿
èŠããããšããŠãã(1)ã
ãæ
éã«è§£éããããšãå¿
èŠã§ãããšè¿°ã¹ãŠãã(1)ããŠã€ã«ã¹ãæ€åºããããã«å¿
èŠãªãµã€ã¯ã«éŸå€ïŒCtïŒã¯ãæ£è
ã®ãŠã€ã«ã¹éã«åæ¯äŸããŠãããæ€æ»çµæãèšåºçç¶ãšäžèŽããªãå Žåãæ°ããæ€äœãæ¡åããåããŸãã¯ç°ãªãNATæè¡ã䜿çšããŠåæ€æ»ããå¿
èŠããããŸãã
WHOã¯ãIVDã®äœ¿çšè
ã«å¯ŸããçŸç
ã®æµè¡ã«ãã£ãŠæ€æ»çµæã®äºæž¬å€ãå€åããããšãåèµ·ããŠããŸãã
æç
çãäœäžãããšãåœéœæ§ã®ãªã¹ã¯ã¯å¢å ããŸã(2)ãã€ãŸããéœæ§ãšãªã£ã人ïŒSARS-CoV-2æ€åºïŒãæ¬åœã«SARS-CoV-2ã«ææããŠãã確çã¯ãç¹ç°åºŠã®é«äœã«é¢ããããæç
çã®æžå°ã«äŒŽã£ãŠäœäžããã
41
ã»ãšãã©ã®PCRã¢ãã»ã€ã¯èšºæã®è£å©ãšããŠæç€ºãããŠããã®ã§ãå»çåŸäºè
ã¯ããµã³ããªã³ã°ã®ã¿ã€ãã³ã°ãæ€äœã®çš®é¡ãã¢ãã»ã€ã®è©³çްãèšåºèгå¯ãæ£è
ã®ç
æŽãæ¥è§Šè
ã®ç¢ºèªç¶æ³ãããã³ç«åŠçæ
å ±ãšçµã¿åãããŠçµæãèæ
®ããªããã°ãªããªãã
IVD䜿çšè
ãåãã¹ãè¡å
 IFUå šäœããããèªã¿ãã ããã
IFUã®äžã§äžæãªç¹ãããå Žåã¯ãæå¯ãã®ä»£çåºã«ãåãåãããã ããã
 åå ¥åããšã« IFU ã確èªããIFU ã«å€æŽããªãããšã確èªããŠãã ããã
Â å ±åæžã«èšèŒããã Ct å€ãäŸé Œå ã®å»çæ©é¢ã«æäŸããã
åè
1. SARS-CoV-2ã®èšºææ€æ»ã«ã€ããŠããžã¥ããŒããäžçä¿å¥æ©é¢ïŒ2020幎ãWHOåç
§çªå· WHO/2019- nCoV/laboratory/2020.6.
2. ã¢ã«ããã³DGããã©ã³ãJMã蚺æãã¹ã 2: äºæž¬å€. BMJ. 1994幎7æ9æ¥;309(6947):102.doi: 10.1136/ bmj.309.6947.102.
泚é
1. WHOã2020幎3æ8æ¥ãã¡ãã£ã¢ã¹ããŒãã¡ã³ããCOVID-19ã®ãªã¹ã¯ãç¥ãã
https://www.who.int/indonesia/news/detail/08-03-2020-knowing-the-risk-for-covid-19
2. CDC, n.d. ã€ã³ãã«ãšã³ã¶ãš COVID-19 ã®é¡äŒŒç¹ãšçžéç¹. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm#table
3. Michel Chossudovskyææã2020幎4æ5æ¥ãåœã®ã³ãããŠã€ã«ã¹ããŒã¿ãææã®ãã£ã³ããŒã³ãCOVID-19 ææã®æ¡å€§ https://www.globalresearch.ca/fake-coronavirus-data-fear-campaign-spread-of-the-covid-19-infection/5708643
4. Anthony FauciãClifford Laneãä»ã2020幎3æ26æ¥ãCovid-19 - Navigating the Uncharted.
https://www.nejm.org/doi/full/10.1056/NEJMe2002387#
5. ããã«ãã»ãã€ãªãŒã2020 幎 3 æ 11 æ¥ãCOVID-19ã®æ»äº¡çã¯å£ç¯æ§ã€ã³ãã«ãšã³ã¶ããã10åæªãããšAnthony Fauciå士ãè¿°ã¹ãŠãããhttps://reason.com/2020/03/11/covid-19-mortality-rate-ten-times-worse-than-seasonal-flu-says-dr-anthony-fauci/
6.åäž
7. ãã¹ã«ã«ã»ãµã¯ã¬å士ã2020幎11æ5æ¥ãCOVID-19 RT-PCR Test: How to Mislead All Humanity. 瀟äŒãããã¯ããŠã³ããããã®ããã¹ããã®äœ¿çš https://www.globalresearch.ca/covid-19-rt-pcr-how-to-mislead-all-humanity-using-a-test-to-lock-down-society/5728483
8. CDCã2021幎7æ21æ¥ãCDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
https://www.fda.gov/media/134922/download
9. ãã¹ã«ã«ã»ãµã¯ã¬å士ã2020 幎 11 æ 5 æ¥ãCOVID-19 RT-PCR Test: How to Mislead All Humanity. 瀟äŒãããã¯ããŠã³ããããã®ããã¹ããã®äœ¿çš https://www.globalresearch.ca/covid-19-rt-pcr-how-to-mislead-all-humanity-using-a-test-to-lock-down-society/5728483
10. Joseph Hadaya, Max Schumm, et al., April 1, 2020. ã³ãããŠã€ã«ã¹ç
2019ïŒCOVID-19ïŒã®åäººæ€æ»ã«ã€ã㊠https://jamanetwork.com/journals/jama/fullarticle/2764238
11. ãã M ãµãã©ãŒã2020 幎 7 æ 2 æ¥ãã³ãããŠã€ã«ã¹ããªã誰ããééã£ãŠããã®ããããã¯ãæ°ãããŠã€ã«ã¹ãã§ã¯ãªãããå
ç«ããªã ããšãããããšã話ã
https://www.globalresearch.ca/coronavirus-why-everyone-wrong/571804942
42
12. ãã¹ã«ã«ã»ãµã¯ã¬å士ã2020幎8æ7æ¥ãCOVID-19ã§ããããçå®ã«è¿ã¥ãïŒãã¹ããšå
ç«ãhttps://www.globalresearch.ca/covid-19-closer-to-the-truth-tests-and-immunity/5720160
13. Victor M Corman, Olfert Landt, et al., January 23, 2020. ãªã¢ã«ã¿ã€ã RT-PCR ã«ãã 2019 幎æ°åã³ãããŠã€ã«ã¹ (2019-nCoV) ã®æ€åº https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045
14. åäžã
15. åäžã
16. ã¯ãªã¹ãã£ã³ã»ããã·ãŒã2021幎8æ4æ¥ããŠã€ã«ã¹ã®æ£äœ äžçäžã®ä¿å¥/ç§åŠæ©é¢ã¯SARS-COV-2ã®åé¢/æµåã®ãèšé²ããªãã https://www.globalresearch.ca/foi-reveal-health-science-institutions-around-world-have-no-record-sars-cov-2-isolation-purification-anywhere-ever/5751969
17. Chaolin Huang, Yeming Wang, et al., January 24, 2020. äžåœæŠæŒ¢åžã«ããã2019幎æ°åã³ãããŠã€ã«ã¹æææ£è
ã®èšåºçç¹åŸŽhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299/
18. Fan WuãSu Zhaoãä»ã2020 幎 2 æ 3 æ¥ãäžåœã«ãããããåŒåžåšçŸæ£ã«é¢é£ããæ°åã³ãããŠã€ã«ã¹ https://www.nature.com/articles/s41586-020-2008-3
19. ã¯ãªã¹ãã£ã³ã»ããã·ãŒã2021 幎 8 æ 4 æ¥ããŠã€ã«ã¹ã®æ£äœ äžçäžã®å¥åº·/ç§åŠæ©é¢ã¯SARS-COV-2ã®åé¢/粟補ã«ã€ããŠãèšé²ããªãã https://www.globalresearch.ca/foi-reveal-health-science-institutions-around-world-have-no-record-sars-cov-2-isolation-purification-anywhere-ever/5751969
20. WHOã2021幎1æ20æ¥ãSARS-CoV-2ã®æ€åºã«ããªã¡ã©ãŒãŒé£éåå¿ïŒPCRïŒãçšããæ žé
žæ€æ»ïŒNATïŒæè¡ https://www.who.int/news/item/20-01-2021-who-information-notice-for-ivd-users-2020-05
21. Pieter BorgerãBobby Rajesh Malhotraãä»ã2020 幎 11 æ 27 æ¥ãã¬ãã¥ãŒã¬ããŒã Corman-Drosten et al. Eurosurveillance 2020. https://cormandrostenreview.com/report/
22. åäž.
23. WHOã2020 幎 9 æ 11 æ¥ãSARS-CoV-2ã®èšºææ€æ»ã«ã€ã㊠https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2
24. Pieter BorgerãBobby Rajesh Malhotraãä»ã2020 幎 11 æ 27 æ¥ãã¬ãã¥ãŒã¬ããŒã Corman-Drosten ããEurosurveillance 2020. https://cormandrostenreview.com/report/
25. CDCã2021 幎 7 æ 21 æ¥ãã©ãã¢ã©ãŒãïŒCDC RT-PCR for SARS-CoV-2 Testing ã®å€æŽç¹ https://www.cdc.gov/locs/index.html
26. CDCã2022幎1æ20æ¥ãConditions Contributing to COVID-19 Deaths, by State and Age, Provisional 2020-2021. https://data.cdc.gov/NCHS/Conditions-Contributing-to-COVID-19-Deaths-by-Stat/hk9y-quqm
27. ãããžã§ã¯ãã»ããªã¿ã¹ã2020 幎 4 æ 30 æ¥ãhttps://www.projectveritas.com/news/breaking-funeral-directors-in-covid-19-epicenter-doubt-legitimacy-of-deaths/
28. H. Ealy, M. McEvoy, et al., July 24, 2020. ã³ãŽã£ãã-19 çåã®ããããªã·ãŒãããŒã¿åéãšå ±åã®æäœãããã«ãŒã«ãIs It Safe for Students to https://www.globalresearch.ca/covid-fatalities-wer-90-2-lower-how-would-you-feel-about-schools-reopening/5720264
29. å
šåœäººå£åæ
çµ±èšã·ã¹ãã ã2020 幎 3 æ 24 æ¥ãCOVID-19æ»äº¡ã®ããã«å°å
¥ãããæ°ããICDã³ãŒã https://www.cdc.gov/nchs/data/nvss/coronavirus/Alert-2-New-ICD-code-introduced-for-COVID-19-deaths.pdf?fbclid=IwAR2XckyC93jfKqvOue5EdPlNA8LlKKgz4vPZTU1whI4vXLSOADSjsL9XY-M
30.åäž
31. åäž
32. åäž
33. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2021幎2æ14æ¥ãã±ããã¯å·ãCovid-19ã«é¢é£ããæ»äº¡çããŒã¿ã®æ¹ãã https://www.globalresearch.ca/quebec-falsification-of-mortality-data-pertaining-to-covid-19/5737290
43
34 ãã¡ããã芧ãã ããhttps://amol.ca/wp-content/uploads/2020/04/19_avril_20-AU-00603_LET_Opatrny-Codirecteurs_Orientations_ministerielle....pdf
35. åäž
36. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022幎7æ19æ¥ãäžçå²ã«ãããæå€§ã®åããã³ãããã¯ã¯ååšããªãã£ããããŒã¿ã»ããŒã¹ã¯æ¬ é¥ããããhttps://www.globalresearch.ca/biggest-lie-in-world-history-the-data-base-is-flawed-there-never-was-a-pandemic-the-covid-mandates-including-the-vaccine-are-invalid/5772008
37. WHOã2021幎1æ20æ¥ãSARS-CoV-2ã®æ€åºã«ããªã¡ã©ãŒãŒé£éåå¿ïŒPCRïŒã䜿çšããæ žé
žæ€æ»ïŒNATïŒæè¡ https://www.who.int/news/item/20-01-2021-who-information-notice-for-ivd-users-2020-05
44
-------------------第4ç« --------------------
ä»çµãŸããçµæžäžæ³
ã¯ããã«
çµæžåŠ101 2020幎3æ11æ¥ã190ã«åœã§åæã«é©çšãããããã¯ããŠã³ã¯ãçµæçã«
ãåŽååã®æçžããšãè·å Žã®éº»çºãã§ããã
ãè·å Žã®éº»çºãã§ãã
äºæ³ããã圱é¿
äžçå²äžãæãæ·±å»ãªçµæžå±æ©ã
çµæžåŠã®å°éå®¶
åžå ŽåçãéèŠããçµæžåŠã®å°éå®¶ã¯ããã®åºæ¬çãªå æé¢ä¿ãããããªãç¡èŠããŠããã
æ°å€å
žæŽŸã鲿©æŽŸã®æ¿æ²»çµæžåŠè
ã瀟äŒç§åŠè
ã®éã§ã¯ããV the virusããããªãã¡SARS-CoV-2ãçµæžæŽ»åã®èœã¡èŸŒã¿ã®åå ã§ãããšããã®ãã³ã³ã»ã³ãµã¹ã§ããã
åæ§ã®ç«å Žã¯ãAFL-CIOãå«ãåŽåçµåçµç¹ã§ãæ¡çšããããåŽååã®éã蟌ãã¯ãåŽåè
ã®æš©å©ããå®ããããã®ææ®µãšã¿ãªãããã®ã§ããã
åŽåè
ãå®¶ã«éã蟌ããããè·å Žã«è¡ãããšãã§ããªããªãã°ããåžžèçãªåœ±é¿ãã¯æããã§ããïŒç£çŠã¯äžççãªçµæžãšç€ŸäŒã®æ··ä¹±ãå©é·ããã
äž»æµã®çµæžåŠè
ãéèã¢ããªã¹ãã«ããã°ãçµæžå±æ©ã¯2022幎3æåæ¬ã«å§ãŸãããŠã¯ã©ã€ãæŠäºã®çåšãšéãªããšãããŠããã
ãã®èŠè§£ã¯èª€ãã§ããã
çŸåšé²è¡äžã®çµæžã»ç€ŸäŒå±æ©ã¯ã2020幎1æã®ããã¹äŒè°ãšWHOã«ããåœéä¿å¥ç·æ¥äºæ
ïŒPHEICïŒçºä»€ïŒ2020幎1æ30æ¥ïŒã«ç«¯ãçºããå
šäžçã®äººé¡ã«åœ±é¿ãäžããŠããã®ã ã
æç¢ºãªãã§ãŒãºãšãã®çµæ
æ¬ç« ã§ã¯ãäžççµæžã®äžå®å®åã«ã¯ããã€ãã®æç¢ºãªæ®µéãããããšãæ€èšŒããã
45
2020幎1æäžæ¬ïŒãã©ã³ãæ¿æš©ã¯ãç±³åœããéå»14æ¥éã«äžåœãæ è¡ãããå€åœäººã®å ¥åœãæåŠãããšçºè¡šïŒ2020幎1æ31æ¥ïŒ1 ãã©ã³ãã®æ±ºå®ã¯çŽã¡ã«èªç©ºæ è¡ãšäº€éæ©é¢ã®å±æ©ãåŒãèµ·ãããçŸåšãé²è¡äžã§ãããäžç±³è²¿æã ãã§ãªãã芳å ç£æ¥ãæ··ä¹±ããã
2020幎2æ20æ¥ãWHOäºåå±é·ã®ãããã¹å士ã®ãã³ãããã¯ãè¿«ã£ãŠãããšããèŠåã¯ã1929å¹Žä»¥æ¥æãæ·±å»ãªéèæŽèœã®åŒãéãšãªã£ãã
2020幎3æ11æ¥ã®ããã¯ããŠã³ã¯ãçŽ193ã«åœã®çµæžã®ãééããå©é·ããçµæžçã»ç€ŸäŒçã«å£æ» çãªåœ±é¿ãåãŒããã
2020幎11æïœ12æãéšåçãªããã¯ããŠã³ã®ã»ããCOVID-19 ã¯ã¯ãã³ã®çºå£²
2021幎11æïœ2022幎1æïŒãªãã¯ãã³ã®å€çš®ã¯ãéšåçãªããã¯ããŠã³ãã¯ã¯ãã³ãã¹ããŒãã®çºå£²ãã¯ã¯ãã³æªæ¥çš®è ã«åããããå¶éæªçœ®ã®å®æœãæ£åœåããããã«äœ¿çšãããã
2022幎4æïœ7æïŒäžæµ·ãšäžåœã®äž»èŠéœåžéšã«ãããäžåœã®ãŒãã»ãã¬ã©ã³ã¹COVIDãã³ããŒãã«åºã¥ãããã¯ããŠã³æä»€ã®é©çšã
ç±³äžè²¿æã®æ··ä¹±
2020幎1æ31æ¥ã®ãã©ã³ãæ°ã®æ±ºå®ã¯ãWHOäºåå±é·ã«ããåœéçã«æžå¿µãããå
¬è¡è¡çäžã®ç·æ¥äºæ
ïŒPHEICïŒã®çºå決å®ïŒ2020幎1æ30æ¥ïŒã®çºè¡šçŽåŸã«è¡ãããŸãããå€ãã®ç¹ã§ãããã¯äžåœã«å¯ŸãããçµæžæŠäºãè¡çºã§ãã£ãã
ãããŠã2020幎1æ31æ¥ã«ãã©ã³ããäžåœãžã®èªç©ºäŸ¿ãèŒžéææ®µã®æå¶ã決å®ããããšãåããæ¬§ç±³è«žåœã§ã¯äžåœã ãã§ãªãäžåœç³»æ°æã«å¯Ÿãããã£ã³ããŒã³ãå±éãããããšã³ããã¹ãèªã¯ããã³ãããŠã€ã«ã¹ã¯äžåœäººã«å¯ŸããããããŠäžåœäººæ°æã®éã®äººçš®å·®å¥ãåºããããšå ±ãã2ã
"è±åœã®è¯äººç€ŸäŒãã³ãããŠã€ã«ã¹çºçã§äººçš®å·®å¥ã«çŽé¢"
ãµãŠã¹ãã£ã€ãã»ã¢ãŒãã³ã°ã»ãã¹ãïŒéŠæž¯ïŒã«ãããš ãã³ãããŠã€ã«ã¹ãæµè¡ããäžãæµ·å€ã®è¯äººç€ŸäŒã¯äººçš®å·®å¥çãªçœµåãå·®å¥ã«çŽé¢ããããšãå¢ããŠãããè±åœã«äœãäžéšã®è¯äººãã¡ã¯ãäžåœçºã®èŽæ»çãªãŠã€ã«ã¹ãåå ã§æµæã匷ãŸã£ããšèªã£ãŠããã3ã
ç±³äžè²¿æãã¢ã¡ãªã«ã® "ã¡ã€ãã»ã€ã³ã»ãã£ã€ã "ãžã®äŸå床
ã³ãã屿©ãçºçããåœåãç±³äžäºåœéã®è²¿æé¢ä¿ãžã®åœ±é¿ã¯å£æ»
çã§ãã£ããç±³åœã®äžåœããã®åå茞å
¥ã¯ãã³ãã屿©ã®æåã®3ã«æéã§28.3ïŒ
æžå°ããã
2020幎3æ11æ¥ã®äžççãªçµæžæŽ»åã®å°éãšïŒäžéšïŒééãåãã2020幎3æã®ç±³åœã®äžåœããã®èŒžå
¥ã®æžå°çã¯36.5ïŒ
ïŒ2019幎3ææ¯ïŒ4ãããã«2020幎2æã«å§ãŸã£ãæ ¹æ·±ãéè屿©ã®çµæãäžåœã®ç±³åœãžã®ïŒçºè¡šæžã¿ã®ïŒçŽæ¥æè³ãããžã§ã¯ãã®éé¡ã¯çŽ90ïŒ
æžå°ããïŒãã£ãã³ã·ã£ã«ã¿ã€ã ãºïŒ5
46
ã¢ã¡ãªã«ã¯å
é²çã§å€æ§ãªãã€ãã¯çµæžïŒæ°éããã³è»äºçç£ïŒãæã£ãŠããããè£œé æ¥ã®åºç€ã¯åŒ±ããã¢ã¡ãªã«ã¯ãäžè¯äººæ°å
±ååœããã®åå茞å
¥ã«å€§ããäŸåãã茞å
¥äž»å°åçµæžïŒãªãã·ã§ã¢ãªã³ã°ã®çµæïŒã§ããã
ããã«ãã¢ã¡ãªã«ã®éèæ¯é
ãšãã«ãã¯ãŒã«ãããããããã¢ã¡ãªã«ã®ãå®äœçµæžãã®æ§é ã«ã¯æ·±å»ãªæ¬ é¥ããããã³ãã屿©ã«ãã£ãŠããã«æªåããŠããã
ãŸãã2020幎2æã«éå§ãããåäžãã£ã³ããŒã³ããäžåœãããŠã€ã«ã¹ãåºããã責任ããããšããã¯ã·ã³ãã³ã«ããè
ããªã©ãæ¿æ²»çã»å°æ¿åŠçèŠå ãéèŠãªåœ¹å²ãæ
ã£ãŠããã
ç±³åœçµæžã2020幎2æã®éèæŽèœã3æã®ããã¯ããŠã³ãç®åãã«æ ¹æ·±ã屿©ã«é¥ã£ãã®ã«å¯Ÿããäžåœã®åœæ°çµæžã¯å埩ããŠããã2021幎ã«å
¥ããäžåœã®èŒžåºã¯å€§å¹
ã«å¢å ããã
ããã«ãããããããäºåœéã®ç±³äžè²¿æé¢ä¿ã¯å±ãããäžåœã®ç±³åœããã®èŒžå
¥ã®å€§å¹
ãªæžå°ãé¡èã§ããã2021幎ã«äžåœã®å¯Ÿç±³èŒžåºãå¢å ããäžæ¹ã§ãäžåœã®å¯Ÿç±³è²¿æé»åã¯æé31.1ïŒ
å¢å ããïŒãæå ±ã2022幎1æ14æ¥ä»ïŒ6ã
2022幎4æãäžåœçµæžã®åçãªå¥œè»¢ããããCOVID-19ã®ãŒãã»ãã¬ã©ã³ã¹æä»€ã®æ¡æïŒæ°çŸäžäººãèªå®
ã«éããããïŒãé¡èã§ãäžæµ·ã®éèéšéã®äžéšééãšãäžçæå€§ã®æž¯ããã®ååååŒã®éº»çºããããããïŒä»¥äžã®åæåç
§ïŒã
2020幎2æã®ã³ããéè倧æŽèœ
ææ©çãªååŒãšéèè©æ¬ºãéèŠãªåœ¹å²ãæãããã2æ20æ¥ïŒæšïŒååŸããžã¥ããŒãïŒäžå€®ãšãŒãããæéïŒã§ãWHOäºåå±é·ã®ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å士ãèšè äŒèŠãéãããç§ã¯ãã³ãããŠã€ã«ã¹ã®çºçãé£ãæ¢ãããã£ã³ã¹ãçãŸã£ãŠããããšãæžå¿µããŠããããšè¿°ã¹ãŸããã
ãç§ã¯ãæ©äŒã®çªã¯ãŸã ãããšä¿¡ããŠãããããã®çªã¯çãŸãã€ã€ããã7
ãããã®ãè¡æãšçæãã®çºèšã¯ãäžåœä»¥å€ã®åœã§ç¢ºèªãããææè
æ°ã64å人ã®äººå£ã«å¯ŸããŠ1076人ïŒãã€ã€ã¢ã³ãã»ããªã³ã»ã¹ãé€ããšãäžçã§452人ã®ãããããç¢ºèªæ£è
ããããïŒã𿥵ããŠå°ãªãã£ãã«ããããããããããã¯ãèªçºããããšã«è²¢ç®ããïŒç¬¬IIç« ãåç
§ïŒã
ãããã¹å士ã®å£°æïŒæ¬ é¥ã®ããæŠå¿µãšçµ±èšã«åºã¥ãïŒã¯ãå
éšæ
å ±ãäºèŠãããªããã£ãååŒã空売ãã倿°ã®ãããžãã¡ã³ãæ¥åã«ãã£ãŠåŒãèµ·ãããã2æã®éè厩å£ã®èå°ãæŽããã®ã§ããã
COVID-19ã¯ãéèã¯ã©ãã·ã¥ã®è§ŠåªãšããŠç矩ã«ç¹å®ãããã
ãã®è§Šåªã®èåŸã«ã¯èª°ãããã®ã ãããïŒ
éèåžå Žã®æ··ä¹±ãšäžå®ã®åŒãéãšãªã£ãææãã£ã³ããŒã³ã®èåŸã«ã¯èª°ãããã®ãïŒ
äžåœä»¥å€ã®åœã§ç¢ºèªããããCOVID-19ææè
ãã®æ°ã1,076人ãšå°ãªãã£ãããšã¯ãäžççãªæµè¡ã瀺åãããã®ã§ã¯æ±ºããŠãªãã£ããããããããã§åžå Žãæ¥èœããããšã¯ãªãã£ãã
åžå Žã¯æäœãããŠããã®ã ãWHOã®çºè¡šãäºç¥ïŒãå
éšæ
å ±ãïŒããŠããè
ã¯èª°ã§ãããã
47
äºåå±é·ã®2020幎2æ20æ¥ã®å£°æã¯ã倧ããªééçå©çãåŸãããšãã§ããã ããã
å©ççžåïŒWHOã®å®çŸ©ïŒã¯ãã£ãã®ã8 WHOã¯ã²ã€ã財å£ããäžéšè³éæäŸãåããŠããã2019幎9æã®CNBCã®å ±éã«ãããšããã«ã»ã²ã€ãã¯ãè³ç£ã®60ïŒ
ãæ ªåŒïŒæ ªåŒãã€ã³ããã¯ã¹ãã¡ã³ããå«ãïŒã«æè³ããŠããã9ã
2020幎ã³ãããŠã€ã«ã¹æŽèœïŒ2020幎2æ20æ¥ïœ4æ7æ¥ïŒãšåŒã°ãã2æ20æ¥ã«å§ãŸã£ãæ ªåŒåžå Žã®æŽèœã¯ã次ã®ããã«åé¡ãããã
"éèå²äžæãéãäžçæ ªåŒåžå Žã®äžèœã§ããã1929幎ã®ãŠã©ãŒã«è¡å€§æŽèœä»¥æ¥ã®æãç Žå£çãªæŽèœ"
éèã¯ã©ãã·ã¥ã®åå ã¯ãïŒãã¢ããªã¹ããã«ããã°ïŒVãŠã€ã«ã¹ãããªãã¡äžåœåœå€ã§ã®äŒæç ã®ãå€§èŠæš¡ãªæ¡æ£ãã§ãã£ããšãããããããããã¯çã£èµ€ãªåã ã£ããäžåœä»¥å€ã®64å人ã®äººå£ã«å¯ŸããŠãå šäžçã§ã®ææè ã¯ããã1,076人ã§ãã£ãïŒç¬¬IIIç« åç §ïŒãã¡ãã£ã¢ã®åœæ å ±ã¯ãææãã£ã³ããŒã³ã®å éãšããŠéèŠãªåœ¹å²ãæãããã
ã€ã³ãµã€ããŒååŒãšéèè©æ¬º
éèè©æ¬ºããã€ã³ãµã€ããŒååŒãïŒããã¯éæ³ã§ããïŒã®å¯èœæ§ã¯ãéèã¢ããªã¹ããã¡ãã£ã¢ã®å ±éã«ãã£ãŠããããªãææãããã
人éã®æãä»ããªãéãã埮现ãªãŠã€ã«ã¹ãšè€éãªéè倿°ã®éã«å æé¢ä¿ã¯ååšããªãã
ãããã¹å士ã®äžççãªãã³ãããã¯ã®å¿
èŠæ§ã«å¯Ÿããã¿ã€ã ãªãŒãªãèŠåããšçžãŸã£ãŠããæ®ºäººãŠã€ã«ã¹ãã®ææãã£ã³ããŒã³ã¯ããŠã©ãŒã«è¡ã®æ©é¢ææ©å®¶ããããžãã¡ã³ãã®å©çãåŠå¿ãªãã«å¢å€§ãããããšã«ãªã£ããéè屿©ã¯ãå¯ã®åé
ã«å€§ããªå€åããããããïŒç¬¬Vç« ã®åæåç
§ïŒã
2æ20-21æ¥ã®WHOçºè¡šåŸã®1é±éã§ãããŠå¹³åæ ªäŸ¡ã¯12ïŒ
æŽèœããïŒCNBC, February 28, 2020ïŒ10ãã¢ããªã¹ãã«ããã°ãDJIAã®æ¥èœã¯ããŠã€ã«ã¹ã®äžççèå»¶ã®çµæã§ãã£ããšãããWHOã®COVIDéœæ§è
æ°ã®ïŒå°ãªãïŒæšå®å€ïŒäžåœä»¥å€ã§ã¯1,076人ïŒãšççŸããç¡æå³ãªçºèšã§ããã®ã»ãšãã©ã誀ã£ãPCRæ€æ»ã«åºã¥ããŠããã
2æ24æ¥ïŒæïŒãæ ªåŒåžå ŽãåéããããšããCOVIDãäžçäžã«åºãããéèåžå Žã«äžç¢ºå®æ§ããããããŠããããšãããå·®ãè¿«ã£ãå±éºæ§ããããããŠå¹³åæ ªäŸ¡ã¯åäŸã®ãªãæ¥èœãèŠããã
ãäžåœä»¥å€ã§ã®ã³ãããŠã€ã«ã¹ææè æ°ãæ¥å¢ãããŠã€ã«ã¹ã®èå»¶ã«ããäžççµæžã®æžéãé·æåãããšã®æžå¿µã匷ãŸã£ããããæææ¥ïŒ2æ24æ¥ïŒã«æ ªäŸ¡ã¯æ¥èœãããããŠå¹³åã¯1,031.61ãã€ã³ãïŒ3.56ïŒ ïŒå®ã®27,960.80ã§ååŒãçµãããã (CNBC)(匷調)
48

ãŸãã2æ24æ¥ããã©ã³ãã¯12åãã«ã®ç·æ¥æŽå©ãèŠè«ããã

BBCã«ãããšãäžçã®æ ªåŒåžå Žã¯ããŠã€ã«ã¹ã®çµæžç圱é¿ãžã®æžå¿µãããæ¥èœãããŠã€ã«ã¹ãéèåžå Žã®äžèœããããããèŠãããæãã§ãã£ãããšã瀺åãããã
COVID-19ã¯ãéèã¯ã©ãã·ã¥ã®è§ŠåªãšããŠç矩ã«ç¹å®ãããã
49
éèåžå Žã®æ··ä¹±ãšäžå®ãåŒãèµ·ãããåç£ãå¯ã®ååé ãæããæææ¿æ²»ã®é»å¹ã¯èª°ãïŒ
2020幎3æ11æ¥ïŒCOVID-19ã®ãã³ãããã¯ãããã¯ããŠã³ã190ã®åœæ°çµæžã®éé
2020幎3æ11æ¥ãäžåœïŒäººå£64å人ïŒä»¥å€ã®ç¢ºå®æ£è
æ°ã44,279äººãæ»äº¡è
æ°ã1,440人ã®ãªãŒããŒã§ãWHOã¯äžçãã³ãããã¯ãå
¬åŒã«å®£èšããïŒ2020幎3æ12æ¥ã«WHOã3æ11æ¥ã«èšé²ããæ°åïŒ11ã
ãã®äžççãªããã¯ããŠã³ã®æ±ºå®ã®èåŸã«ãããç§åŠãã¯ãè±åœã§ãäºæž¬ãããã60äžäººã®æ»äº¡ãåé¿ããææ®µãšããŠããã³ãã³ã®ã€ã³ããªã¢ã«ã«ã¬ããžã®ããŒã«ã»ãã¡ãŒã¬ãœã³å士ã«ãããæ°åŠã¢ãã«ãã«åºã¥ããŠããã
ãã¡ãŒã¬ãœã³ã®ãã¢ãã«ãïŒå²ç¬ã«è¿ãïŒã¯ãéèåœå±ã«ãã£ãŠãäžçäžã§çµæžãšç€ŸäŒã®æ··ä¹±ãåŒãèµ·ããæ£åœãªçç±ãšããŠå©çšãããã®ã§ããããã¡ãŒã¬ãœã³ã®è©Šã¿ã¯ããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ããæãã¿ãªãè³éæäŸãåããŠããã
2020幎3æ11æ¥ã®WHOã®çºè¡šã®çŽåŸãããææãã£ã³ããŒã³ãæ¬æ Œåããã2020幎2æ20æ¥ïœ21æ¥ã®æŽèœã®å Žåãšåæ§ã«ã2020幎3æ11æ¥ã®WHOäºåå±é·ã«ãã声æã¯èå°ãæŽããã
æ ªåŒåžå Žã¯äžçäžã§æŽèœãããç¿æãããŠïŒDJIAïŒã¯9.99ïŒ
ã®æ¥èœïŒ2,352.60ãã«ã®äžèœãçµå€21,200.62ãã«ïŒã2020幎3æ12æ¥ã®ãé»ãæšææ¥ãã¯ã1987幎以æ¥ãããŠææªã®æ¥ããšãªã£ã12ãéèè©æ¬ºãåŒãéãšãªã£ãã®ã§ãããã¢ã¡ãªã«ã®åäžé·è
ã«æå©ãªéèå¯ã®å€§èŠæš¡ãªç§»è»¢ãè¡ãããŠããïŒç¬¬â
€ç« åç
§ïŒã
åœé£å çåœ193ã«åœã« "Stay at Home "ã®ç£çŠæç€ºãäŒéããããæ¿æ²»å®¶ã¯åŒ·åãªéè婿š©ã®éå
·ã§ããããã®é å€§ãªæ±ºå®ã¯ããŠã€ã«ã¹å¯Ÿçã®ææ®µãšããŠæ£åœåãããã®ã ãããïŒ
ãã®æ±ºå®ã¯ãã€ã³ããªã¢ã«ã»ã«ã¬ããžã»ãã³ãã³ãèšèšããæ¬ é¥ã®ããç£çŠã¢ãã«ã«åºã¥ããŠããã
ãåŽååã®éã蟌ããã¯ãè·å ŽãïŒçç£æŽ»åãåæ¥æŽ»åãªã©ïŒã®éº»çºãšçžãŸã£ãŠãæ ¹æ·±ãäžççãªçµæžææ
ãäžå¯é¿çã«åŒãèµ·ããã
æŽå²äžåäŸã®ãªãããšã ããå€ãã®åœã§ã»ãŒåæã«é©çšãããäžççµæžã®å
šåéãäžå®å®ã«ãªã£ããäžå°äŒæ¥ã¯åç£ã«è¿œã蟌ãŸããã倱æ¥ãšè²§å°ãèå»¶ããŠããã
ããã€ãã®çºå±éäžåœã§ã¯ã飢é¥ãçºçããïŒäžèšã®åæåç
§ïŒããããã®æªçœ®ã®ç€ŸäŒç圱é¿ã¯å£æ»
çã§ãããåœæ°å»çå¶åºŠã®äžå®å®åãå«ãå¥åº·ãžã®åœ±é¿ïŒæ»äº¡çãšçœ¹æ£çïŒã¯ãïŒå€ãã®åœã§ïŒCOVID-19ã«èµ·å ãããã®ãã¯ããã«åé§ããŠããŸãã
çµæžæŠäº
ãã®æç€ºã¯ããŠã©ãŒã«è¡ãäžççµæžãã©ãŒã©ã ãåäžé·è ã®è²¡å£ãããäžããäžããŠããããã®æ¥µæªééãªãããžã§ã¯ãã¯ãäŒæ¥ã¡ãã£ã¢ã«ãã£ãŠã人éçããªå ¬è¡è¡ç掻åãšããŠããããªã説æãããŠããããåœé瀟äŒãã¯ãä¿è·ãã責任ãïŒR2PïŒãè² ã£ãŠãããäžççµæžãã©ãŒã©ã ïŒWEFïŒã®åŸæŽã®ããšãéžæã§éžã°ããããã§ããªãã宿°ããŒãããŒã·ãããããå°çäžã®79å人ã®äººã ãæãããã«ãã£ãŠããã®ã ãäžççµæžã®ééã¯ãããŠã€ã«ã¹ã殺ããããã®ææ®µãšããŠæç€ºãããã
50
ã°ãããŠããããã«èããããå°çã®å®äœçµæžãééããããšã¯ãã解決çãã§ã¯ãªãããããäžççãªäžå®å®åãšè²§å°åã®ããã»ã¹ã®ãåå ãã§ããããã®çµæã眹æ£çãšæ»äº¡çã®ãã¿ãŒã³ã«åœ±é¿ãåãŒãã®ã§ããããã®ç¹ã§ãåãçµãŸãªããã°ãªããªãã®ã¯ãçµæžç倿°ïŒè³Œè²·åã倱æ¥çãªã©ïŒãšåœæ°ã®å¥åº·ç¶æ
ãšã®å æé¢ä¿ã§ããã
åœæ°çµæžã¯ãæ¿æ²»çã瀟äŒçãæåçå¶åºŠãšçµã¿åããã£ãŠãæåŸãéçšãçç£ã貿æãã€ã³ãã©ã瀟äŒãµãŒãã¹ãšãã£ããå®ç掻ã®åçç£ãã®åºç€ãšãªããã®ã§ããã
å°çãšããææã®çµæžãäžå®å®ã«ããããšã¯ããŠã€ã«ã¹ãšéãããã®ã解決çãã«ã¯ãªãåŸãªããããããããã¯åœŒããç§ãã¡ã«ä¿¡ããããããšããæŒãä»ããããã解決çãã§ããããããŠãããã圌ãã®ãã£ãŠããããšãªã®ã§ãã
ããã¯ããŠã³ãšç Žç¶»ã®ããã»ã¹
ãå®äœçµæžããšãããã°ãããŒããããªãã¡éèæ©é¢ã®éã«ã¯éèŠãªé¢ä¿ãããã
çŸåšé²è¡äžã®å¯ã®éäžã¯ãéèæ©é¢ïŒã€ãŸãæ°ååãã«ã®åµæš©è
ïŒãåç£ããäŒæ¥ãåœå®¶è³ç£ã®å®ç©è³ç£ãå奪ããäºå®ã§ããã
ãå®äœçµæžããšã¯ãçç£è³ç£ã蟲æ¥ãå·¥æ¥ãååã»ãµãŒãã¹ã貿æãæè³ãéçšããããŠåŠæ ¡ãç
é¢ã倧åŠãåç©é€šãªã©ã®ç€ŸäŒã»æåçã€ã³ãã©ãªã©ãå®éã®çµæžæŽ»åã®ãçµæžæ¯èгããæ§æãããã®ã§ãããçµæžæŽ»åã®ããã¯ããŠã³ãšééã«ãã£ãŠãäžçãšåœå®¶ã¬ãã«ã®å®äœçµæžãæšçã«ãããŠããã
ååœæ¿åºã«äŒéãããããã¯ããŠã³ã®æç€ºã¯ãè€éãªçµæžç€ŸäŒæ§é ãããªã倿°ã®åœã
ã®ãåœæ°çµæžç¶æ³ããäžå®å®ã«ããããšã«ã€ãªãã£ãŠããã
ãèªå®
åŸ
æ©ãã®ããã¯ããŠã³ã¯ã人ã
ãä»äºã«è¡ãããšãé»ããããæ¥ããæ¬¡ã®æ¥ãŸã§ãïŒäžçäžã§ïŒå€§éã®å€±æ¥è
ãçã¿åºãããããŠããã®ããã¯ããŠã³ã¯ãåœæ°çµæžã®å
šåéã®ééãšçµã³ã€ããŠããã
ããã¯ããŠã³ã¯çŽã¡ã«äººçè³æºïŒåŽååïŒã®é¢è±ãå©é·ãããã®çµæãçç£æŽ»åã忢ãããã
äŸçµŠãšæµéã®çµè·¯ãåçµãããæçµçã«ååã®äŸçµŠäžè¶³ã«é¥ãå¯èœæ§ãããããã®çµæãäžçäžã§æ°å人ã®åŽåè
ãè·ã倱ããåå
¥ã倱ãã
ååœæ¿åºã¯å€±æ¥è
ã®ããã«ããŸããŸãªã瀟äŒçã»ãŒããã£ãããããèšããŠããããéçšäž»ã«ããè³éã絊äžã®æ¯æãã¯äžæããããã®çµæã賌買åãäžççã«åçã«äœäžããããšã«ãªãã
ããã¯æ¯æã®å±æ©ã§ãããè³éã絊æãæ¯æãããªããè²§å°ã«ãããå®¶åºã¯ã飿ã賌å
¥ããããšããå®¶è³ãæ¯æã®äœå®
ããŒã³ãæ¯æãããšãã§ããªããå人ãšå®¶åºã®è² åµïŒã¯ã¬ãžããã«ãŒãã®è² åµãå«ãïŒã¯é«ãèãäžããããããç©ã¿éãªã£ãŠããã
è²§å°ã®ã°ããŒãã«åã¯ãæ¶è²»è
éèŠã®æžéãæãããããçç£ã·ã¹ãã ã«è·³ãè¿ã£ãŠããããªãç Žç¶»ã®é£éãåŒãèµ·ãããå¿
ç¶çã«ãåœéåå貿æã®æ§é ã«ã圱é¿ãåã¶ã
51
äžçã®åµæš©è
ã°ããŒãã«ãããŒã®éèæ©é¢ã¯ã屿©ã«çããŠããå®äœçµæžã®ã嵿š©è
ãã§ããã2020幎3æããã®äžççµæžã®éå¡ã¯ãäžççãªåµåè¶
éã®ããã»ã¹ãåŒãèµ·ããããäžçå²äžåäŸã®ãªããæ°å
åèŠæš¡ã®ãã«å»ºãŠå€§ç€æ¯ãèãåµåãã190ã«åœä»¥äžã®åœæ°çµæžãåæã«çŽæããŠããã
嵿š©è
ã¯ãŸããIMFãäžçéè¡ãå°åéçºéè¡ãªã©ã®åµæš©è
æ©é¢ã®ç£èŠäžã§ãå€§èŠæš¡ãªåµåãããžã§ã¯ããéããŠãåœå®¶ã®ç€ŸäŒçã»çµæžçè³ç£ãå«ããå
Œ
±è²¡ãã®æææš©ããã³ïŒãŸãã¯æ¯é
æš©ãç²åŸããããšããã®ã§ããã
äžççµæžãã©ãŒã©ã ïŒWEFïŒãæå±ããããããããã¥ãŒããŒãã«ããã°ã¬ãŒããªã»ããã®ããšã嵿š©è
ïŒåäžé·è
ãå«ãïŒã¯å®äœçµæžã®éèŠéšéã®è²·åãç Žç¶»äŒæ¥ã®è²·åã«èºèµ·ã«ãªã£ãŠããïŒç¬¬XIIIç« åç
§ïŒ13ã
äžççµæžã®å±æ©ããã®èšŒæ
以äžã§ã¯ãäžççµæžã®åŽ©å£ããããããåçãªåœ±é¿ããåç£ãè²§å°ã倱æ¥ã飢é¥ã®çºçãæè²ã·ã¹ãã ã®åŽ©å£ã«çŠç¹ãåœãŠãªããç°¡åã«æŠèгããŠããã
以äžã«åŒçšããæ°å€ã®ã»ãšãã©ã¯ãåœé£ãååœæ¿åºãé¢ä¿çããã®ãã®ã§ãããæåéã人ã
ã®ç掻ãç Žå£ããŠãããã®é²è¡äžã®äžç屿©ã®æ·±å»ããéå°è©äŸ¡ããã¡ã§ããã
äžçã®çµæžæŽ»åã®ããããéšéã«ãããåµåãããã®åååãšãªã£ãŠããã
以äžã«ç޹ä»ããã®ã¯æ°·å±±ã®äžè§ã«éããªãã
åç£ä»¶æ°
äžççµæžã®é塿ãèæ¯ã«ããåç£ã®æ³¢ã¯ãå€§äŒæ¥ã ãã§ãªããäžå°äŒæ¥ã«ãåãã§ããããã®èšŒæ ã«ãäžå°äŒæ¥ã¯æåéãäžæããã€ã€ããã
OECDãåŒçšããã132ã«åœã®äžå°äŒæ¥ã«é¢ããåœé貿æã»ã³ã¿ãŒã«ãã2020幎ã®èª¿æ»ã«ãããšã
é¶çްã»å°äŒæ¥ã®3åã®2ã¯å±æ©ãçµå¶ã«åŒ·ã圱é¿ãããšå ±åãã5åã®1ã¯3ã«æä»¥å ã«æ°žä¹ ã«ééãããå±éºæ§ããããšææããŠããããããã³ãŒãŒïŒ2020ïŒã¯ãæ§ã ãªåœã§ã®è€æ°ã®èª¿æ»ã«åºã¥ãããã³ãããã¯ã®æåã®4ã¶æã®æ··ä¹±ããã25ïŒ ãã36ïŒ ã®å°èŠæš¡äŒæ¥ãæ°žä¹ ã«ééãããå¯èœæ§ããããšææããŠããã(OECDå ±åæžã匷調)14
ãã«ãŒã ããŒã°ã«ãããš
ãæ¬§å·ã®äžå°äŒæ¥ã®åæ°ä»¥äžããåçãäžãããªããã°æ¥å¹Žã«ã¯åç£ãããšçããŠãããã³ãã19屿©ãããããæå®³ã®å€§ãããæµ®ã圫ãã«ãªã£ãŠããã
ã€ã¿ãªã¢ãšãã©ã³ã¹ã§ã¯5瀟ã«1瀟ã6ã¶æä»¥å ã«ç Žç£ãç³è«ãããšäºæž¬ããŠããã
52
ãããã³ãŒãŒã»ã¢ã³ãã»ã«ã³ãããŒã8æã«æ¬§å·ã®5å€§çµæžåã®2,200以äžã®äžå°äŒæ¥ã察象ã«è¡ã£ã調æ»ã«ãããã15
調æ»ã¯ããã®å±éãã倧çœå®³ã®èŠæš¡ãéå°è©äŸ¡ããåŸåãããããã®æ°ã¯å ±éãããŠãããã®ãããã£ãšå€§ããã
ç±³åœã§ã¯ãç Žç£æç¶ããé²è¡äžã§ãããè°äŒã«å®ãŠãæžç°¡ã®äžã§ãããåŠè
éå£ã«ãããš
ãåç¶å¯èœãªäžå°äŒæ¥ã®ããªãã®éšåãæž ç®ãäœåãªããããé«é¡ã®ããããŠåãè¿ãã®ã€ããªãçµæžçæå€±ãåŒãèµ·ãããšäºæ³ããããåŽåè ã¯ãåç¶å¯èœãªäŒæ¥ã§ãã£ãŠãè·ã倱ãã ãã...
åµåäžå±¥è¡ã®çºçã¯ã»ãŒäžå¯é¿ãšæããããä»å¹Žã®ç¬¬1ååææ«ã§ãç±³åœäŒæ¥ã¯10å 5000åãã«è¿ãè² åµãæ±ãããããã¯ãã»ã³ãã«ã€ã¹é£éŠæºåéè¡ãç¬¬äºæ¬¡äžç倧æŠåŸã«ãã®æ°åã®è¿œè·¡ãå§ããŠä»¥æ¥ãæç¶å€ããã¢ã«ããã³æ°ã¯ããäŒæ¥ã®è² åµãççºçã«å¢ããŠããããšèšã£ããã(NYT, June, 16, 2020)16
ç±³åœã®äžå°äŒæ¥ã«é¢ããŠ
ã»ãŒ90ïŒ ã®äžå°äŒæ¥ããã³ãããã¯ã«ãã匷ãïŒ51ïŒ ïŒãŸãã¯äžçšåºŠã®ïŒ38ïŒ ïŒæªåœ±é¿ãçµéšãã45ïŒ ã®äŒæ¥ããµãã©ã€ãã§ãŒã³ã®æ··ä¹±ãçµéšãã25ïŒ ã®äŒæ¥ã®æå è³éã¯1-2ã¶ææªæºã§ããã"(OECD) 17
ç±³åœã§ 5,800 瀟以äžã®äžå°äŒæ¥ã察象ã«è¡ã£ã調æ»çµæã
åçããäŒæ¥ã® 43ïŒ ããã§ã«äžæçã«äŒæ¥ããŠãããå¹³åããŠãäŒæ¥ã¯åŸæ¥å¡ã 40ïŒ åæžãããåçè ã®4åã®3ã¯ã2ã¶æä»¥äžã®çŸéããæºåããŠããªããšåçã... (OECD)
ãç±³åœã®å šäžå°äŒæ¥çµå¶è ã®åæ°ããè¿ããã¡ã«æ°žä¹ ã«å»æ¥ã«è¿œã蟌ãŸãããããããªããšèããŠããã1930幎代ã®äžçææ ã®æã§ããããã®ãããªããšã¯ãªãã£ãã19ã
ãªãã2020幎3æã®ããã¯ããŠã³ä»¥éïŒç±³åœãã«ãããšãïŒãäžå°äŒæ¥ã ãã§ãªãå€§äŒæ¥ãããããç·æ¥èè³ã§å€ãã®æåœãŠãèè³ãåããŠããããããå®éã®ç Žç£ç³è«ãé ãããèŠå ã«ãªã£ãŠããïŒç±³åœã§ã¯ç¬¬7ç« ã第11ç« åç §ïŒãäžççã«ã¯ãäžçéè¡ããæ¿åºããã®äœå ãã«ãã®è²¡æ¿æ¯æŽããšè¡šçŸããããã«ãããã°ãããŒåµæš©è ããæœ€æ²¢ãªè³éæäŸãåããŠãåç£ã®ç³è«ãéœåããå å»¶ã°ããããŠããã®ã§ããã
äžççãªå€±æ¥
äžççãªéçšã®å€§èŠæš¡ãªçž®å°ãé²è¡äžã§ããã2020幎8æã®å ±åæžã§ãåœéåŽåæ©é¢ïŒILOïŒã¯æ¬¡ã®ããã«ç¢ºèªããŠããã
COVID-19屿©ã¯ãäžçã®ãã¹ãŠã®å°åã§çµæžãšåŽååžå Žã«æ·±å»ãªæ··ä¹±ãããããã以äžã®å°åã§çŽ4åã®ãã«ã¿ã€ã éçšã«çžåœããåŽåæéã®æå€±ãæšå®ãããŠããã
53
2020幎第2ååæããã®ã»ãšãã©ãæ°èåœã»éäžåœã§ãã...ïŒILO, 2020aïŒã...
æãè匱ãªã®ã¯ãäžçã®åŽååã®ååãå ãã 16 å人ã®ã€ã³ãã©ãŒãã«çµæžåŽåè ã§ã圌ãã¯å€§ããªéçšåªå€±ãçµéšããŠããã»ã¯ã¿ãŒã§åããŠããããããã¯ããŠã³ã«ãã£ãŠãã®æåŸãæ·±å»ãªåœ±é¿ãåããŠããã
COVID-19屿©ã¯ãç¹ã«å°å£²æ¥ã宿æ³ã»é£²é£ãµãŒãã¹ãè£œé æ¥ãªã©ã®æã被害ã®å€§ããã»ã¯ã¿ãŒã§ããªã¹ã¯ã®ããä»äºã«å°±ã12å5000äžäººã®åŽåè ã«äžé£ãåãã«å€§ããªåœ±é¿ãäžããŠããïŒILO, 2020bïŒããããã®åŽåè ã®ã»ãšãã©ã¯èªå¶æ¥ã§ãã€ã³ãã©ãŒãã«ã»ã»ã¯ã¿ãŒã®äœåå ¥ã®ä»äºã«å°±ããŠãã...ãäŸãã°ãè¥è ã¯ãå°±è·ãããå°é£ã«ãªãããšã«å ããæè²ãèšç·Žãéçšãåå ¥ã®éçµ¶ãªã©ãè€æ°ã®ã·ã§ãã¯ãçµéšããŠãã20ã
ILOã¯ãCOVIDã®æµè¡ã解決ããããã«ååœæ¿åºãåã£ããšãããè¡åããçãã倧é倱æ¥ã®æ¿æ²»çåå ã«ã€ããŠãäœã説æãããŠããªããããã«ãILO ã¯å€±æ¥ã®æ°Žæºãšæ¿å¢ã®äž¡æ¹ãéå°è©äŸ¡ããåŸåãããã
2022-23幎ãäžçã®å€±æ¥çã¯äžæã®äžéããã©ã
ãã³ãããã¯ã¯å€±æ¥ã®åå ãšããŠæç€ºãããŠãããILOã«ãããš
äžçã®å€±æ¥çã¯å°ãªããšã2023幎ãŸã§COVID-19以åã®ã¬ãã«ãäžåãããšãäºæ³ãããã
2019幎ã®1å8600äžäººã«å¯Ÿãã2022å¹Žã®æ°Žæºã¯2å700äžäººãšæšå®ãããŠãã21ã
ILOã¯ããå€ãã®äººã
ãåŽååãé¢ããããããéçšãžã®å
šäœçãªåœ±é¿ãäžèšã®äžç倱æ¥çã®äºæž¬ããæããã«ãªããªãããšãèªããŠããã
åé¡ãšãªã£ãŠããã®ã¯ãåŽååã®å€§éšåã¯ãåç£ã ãã§ãªããåŽååžå Žããçå€ãããå·®å¥çãªæ¿çåœä»€ã«ããç ç²è
ã§ãããšããããšã§ãã
ååœæ¿åºã¯äŸç¶ãšããŠäžççãªåµæš©è
ã®æ¯é
äžã«ããããã¹ãCOVIDæä»£ã«äºå®ãããŠããã®ã¯ãåŽåè
ã®çµŠä»éã瀟äŒçã»ãŒããã£ãããã®åãæ¶ããå«ãå€§èŠæš¡ãªç·çž®æªçœ®ã®å®æœã§ããã
ç±³åœã«ããã倱æ¥ç
ç±³åœã§ã¯ã3æã®ãªãŒãã³ã·ã§ãã¯çŽåŸããåŽåè
ã®15ïŒ
以äžã«ããã3000äžäººä»¥äžãå€±æ¥æåœãç³è«ã......ããã2020幎3æã®ããã¯ããŠã³ã®çŽåŸããã(CSMã2020 幎 5 æ 6 æ¥)22ã
2020幎12æåæ¬ã«çºè¡šãããããè°äŒãäž»èŠãªãã³ãããã¯é¢é£ããã°ã©ã ãå»¶é·ããè¡åããšããªãéãã1000äžäººä»¥äžã®ã¢ã¡ãªã«äººãã¯ãªã¹ãã¹ã®ç¿æ¥ïŒ2020幎ïŒã«å€±æ¥æåœã倱ããšäºæž¬ãããŠãã-ä»ã®ãšããããã®èŠéãã¯ãããŠãäžç¢ºå®ãªããã ãã(US News and World Report)23ã
ã³ãããŠã€ã«ã¹ã®ææè ãå šåœã§æ¥å¢ããå·ãèªæ²»äœããŠã€ã«ã¹é¢é£ã®èŠå¶ã匷åããå€±æ¥æåœã®ç³è«ãå¢å ããäžãåŽã£ã·ã¡ãè¿«ã£ãŠããããŸããå家人ãåŠçããŒã³å©çšè ãäœå® ææè ã«å¯Ÿããä¿è·ã倱å¹ããã®ãããã®åŽã£ã·ã¡ã®ææã§ããã貯èã倱ã£ãå人ãšäœå® ææè ã®åæ¹ã«ãšã£ãŠãç Žæ» çãªäºæ ãšãªãå¯èœæ§ãããã
54
ã³ãããŠã€ã«ã¹ã«ããäžæ³ããåŸã ã«ç«ã¡çŽãã€ã€ããçµæžå šäœãšããã³ãããã¯ã«ãã£ãŠç Žå£ããã人ã ãšã
ã»ã³ãã¥ãªãŒè²¡å£ã«ããã°ã12ææ«ïŒ2020幎ïŒã«å¶åºŠã倱å¹ãããšãæšå®1200äžäººã倱æ¥çµŠä»ã倱ãå¯èœæ§ããããšããã(US News and World Report)24ã
åŽå幎霢ã®ã¢ã¡ãªã«äººã®4åã®1以äžãè·ã倱ããšãããã¢ã¡ãªã«å²äžæãæ·±å»ãªã¡ã€ã³ã¹ããªãŒãã®çµæžåŽ©å£ã®æäžã«ããããªãçœé£ãç«ã¡ã¯ã ããã
åœå¢èª¿æ»å±ã®æšèšã«ããã°ã3000äžãã4000äžäººã®ã¢ã¡ãªã«äººããå®¶è³ãäœå® ããŒã³ãæ¯æãããã®åå ¥ããªãããã«ã2021幎ãã22幎ã«ãããŠç«ã¡éããè¿«ãããå¯èœæ§ããããšããã
é£éŠæ¿åºã®æŽå©ãå®¶è³ã®ã¢ã©ããªã¢ã ã®å»¶é·ããªããã°ãèæžã®ãããªå€§æšäºãä»åŸæ°ã«æã§èµ·ãããããããªãã(ã¹ãã£ãŒãã³ã»ã¬ã³ããã³)25
欧å·é£å(EU)ã®å€±æ¥ç
ãã³ãããŠã€ã«ã¹ã®å€§æµè¡ãšããã«ç¶ãååœæ¿åºã«ããééã®åœ±é¿ã§ãEUå šäœã®å€±æ¥çã¯2020幎ã«ã¯9%ã«äžæãããšäºæ³ãããŠããã26ã
EUã®å ¬åŒçºè¡šã«ããã°ãã®ãªã·ã£ãã¹ãã€ã³ããã«ãã¬ã«ã¯ããã³ãããã¯ã®éå§ä»¥æ¥ãè¥å¹Žå±€ã®å€±æ¥çãåã³å€§ããäžæãããã®ãªã·ã£ã§ã¯ã[2020]幎3æã®31.7ïŒ ãã6æã®39.3ïŒ ãžãšæ¥å¢ããã¹ãã€ã³ãšãã«ãã¬ã«ã§ãããããã33.9ïŒ ãã41.7ïŒ ã20.6ïŒ ãã27.4ïŒ ãšåæ§ã®å¢å ãèŠããã27ã
ã©ãã³ã¢ã¡ãªã«ã®å€±æ¥ç
ã©ãã³ã¢ã¡ãªã«ã§ã¯ã2019幎æ«ã®å¹³å倱æ¥çã¯8.1ïŒ ãšæšå®ããããILOã¯ã4ïœ5ïŒ ãã€ã³ããšå°å¹ ã«äžæãã4100äžäººã®å€±æ¥è ãåºãå¯èœæ§ããããšããŠãã28ã
絶察æ°ã§ããã°ããããã®çã¯ãä»äºãæ¢ããŠããã®ã«æ¡çšãããªãäººã®æ°ãããã³ãããã¯åã®2600äžäººãããILOã®å°éå®¶ãçºè¡šãã2020幎ã«ã¯4100äžäººã«å¢å ããããšãæå³ããã
ILOãšäžçéè¡ã®ãããã詊ç®ã¯èª€è§£ãæããããªããç±³å·éçºéè¡ïŒIDBïŒã«ããã°ãäžåç±³å°åã®å€±æ¥è
ã®å¢å ã¯2020幎ã«2400äžäººèŠæš¡ã§ãããã³ãã³ãã¢ã§ã¯360äžäººèŠæš¡ããã©ãžã«ã§ã¯700äžäººèŠæš¡ãã¡ãã·ã³ã§ã¯700äžäººèŠæš¡ã®éçšåªå€±ãçºçããŠãã29ã
ãããã®æ°åã§ããã倱æ¥ã®æ¿å¢ãéå°è©äŸ¡ããåŸåãããããããŠã2021-22幎ã«ã¯ãéšåçãªããã¯ããŠã³ãåããŠç¶æ³ãé²å±ããåç£ã®æ³¢ãåã³æŒãå¯ããŠããŠããã
INEGIïŒInstituto Nacional de EstadÃstica y GeografÃaïŒã®èª¿æ»ã«ãããšãã¡ãã·ã³ã®å€±æ¥è
ã®å¢å ã¯ã2020幎4æãããªãã¡2020幎3æ11æ¥ã®åœæ°çµæžã®ããã¯ããŠã³ãšééã®ç¿æã«1250äžäººã®ãªãŒããŒã§ãã£ã30ã
55
飢é¥ã®çºç
è²§å°ãšæ
¢æ§çãªæ é€äžè¶³ã¯æ¢æäºå®åãããŠããã
第äžã«ããã¯ãçµæžæ¿çæ¹é©ãšã°ããŒãã«ãªçµæžåç·šã®é·æçãªæŽå²çããã»ã¹ãããããããçºå±éäžåœãšå
é²åœã®äž¡æ¹ã«ãããŠãäžçäžã®ç掻氎æºãæŒãäžããããšã«è²¢ç®ããŠããã
第äºã«ãããããæ¢åã®æŽå²çãªå€§éè²§å°ã®ç¶æ³ã¯ãCOVIDã®ããã¯ããŠã³ã®è³Šèª²ã«ãã£ãŠæªåããæ·±å»åããã
äžç人å£ã®å€§éšåã¯ã2020幎3æã®COVID-19ããã¯ããŠã³ã®åã«ãã§ã«è²§å°ã©ã€ã³ã倧ããäžåã£ãŠãããåºæ¬çãªé£ç³§äž»é£ã®æè¿ã®äŸ¡æ Œäžæã¯å£æ»
çã§ããã
äžçé£ç³§èšç»ïŒWFPïŒã«ãããšãã6å9000äžäººãååã«é£ã¹ãããšãã§ãããããã«1å3000äžäººã飢é€ã®ç¬æžéã«è¿œãããããå±éºæ§ããã ããšããã(2020幎11æå£°æ)
ãã®æ°åã«ã¯çåããããFAOãWFPããéäžåœãå
é²åœãåãããäžçã®äž»èŠå°åã«ãããŠã蟲æ¥çç£ã®äžå®å®åãšçžãŸã£ãŠå€§éã®è²§å°ãåæã«èªçºãããã·ã§ãã¯ã¡ã«ããºã ããšããŠãåœæ°çµæžã®ããã¯ããŠã³ãšééãäžå¿çãªåœ¹å²ãæ
ã£ãŠããããšã«è§ŠããŠããªãã
æ ¹æ¬çãªå æé¢ä¿ã«ã¯è§ŠããŠããªããæ°åå€åãçŽäºåæãåªå
ãããã
ãç§ãã¡ã¯ç®ã®åã§å€§æšäºãç®ã®åœããã«ããŠããã®ã§ãã飢é¥ã¯ãçŽäºã«ãã£ãŠåŒãèµ·ããããæ°åå€åãšCOVID-19飢é€ã®ãã³ãããã¯ã«ãã£ãŠç œãããäœçŸäžãã®å®¶æã®éãå©ããŠããã®ã§ãã(WFPäºåå±é· ããããã»ããŒãºãªãŒïŒ
FAOã®å ±åæž
FAOã«ãããšãå°ãªããšã25ã®çºå±éäžåœã§é£¢é¥ãçºçããŠãããã¢ãžã¢ãšã©ãã³ã¢ã¡ãªã«ã®å€§éšåããšãŒããããäžæ±ãåã¢ã¡ãªã«ã¯å«ãŸããŠããªãïŒäžã®å°å³åç §ïŒã
ãåœé£é£ç³§èŸ²æ¥æ©é¢ïŒFAOïŒããã³äžçé£ç³§èšç»ïŒWFPïŒã¯ã以äžã®27ã«åœãé£ç³§å±æ©ã«çããŠãããšèªå®ããŠããŸããåœé£é£ç³§èŸ²æ¥æ©é¢ïŒFAOïŒãšäžçé£ç³§èšç»ïŒWFPïŒã¯ãCOVID-19ã«èµ·å ããé£ç³§å±æ©ã®æåç·ã«ãã27ã«åœãç¹å®ããŸããããã³ãããã¯ã®æ³¢å广ã¯ãæ¢åã®é£¢é€ã®èŠå ãæªåãããããã§ãã
ã¢ãžã¢ã®ã¢ãã¬ãã¹ã¿ã³ããã³ã°ã©ãã·ã¥ããããã€ãããããºãšã©ãäžå€®ã¢ã¡ãªã«ãäžæ±ã®ã€ã©ã¯ãã¬ããã³ãã¹ãŒãã³ãã·ãªã¢ãã¢ããªã«ã®ãã«ãããã¡ãœãã«ã¡ã«ãŒã³ããªããªã¢ãããªãããžã§ãŒã«ããã€ãžã§ãªã¢ãã¢ã¶ã³ããŒã¯ãã·ãšã©ã¬ãªãããžã³ãããšãŸã§ãã©ã®å°åãç¡çžã§ã¯ãããŸããã
FAOãšWFPã®å ±ååæã¯ããããã®ããããã¹ãããåœãã¯ãä»åŸæ°ã¶æã®éã«ãæ·±å»ãªé£¢é€ã«è¿œã蟌ãŸãã人ã ã®æ°ã®å¢å ãªã©ãé£ç³§å®å šä¿éãèããæªåãããªã¹ã¯ãé«ããå Žåã«ãã£ãŠã¯ãã§ã«æªåããŠãããšèŠåããŠããŸãã
56

COVID-19ã®ãã³ãããã¯ã¯ã瀟äŒãšçµæžã«åºç¯å²ãã€å€é¢çãªéæ¥ç圱é¿ãåãŒãå¯èœæ§ããããããã¯å¥åº·äžã®ç·æ¥äºæ ãçµãã£ãåŸãé·ãç¶ãå¯èœæ§ãããããããã¯ãæ¢åã®äžå®å®ã屿©ãæªåãããããé£ç³§å®å šä¿éãæ é€ãçæŽ»ã«åœ±é¿ãåãŒããããªæ°ãã屿©ãåŒãèµ·ããããããå¯èœæ§ãããã
ILOã®ããŒã¿ã«ããã°ãäžçã§åã人ã®62%ã«ããã20å人以äžãã€ã³ãã©ãŒãã«çµæžã«åŸäºããŠãããäœçŸäžäººãã®äººã ã飢é€ã®ãªã¹ã¯ã®é«ãŸãã«çŽé¢ããŠãããã€ã³ãã©ãŒãã«åŽåè ã®åå ¥ã¯82ïŒ æžå°ããã¢ããªã«ãšã©ãã³ã¢ã¡ãªã«ãæå€§ã®æžå°ã«çŽé¢ãããšæšå®ãããŠããŸãïŒILO 2020ïŒã(FAO, p.6)31
äžçã®é£¢é¥ã80ã«åœã®æ¥æ§é£¢é€
äžçé£ç³§èšç»ïŒWFPïŒã®2021幎11æã®å ±åæžãææããŠããã
äžççãªé£¢é¥ãšã80ã«åœã®æ¥æ§é£¢é€ã
äžçã®é£¢é€ã¯ææ ®ãã¹ãé床ã§å¢å ãç¶ããŠããŸãïŒç§ãã¡ã®ææ°ã®æšèšã§ã¯ã80ã«åœã§2å8270äžäººã極端ãªã¬ãã«ã®æ¥æ§é£¢é€ã«é¥ã£ãŠããããšãåãã£ãŠããŸããããã¯ã2019幎ïŒ58ã«åœã®1å3500äžäººãæ¥æ§é£æäžå®ã«åé¡ãããæïŒãšæ¯èŒããŠãçŽ110ïŒ å¢å ããŠããããšãæå³ããŸãã
ãã®2å8770äžä»¶ã®æ¥æ§é£¢é€ãšãããæšæž¬ãã¯ãå²ç¬ãšãåœã®çµ±èšãã®å¢çç·äžã«ããã倧éã®è²§å°ã¯äžçäžã«åºãã£ãŠããããã®ãæšèšãã¯ãäžçé£ç³§èšç»ïŒåœé£æ©é¢ïŒã人éçã»åæ çãªåºæºãšããŠæã¡åºããŠããæ¬¡ã®æŠå¿µã«åºã¥ããŠããã
ãçããããã«å¿ èŠãªåºæ¬çãªé£äºã1æ¥1é£ã1人åœãã1æ¥0.43ç±³ãã«ã(WFPãP1)
57
ãã£ãŒãã£ã³ã°ã»ã¢ã¡ãªã«ã«ããæè¿ã®æšèšã§ã¯ã2020幎ã«ã¯1500äžäººã®åã©ããå«ã4500äžäººã«ãããã¢ã¡ãªã«äººã®7人ã«1人ãã飿äžå®ããçµéšãããšãããŠããŸãã
ãã³ãããã¯ãå§ãŸãåãå šäœã®é£ç³§äžå®çã¯ã1990å¹Žä»£ã«æž¬å®ããå§ããŠä»¥æ¥ãæäœå€ãèšé²ããŠãããããã®æ¹åã¯ãã³ãããã¯ã«ãã£ãŠèŠããã€ã€ãã35ã
ã¹ãã£ãŒãã³ã»ã¬ã³ããã³ã«ããã°
ã¹ãã£ãŒãã³ã»ã¬ã³ããã³ã«ããã°ããä»å¹ŽïŒ2020 幎ïŒãç±³åœã®çŽ 4 äžåž¯ã« 1 äžåž¯ãé£ç³§é£ãçµéšããåã©ãã®ããäžåž¯ã® 27ïŒ
以
åã©ãã®ããäžåž¯ã® 27ïŒ
以äžã§ããã
ããŒã¹ãŠã§ã¹ã¿ã³å€§åŠæ¿çç ç©¶æã®èª¿æ»ã§ã¯ãåã©ãã®ããé£ç³§äžå®äžåž¯ã¯30ïŒ
è¿ãã«äžããšæšå®ãããŠãããé»äººã®å®¶åºã¯ãçœäººã®å®¶åºã®2åãé£ç³§é£ã«é¥ã£ãŠããŸããã©ãã³ç³»ã®äžåž¯ãäžé£ãåãã§ããã36ã
åäžé·è ã®ãäžç飢é¥ãžã®è§£æ±ºçãïŒ
ç®èãªããšã«ãäžçé£ç³§èšç»ïŒWFPïŒã¯ãCOVID-19屿©ã®éçšã§å¯ãåŸãåäžé·è ã®æ åå®¶ãã¡ïŒãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãããã¯ãã§ã©ãŒè²¡å£ãªã©ïŒãã飢é¥ã«èŠãã4200äžäººãå¯å€§ã«ãææžããããšãçºè¡šããŠããã
ãã®ãããªäžççãªè²§å°åã®ããã»ã¹ã¯ãåäžé·è ãåœã®ç§åŠãšè©æ¬ºçãªååŒãéããŠå¿ ãè¡ãå¯è£åã®çŽæ¥çãªçµæã§ããããšãå¿ã«çããŠãããŠã»ããïŒç¬¬Vç« åç §ïŒã
Oxfamã«ããã°ãããã³ãããã¯äžã«æ°ããªåäžé·è ãçãŸããããšã«ã......äœçŸäžãã®äººã ã远ããããããæ°çŸäžäººã極貧ã«è¿œã蟌ãŸãããã
ãããã¹äŒè°ã«éãŸã£ãåäžé·è ãã¡ã¯ãéå»2幎éããã®è²¡ç£ã®è«å€§ãªæ¥å¢ã享åããŠããããã³ãããã¯ãšä»åã®é£ç³§ã»ãšãã«ã®ãŒäŸ¡æ Œã®é«éš°ã¯ãå¯è£å±€ã«ãšã£ãŠã¯å€§åœããã§ããããäžæ¹ã§äœçŸäžäººãã®äººã ãçæŽ»è²»ã®é«éš°ã«ãã飢é€ãšè²§å°ã«çŽé¢ããŠããã®ã ã(ãªãã¯ã¹ãã¡ã )
æè² åã©ããã¡ãžã®åœ±é¿
åžæ°ç€ŸäŒã®æ ¹å¹¹ãè ããããŠããããŠãã»ãã®æšèšã«ãããšãäžçäžã§16å人ã®åã©ããšéå°å¹ŽãåŠæ ¡ã®ééã®åœ±é¿ãåããŠãã37ã
COVID-19ã®æµè¡ãäžçäžã«åºããã«ã€ãã倧倿°ã®åœãåŠæ ¡ã®äžæééãçºè¡šããäžçäžã®çåŸã®91ïŒ ä»¥äžã«åœ±é¿ãåãŒããŠãã...ããã»ã©å€ãã®åäŸãã¡ãåæã«äžå°±åŠã«ãªã£ãããšã¯ãã€ãŠãªãã£ã...
倧åŠãå°éåŠæ ¡ã麻çºããŠãããåŠçãã¡ã¯æè²ãåããæš©å©ãåŠå®ãããŠããã®ã§ãããŠãã¹ã³ã¯10å人以äžã®åŠç¿è ã圱é¿ãåããŠããããšã確èªããäžæ¹ã§ãå ·äœçãªè§£æ±ºçãæ¹å€ã¯äœã瀺ããŠããªããååœæ¿åºã«æŒãä»ãããããããããã宿°é£æºãã®å ¬åŒã·ããªãªãé¡é¢éãã«æ¡çšãããŠããã®ã§ãã38ã
59
132ã«åœã§åŠæ ¡ééã宿œããããäžå³åç §ïŒãŠãã¹ã³ã2020 幎 5 æïŒ

çµæžçã»ç€ŸäŒç圱é¿ã«é¢ããäžèšã®æ€èšã¯ãè€éãªããã»ã¹ãæã瀺ããŠãããäžç人å£ã®å€§éšåã¯è²§å°ãšçµ¶æã«é¥ã£ãŠãããäžèšã®åœé£ã®æ§ã ãªæ©é¢ã¯ã衚é¢ã ããåãäžããŠããã«éããªããæ ¹æ¬çãªåå ã¯ãåã«å¯ŸåŠãããŠããªãã ããªã®ã ã
äžçã®æ è¡ã»èгå çµæž
ã³ãã屿©ä»¥åã¯ãæ
è¡ã»èгå
ç£æ¥ã¯äžççµæžã®äž»èŠãªéšåãå ããŠãããäžçã® GDP ã®çŽ 10ïŒ
ãå ããå
šäžçã§ 3 å 2 åäžäººä»¥äžã®åŽåè
ãåããŠãããšæšå®ãããŠãã39ã
æ
è¡ã»èгå
ç£æ¥ã¯ãèªç©ºäŒç€Ÿã空枯æœèšãéžäžèŒžéãããã«ããªãŸãŒããã¬ã¹ãã©ã³ãåç©é€šãã³ã³ãµãŒãããŒã«ãå
¬åããã®ä»æ§ã
ãªéœåžãµãŒãã¹ãå«ãã§ããããåç£ã«è¿œã蟌ãŸãã倧éã®å€±æ¥è
ãçºçããã
ç¹ã«èгå
ç«åœã§ããã€ã¿ãªã¢ããã©ã³ã¹ãã¹ã€ã¹ãã¿ã€ããããã ãã¡ãã·ã³ããã¥ãŒãããããã«å
±ååœããã«ãŒãããããªã©ã§ã¯ãçµæžçã瀟äŒçã«å£æ»
çãªææãåããŠããã
芳å
ç£æ¥ã«ãããéçšã®åªå€±ã¯ãäžçã§1åäººèŠæš¡ã«ãªããšæšå®ãããŠããïŒ2020幎11æå ±åãIMFå ±åæžãåç
§ïŒ40ã
ç±³åœã«ãããéçšã®åªå€±
äžçæ è¡èгå åè°äŒïŒWTTCïŒã«ããã°ããäžçæ è¡ã«å¯Ÿããéå£ããã®ãŸãŸã§ããã°ãç±³åœã§ã¯...920äžäººãšããé©ç°çãªéçšã倱ãããå¯èœæ§ããããWTTCã¯ã2019幎ã«ç±³åœã§åéšéãæ¯ããå šéçšã®åå以äžã倱ãããäºå®ã ãšèŠç©ãã£ãŠããŸããæ è¡ã»èгå ã»ã¯ã¿ãŒå ã®1080äžãã1380äžäººã®éçšããæ·±å»ãªå±éºã«ãããããŠããã41ã
60
2020幎3æ11æ¥ã®å°éãšçžãŸã£ãŠãç©ºã®æ
ã®å¶éãäžå°ã®å°åèªç©ºäŒç€Ÿã®çµçãåŒãèµ·ããããã2020幎ãã2022幎ã«ãããŠãã¢ãšãã»ã¡ãã³èªç©ºãã¢ãã¢ã³ã«èªç©ºãåã¢ããªã«èªç©ºãªã©ã倿°ã®ãã·ã§ãã«ãã©ãã°ãã£ãªã¢ãäºå®äžã®ç Žç¶»ç¶æ
ã«é¥ã£ãŠãããå ±åæžã«ãããšã2020幎1æä»¥éãã43ç€Ÿã®æ°éèªç©ºäŒç€Ÿãç Žç¶»ãã...å®å
šã«éèªã忢ãŸãã¯äžæãããŠãããšã®ããšã§ããããŸããæ°éèªç©ºæ©ã®çç£ã«ãåçºããã£ã42ã
ç±³åœã§ç¢ºèªããã5ä»¶ã®COVID-19éœæ§äŸã«åºã¥ãã2020幎1æ31æ¥ã«ãã©ã³ããäžåœãžã®èªç©ºæ
è¡ã忢ããããšã¯ãæ¬çš¿å·çæç¹ã§ãç¶ããŠããèªç©ºæ
è¡ã»èгå
屿©ã®èå°ãæŽããäžã§éèŠãªåœ¹å²ãæãããã
ãã®ééã¯ããšãŒãããæå€§ã®äº€éã€ã³ãã©ãããžã§ã¯ãã§ããã€ã®ãªã¹ãšãšãŒããã倧éžãçµã¶å°äžãã³ãã«ã«ãæ¯éãããããããŠãŒãã¹ã¿ãŒã¯äºå®äžã®åç£ãšããäºæ
ã«é¥ã£ãã
ããããåœéæ
è¡ã®æ··ä¹±ã¯ãã¹ãŠã殺人ãŠã€ã«ã¹ã«å¯Ÿæããææ®µãšããŠäžè«ã«æç€ºãããŠããã倧ãŠãœã§ããã
åç£ããããã«ãã§ãŒã³ã倧æèªç©ºäŒç€Ÿã¯ãã©ãèããŠããæ°ååã®éæã¡ã«åºå€ã§ãæŸããããã ããã
äžæµ·2022幎COVIDã®ãŒãã»ãã¬ã©ã³ã¹æä»€ãäžåœèŒžåºçµæžã®äžå®å®åïŒ
2022幎3æäžæ¬ãã4æäžæ¬ã«ãããŠãäžåœæ¿åºã¯äººå£2600äžäººã®æž¯æ¹Ÿéœåžãäžæµ·ã«é¢ããå°éãåœããã
äžæµ·ã®åŽååã®ç£çŠã¯ããCOVID Zero Tolerance Mandateãã«åºã¥ããŠå®æœãããããäžåœå
šåããå°ãªããšã 38,000 人ã®å»çåŸäºè
ãäžæµ·ãæ¯æŽããããã«é
åããã......ãªãã¯ãã³å€çš®ãšã®æŠãã«ãããŠãïŒGlobal TimesïŒ43Â

ç®ã«èŠããŠãäžåœã®ä¿å¥åœå±ã¯ãã¡ãŠãã»ã²ã€ãã®ããã»ç§åŠãå°ã蟌ãã®ã³ã³ã»ã³ãµã¹ãå¹³ç¶ãšæ¿èªããŠããã®ã§ãããäžåœã®çŸç
管çäºé²ã»ã³ã¿ãŒïŒCCDCïŒã¯ãã¢ã³ãœããŒã»ãã¡ãŠããã®ååã§ãããžã§ãŒãžã»ã¬ãªã»ããŒå士ã責任è
ã§ãããã¢ã³ãœããŒã»ãã¡ãŠãã¯ã¬ãªã»ããŒå士ã®åž«å ã§ããã
äžåœã®ãŒãã»ãã¬ã©ã³ã¹COVIDæä»€ã¯ãã¢ã³ãœããŒã»ãã¡ãŠãããã«ã»ã²ã€ãããWHOã®åŸæŽã®ããšïŒäžççµæžãã©ãŒã©ã ãšç·å¯ã«åè°ïŒäž»å¬ãã2020幎3æ11æ¥ã®ããã¯ããŠã³ïŒãåœç§åŠãã«åºã¥ãïŒããã³ããŒïŒããŒã¹ãããããã®ã§ãããäžåœã®Zero Tolerance COVID Mandateã¯ææãã£ã³ããŒã³ãåæã«ããŠããã
2022幎7æäžæ¬ãäžåœã®ä¿å¥åœå±ã¯ããææåã®åŒ·ããªãã¯ãã³BA.5äºåã察çãšããŠãè€æ°ã®å€§éœåžåã«ãCOVID Zero Tolerance Mandateãã宿œããããæç€ºããããšãçºè¡šããŸããã
åŽååã¯å€ãã®å·¥æ¥éœåžã«éã蟌ããããçµæžã»ç€ŸäŒã®æ··ä¹±ãšçµæžæŽ»åã®åçãªæžå°ãæããããã€ã¿ãŒéä¿¡ã«ãããš
61
BA.5äºçš®ïŒœç³»çµ±ã¯ãä»ã®å€ãã®åœã ã§æ¥éã«åºãã£ãŠãããé西çã®è¥¿å®ãéŒå¯§çã®å€§é£ãªã©ã®éœåžã§æ€åºãããŠããã...ãäžåœçŸç äºé²ç®¡çã»ã³ã¿ãŒã«ãããšã5æ13æ¥ã«ãŠã¬ã³ãããäžæµ·ã«é£ãã§ããæ£è ããäžåœã§åããŠçºèŠããããã®æã«ã¯çŸå°ã§ã®ææãšã®é¢é£ã¯ãªãã£ã44ã
ãã®æã®ãŠã¬ã³ãããã®ãæ£è
ãã¯ãäžåœã«åž°åœåŸãPCRæ€æ»ãåããã®ã§ããããïŒ
äºçš®ãå€çš®ã¯ããããªãç¶æ³ã§ãPCRæ€æ»ã§ã¯æ€åºã§ããªãïŒãªãªãžãã«ã®SARS-CoV-2ãŠã€ã«ã¹ã¯PCRæ€æ»ã§ã¯æ€åºã§ããªãã第IIIç« åç
§ïŒã
äžåœã®äž»èŠå°åã§å€æ°ã®éœåžéšãééãããã2022 幎 7 æ 11 æ¥ãäžåœåœå®¶è¡çå§å¡äŒã¯ãäžåœæ¬åã®ä»¥äžã®ããŒã¿ã確èªãã45ã
7æ10æ¥ã«èšé²ãããæ°ããªåœå ææCOVIDææè ã¯åèš352人
7æ10æ¥ã«èšé²ãããåœå ææCOVIDã®æ°èŠææè æ°352åãæçç¶è æ°46åãç¡çç¶è æ°306å
ç¡çåæ§ææè 306å
14å5åäžäººã®äººå£ã®ãã¡ãæ°ãã«46äººã®æçç¶è ãåºããããšãã£ãŠãäžåœã®äž»èŠéœåžéšãééããããšã¯ã§ããªãã
çµæžã®äžå®å®å äžæµ·ãšäžççµæž
äžåœåœå®¶è¡çå§å¡äŒãšäžåœCCDCãæã¡åºãããããã®æªçœ®ã®åœ±é¿ã¯ãäžåœã®ãµãã©ã€ãã§ãŒã³ã屿©ã«é¥ããŸããã
ãCOVID Zero Toleranceãã¯ãäžæµ·ã®éèã»ã¯ã¿ãŒãšå¥œèª¿ãªèŒžåºçµæžãäžå®å®ã«ãããäžå ãšãªããŸããããŸããåœå
ã®èŒžéãç©è³ã®äŸçµŠã©ã€ã³ã匱äœåãããèŠå ã«ããªã£ãŠããŸãã
2022幎4æäžæ¬ïŒäžæµ·ã®å°éãšåææïŒä»¥éã人æ°å
ïŒCNYïŒã¯ç±³ãã«ïŒUSDïŒã«å¯ŸããŠæ¥æ¿ã«äžèœããã

62
äžæµ·æž¯ïŒããã³äž»èŠæž¯æ¹ŸéœåžïŒãåºå ¥ãããåå貿æéãèœã¡çããå¿ ç¶çã«Made in Chinaååã®äžççãªäŸçµŠéã«åœ±é¿ãäžããããšã«ãªãã

ãã¡ã€ãã»ã€ã³ã»ãã£ã€ããã¯ãè¡£æåãå±¥ç©ãããŒããŠã§ã¢ãé»åæ©åšãæºåž¯é»è©±ããã¬ããããã¡ããå®ç³ãå®¶åºçšåãé£åãªã©ãã»ãŒãã¹ãŠã®äž»èŠãªååã«ããŽãªãŒã«ãããŠãå®¶åºã®æ¶è²»ãæ ¹åŒ·ãæ¯ããŠããå°å£²ååŒã®åºå¹¹ã§ãããã¢ã¡ãªã«ã®æ¶è²»è
ã«èããŠã¿ããšããã®ãªã¹ãã¯é·ãã
äžåœããã®èŒžå
¥ã¯ãæ°å
ãã«èŠæš¡ã®å²ããããžãã¹ã§ãããäžåœã®äœè³éçµæžãã茞å
¥ãããæ¶è²»è²¡ã¯ããã°ãã°å·¥å ŽäŸ¡æ Œã®10å以äžã®äŸ¡æ Œã§å°å£²ã¬ãã«ã§è²©å£²ããããããç±³åœã§ã¯è«å€§ãªå©çãšå¯ã®æºæ³ãšãªã£ãŠããã®ã§ããã
åžå£²ã»å°å£²ã¬ãã«ã«ãããäžçã®ååååŒã¯å±æ©çç¶æ³ã«ãããäžçã®ãã¹ãŠã®äž»èŠå°åã§èµ·ãããã圱é¿ã¯å£æ»
çã§ãããå¿
èŠäžå¯æ¬ ãªæ¶è²»è²¡ãäžççã«äžè¶³ããã€ã³ãã¬å§åããããã
ããããåãã¯ãäžåž¯äžè·¯æ§æ³ã¯ããšãããçµæžåã匱äœåããäžåœã®åœæ°åœå®¶ãšããŠã®äž»æš©ã«ã圱é¿ãåãŒãã
ã¯ã·ã³ãã³ã® "Pivot to Asia "ãå«ãçŸåšã®å±æ©ã®æèã§ã¯ãäžåœãšç±³åœã®å¯Ÿç«ã«çŽæ¥é¢ä¿ããæ·±å»ãªå°æ¿åŠç嫿ãååšããã
詳现ã¯ãMichel Chossudovsky, The Shanghai "COVID Zero Tolerance Mandate "ãåç
§ãããããäžåœçµæžã®ææ
ã¯ä»çµãŸãããã®ïŒ
èªåè»ç£æ¥ã®äœè¿·ïŒåå°äœã®çç£äžè¶³ãåå ãïŒ
äžçã®èªåè»ç£æ¥ã¯2020幎ã«15ïŒ
ã®çç£æžãçµéšããã2021-22å¹Žã®æžå°å¹
ã¯å€§ãããæ¥æ¬ãéåœãäžåœã®çç£ã«å€§ãã圱é¿ããã
ãã®æžå°ã«æè»ããããŠããã®ããåå°äœã®äŸçµŠäžè¶³ã§ããã
ã1å°ã®è»ãäœãããã«æ°ååã®ãããã«äŸåããŠããèªåè»ã¡ãŒã«ãŒã¯ãç¹ã«å³ããç¶æ³ã«ãã
63
ãããã®äŸçµŠåŸ ã¡ã®ãããäžççã«çç£ã©ã€ã³ã®åæ¢ãäœåãªããããŸããããã®å€§å€±æã§ãèªåè»æ¥çã®äžç売äžã¯4500åãã«ïŒçŽ46å åïŒã«ãªãããã ïŒ2021幎9æãããšã¿ã¯åå°äœã®äžè¶³ãçç±ã«åœå ã®14å·¥å Žã§æžç£ãäœåãªãããããæ±åã¢ãžã¢ããã®éšåäžè¶³ã®ãããäžéšã®åæžã¯10æãŸã§ç¶ããšããšã¿ã¯çºè¡šããŠãããã (ã¯ã·ã³ãã³ãã¹ãã2021 幎 9 æ)46
åå°äœã¯æŠç¥ç©è³ãæ§æããé»åæ©åšãå»çæ©åšãé»åã»éä¿¡ãããã¯ãŒã¯ãªã©æ§ã
ãªåéã§äœ¿çšãããã
åå°äœã®äººçºçãªäžè¶³ãäžççµæžã®å€ãã®äž»èŠéšéã«åœ±é¿ãäžãããããªãæäœã®å¯èœæ§ãææãããŠããã
å°æ¿åŠçãªåœ±é¿ããããäžçæå€§ã®åå°äœçç£äŒæ¥ã¯å°æ¹Ÿç©äœé»è·¯è£œé å
¬åžïŒTSMCïŒã§ããã
äžççãªããµãã©ã€ãã§ãŒã³ã®æ··ä¹±ããšãéèŠé¢ä¿ã
2020幎3æ11æ¥ä»¥éã®ããã¯ããŠã³ã¯ããäŸçµŠããšãéèŠãã®äž¡é¢ä¿ã«çŽæ¥åœ±é¿ãäžããäžççµæžã®äžå®å®åã®ããã»ã¹ãåŒãèµ·ãããã190ã«åœä»¥äžãåæã«åœ±é¿ãåããäžçå²äžæãæ·±å»ãªçµæžå±æ©ã§ããã
ãäŸçµŠããšã¯ã財ããµãŒãã¹ã®çç£ãããªãã¡ãå®äœçµæžãã®æŽ»åã«é¢ãããã®ã§ããã
ãéèŠããšã¯ã賌買åã®ããå®¶èšãå¿
èŠãªã¢ãããµãŒãã¹ãæã«å
¥ããèœåã§ãããéèŠã§ããã
é絊é¢ä¿ã¯ãšãã«å±æ©çç¶æ³ã«ããã
äžçã§ã¯ãç£æ¥ã蟲æ¥ãéœåžãµãŒãã¹ãªã©ã®å€§éšåã¯äŒæ¢ç¶æ
ã§ããã2020幎3æã«éå§ãããããã¯ããŠã³æ¿çã¯ãåç£ãšå€±æ¥ãèªçºãããã®çµæã人æïŒåŽååïŒãšçç£è³ç£ãçµæžããåãé¢ãããéçšãå©é·ããŠããã
äŸçµŠé¢ã§ã¯ã財ããµãŒãã¹ïŒã³ã¢ãã£ãã£ïŒã®çç£ãšäŸçµŠåã®å€§èŠæš¡ãªçž®å°ãé²è¡ããŠãããäžççµæžã®å
šéšéããçç£ãããªããç¶æ
ã«ãªã£ãŠãããç¹å®ã®ååããµãŒãã¹ã®åèç¶æ
ãåºçŸããŠãããããã«äŒŽãã2020幎3æä»¥éãéžäžã»æµ·äžã§ã®èŒžéçµè·¯ïŒã³ã³ãã貿æãªã©ïŒã寞æãããŠããã
éèŠé¢ã§ã¯ãéåœæ¿çã«ç«¯ãçºãã倧éã®å€±æ¥ãšè²§å°ããïŒäžçäžã®å®¶åºãå®¶èšã®ïŒè³Œè²·åã®æªæŸæã®åŽ©å£ãããããããããååããµãŒãã¹ã®éèŠã®åŽ©å£ãæãããè²§å°ãèå»¶ããäžçã®äººå£ã®å€§éšåã¯é£ç³§ãå¿
èŠãªæ¶è²»è²¡ãè²·ããéãæã£ãŠããªãã
çç£ïŒäŸçµŠïŒã®çž®å°ãšè³Œè²·åïŒéèŠïŒã®åŽ©å£ã¯ãã€ã³ãã¬å§åãšçžãŸã£ãŠãäžççã«æ ¹åŒ·ãçµæžææ
ãå©é·ããŠããã
ããã«ã倧é倱æ¥ã«ãã賌買åã®åŽ©å£ã¯ãæ¯æã®å®¶è³ãäœå®
ããŒã³ã®æ¯æããã§ããªããªã©ãå人ã®åµå屿©ãå¢å€§ãããããã®ãããªããã»ã¹ã¯ãæçµçã«å®ç©è³ç£ã®æ²¡åã«ã€ãªããã
ç±³åœã§ã¯ãå®¶è³ãæ»çŽãã人ã®68ïŒ
ïŒ2021幎5æã®æ°åïŒããç£çŠã®çµæã倱æ¥ããŠãã47ã
64
ãã®ãããªäºæ ããããã³ãããã¯ã«ããçµæžç圱é¿ãã®ããã«ãããããã¯ããŠã³æ¿çãã®å€±æãããã«äžççãªçµæžæ··ä¹±ãšå€±æ¥ã®åŒãéã«ãªã£ãããåæããããšã¯ãªãã
åœå®¶è²¡æ¿ã®å±æ©
å»çãæè²ãæåãã¹ããŒããèžè¡ãªã©åœå®¶ãåºè³ããå
Œ
±äºæ¥ã屿©ã«çããŠãããäžæ¹ãç±³åœã§ã¯ããã€ãã³æ¿æš©ããè»äºã»å®å
šä¿éé¢é£æ¯åºããã€ãªãã¯ãããžãŒã®å€§å¢åŒ·ãæ¯æãã倧æè£œè¬äŒç€Ÿãè»ç£è€åäœã«æåãæåœãŠãããŠããã
ã³ãã屿©ãå§ãŸã£ãŠä»¥æ¥ãååœã®å
¬çåµåã¯ãäž»ã«çµæžã®æ··ä¹±ã«ãã£ãŠé«éš°ããŠããã
åç£ããäŒæ¥ã¯ããã¯ãçšéãæã£ãŠããªãã倱æ¥è
ïŒåå
¥ã®ãªãïŒã¯ããã¯ãçšéãæã£ãŠããªããåœå®¶ã®è²¡æºã«çšéãå
¥ããªããªã£ãã
äžççãªå€±æ¥çã®äžæãšè²§å°ã®æ¡å€§ãããã«åç£ãéãªããæªæŸæã®è²¡æ¿å±æ©ãæããã
ãã®çµæãæ¿åºã®æ³å
¥ãäŒæ¥ã®æåœãŠã®è³éã«æ¯ãåããããã
å¯ã®ç§çæµçšã¯ãäžççãªåµå屿©ãåŒãèµ·ããããååœãšãå
¬çåµåãæ¥å¢ããŠããã
å€§èŠæš¡ãªç·çž®è²¡æ¿ãäžççãªåµåè¶ é
COVID-19ã®æä»€ã®éµå®ãšåãå
¥ãã匷å¶ããææ®µãšããŠãååœæ¿åºã¯æåãé
絊ãšç€ŸäŒçã»ãŒããã£ããããå©çšããŠããããããã®æåœãŠïŒ0ïŒ
ã§ã®èè³ãå«ãïŒã¯æçµçã«å»æ¢ãããäžçå²äžæã倧å¹
ãªç·çž®çã«åã£ãŠä»£ããããäºå®ã§ããã
è¿æžäžå¯èœãªæ°å
ãã«ã®å
¬çåµåãäžçäžã§å±éããããäžççãªåç£ããšã§ã圢容ãã¹ãããã»ã¹ãé²è¡ããŠããã
åœå®¶ã®åµæš©è
ã¯ãããã°ãããŒãã§ãããæçµçã«ã¯ã圌ããäž»å°æš©ãæ¡ã£ãŠããã
åäžé·è
å±€ã®å¯è£åã¯ãåœæ°åœå®¶ã®äžå®å®åã«ãã€ãªãã£ãŠããïŒç¬¬Vç« åç
§ïŒã
ãããŠããçŠç¥åœå®¶ããšãã®å
Œ
±æ©é¢ïŒæè²ãå»çãæåïŒã®åŽ©å£ãå«ããåœæ°åœå®¶ã®æ°å¶åããé²è¡ããŠããã®ã§ããã
å·»æ«è³æ
1. ã¢ãªãœã³ã»ãªãŒããªãŒã2020 幎 1 æ 31 æ¥ããã©ã³ã倧統é ãã³ãããŠã€ã«ã¹ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ãšå®£èšããäžåœããã®æž¡èªãå¶éã https://www.npr.org/sections/health-shots/2020/01/31/801686524/trump-declares-coronavirus-a-public-health-emergency-and-restricts-travel-from-c
65
2. ãšã³ããã¹ãã2020幎2æ17æ¥å·ãã³ãããŠã€ã«ã¹ã¯äžåœäººã«å¯ŸããããããŠäžåœäººã®éã®äººçš®å·®å¥ãåºãã https://www.economist.com/china/2020/02/17/the-coronavirus-spreads-racism-against-and-among-ethnic-chinese
3. Wallis Wang, February 13, 2020. è±åœã®äžåœäººã³ãã¥ããã£ã¯ã³ãããŠã€ã«ã¹çºçã§äººçš®å·®å¥ã«çŽé¢ããŠãã https://www.scmp.com/video/world/3050436/britains-chinese-community-faces-racism-over-coronavirus-outbreak
4. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020 幎 11 æ 5 æ¥ãã³ããã»ãã³ãããã¯ãšãã©ã³ãã®å¯Ÿäžè²¿ææŠäºãã¢ã¡ãªã«ã®ãã¡ã€ãã»ã€ã³ã»ãã£ã€ããäŸåãç±³åœçµæžã®æœåšçæ··ä¹±
https://www.globalresearch.ca/the-corona-pandemic-and-trumps-trade-war-against-china-americas-dependence-on-made-in-china-potential-disruption-of-the-us-economy/5713552
5. ãã£ãã³ã·ã£ã«ã»ã¿ã€ã ãºã2020 幎 5 æ 11 æ¥ãç±³äžçµæžã®ãã«ãããªã³ã°ã¯2020幎第1ååæã«å éããã
https://www.ft.com/content/115fc14f-4a8a-45da-8688-c59605a5191a
6. ãžã§ãŒã»ãã¯ããã«ãã2022 幎 1 æ 14 æ¥ãäžåœã®è²¿æé»åã¯2021幎ã«é廿é«ãèšé²-ãã³ãããã¯éèŠã§èŒžåºã30ïŒ
æ¥å¢https://time.com/6139334/china-record-trade-surplus-2021/
7. WHOã2020 幎 2 æ 20 æ¥ã2020 幎 2 æ 20 æ¥ã® COVID-19 ã«é¢ããã¡ãã£ã¢ããªãŒãã£ã³ã°ã§ã® WHO äºåå±é·åé çºèšãhttps://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-on-20-february-2020
8. WHO, n.d. é¢å¿è¡šææž https://www.who.int/about/ethics/declarations-of-interest
9. ãã®ãŒã»ãã£ãããžã§ã©ã«ãã2019 幎 9 æ 17 æ¥ããã«ã»ã²ã€ãã®è²¡ç£ã® 60ïŒ
以äžã¯æ ªåŒã«æè³ãããŠãã
https://www.cnbc.com/2019/09/17/bill-gates-gave-away-35-billion-this-year-but-net-worth-didnt-drop.html
10. ãã¬ããã»ã€ã³ããŒãããã®ãŒã»ãã£ãããžã§ã©ã«ããä»ã2020 幎 2 æ 28 æ¥ãæ ªåŒåžå Žéææ¥ã®æ¯ãè¿ããããŠã¯é±è¶³ã§3,500ãã€ã³ãäžèœãå®å€åŒããFRBã¯æ¯æŽãçŽæ
https://www.cnbc.com/2020/02/28/stock-market-live-updates-dow-loses-3200-points- and-counting-on-week-bond-yields-collapsing.html.
11. WHOã2020幎3æ12æ¥ãã³ãããŠã€ã«ã¹ç2019ïŒCOVID-19ïŒç¶æ³å ±å-52.
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf
12. ããã»ã¹ãã£ãŒãã³ã¹ããã®ãŒã»ãã£ãããžã§ã©ã«ããä»ã2020幎3æ12æ¥ãæ ªåŒåžå Žã©ã€ãæšææ¥ãããŠã¯2,300ãã«æŽèœããã©ãã¯ãã³ããŒä»¥æ¥ã®ææªã®æ¥ãS&P500ã¯åŒ±æ°çžå Ž
https://www.cnbc.com/2020/03/12/stock-market-today-live.html.
13. WEF, n.d. The Great Reset. https://www.weforum.org/great-reset/
14. OECDã2020 幎 7 æ 15 æ¥ãã³ãããŠã€ã«ã¹ïŒCOVID-19ïŒãäžå°äŒæ¥ã®æ¿ç察å¿.
https://www.oecd.org/coronavirus/policy-responses/coronavirus-covid-19-sme-policy-responses-04440101/
15. ãã¡ããã芧ãã ããïŒhttps://www.bloomberg.com/news/articles/2020-10-22/half-of-europe-s-smaller-businesses-risk-bankruptcy-within-year#xj4y7vzkg
16. ãã¡ããã芧ãã ããïŒ https://www.nytimes.com/2020/06/18/business/corporate-bankruptcy-coronavirus.html
17. OECDã2020 幎 7 æ 15 æ¥ãã³ãããŠã€ã«ã¹ïŒCOVID-19ïŒãäžå°äŒæ¥æ¿çãžã®å¯Ÿå¿
https://www.oecd.org/coronavirus/policy-responses/coronavirus-covid-19-sme-policy-responses-04440101/
18. ãã€ã±ã«ã»ã¹ãã€ããŒã2020 幎 12 æ 10 æ¥ãç±³åœã®äžå°äŒæ¥ã®48ïŒ
ããéããªããæ°žä¹
ééããäœåãªãããããããããªããšæããŠãããhttps://www.globalresearch.ca/48-us-small-businesses-fear-forced-shut-down-permanently-soon/5732050
19. ãã£ãã¯ã»ãã£ã¹ãã2020 幎 11 æ 25 æ¥ãAlignable: 48% Of Small Businesses Risk Closing in Q4, New Poll Says.
https://www.alignable.com/forum/alignable-48-of-small-businesses-risk-closing-for-good-new-poll
20. ILOã2020 幎 9 æ 23 æ¥ãCOVID-19 led to massive labour income losses worldwide. https://www.ilo.org/global/about-the-ilo/newsroom/news/WCMS_755875/lang--en/index.htm
21. ILOã2022幎1æ17æ¥ãILOã2022幎ã®åŽååžå ŽååŸ©äºæž¬ãäžæ¹ä¿®æ£ https://www.ilo.org/global/about-the-ilo/newsroom/news/WCMS_834117/lang--en/index.htm
66
22. ãããã»ãã ã³ã2020幎5æ6æ¥ãä»äºããªããã ããã©ããªæªæ¥ïŒäžçã®åŽååã®ååã端㫠https://www.csmonitor.com/World/2020/0506/No-jobs-so-what-future-Half-the-world-s-workforce-on-the-edge
23. ã¯ã¬ã¢ã»ãã³ã»ã³ã2020 幎 12 æ 2 æ¥ãã¯ãªã¹ãã¹åŸã«å€±æ¥æ¯æŽã倱ãçŽ1200äžäºº åºæ¿ã¯ãŸã äžç¢ºå® https://www.usnews.com/news/national-news/articles/2020-12-02/some-12-million-to-lose-unemployment-aid-after-christmas-with-stimulus-still-uncertain
24. IÂ åäž
25. ã¹ãã£ãŒãã³ã»ã¬ã³ããã³ã2020 幎 12 æ 2 æ¥ãæ°çŸäžäººã®ã¢ã¡ãªã«äººãç«ã¡éãã®å±æ©ã«ãããããŠãã https://www.globalresearch.ca/millions-americans-vulnerable-eviction/5730985
26. ã¹ã¿ãã£ã¹ã¿ã2022 幎 1 æã2021幎11ææç¹ã®æ¬§å·ç¹å®åœã®å€±æ¥ç https://www.statista.com/statistics/1115276/unemployment-in-europe-by-country/
27. ãžã§ãŒã ãºã»ãã«ã¿ãŒã2020 幎 9 æ 15 æ¥ããšãŒãããã¯è¥è
ã®å€±æ¥å±æ©ã«çŽé¢ããŠãããhttps://www.vice.com/en/article/v7gknm/europe-is-facing-a-youth-unemployment-crisis
28. ILOã2020 幎 7 æ 1 æ¥ãILO: Sharp rise in unemployment in Latin America and the Caribbean leaves millions without income. https://www.ilo.org/caribbean/newsroom/WCMS_749692/lang--en/index.htm
29. ã»ããã2020 幎 8 æ 19 æ¥ãColombia, el tercer paÃs que más empleos perdió en América Latina. https://www.semana.com/empresas/confidencias-on-line/articulo/empleos-que-mas-se-perdieron-en-america-latina-segun-el-bid/296265/
30. ãã©ãŒãã¹ã2020幎6æ3æ¥ãDesempleo en México alcanza a casi 25% de la población: Heath. https://www.forbes.com.mx/economia-desempleo-mexico-casi-25-poblacion-heath/
31. FAO ãš WFPã2020 幎 7 æãFAO-WFP early warning analysis of acute food insecurity hotspots. https://www.fao.org/3/cb0258en/CB0258EN.pdf
32. ã°ããŒãã«ã»ãªãµãŒãã»ãã¥ãŒã¹ã2020 幎 12 æ 4 æ¥ãã€ã³ã ã€ã³ãïŒLargest Strike in World History : Over 200 Million Workers and Farmers Protest against Poverty and Unemployment Triggered by Covid Lockdown. https://www.globalresearch.ca/india-largest-strike-in-world-history-over-200-million-workers-and-farmers-paralyze-india/5731395
33. åäž
34. åäž
35. ãã£ãŒãã£ã³ã°ã»ã¢ã¡ãªã«ã2021 幎 3 æãThe Impact of the Coronavirus on Food Insecurity in 2020 & 2021. https://www.feedingamerica.org/sites/default/files/2021-03/National%20Projections%20Brief_3.9.2021_0.pdf
36. ã¹ãã£ãŒãã³ã»ã¬ã³ããã³ã2020 幎 10 æ 3 æ¥ãã³ãã屿©ãã¢ã¡ãªã«ã®å€§é倱æ¥ã®åŒãéã«ãç±³åœã§28é±é£ç¶100äžä»¶ä»¥äžã®UIã¯ã¬ãŒã https://www.globalresearch.ca/over-one-million-ui-claims-us-28-straight-weeks/5725527
37. ãžã§ã€ãœã³ã»ãã¯ã¹ãšãžã§ã³ã»ããã«ãŠã§ã€ã³ã2020 幎 4 æ 20 æ¥ãCOVID-19 ãéããŠäžçã®åã©ããã¡ã®åŠã³ãç¶æãã https://www.unicef.org/coronavirus/keeping-worlds-children-learning-through-covid-19
38. UNESCO, n.d. Education: æ··ä¹±ããå埩㞠https://www.unesco.org/en/covid-19/education-response
39 Adam Behsudiã2020 幎 12 æã芳å
æ¥ã«äŸåããçµæžã¯ããã³ãããã¯ã«ãã£ãŠæã被害ãåããåœã®äžã€ã§ããã
ãã³ãããã¯ã«ãã£ãŠæã被害ãåããã®ã¯èгå
äŸåã®çµæžã§ãããhttps://www.imf.org/Publications/fandd/issues/2020/12/impact-of-the-pandemic-on-tourism-behsudi
40. Margaux MacDonald, Roberto Piazza, et al., September 2, 2020. COVID-19 ã®åœ±é¿ãæšå®ããããã®ç°¡åãªã¬ã€ã
on Travel and Hospitality ActivityïŒæ
è¡ãšãã¹ãã¿ãªãã£ã®æŽ»åã«å¯Ÿãã圱é¿ïŒãPDFãªã³ã¯
41. äžçæ
è¡èгå
åè°äŒã2020 幎 11 æ 11 æ¥ãç±³åœã¯COVID-19ãšæ
è¡å¶éã®ããã«2020幎ã«920äžäººã®éçšã倱ãããã ãšWTTCã¯è¿°ã¹ãŠãããhttps://wttc.org/Portals/0/Documents/Press%20Releases/US-looks-set-to-lose-9-million-jobs-in-2020-due-to-COVID-19-and-travel-restrictions.pdf
42. ã¢ãã²ã€ã«ã»ã³ã2020 幎 10 æ 8 æ¥ãä»å¹ŽãããŸã§ã«40瀟以äžã®èªç©ºäŒç€Ÿãç Žç¶» - ããã«å€ãã®èªç©ºäŒç€Ÿãç Žç¶»ããäºå®ãhttps://www.cnbc.com/2020/10/08/over-40-airlines-have-failed-in-2020-so-far-and-more-are-set-to-come.html
67
43. ã°ããŒãã«ã»ã¿ã€ã ãºã2022 幎 4 æ 4 æ¥ããªãã¯ãã³ã®æŠãã§äžæµ·ãæ¯æŽããããã«38k以äžã®å»çåŸäºè
ãé
åããã2020幎åé ã®æŠæŒ¢ä»¥æ¥æãå€ããhttps://www.globaltimes.cn/page/202204/1257497.shtml
44. Roxanne Liu& Ryan Woo, July 11, 2022. Update 3-Shanghai plans more COVID testing amid fresh curbs across China.ïŒäžåœå
šåã§æ°ããªæå¶ãè¡ãããäžãäžæµ·ã¯ãããªãCOVIDãã¹ããèšç»ïŒhttps://ca.news.yahoo.com/1-shanghai-braces-more-mass-040242739.html
45. åäž.
46. Jeanne Whalenã2021幎9æ23æ¥ãäžçã®è£œé æ¥ã«æ¯éãããããåå°äœäžè¶³ãæªåããŠããã
ã¯æªåããŠãããhttps://www.washingtonpost.com/us-policy/2021/09/23/chip-shortage-forecast-automakers/
47. ãµã©ã»ãã¬ãŠããããããã·ã§ã«ã»ãã¡ã³ãä»ã2021幎9æ16æ¥ãã¢ã¡ãªã«ã«ãããå®¶è³åµåãè³å人ãå®å®ãããããšãå
¬å¹³ãªåŸ©èã®éµ
å
¬å¹³ãªå埩ã®ããã«https://nationalequityatlas.org/rent-debt-in-america
68
-------------------第5ç« ------------------
è¶
å¯è£å±€ã®å¯è£å
å¯ã®å奪ãšååé
"Vã»ã¶ã»ãŠã€ã«ã¹ "ã¯ãåç£ã倱æ¥ã®æ³¢ã®åå ã ãšèšãããŠãããããã¯åã ããŠã€ã«ã¹ãšçµæžã®å€æ°ãšã®éã«å æé¢ä¿ã¯ãªãã
æææ±ºå®ã®ããã»ã¹ã«å¯ŸåŠããªããã°ãªããªããå®äœçµæžã®ïŒäžççãªïŒäžå®å®åã«è²¢ç®ãããã®ãããžã§ã¯ãã®èåŸã«ããã®ã¯ã匷åãªéèæ¥è
ãšåäžé·è
ãã¡ã ã
2020幎2æåæ¬ãããã¹ãŒããŒãªããã¯æ°åååãçŸéåããã2020幎3æ11æ¥ã®ããã¯ããŠã³ãšæãåããããŠãããã4ã¶æã®éã«ãäžçäžã®ããªãªãã¢ãä¿æããç·è³ç£ã¯ã8å
ãã«ãã10å
ãã«ä»¥äžã«èšãäžãããŸããã
ã³ãã屿©ãšçŽæ¥é¢ä¿ãã3ã€ã®æç¢ºãªæ®µéãããããããããäžçã®å¯ã®ååžã倧ããå€åããããšãç¹åŸŽã§ããã
2æ20æ¥ã«å§ãŸã£ãéè屿©ã¯ãå¯ãšéèè³ç£ã®æææš©ã®åçãªååé ãå©é·ãããã®ã§ãã£ããäºèŠãå éšæ å ±ãææ©çååŒãéèŠãªåœ¹å²ãæããããWHOã®ãããã¹å士ã®2æ20æ¥ã®å£°æã«ã€ããŠãäºèŠãå éšæ å ±ããã£ãã®ãïŒ(第åç« åç §ïŒ
3æ11æ¥ã®åœé£å çåœ190ã«åœã®éåœãšçµæžå°éã¯ãäžçäžã®äŒæ¥ãäžå°äŒæ¥ã®åç£ãèªçºããããŸãã3æ11æ¥ã®åºæ¥äºã¯ã2020幎3æ12æ¥ã®é»ãæšææ¥ãããäžçäžã®æ ªåŒåžå Žãæ¥èœããããšãæå³ããïŒç¬¬IVç« åç §ïŒã
3.åäžé·è å¯è£åã®ç¬¬äžæ®µéã¯ã2021-2022幎ã®ãéšåçããã¯ããŠã³ããæ¿çç矩åä»ããå¶éæªçœ®ã®å®æœã«é¢é£ããåç£ãšçµæžæ··ä¹±ã®åæ¥ãèªçºãããã®ã§ããã
åäžé·è
å±€ã«æå©ãªå¯ã®ååé
ã¯ã2020幎3æã®äžççµæžã®ééã«èµ·å ããIPSã®èª¿æ»ã«ãã£ãŠç¢ºèªãããŠãã1ã
äžçã¬ãã«ã§ã¯ãCOVID-19ã®ãã³ãããã¯æã«åäžé·è
ã倧åå©ãåããã
UBSã®2020幎çã¬ããŒãã«ãããšãäžçã®åäžé·è
ããã2,189人ã®è³ç£ã¯10å
2,000åãã«ãšæšå®ãããŠããŸã2ã
ããã¯ã2019幎ã®UBSãšForbesã®äž¡æ¹ã®ããªãªãã¢ããŒã¿ã«åºã¥ããŠã2020幎ã®ãã³ãããã¯ã®éã«1.5å
ãã«å¢å ãããšæšå®ãããŸãã
UBSã®ã¬ããŒãã¯ãåäžé·è
ãã¡ã¯ã驿°è
ããªã®ããç Žå£è
ããªã®ãããšããåããæããããŠããŸãã
åµãéãå»ã£ããšããåäžé·è ã®æ°äžä»£ã®ã€ãããŒã¿ãŒã¯ããã¡ãŒãžã®ä¿®åŸ©ã«éèŠãªåœ¹å²ãæããããšã«ãªãããã§ããæ°èãã¯ãããžãŒã®ã¬ããŒããªãŒãå¢ãããªãããææ¥ã®ã€ãããŒã¿ãŒãã¡ã¯ãçµæžãããžã¿ã«åãããªãã¬ãã·ã¥ããé©åœãèµ·ãããŠããããšã§ãããã
69
å¹»æ³ãæ±ããªãããã«ãããããã®è æããåäžé·è ãã¡ã¯ãè²§å°è ããªã®ã ã
ãéè倧éç Žå£å µåšã(FWMD)
UBSãšãã©ãŒãã¹ã®ã¬ããŒãïŒäžèšåŒçšïŒã¯ãCOVID-19ã®ãã³ãããã¯ããã®å€§èŠæš¡ãªå¯ã®ååé
ã«ã©ãè²¢ç®ãããã説æããŠããªãããããã§ã圌ãã¯ããåäžé·è
ã®å¯ã®éå£ãéå»10幎éã®ã©ã®æéãããæãéãããŒã¹ã§å¢å ããŠããã3ããšã確èªããŠããã
å®éãããã¯äžçå²äžæå€§ã®å¯ã®ååé
ã§ãããããã¯ãäžççãªè²§å°åã®çµç¹çãªããã»ã¹ã®äžã«æãç«ã£ãŠãããããã¯ãçµæžæŠäºè¡çºã§ããã
åäžé·è
ãã¡ã¯ãå¯å€§ãªãæ¿åºã®æ¯æ°åºæ¿çãïŒããªãã¡æœãïŒãåããã ãã§ãªãã2020幎2æåæ¬ã®COVIDææãã£ã³ããŒã³éå§ããã®åœŒãã®çµæžçå©çã®å€§éšåã¯ãã€ã³ãµã€ããŒååŒãããªããã£ãååŒãéèããã³åååžå Žã®äž¡æ¹ã®æäœã®çµæã§ãã£ãã
ãŠã©ãŒã¬ã³ã»ããã§ããã¯ãïŒé«åºŠãªã¢ã«ãŽãªãºã ã«æ¯ããããïŒãããã®ææ©ååããéè倧éç Žå£å
µåšããšæ£åœã«äœçœ®ã¥ããŠããã
2020幎3æ18æ¥ïŒç±³åœã®ããã¯ããŠã³ãšåææïŒãç±³åœã®åäžé·è
ã®ç·è³ç£ã¯2å
947åãã«ã«éããã2020幎10æ8æ¥ãŸã§ã«ã圌ãã®è³ç£ã¯3å
8000åãã«ã«æ¥å¢ãããããã¯8500åãã«ã®å¢å ã§ããã圌ãã®ç·è³ç£ã¯28%以äžå¢å ããããšã«ãªãïŒIPS調æ»åç
§ïŒ4ã
ãã®è©Šç®ã§ã¯ã2020幎3æ18æ¥ä»¥åã®ãäžé£ã®æ ªåŒåžå Žã®æŽèœããã£ãæéã®å¯ã®å¢å ã¯èæ
®ãããŠããªã5ã
ãããŠã2020幎åŸåãããåäžé·è
å±€ã¯äžççµæžã®äžéšééã䌎ãç¬¬äºæ³¢ã®ããã¯ããŠã³ã®ç¶æã«é¢äžããããšã«ãªãã
äžè¡šã¯ãç±³åœã®5倧åäžé·è
ã®å人è³ç£å¢å é¡ã§ããïŒ2020幎3æ18æ¥ïœ6æ17æ¥ïŒã(衚ã«ã¯ãªããã2020幎6æãã10æãŸã§ã«ããã«2660åãã«å¢å ããç±³åœã®åäžé·è
ã®å¯ã¯ããã®æŠèŠã§ããïŒ

70
åäžé·è ã®å¯ã®æé·ïŒ2020幎3æïœ2021幎3æïŒ2020幎3æã®ããã¯ããŠã³ã®å®æœã«ããããã£ãã¯ã»ã³ãªã³ãºã¯ïŒInequality.orgãçºè¡šããéãç ç©¶ã§ïŒATFãšIPSããã®å ±åæžã§ãŸãšãããã©ãŒãã¹ã®ããŒã¿ãããé幎ã§åäžé·è ã®å¯ã®æé·ãæšå®ããŠãã6,7ã
3æ18æ¥[2020幎]ã屿©ã®éå ¬åŒãªå§ãŸããšããŠäœ¿ãããŠããã®ã¯ããã®æãŸã§ã«ãŠã€ã«ã¹ã«å¯Ÿå¿ããé£éŠããã³å·ã®çµæžèŠå¶ã®ã»ãšãã©ã宿œãããããã§ããã3æ18æ¥ã¯ããã©ãŒãã¹ãæ¯å¹Žçºè¡ããããªãªãã¢ã¬ããŒãã®2020幎çã®ããã«ããªãªãã¢ã®å¯ã枬å®ããããã«éžãã æ¥ã§ããããATFãšIPSããã©ãŒãã¹ã®ãŠã§ããµã€ãããã®ãªã¢ã«ã¿ã€ã ããŒã¿ã§å®æçã«æ¯èŒããåºæºå€ãšãªã£ããPolitiFactã¯ãã®æ¹æ³è«ã奜æçã«è©äŸ¡ããŠãã8ã

71


72
倧æè£œè¬äŒç€Ÿã®å¯è£å
ãã©ãŒãã¹èªã®å ±åæžã¯ãã³ããã¯ã¯ãã³ããã¹ã¯ãå»ççšåã®æå©ãªè²©å£²ïŒäžççïŒã«é¢äžããŠããæ¬§ç±³ãšäžåœã®å€§æè£œè¬äŒç€Ÿã®CEOãæœ€ã£ãŠããããšã匷調ããŠãã9ã
ãã®äžã«ã¯ãModernaã®CEOã§ããStéphane BancelãBioNTechã®å
±åèšç«è
ã§ããUÄur Åahinãå«ãŸããŠããã
äžåœã®å€§æè£œè¬äŒç€Ÿã¯ããã®å¯è£åéçšã®æ¬æ ŒçãªããŒãããŒã§ãããäžåœã«æ ç¹ã眮ãè€æ°ã®è£œè¬äŒç€Ÿã®CEOã«ã¯ã倩接ã®CanSino BiologicsãIncoãæ·±ã»ã³ã®Contec Medical SystemsãCOVID-19ãã¹ãã補é ããSansure BiotechããããŠäžåœã®ã¯ã¯ãã³ã³ã³ã°ãããªããSinovacãå«ãŸããŠããŸãã
äžåœã®ããã°ãã¡ãŒãã®æ°ååã®å¯è±ªã®äžã«ã¯ãäžåœã®å»ç補åã¡ãŒã«ãŒããŠã£ããŒã¡ãã£ã«ã«ã®ç€Ÿé·ã§ããæå»ºæ³æ°ãããããã§ã€ã¹ãã¹ã¯ãªã©ãCOVIDãã³ãããã¯ã«é¢é£ãã補åã®ããã€ãã¯ããŠã£ããŒã»ã¡ãã£ã«ã«ã補é ããŠããã
Li Jianquanã®çŽè³ç£ã¯68ååã§ããïŒè©³çްã¯Forbes Reportãåç
§ïŒ10ã
2020-2021幎ã®åäžé·è
ã®å
šãªã¹ãã¯ããã©ãŒãã¹ã®ãªã¹ããåç
§ãããã(11)ã
倧æè£œè¬äŒç€Ÿã®å¯è£å
ãã©ãŒãã¹èªã®å ±åæžã¯ãã³ããã¯ã¯ãã³ããã¹ã¯ãå»ççšåã®æå©ãªè²©å£²ïŒäžççïŒã«é¢äžããŠããæ¬§ç±³ãšäžåœã®å€§æè£œè¬äŒç€Ÿã®CEOãæœ€ã£ãŠããããšã匷調ããŠãã9ã
ãã®äžã«ã¯ãModernaã®CEOã§ããStéphane BancelãBioNTechã®å
±åèšç«è
ã§ããUÄur Åahinãå«ãŸããŠããã
äžåœã®å€§æè£œè¬äŒç€Ÿã¯ããã®å¯è£åéçšã®æ¬æ ŒçãªããŒãããŒã§ãããäžåœã«æ ç¹ã眮ãè€æ°ã®è£œè¬äŒç€Ÿã®CEOã«ã¯ã倩接ã®CanSino BiologicsãIncoãæ·±ã»ã³ã®Contec Medical SystemsãCOVID-19ãã¹ãã補é ããSansure BiotechããããŠäžåœã®ã¯ã¯ãã³ã³ã³ã°ãããªããSinovacãå«ãŸããŠããŸãã
äžåœã®ããã°ãã¡ãŒãã®æ°ååã®å¯è±ªã®äžã«ã¯ãäžåœã®å»ç補åã¡ãŒã«ãŒããŠã£ããŒã¡ãã£ã«ã«ã®ç€Ÿé·ã§ããæå»ºæ³æ°ãããããã§ã€ã¹ãã¹ã¯ãªã©ãCOVIDãã³ãããã¯ã«é¢é£ãã補åã®ããã€ãã¯ããŠã£ããŒã»ã¡ãã£ã«ã«ã補é ããŠããã
Li Jianquanã®çŽè³ç£ã¯68ååã§ããïŒè©³çްã¯Forbes Reportãåç
§ïŒ10ã
2020-2021幎ã®åäžé·è
ã®å
šãªã¹ãã¯ããã©ãŒãã¹ã®ãªã¹ããåç
§ãããã(11)ã
äžçã®å¯ããããå°æ¿åŠ
2022幎ããã©ãŒãã¹ã¯äžçã®åäžé·è ã®å¯ããã·ã¢ãšäžåœã«äžå©ã«ãªãããã«åç·šæãããããšãå ±åããããã·ã¢ã®åäžé·è ã34人æžãïŒ2021幎æ¯ïŒããäžåœã®åäžé·è ã®ãªã¹ãã87人æžã£ãã
ã¢ã¡ãªã«ã¯äŸç¶ãšããŠäžçããªãŒãããŠãããã€ãŒãã³ã»ãã¹ã¯ãåããŠäžçã®ããªãªãã¢ãªã¹ãã®ãããã«ç«ã€ãªã©ãç·é¡4å 7000ååã®735人ã®ããªãªãã¢ãååšããŸããäžåœïŒãã«ãªãéŠæž¯ãå«ãïŒã¯607人ã®åäžé·è ãç·é¡2å 3ååãã«ã§2äœãç¶æããŠããŸãã
2022幎ã®äžçã®åäžé·è ã®å šãªã¹ãã¯ããã©ãŒãã¹ã®ãªã¢ã«ã¿ã€ã åäžé·è ã©ã³ãã³ã°ãã芧ãã ããã
åäžé·è ã®å¯è£åãšå®¶æçµå¶ã®èŸ²æ¥ã®çµç
çŸåšé²è¡äžã®å®¶æçµå¶ã®èŸ²æ¥ã®çµçã¯ãããã¯ããŠã³æ¿çã«ãã£ãŠããã«æªåããŠããã
ãã«ã»ã²ã€ãã¯ãéè屿©ã®éã«èšäžããè³éã䜿ã£ãŠã蟲å°ã®ååŸãå«ããåãäžããããè³ç£ãç¹å£²äŸ¡æ Œã§è³Œå
¥ããããªã©ãããŸããŸãªçµæžæŽ»åã§äŒæ¥æ¯é
ãæ¡å€§ããŠããïŒããªå°å»ºäž»çŸ©ã«é¢ãããããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢ãåç
§ïŒ12 ã
The Land ReportïŒ2021幎2æïŒã«ãããšããã«ãšã¡ãªã³ãã»ã²ã€ãã¯ä»ãã¢ã¡ãªã«æå€§ã®èŸ²å Žææè
ã§ãããé·å¹Žã«ããã£ãŠç Žç£ã«è¿œã蟌ãŸããŠããå®¶æèŸ²æ¥ã«äžå©çãäžããŠããã
ã²ã€ãã®ããŒããã©ãªãªã¯ããã«ã€ãžã¢ããã¢ãŒã«ã³ãœãŒãããã©ã¹ã«ãã¢ãªãŸãããããªããã¯ã·ã³ãã³ããã®ä»18å·ã«ããã24äž2000ãšãŒã«ãŒã®ã¢ã¡ãªã«ã®èŸ²å°ãšçŽ2äž7000ãšãŒã«ãŒã®ãã®ä»ã®åå°ãïŒãããŒã F. ã±ããã£Jr.ã®åæåç
§ïŒã§æ§æãããŠãã13ã
ã²ã€ãã«åž°å±ããç·é¢ç©268,984ãšãŒã«ãŒã瀺ãäžã®å°å³ãã芧ãã ãããããã¯ãç±³åœã®åºå€§ãªå°åã«ããäœåãã®å®¶æçµå¶ã®èŸ²å Žãäºå®äžå奪ããã«çããã
73
è² åµãšåç£ã®å¢å€§ãå å°ãããã®ããã»ã¹ã¯ããã³ãããã¯ä»¥åããå§ãŸã£ãŠããããããã "ãã¥ãŒããŒãã« "ã®ããšã§ããããããã¯ç¶ãã ããã

åäžé·è ã®å¯ã¯çµæžæé·ã®çµæã§ã¯ãªã
ãã®ããã«ç€ŸäŒçå°æ°æŽŸãè±ãã«ãªãã®ã¯ãçã®çµæžæé·ã«ãããæ°ããªå¯ãã®åµé ã«åºã¥ããã®ã§ã¯ãããŸããã
çµæžæé·ã«ãããæ°ããªå¯ãã®åµé ã«åºã¥ããã®ã§ã¯ãªããå
šãéã§ãããäžççãªçµæžäžæ³ã®çµæãªã®ã ã
åäžé·è ã®å¯è£åã®ããã»ã¹ã¯ãçµæžçã»ç€ŸäŒçæ··ä¹±ãç³§ãšããŠãããããã¯ãææã®ãã£ã³ããŒã³ããšãéèåžå Žãšå®äœçµæžã®äž¡æ¹ã®äžççãªäžå®å®åã«å€§ããäŸåããŠããã
ããã¯ãåäŸã®ãªãæåŸãšå¯ã®ååé ã®ããã»ã¹ãèªçºããã®ã«åœ¹ç«ã£ãŠãããäžçã®äººå£ã®å€§éšåã¯æ¥µåºŠã®è²§å°ã«è¿œãããããã
74
åäžé·è
ã®å¯è£åã«ã¯ãåºå€ã§ã®çµæžã»éèè³ç£ã®ååŸãçµæžæŽ»åã®äž»èŠåéã«ãããç Žç¶»äŒæ¥ã®è²·åããäºèŠããšãå
éšæ
å ±ããäŒŽãææ©çææ³ãããªããã£ãååŒãå«ãåžå ŽæäœïŒåµåžãæ ªåŒãååãçºæ¿åžå Žãªã©ïŒãå«ãŸããïŒç¬¬IVç« åç
§ïŒã
å·»æ«è³æ
1. ãã£ãã¯ã»ã³ãªã³ãºã2020 幎 10 æ 8 æ¥ãU.S. Billionaire Wealth Is Up $850 Billion Since March 18th. https://ips-dc.org/u-s-billionaire-wealth-up-850-billion/
2. UBSã2020幎ãåµã«ä¹ããhttps://www.ubs.com/content/dam/static/noindex/wealth-management/ubs-billionaires-report-2020-spread.pdf
3. ãªãªãŒã»Aã»ãŠã£ãªã¢ã ãºã2020幎10æ6æ¥ãåäžé·è
ã®å¯ã¯ãæ¿åºã®æ¯æ°åºæ¿çã®ãããã§å²äžåããŠ10å
ãã«ãéæãUBS. https://www.forbes.com/sites/oliverwilliams1/2020/10/06/billionaire-wealth-hits-10-trillion-for-first-time-ever-thanks-to-government-stimulous/?sh=86282fa49ba8
4. ãã£ãã¯ã»ã³ãªã³ãºã2020 幎 10 æ 8 æ¥ãç±³åœã®ããªãªãã¢å¯ã¯3æ18æ¥ä»¥æ¥8500åãã«å¢å https://blackstarnews.com/?c=123&a=4392
5. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020 幎 11 æ 7 æ¥ãã³ãã19ã®ããŒãããããäžççµæžã®ã«ãªã¹ãšç€ŸäŒçç Žå£ã«åããŠãhttps://www.globalresearch.ca/the-covid-19-roadmap-towards-economic-chaos-and-societal-destruction/5725602
6. ãã£ãã¯ã»ã³ãªã³ãºã2021幎3æ23æ¥ãWho Are the 10 Biggest Pandemic Profiteers? https://www.ubs.com/content/dam/static/noindex/wealth-management/ubs-billionaires-report-2020-spread.pdfïŒãã³ãããã¯ã®10倧å©ç远æ±è
ã¯èª°ãïŒ
7. çšéå
¬å¹³ã®ããã®ã¢ã¡ãªã«äººããš IPSã2021 幎 3 æ 18 æ¥ãBillionaires Data. https://www.forbes.com/sites/oliverwilliams1/2020/10/06/billionaire-wealth-hits-10-trillion-for-first-time-ever-thanks-to-government-stimulous/?sh=86282fa49ba8
8. ããµã€ãã»ãã¶ã³ã2020幎10æ12æ¥ããã€ãã³æ°ã¯åäžé·è
ã8000åãã«ãåŸããšãããã調æ»ã¯åžå Žãåºãã€ããŠããã®äŒžã³ãã¿ãŠããhttps://www.politifact.com/factchecks/2020/oct/12/joe-biden/biden-says-billionaires-gained-800-billion-study-l/
9. ãžã£ã³ã¢ã»ãããŒãã2021幎4æ6æ¥ãMeet The 40 New Billionaires Who Got Rich Fighting Covid-19. https://www.forbes.com/sites/giacomotognini/2021/04/06/meet-the-40-new-billionaires-who-got-rich-fighting-covid-19/?sh=8270f0c17e54
10. Ibid.
11. ãã¡ããã芧ãã ããïŒhttps://www.forbes.com/billionaires/
12. ãããŒãã»Fã»ã±ããã£ã»Jrã2021幎2æ4æ¥ãBill Gates and Neo-Feudalism: 蟲æ°ãã«ã«è¿«ããhttps://docs.google.com/spreadsheets/d/15n35QH3mq7jxxLmOnrcn2LGtMSssi-x1aCU9_2V9YVM/edit#gid=1259834744
13. Ibid.
75
------------------- 第6ç« -------------------
粟ç¥è¡çãžã®åœ±é¿
ãä»ãããã®ç£çŠã®çæ°ã«ç«ã¡åãããªããã°ãç§ãã¡ã¯åã©ããã¡ã®éã®æ®ºå®³ã«å æ
ããããšã«ãªãã®ã§ãã ãããã倧倿°ã®èŠªã幌çšåãåŠæ ¡ã®æè²è
ã¯......è
æããæ¿åºãåã©ããã¡ãçæ°ãèªæ®ºã«è¿œã蟌ã¿ããã®çµæãç§ãã¡å
šå¡ã®æªæ¥ãçµã殺ããŠããããšãé»ã£ãŠåãå
¥ããŠããã®ã§ããã
-ã«ãã«ãã»ããŒã³ãŒã«ã2021幎9æå·
ãé¡ã®è¡šæ
ãšããŠã®ç¬é¡ã¯ã人é¡ã®å€æãããååšããŠãããããã¯äººéãæ¬æ¥æã£ãŠããç¹åŸŽã§ããã瀟äŒçè·é¢ã®åŒ·å¶ãšçžãŸã£ãŠãã³ãããã¹ã¯ã¯ç§ãã¡ã®é¡ãé ãã仲éã«äŒãã亀æµããéã«ææ
ã衚çŸããããšã劚ããŠããŸãããã®çŸ©ååã¯ã瀟äŒçãªçµ¶æã®ãªãŒã©ãäœãåºããŠããŸããç¬é¡ãšç¬ãã¯ã¹ãã¬ã¹ã軜æžãã察話ã亀æµãé£åž¯ãçŽäºè§£æ±ºãä¿ããŸããç¬é¡ã¯ãŸããCovid-19ã®ææãã£ã³ããŒã³ã«ç«ã¡åããææ®µãæ§æããŠããã
" -ããã·ã§ã«ã»ãã§ã¹ããã¹ããŒã2022幎5æå·
"ç¹ã«é«æ ¡ã§èŠãããå¥ã®ç ç²ããããŸãããæ²ããããšã«ãç§ãã¡ã¯ä»ãã³ããã«ããæ»äº¡è
æ°ãããã¯ããã«å€ãèªæ®ºè
æ°ãç®ã®åœããã«ããŠããŸããè¬ç©ã®éå°æåã«ããæ»ãã¯ããã«å€ãã®ã§ãã
-ãããŒãã»ã¬ãããã£ãŒã«ãå士ãCDCåå±é·ã2020幎7æ14æ¥ä»

ã¯ããã«
ã³ãããŠã€ã«ã¹ã«ããäžçäººå£æ°åå人ã®ç²Ÿç¥çèŠå¢ã¯ãç£çŠãéé¢ã瀟äŒçè·é¢ããã¹ã¯ãªã©ã®ç€ŸäŒå·¥åŠã®çµæã§ããã
- ç£çŠãéé¢ã瀟äŒççå€ãä»®é¢ãªã©ã®ç€ŸäŒå·¥åŠã
- ã¡ãã£ã¢ãæ¿åºã«ãã24æé365æ¥ã®çµ¶ãéãªãææãã£ã³ããŒã³ã
- äžççãªçµæžã®äžå®å®åã«ãã£ãŠåŒãèµ·ãããã倱æ¥çã®æ¥äžæã倧éã®è²§å°ãšçµ¶æã
粟ç¥ç§å»ã¯ãäžèšã®ãããªèŠå ã粟ç¥è¡çã«åãŒããè² ã®åœ±é¿ããåãäžããŠããŸãããå°éå®¶ã«ããå ±åã§ç¢ºèªãããããã«ãééçãªç°å¢ã¯ããã€ç ãäžå®ãäžç¢ºå®æ§ãèªçºããèŠå ãšãªã£ãŠããã®ã§ãã
ãã³ãããŠã€ã«ã¹ææçïŒCOVIDïŒ-19ã®ãã³ãããã¯ã¯ãææãäžç¢ºå®æ§ãäžå®ã瀟äŒçè·é¢/å€ç«ãå€ç¬ãçµæžç圱é¿ãªã©ãããŸããŸãªç€ºåã«å¯ãã ã¡ã«ããºã ãéããŠãäžè¬åžæ°ã®ç²Ÿç¥è¡çã«ãã€ãã¹ã®åœ±é¿ãäžããŠããããšãæžå¿µãããŠããã1ã
ã³ãã屿©ãã¡ã³ã¿ã«ãã«ã¹ã«äžãã圱é¿ã®å šäœåã¯ããŸã ååã«è§£æãããŠããªããç§ãã¡ã®åæã¯ãããŒã¿ãå ¥æå¯èœãªä»¥äžã®åé¡ã«çŠç¹ãåœãŠãã
1. ééæªçœ®ããšãããåœã ã§ãäžççã«èªæ®ºãæ¿å¢ããŠããããšã76
76
2.è¬ç©ã®éå°æåïŒã³ã«ã€ã³ããªããªã€ãïŒã«ããæ»äº¡çã®å¢å ã
3.飲é éã®å¢å ã«äŒŽãã¢ã«ã³ãŒã«äŸåçã®å¢å
äžççãªèªæ®ºã®å¢å
WHOã¯ããã³ãããã¯çºç以æ¥ãèªæ®ºã«ããæ»äº¡è
æ°ãå ±åããŠããªããåæ§ã«ãæ¬çš¿å·çæç¹ã§ã¯ã2021-22幎ã«ä¿ãç±³åœã§ã®èªæ®ºçµ±èšã®å ±åããªããæã
ã®åæã¯ãäž»ã«äºäŸå ±åã«åºã¥ããã®ã§ããã
ç±³åœã«ãããèªæ®ºè
æ°
2019幎ãç±³åœã§ã¯èªæ®ºãæ»å ã®ç¬¬10äœã§ã47,511人ã®ç±³åœäººãèªæ®ºã§æ»äº¡ãã2ã2019幎ã®èªæ®ºæªéã®æšå®ä»¶æ°ã¯138äžä»¶ã®èŠæš¡ã§ãã£ã3ã
ãšããã³ã¹ã¯ä¹ããã
CDCäž»å¬ã®æ»èªä»ãå ±åæžïŒMark Ã. Czeisler, Rashon I. Lane, Emiko Petrosky, et al.ïŒã¯ã2020幎3æã®ããã¯ããŠã³çŽåŸã®éçšãšè³Œè²·åã®åªå€±ããç¹ã«ãè匱ãªã瀟äŒå±€ãäœæåŸå±€ã®éã§ããã€ãšäžå®ã®æ³¢ãåŒãèµ·ãããããããèªæ®ºå¿µæ
®ïŒæ§ã
ãªæ»ã«æ¹ã«ã€ããŠèããïŒããšããŠèšè¿°ããçµæã«ã€ãªããéèŠãªåœ¹å²ãæ
ã£ããšç¢ºèªãã4ã
èè
ãã¯æ¬¡ã®ããã«ç¢ºèªããŠããŸãã
äžå®é害ãšãã€ç æ§é害ã®çç¶ã¯ã2020幎4æãã6æã«ãããŠãç±³åœã§ããªãå¢å ããŸããã
2020幎4-6ææã®ç±³åœã¯ã2019幎åæãšæ¯èŒããŠ(1,2)......ã
調æ»å®äºåã®30æ¥éã«èªæ®ºãçå£ã«èããããšããããšåçãã人ã®å²åïŒ10.7ïŒ ïŒã¯ã18ïœ24æ³ã®åçè ïŒ25.5ïŒ ïŒãå°æ°äººçš®ã»æ°æïŒãã¹ãããã¯åçè 18.6ïŒ ïŒœãéãã¹ãããã¯é»äººïŒ»ãã©ãã¯ïŒœåçè 15.1ïŒ ïŒœïŒãæäººã®ç¡çµŠä»è·è ã®èªå·±ç³åïŒ30.7ïŒ ïŒãå¿ é åŽåè ïŒ21.7ïŒ ïŒã§èããé«ãããšãåãããŸãã...5ã
ãŸããå¥ã®ç ç©¶ã§ã¯ãç£çŠæ¿çã«ããã瀟äŒçè·é¢ïŒå€ç«ãšå€ç¬ããèªæ®ºã®èŠå ãšãªã£ãå¯èœæ§ã確èªãããŠããã
ã瀟äŒçè·é¢æã®äºæ¬¡çãªçµæãèªæ®ºã®ãªã¹ã¯ãé«ããå¯èœæ§ããã ããšç ç©¶è ã¯2020幎4æ10æ¥ã«ç±³åœå»åž«äŒããçºè¡šãããè«æã§ææããŠãã6ã
ãçµæžçãå¿ç瀟äŒçãå¥åº·ã«é¢é£ããæ§ã ãªãªã¹ã¯èŠå ã®å€åãèæ ®ããããšãéèŠã§ãããã (FEEåç §)
æ¬è³ªçã«ãç ç©¶è ã¯ã匷å¶çãªå€ç«ãèªæ®ºã®ããã®ãå®ç§ãªåµãã§ããããšã蚌æããå¯èœæ§ããããšèŠåããŠããŸãã(匷調)7
äžå¿çãªåé¡ã¯ãå°éå®¶ã«ããå ±åæžã§ã¯æ±ãããŠããªãããç£çŠãšçžãŸã£ãŠçããéçšãšè³Œè²·åã®åªå€±ããã©ã®ããã«ãã€ç
ãšçµ¶æã«ã€ãªããããšããããšã§ãã8ã
倱æ¥ãåå
¥æžã«ããäžå®ãæãã€ã¯ãäžçå²äžåäŸã®ãªãçŸè±¡ã§ãããåœå¥ã«èŠãŠããåããããªåŸåãèŠããããäœæåŸè
77
ã€ã³ãã®ãããªçºå±éäžåœã§ã¯ãè²§å°ã«ããã人ã ã®å€§éšåãçµ¶æçãªç¶æ³ã«é¥ã£ãŠããŸãã
ã€ã³ãã§ã®èªæ®º
ã€ã³ãã§ã¯ããæ·±å»ãªèŠé£......éçšå±æ©ãæ·±å»åãããªãã§ãçæŽ»å šäœã厩å£ãããçµæãšããŠãç£çŠãèªæ®ºã®æ¥å¢ãå©é·ããŠãã9ã
ãèªæ®ºãšããç æ°ãé ãããããéå¢ã«å€åããªããšå€æãã人ã ãèªãåœãçµ¶ã€ãšããå ±åãæ¥å¢ããŠããã®ã¯ãé©ãã«ã¯ããããªãã
ãã«ããã³ã°ã¹ç ç©¶æããã€ã³ãã§ã®èªæ®ºã®åŒãéãšãªã£ãã³ãã屿©ã®åœ¹å²ã«ã€ããŠåãäžããŠããã
äžæ¹ãã€ã³ãã®éžè©±ç蚌æ ã¯ã蟲æéšã®èªæ®ºã®å¢å ã瀺åããŠãããã€ã³ãã¯é«ãè²§å°çã®äžã§ãäžçã§æãå³ããããã¯ããŠã³ã®1ã€ãå¶å®ããã... ããã¯ããŠã³ã¯äœçŸäžäººãã®ã€ã³ã人ãè²§å°ã«é¥ããäžçã§æãèªæ®ºçã®é«ãåœã®ã²ãšã€ãæªåãããçµæãšãªã£ããèªæ®ºè ã®æ°ã¯æ°å人ã«äžããšæšå®ãããŠãã10ã
æ¥æ¬ã«ãããèªæ®º
è¿å¹Žãèªæ®ºè æ°ã¯æžå°åŸåã«ãã£ããã2020幎ã«ã¯ãéå»10幎éã§åããŠèªæ®ºè æ°ãåã³å¢å ããã(ã¹ã¿ãã£ã¹ã¿)11

ãã®æ¥æ¿ãªäžæåŸåã¯ãCOVID-19ã®ããã¯ããŠã³æ¿çãåŒãéãšãªã£ãã2020 å¹Žãæ¥æ¬ã§ã¯çŽ 21,000 人ãèªæ®ºãã12ã
"COVID-19 "ãšããç æ°ãã®ãã®ãããããã³ãããã¯ã®çµæžçã»ç€ŸäŒç圱é¿ã«ãã£ãŠæªåãããšæãããèªæ®ºã§äº¡ããªãæ¥æ¬äººã®æ¹ãã¯ããã«å€ãã®ã§ãã...
78
èŠå¯åºã®æ«å®çµ±èšã«ãããšãèªæ®ºè
ã¯10æïŒ2020幎ïŒã ãã§2153äººã«æ¥å¢ãã4ã«æé£ç¶ã®å¢å ãšãªã£ãã" CBS 2020 幎 11 æå ±éïŒåŒ·èª¿ïŒ13
äžèšã®å ±éã¯ã2020 幎 3 æã®ç£çŠäºä»¶ããã£ããã«ãæ¥æ¬ã®å¥³æ§ã®èªæ®ºãæ¥æ¿ã«å¢å ããããšãè£ä»ãããã®ã§ããã2020幎10æïŒå幎10ææ¯ïŒã女æ§ã®èªæ®ºè
ã¯83ïŒ
å¢å ããŠããïŒåææã«22ïŒ
å¢å ããç·æ§ã®èªæ®ºè
ãšæ¯èŒãããšïŒ14ã
æ¥æ¬ã®å°åŠçã®èªæ®ºè æ°
2021å¹Žãæ¥æ¬ã®æéšç§åŠçãçºè¡šããå ±åæžã«ãããšãæ¥æ¬ã®å°åŠçã®èªæ®ºã¯é廿é«ãèšé²ããã
æ¥æ¬ã®åŠç«¥ã®èªæ®ºã¯ã2020 幎床ã®éã«é廿é«ãèšé²ããããšããæéšç§åŠçã® 2021 幎床ã®å ±åæžã§ç¢ºèªãããŠããã
2020幎床ã®6æ³ãã18æ³ã®å ç«¥çåŸã®èªæ®ºè æ°ã¯415人ã§ã1974幎ã®èšé²éå§ä»¥æ¥æå€ãšãªã£ã......ããã®æ°åã¯ã317 åã®åŠç«¥ãæ»äº¡ããååŠå¹Žãã 31ïŒ é«ããã®ã§ãã£ãã15ã
æéšç§åŠçã®å ±åæžã§ã¯ãããã³ãããã¯ã«ãã£ãŠåŠæ ¡ãå®¶åºã®ç°å¢ã«å€åãçããåã©ããã¡ã®è¡åã«åœ±é¿ãäžããããšææããŠããã
è¬ç©ã®éå°æåã«èµ·å ããæ»äº¡æ°
äž»ãªè¬ç©ãªããªã€ãã®åé¡ïŒCDCïŒã¯ä»¥äžã®éãã§ããã
- éæ³ããã€ã³
- ãã§ã³ã¿ãã«ã®ãããªåæãªããªã€ã
- ãªãã·ã³ãã³ïŒãªãã·ã³ã³ãã³Â®ïŒããããã³ãã³ïŒãã€ã³ãã£ã³Â®ïŒãªã©ã®ãããããé®çå€ã
- ã³ãã€ã³
- ã¢ã«ãã
- ãã®ä»
äžèšã®è¬ç©ã¯ããååŠçãªé¢é£æ§ããããäœãè³ã®ç¥çµçްèäžã®ãªããªã€ãå容äœãšçžäºäœçšãããïŒCDCïŒ
2020幎ã«èšé²ãããã³ãã屿©ã¯ãç±³åœã«ããããªããªã€ããšã³ã«ã€ã³ã®äž¡æ¹ã®å£²äžã倧å¹
ã«å¢å ãããèŠå ãšãªããŸããã
CDCã«ãããš
åæãªããªã€ãïŒïŒ»CDCã§ã¯ïŒœäž»ã«äžæ£ã«è£œé ããããã§ã³ã¿ãã«ã«åé¡ãããŠããïŒã¯ãéå°æåã«ããæ»äº¡è æ°ã®å¢å ã®äž»å ãšãªã£ãŠããããã§ã2020幎5æãŸã§ã®12ã«æéãšæ¯èŒããŠã2019幎6æãŸã§ã®12ã«æéã¯38.4ïŒ å¢å ããŠããã...
79
ã³ã«ã€ã³ãå«ãéå°æåã«ããæ»äº¡ã26.5ïŒ å¢å ããã... ã¡ã¿ã³ãã§ã¿ãã³ïŒGSM瀟補ïŒãªã©ã®ç²Ÿç¥åºæ¿å€ãé¢äžããéå°æåã«ããæ»äº¡ã¯ã34.8ïŒ å¢å ããã粟ç¥åºæ¿å€ãé¢äžããæ»äº¡è æ°ã¯ãä»ãã³ã«ã€ã³ãé¢äžããæ»äº¡è æ°ãäžåã£ãŠãã16ïŒCDC2020幎12æå ±åïŒïŒåŒ·èª¿è¡šç€ºïŒã
ç±³åœçŸç 察çã»ã³ã¿ãŒïŒCDCïŒã¯2020幎12æããã³ãããã¯ã "èŽåœçãªè¬ç©éå°æåã®å¢å "ã«å¯äžããå¯èœæ§ããããšå ±åãããããŒã¿ã¯äžå®å šã§ãããCDCã®å ±åæžã§ã¯ãè¬ç©ã®éå°æåã«èµ·å ããæ»äº¡è æ°ïŒã³ã«ã€ã³ããªããªã€ãã®æåã«é¢é£ããïŒã®å€§å¹ ãªå¢å ã確èªãããŠããŸãã
çŸç 察çäºé²ã»ã³ã¿ãŒã«ãããšã2019幎6æãã2020幎5æã«ãããŠãè¬ç©ã®éå°æåã¯81,000人以äžã®æ»äº¡ã«é¢é£ããŠãããåã®12ã«æéãšæ¯èŒããŠ18ããŒã»ã³ããæ¥å¢ããŸããã25ã®å·ãšã³ãã³ãã¢ç¹å¥åºã§ã¯ãããããæ»äº¡ã20ïŒ ä»¥äžå¢å ãããšããã17ïŒPBSå ±éïŒ
è¬ç©ã®éå°æåã«èµ·å ããæ»äº¡ã®äºæž¬å€ã ãã§ãªãå ±åå€ïŒã€ãŸãæ°åïŒã«ãåºã¥ãCDCã®ã°ã©ãã§ã¯ã2020幎2æããæå¥ã®ã«ãŠã³ããå éãå§ããããšãæããã«ãããŠãã18ã

2020幎4æã«ã¯2,146人ããªããªã€ãã®éå°æåã§æ»äº¡ããç¶ã5æã«ã¯3,388äººãæ»äº¡ããé£éŠæ¿åºããã®ããŒã¿ãåéãå§ãã2015幎以éãæ¯ææå€§ã®å¢å ã瀺ããŠãã17ïŒPBSã¬ããŒãããåŒçšïŒã
次ã®ã°ã©ãã¯ãç±³åœã®ææ¬¡ããŒã¿ã瀺ãããã®ã§ãããã³ãã屿©ã®åã®æïŒ2019幎7æïœ2020幎1æïŒã¯ãæ¯æã®è¬ç©éå°æåã«ããæ»äº¡è æ°ã¯1,000人ãå€§å¹ ã«äžåã£ãŠããã
2æïŒéè屿©ãšåæïŒããäžæãéå§ã3æäžæ¬ã®ããã¯ããŠã³ã®åŸãè¬ç©éå°æåã®æ»è ã¯é«å€ã§é£ã¶ããã«ãªã£ãã
2020幎5æãéå°æåã«ããæ»äº¡è æ°ã¯3,000人ãè¶ ããããªãã¡ã³ãã屿©ä»¥åã«èšé²ãããè¬ç©éå°æåã«ããæ»äº¡è æ°ã«æ¯ã¹ã3å以äžã®å¢å ã§ãã£ããç±³åœã§ã¯ã2020幎ã«èšé²ãããæå¥ã®è¬ç©éå°æåã«ããæ»äº¡è æ°ã¯3å以äžã«ãªã£ãŠãã17ã
80

æè¿ã®CDCã®ããŒã¿ã§ã¯ãè¬ç©ã®éå°æåã«èµ·å ããæ»äº¡è æ°ãå¢å ãç¶ããŠããããšã確èªãããŠããŸããéå°æåã¯å¢ãç¶ããŠããã
2019幎ïŒ2019幎12ææ«ïŒã®æ»äº¡è æ°71,130人ãã2020幎ïŒ2020幎12ææ«ïŒã®æ»äº¡è æ°92,478人ãããªãã¡2019å¹Žã«æ¯ã¹ãŠ2020幎ã®çµéã§21,348人å¢å ãã19ã
ãã®å¢å åŸåã¯ã2021幎ã®éçšã§ãç¶ããŠããã
2021幎6æãŸã§ã®12ãæéã§ãèšé²ãããè¬ç©éå°æåã«ããæ»äº¡è
æ°ã¯ã»ãŒ10äžäººã«éããïŒ2021幎6ææ«ïŒ98,022人ïŒ20ã
ã«ããã«ããããªããªã€ãé¢é£æ»äº¡è æ°
ã«ããã«ãããåŸåã¯ãç±³åœã§èгå¯ããããã®ãšäžèŽããŠããã2020幎3æ17æ¥ã®ããã¯ããŠã³ç·æ¥äºæ ã®åŸãçµæžæŽ»åã®ééã«äŒŽã倱æ¥ãšçžãŸã£ãŠããªã³ã¿ãªãªå·ã§ã¯ãªããªã€ãé¢é£æ»ãåçã«å¢å ããããšãèšé²ãããŠããã
2020幎3æ17æ¥ã«ãªã³ã¿ãªãªå·ã§éåžžäºæ 宣èšãåºãããåŸã®æ°é±éããªããªã€ãé¢é£ã®æ»äº¡è æ°ã¯æ¥éã«å¢å ããŸãããå šäœãšããŠãCOVID-19ãã³ãããã¯ã®æåã®15é±éïŒæ»äº¡è æ°695人ãé±å¹³å46人ïŒã¯ãçŽåã®15é±éïŒæ»äº¡è æ°503人ãé±å¹³å34人ïŒãšæ¯èŒããŠããªããªã€ãé¢é£ã®æ»äº¡è æ°ã38.2ïŒ å¢å ãã21ã
ãã³ãããã¯ã®éçšã§ããã§ã³ã¿ãã«ïŒå»è¬åãªããªã€ãïŒããªããªã€ãé¢é£æ»äº¡ã®87ïŒ ãå ãïŒ87.2ïŒ ïŒ»N=617äž538ïŒããã³ãããã¯åã®ã³ããŒãïŒ79.2ïŒ ïŒ»N=504äž399ïŒãšæ¯èŒããŠããããšã¯æ³šç®ã«å€ãã22ã
81

次ã®ã°ã©ãã¯ããªããªã€ãéå°æåã®ç·æ¥äºæ ã®åçãªå¢å ã®æç¢ºãªç»åãæäŸããŸãã2020幎1æãã2020幎12æãŸã§ãªã¿ã¯ã蚪åã

ãªããªã€ãã®çç£ãšååŒ
åœé£ã®çºè¡šã«ãããšãã¢ãã¬ãã¹ã¿ã³ã¯çŸåšãäžçã®ã¢ãã³ã®94ïŒ ãçç£ããŠããŸãã
82
ããã€ã³ãã¢ã«ãããå»è¬åãªããªã€ãã«å€æããããããã€ã³ã®ååŒã¯ä¿è·ãããŠããŸãã23 ã¢ãã¬ãã¹ã¿ã³ã«ãããç±³è»ã®ååšãéèŠãªåœ¹å²ãæ
ã£ãŠããŸããããã¯ãæ°ååãã«èŠæš¡ã®å»è¬åãªããªã€ãã®è²©å£²ãšæµéã«é¢äžãã麻è¬ã«ã«ãã«ïŒéæ³ããã€ã³ïŒ24ãšãïŒéæ¥çã«ïŒå€§æè£œè¬äŒç€Ÿãé¢äžããæ°ååãã«ã®äœæŠã§ãã
ãã¡ã€ã¶ãŒããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãªã©ãCOVID-19ã¯ã¯ãã³ã®è²©å£²ã«é¢ããããã€ãã®ããã°ã»ãã¡ãŒãã¯ãã³ãã屿©ïŒ2020-2021ïŒã®éçšã§è¬ç©éå°æåã®äž»èŠåå ã®1ã€ãšãªã£ããé«åçïŒãã€åæ³ïŒã®å»è¬åãªããªã€ãã®è²©å£²ã«ãé¢äžããŠããã®ã§ãã
è æãã倧æè£œè¬äŒç€Ÿ
ã¢ã¡ãªã«åå°ã®å°å瀟äŒã¯ããªããªã€ãã«é¢ããŠè£œè¬å€§äŒæ¥ã«å¯Ÿæããå§¿å¢ã瀺ããã2019-20å¹Žãæ°åã®ç±³åœã®éœåžãé¡ã代衚ããŠãæ°ååãã«ã®ãªããªã€ãåè§£ãããã¥ãŒã»ãã¡ãŒããšçµã°ããã
ããªãã·ã³ã³ãã³ ãã¡ãŒã«ãŒã®ããã¥ãŒã¯10æïŒ2020幎ïŒããæ£åœãªå»çç®çã®ãªããè¬ã®äŸçµŠãå¯èœã«ããããšãå»åž«ãªã©ã«éæ³ãªããã¯ããã¯ãæ¯æã£ãŠè¬ãåŠæ¹ãããããšããã®ä»ã®äž»åŒµã«ã€ããŠèªããã83åãã«ã®æ¯æãã«åæããã(BBCã2021 幎 2 æ 4 æ¥)25ã
ã³ãã屿©ã®æäžïŒ2020幎11æïŒ
åŠæ¹è¬ãªããªã€ãã®è£œé ïŒJ&JïŒãšæµéã«é¢ãã倧æè£œè¬äŒç€Ÿ4瀟ïŒãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãããã±ãœã³ãã«ãŒãã£ãã«ã»ãã«ã¹ãã¢ã¡ãªãœãŒã¹ã»ãã«ã²ã³ïŒã¯ãæå®³è³ åãæ±ããŠèšŽããé¡ãåžãšæ°ååãã«ã®æ«å®çåè§£ã«è³ã£ãã26ã
ãã®åè§£ã¯ãããªããªã€ãã»ãšãããã㯠ããšåŒã°ãããã³ãã屿©ãšã®é¢ä¿ã¯ã©ããªã£ãŠããã®ã ããããèŠãç®èã ããåŠæ¹ç®ãªããªã€ãã®éå£èšŽèšã®å¯Ÿè±¡ãšãªã£ãŠãããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã¯ãCOVID-19ã¯ã¯ãã³ã®äž»èŠãªè²©å£²å
ã§ãããã
ãããåãããã°ãã¡ãŒãã®è²©å£²æ¥è
ã¯ãããã¯ããŠã³ã«èµ·å ãããªããªã€ãã®è²©å£²æ¥å¢ã®æ©æµãåãããã®çµæã2020幎ãã2021幎ã«ãããŠã®è¬ç©éå°æåã«ããæ»äº¡ã®å€§å¹
ãªå¢å ã«è²¢ç®ããŸããïŒäžèšã®ã°ã©ããåç
§ïŒã
èŠãç®èã«ããè¬ç©éå°æåã®æ¥å¢ã¯ãããã°ã»ãã¡ãŒãã®å©çå¢ã«ã€ãªãã£ãã
ããã°ãã¡ãŒãã¯ãåŠæ¹ç®ãªããªã€ãã®äžæ£ãªæµéã«é¢ããæ°ååãã«ã®æ°äºèšŽèšã®å¯Ÿè±¡ã«ãªã£ãŠããããããããè
æããäŒæ¥ã®ããã€ãã¯ãçŸåšãCOVID-19ã¯ã¯ãã³æ§æ³ã®æšé²ã«çµ¡ãã§ããããã«ãŒã ããŒã°ã«ããã°ããéå»20幎éã«40äžäººä»¥äžã®ã¢ã¡ãªã«äººãïŒè¬ç©ïŒã«ããæ»äº¡ããŠããããšããã27ã
ãããŠä»ã2020幎2æã®ã³ãã屿©ã®çºç以æ¥ãè¬ç©ã®éå°æåã«èµ·å ããæéæ»äº¡è
æ° éå°æåã«ããæ»äº¡è
æ°ã¯3å以äžã«ãªã£ãŠããïŒäžã®ã°ã©ãåç
§ïŒã
ã¢ã«ã³ãŒã«äŸåç
è¬ç©ä¹±çšãšã¢ã«ã³ãŒã«äŸåçã¯ããã°ãã°é¢é£ããŠããã
ãCOVID "ã§è¬ç©ã»ã¢ã«ã³ãŒã«äŸåçãå¢ããèªæ®ºãå¢ããŠããŸãããã«ããããã©ã€ã³ã¯ããµãããããããçš®ã®çµ±èš-ç±³åœã§ã¯ãªã³ã©ã€ã³ã§ã®ã¢ã«ã³ãŒã«è²©å£²ã200ïŒ ä»¥äžå¢å ãã-ã¯æãçµµãæããŠããŸããã
83
ãäžæ¯ãæ¥å¢ããŠããããšèªãã®ã¯ã以åCAMHã«å€åããŠããäžæ¯ã»ã©ãã¹ãã®ã·ã³ãã£ã»ãã©ã³ãã
ãã®å€§æµè¡ã«ãã£ãŠãããããäžå®ãã¹ãã¬ã¹ãå¢å€§ããããã«......ã瀟äŒçè·é¢ã眮ãããšã¯ãäŸåçã®åé¡ãæ±ãã人ã
ããä»å¿
èŠãªå©ããåŸãããªãå¯èœæ§ããããããšãæå³ããããšåœŒå¥³ã¯èšãã(匷調)28
ã¢ã«ã³ãŒã«è²©å£²éã®å¢å
ã¢ã¡ãªã«ã«ãããã³ãã屿©ã®éã®ã¢ã«ã³ãŒã«äžæ¯ã®å¢å åŸåã¯ãã¢ã«ã³ãŒã«ã®è²©å£²éã®å€§å¹
ãªå¢å ã«ãã£ãŠç¢ºèªãããŠãããããŒã«ã»ã³ã®èª¿æ»ã«ãããšã2020幎3æã®çå®çªæ³šæã«ãããã2020幎3æ21æ¥ã«çµããé±ã®å
šç±³ã¢ã«ã³ãŒã«å£²äžé«ã¯1幎åãšæ¯èŒããŠ54ïŒ
å¢å ããªã³ã©ã€ã³å£²äžé«ã¯2019幎ãã262ïŒ
å¢å ããããšããã29
åœç«ã¢ã«ã³ãŒã«ä¹±çšã»ã¢ã«ã³ãŒã«äŸåçç ç©¶æïŒNIAAAïŒã®æ¯æŽãåããŠå®æœãããã©ã³ã瀟ã®ãµã³ãã«èª¿æ»ç ç©¶ã¯ã2019å¹Žã®æäººã®é£²é
ç¿æ
£ãã³ãã屿©æïŒ2020幎ïŒã®ãã®ãšæ¯èŒããããšã§æãç«ã£ãŠããã
ãã¢ã¡ãªã«ã®æäººã¯ãã³ãããŠã€ã«ã¹ã®æµè¡ã«ãã£ãŠåŒãèµ·ããããã·ã£ããããŠã³äžã«ã¢ã«ã³ãŒã«ã®æ¶è²»ãæ¥æ¿ã«å¢å ããã女æ§ã¯å€§é飲é ã®ãšããœãŒãïŒæ°æé以å ã«4æ¯ä»¥äžïŒã41ïŒ å¢å ãããŠãã
...
åœã®èª¿æ»ã«ãããšã30æ³ä»¥äžã®æäººã§ã¯ãæšå¹Žã®åææã«æ¯ã¹ãå šäœã®é£²é é »åºŠã14ïŒ å¢å ããããšãããã£ãã30æ³ãã59æ³ã®æäººå šäœã§ã¯19ïŒ ã女æ§ã§ã¯17ïŒ ããã¹ãããã¯ç³»ä»¥å€ã®çœäººã§ã¯10ïŒ ã®å¢å ã§ãã£ããã(ã©ã³ãã»ã³ãŒãã¬ãŒã·ã§ã³)30
ã©ã³ãã»ã³ãŒãã¬ãŒã·ã§ã³ã®é£²é
ç¿æ
£ã«é¢ãã調æ»ã§ã¯ãã¢ã«ã³ãŒã«ã®æ¶è²»éãå¢å ããŠããããšãæããã«ãªã£ããããã®çµæã«ã¯æ³šæãå¿
èŠã§ãããå®éã«è²©å£²ãããã¢ã«ã³ãŒã«ã®å¢å çïŒ54ïŒ
ïŒã¯ãã©ã³ã瀟ã®ãµã³ãã«èª¿æ»ã«åºã¥ãæšå®é£²é
éã®å¢å çã倧å¹
ã«äžåã£ãŠãããããããåæã«ãããã¯ããŠã³ã®éãã¢ã«ã³ãŒã«ã®æ¶è²»ã¯ãïŒéåºããïŒããŒãã¬ã¹ãã©ã³ã§ã¯ãªããå®¶åºã§è¡ãããããšãã»ãšãã©ã§ãã£ã31ã
ã©ã³ã瀟ã®ç ç©¶ã®äž»å·çè
ã§ãããã€ã±ã«ã»ãã©ãŒãã«ããã°ãã人ã
ã®ãã€ç
ã¯å¢å ããäžå®ã¯å¢å€§ããïŒäžç¥ïŒã¢ã«ã³ãŒã«äœ¿çšã¯ãã°ãã°ãããã®ææ
ã«å¯ŸåŠããæ¹æ³ãšãªãã32ã
å·»æ«è³æ
1. Stefania Chiappini, Amira Guirguis, et al., July 29, 2020. COVID-19: ã¡ã³ã¿ã«ãã«ã¹ãšè¬ç©äŸåçãžã®é ãã圱é¿ãhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403495/
2. ã¢ã¡ãªã«èªæ®ºé²æ¢è²¡å£ãn.d. èªæ®ºã®çµ±èš https://afsp.org/suicide-statistics/
3. National Institute of Mental Health, n.d. SuicideïŒåœç«ç²Ÿç¥è¡çç ç©¶æãè±èªïŒ https://www.nimh.nih.gov/health/statistics/suicide#part_154969
4. Mark Ã. Czeisler, Rashon I. Lane, et al., August 14, 2020. COVID-19 ãã³ãããã¯æã®ã¡ã³ã¿ã«ãã«ã¹ãç©è³ªäœ¿çšãèªæ®ºå¿µæ
® - ç±³åœã2020 幎 6 æ 24 æ¥ïœ30 æ¥https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm
84
5. åäž
6. ããŒã¯ã»Aã»ã¬ã¬ãŒãã€ã¢ã³ã»Hã»ã¹ã¿ã³ã¬ãŒãä»ã2020幎4æ10æ¥ãèªæ®ºæ»äº¡çãšã³ãããŠã€ã«ã¹ç
2019-A Perfect Storm? https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2764584?guestAccessKey=c40eefb2-c634-47ed-b3c3-f00b005e3cf2&utm_
7. ãžã§ã³ã»ãã«ãã£ã¢ã¢ã2020 幎 11 æ 24 æ¥ãSuicide Claimed More Lives in October Than 10 Months of COVID-19 in Japan, Report Shows. https://fee.org/articles/suicide-claimed-more-lives-in-october-than-10-months-of-covid-19-in-japan-report-shows/
8. Mark A. Reger, Ian H. Stanley, et al., April 10, 2020. Suicide Mortality and Coronavirus Disease 2019-A Perfect Storm? https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2764584?guestAccessKey=c40eefb2-c634-47ed-b3c3-f00b005e3cf2&utm_
9. ã¿ã€ã ãºã»ããŠã»ããžã¿ã«ã2020 幎 9 æ 14 æ¥ãAmid COVID-19 outbreak, India's suicide epidemic remain unaddressed - these graphs show how. https://www.timesnownews.com/india/article/amid-covid-19-outbreak-indias-suicide-epidemic-remains-unaddressed-these-graphs-show-how/652188
10. ãã£ãã«ã»ã°ã©ãã ã2020 幎 11 æ 17 æ¥ãThe human costs of the pandemic: Is it time to prioritize well-being? https://www.brookings.edu/research/the-human-costs-of-the-pandemic-is-it-time-to-prioritize-well-being/
11. ã¹ã¿ãã£ã¹ã¿ã2021 幎 3 æã2011幎ãã2020幎ãŸã§ã®æ¥æ¬ã«ãããèªæ®ºè
ç·æ° https://www.statista.com/statistics/622065/japan-suicide-number/
12. L. Kettenhofen, 2021 幎 11 æ 30 æ¥. æ¥æ¬ã®èªæ®º - çµ±èšãšäºå®. https://www.statista.com/topics/5259/suicide-in-japan/
13. ã«ãŒã·ãŒã»ã¯ã©ãã, 2020 幎 11 æ 13 æ¥. 10æã®èªæ®ºã¯COVIDã®10ã¶æåãããå€ãã®æ¥æ¬äººã®åœã奪ã£ããhttps://www.cbsnews.com/news/japan-suicide-coronavirus-more-japanese-suicides-in-october-than-total-covid-deaths/
14. Ibid.
15. å塿µçŸåã2021幎10æ14æ¥ãæ¥æ¬ã«ãããåã©ãã®èªæ®ºãé廿é«ãèšé² https://edition.cnn.com/2021/10/14/asia/suicide-children-japan-intl-hnk/index.html
16. CDCã2020 幎 12 æ 17 æ¥ãCOVID-19 æéäžã«å éããéå°æåã«ããæ»äº¡ãhttps://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
17. ããŒã©ã»ãµã³ã¿ãã ã2020 幎 12 æ 28 æ¥ãCOVID-19 ã®ããšã§ã®è¬ç©éå°æåã«ããæ»äº¡ã®æŽå²çæ¥å¢ã®èåŸã«ãããã® https://www.pbs.org/newshour/health/whats-behind-the-historic-spike-in-drug-overdose-deaths-under-covid-19
18. CDCã2022 幎 1 æ 12 æ¥ãProvisional Drug Overdose Death Counts. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
19. åäžã
20. ãã€ãã¬ã»ãã¯ãã£ãªããã¹ã2021 幎 11 æ 17 æ¥ãè¬ç©éå°æåã«ããæ»äº¡è
æ°ãåããŠå¹Žé10äžäººãçªç Žããã§ã³ã¿ãã«ãçœåŒã
CDC ã®ããŒã¿ã瀺ããhttps://edition.cnn.com/2021/11/17/health/drug-overdose-deaths-record-high/index.html
21. ãªã³ã¿ãªãªå·è¬ç©æ¿çç ç©¶ãããã¯ãŒã¯ããªã³ã¿ãªãªå·éŠåžæ€èŠå®äºåæïŒãªã³ã¿ãªãªå·æ³å»åŠç
çåŠãµãŒãã¹ãä»ã2020 幎 11 æãPreliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en
22. åäžã
23. Michel Chossudovskyææã2005幎6æ14æ¥ãThe Spoils of War: Afghanistan's Multibillion Dollar Heroin TradeïŒæŠäºã®æŠå©åïŒã¢ãã¬ãã¹ã¿ã³ã®æ°ååãã«ã®ããã€ã³ååŒïŒhttps://www.globalresearch.ca/the-spoils-of-war-afghanistan-s-multibillion-dollar-heroin-trade/91
24. ããŒã±ãããŠã©ããã2022幎1æ13æ¥ããªããªã€ãå»è¬åã®åžå ŽèŠæš¡ãã·ã§ã¢2022幎äžçåæãCOVID-19ã€ã³ãã¯ããã«ããŒïœä»åŸã®ååãæé·çã2025幎ãŸã§ã®å°æ¥äºæž¬ã«é¢ããè©³çŽ°ãªæŽå¯ https://www.marketwatch.com/press-release/opioids-drugs-market-size-share-2022-global-analysis-covers-covid-19-impact-detailed-insights-on-upcoming-trends-growth-rate-and-future-forecast-to-2025-2022-01-13
85
25. BBCã2021 幎 2 æ 4 æ¥ããããã³ãŒãŒãç±³åœã§5å7300äžãã«ã®ãªããªã€ãåè§£ã«åæ https://www.bbc.com/news/business-55939224
26. KHN ã¢ãŒãã³ã°ããªãŒãã£ã³ã°ã2020 幎 11 æ 6 æ¥ã補è¬äŒç€Ÿ 4 瀟ã260 åãã«ã®ãªããªã€ãåè§£ã«åæ https://khn.org/morning-breakout/4-drug-companies-agree-to-26-billion-opioid-settlement/
27. ãžã§ãã»ãã£ãŒãªãŒã2021幎2æ4æ¥ãMcKinsey to Pay $573 Million to Resolve U.S. Opioid Claims. https://www.bloomberg.com/news/articles/2021-02-04/mckinsey-said-to-agree-to-550-million-opioid-claim-settlement-kkq6xumb
28. ãªãºã»ãã©ãŠã³ã2020 幎 10 æ 1 æ¥ãCOVIDæéäžã®è¬ç©ã»ã¢ã«ã³ãŒã«äœ¿çšéã®äžæ https://nielseniq.com/global/en/insights/analysis/2020/rebalancing-the-covid-19-effect-on-alcohol-sales/
29. ããŒã«ã»ã³IQã2020幎5æ7æ¥ãã¢ã«ã³ãŒã«è²©å£²ã«å¯ŸãããCOVID-19广ãã®ãªãã©ã³ã·ã³ã° https://nielseniq.com/global/en/insights/analysis/2020/rebalancing-the-covid-19-effect-on-alcohol-sales/
30. ã©ã³ã瀟ã2020 幎 9 æ 29 æ¥ããã³ãããã¯åæ¢äžã«ã¢ã«ã³ãŒã«æ¶è²»éãæ¥å¢ã女æ§ã®å€§é飲é
ã¯41ïŒ
å¢ https://www.rand.org/news/press/2020/09/29.html
31. ãµãŒã·ã£ã»ããŒãã¯ã2020 幎 9 æ 30 æ¥ããã³ãããã¯äžã«ã¢ã«ã³ãŒã«æ¶è²»éãæ¥å¢ãç¹ã«å¥³æ§ã®éã§å¢å https://abcnews.go.com/US/alcohol-consumption-rising-sharply-pandemic-women/story?id=73302479
32. åäž.
86
------------------ 第7ç« -------------------
è æããç§åŠ ãæ²»çæ³ã¯ãªãã
å®äŸ¡ã§å¹æã®ããããããã·ã¯ãããã³(HCQ)ã®
匟å§
COVI-19ã®æ²»çè¬ãšããŠå®äŸ¡ã§æå¹ãªããããã·ã¯ãããã³ïŒHCQïŒã匟å§ããããã®æŠããç¶ããŠãããHCQã«å¯Ÿãããã£ã³ããŒã³ã¯ãäžå·çãªæ¿æ²»ççºèšãã¡ãã£ã¢ã«ããäžå·ã¯ãã¡ããã5æ22æ¥ã«The Lancetèªãçºè¡šããæš©åšããæ»èªä»ããè©äŸ¡ãã¯ãåœã®æ°åãšè©Šéšçãªè©Šã¿ã«åºã¥ããŠããã
ãã®ç ç©¶ã¯ãäžç671ã®ç
é¢ãã2019幎12æ20æ¥ãã2020幎4æ14æ¥ãŸã§ã«COVID-19ã§å
¥é¢ããæ£è
96,032人ã®ããŒã¿åæã«åºã¥ããšãããŠãããããŒã¿ããŒã¹ã¯æé ãããŠãããç®çã¯ãããã°ãã¡ãŒãã«ä»£ãã£ãŠããããã·ã¯ãããã³ïŒHCQïŒã®æ²»çè¬ã殺ãããšã ã£ãã
ã©ã³ã»ããèªã®è«æã¯æ€åãããããã¡ãã£ã¢ã¯ãæ¬ é¥ã®ããããŒã¿ããåºãããšããŠããSFäœå®¶ãšã¢ãã«ãã³ã³ãã³ãã®ã¢ãã«ããåŸæ¥å¡ã«æã€ãµãŒãžã¹ãã£ã¢ãšãããç±³åœã«æ ç¹ã眮ãå°ããªäŒç€Ÿããæ°è»œã«éé£ããïŒã¬ãŒãã£ã¢ã³çŽïŒããã®ã·ã«ãŽã«æ¬æ ã眮ãäŒç€Ÿã¯ãWHOãšååœæ¿åºã欺ããHCQãçŠæ¢ããããã«ç
œã£ããšããŠéé£ããããå®éã«ã¯ããããã®è©Šéšçãªãã¹ãã¯è¡ãããŠããªãã

ãã®è²¬ä»»ã¯ãµãŒãžã¹ãã£ã¢ã«ãããšãããããç§åŠçãã¡ãã£ã¢ãèªããŠããªããç¥ããããçå®ããããïŒç§åŠçãã¡ãã£ã¢ãèªããŠããªããïŒãã®ç ç©¶ã¯ããŒããŒã倧åŠã«ãã£ãŠèª¿æŽããããã®ã§ããã
87
ããŒããŒã倧åŠå»åŠéšãšææºããããªã¬ã ïŒãŠã£ã¡ã³ãºã»ãã¹ãã¿ã«ïŒBWHïŒäž»å¬ã§ããã³ãã£ãŒãã»ã¡ãŒã©ææãè©æ¬ºã«éããŸããã
ãã®è©æ¬ºäºä»¶ãçºèŠãããšããããªã¬ã ïŒãŠã£ã¡ã³ãºã»ãã¹ãã¿ã«ã§ããŒãŽã§ã€ç¹å¥è¬åº§ãæã€ãã³ãã£ãŒãã»ã¡ãŒã©å士ã¯è¬çœªããŸããã
ãç§ã¯åžžã«æé«ã®å«ççã»è·æ¥çã¬ã€ãã©ã€ã³ã«åŸã£ãŠç ç©¶ãè¡ã£ãŠããŸãããããããç§ãã¡ã¯ç ç©¶è ãšããŠãç§ãã¡ã®é«ãåºæºãå®ã£ãŠãããããŒã¿ãœãŒã¹ã«çްå¿ã®æ³šæãæã£ãŠé Œããšããè²¬ä»»ãæ±ºããŠå¿ããããšã¯ã§ããŸããã
ããããç ç©¶è ãšããŠã®è²¬ä»»ãå¿ããããã«ã¯ãããŸãããä»ãšãªã£ãŠã¯ãéåžžã«å°ã£ãŠãããšãã«ãã®ç ç©¶ã«è²¢ç®ããããšé¡ãããŸããããŒã¿ãœãŒã¹ããã®çšéã«é©ããŠãããã©ããã確èªããã®ã«ååãªããšãããŠããªãã£ããšããããšããç§ã«ã¯æããã§ãããã®ããšããããŠçŽæ¥çã«ã鿥çã«ããã¹ãŠã®æ··ä¹±ãæããããšãæ¬åœã«ç³ãèš³ãªãæã£ãŠããŸããã(匷調) (匷調)
Mandeep R. Mehra, MD, MSCïŒBWHãŠã§ããµã€ãäžã®å ¬åŒå£°æïŒ1
ãããããã®ãæ¬åœã«ç³ãèš³ãããŸããããšããèšèã¯ãæ°·å±±ã®äžè§ã«éããªãã£ãããªããïŒ
ã®ãªã¢ãã»ãµã€ãšã³ã·ãºã®ã¬ã ãã·ãã«ã«é¢ããç ç©¶ãšããããã·ã¯ãããã³ïŒHCQïŒã«é¢ããç ç©¶ã¯ãããããããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºç
é¢ïŒBWHïŒãåæã«è¡ã£ããã®ã§ããã
Mandeep Mehraå士ã調æŽããThe Lancetã¬ããŒãïŒ2020幎5æ22æ¥ïŒã¯ãCOVID-19ã®æ²»çè¬ãšããŠã®HCQã®æ£åœæ§ããæ®ºããããšãç®çãšããŠããããBWHã§ã¯ã®ãªã¢ãã»ãµã€ãšã³ã¹ç€Ÿã®ããã«ã¬ã ãã·ãã«ã«é¢ããå¥ã®éèŠïŒé¢é£ïŒç ç©¶ãïŒåæã«ïŒå®æœãããŠããã®ã§ããã
ããŒããŒã倧åŠå»åŠéšåææã§ææçã®å°éå®¶ã§ããFrancisco Martyå士ã¯ãããªã¬ã ãšã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãšã®å¥çŽã«ãããæãŠã€ã«ã¹å€ã¬ã ãã·ãã«ã®èšåºè©Šéšã®èª¿æŽãä»»ãããŠãã2ã
ãããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºç é¢ã¯ãã®ãªã¢ãç€Ÿã®æãŠã€ã«ã¹å€ã¬ã ãã·ãã«ã®2ã€ã®èšåºè©Šéšãžã®æ£è ç»é²ãéå§ããŸãããããªã¬ã ã¯ãäžç床ã®ã³ãããŠã€ã«ã¹çŸæ£ïŒCOVID-19ïŒæ£è 600人ã察象ãšããã®ãªã¢ã瀟䞻å°ã®æ¬å€ã®èšåºè©Šéšãšãé床ã®COVID-19æ£è 400人ã察象ãšããã®ãªã¢ã瀟䞻å°ã®è©Šéšã®è€æ°ã®æ²»éšå®æœæœèšã®1ã€ãšãªã£ãŠããŸãã
... çµæãææã§ããã°ãFDAã®æ¿èªã«ã€ãªããå¯èœæ§ããããããã§ãªããã°ãCOVID-19ãšã®æŠãã«ãããŠéèŠãªæ å ±ãäžããä»ã®æ²»çæ³ã«ç§»è¡ããããšãã§ããŸã ããšè¿°ã¹ãŠããŸãã
Mandeep Mehraå士ã¯ãååã®Francisco Martyå士ã®ç£ç£äžã§è¡ãããGilead Remdesivir BWH詊éšã«ã¯çŽæ¥é¢äžããŠããŸããããããã§ãGilead Sciences, Inc.ãšæ¥è§ŠããŠããŸããã
ã圌ã¯2020幎4æäžæ¬ã«ã®ãªã¢ã瀟䞻å¬ã®äŒè°ã«Covid-19ã®è°è«ã®äžç°ãšããŠåå ãããïŒFrance Soir, May 23, 2020ïŒ3
圌ã®ïŒå€±æããïŒç ç©¶ã®æå³ã¯äœã ã£ãã®ã§ããããïŒããããã·ã¯ãããã³ã®æ£åœæ§ãæããããïŒ
ãã©ã³ã¹ã»ãœã¯ãŒã«çŽã«ãããšãã©ã³ã»ããèªã®æ€ååŸã«çºè¡šãããå ±åæžã®äžã§ã
ããŒããŒã倧åŠå»åŠéšææã®Mandeep R. Mehraå士ã«ãããã°ãã°åé¿çãªåçã¯ãèªä¿¡ã倱ããããã®åé¡§çç ç©¶ãšãã®çµæã®å®å šæ§ã«ã€ããŠã®ç念ãããã£ãŠç œããã®ã§ãã£ãã(ãã©ã³ã¹ã»ãœã¯ãŒã«çŽã2020幎6æ5æ¥)4
88
Mandeep Mehraå»åž«ã¯å©ççžåç¶æ ã«ãã£ãã®ã§ããããïŒ(ããã¯BWHãšããŒããŒãã»ã¡ãã£ã«ã«ã»ã¹ã¯ãŒã«ã倿ããåé¡ã§ããïŒ
䞻圹ã¯èª°ã ã£ãã®ãïŒ
ã¢ã³ãœããŒã»ãã¡ãŠãå士ã¯ããã¢ã¡ãªã«ã®ææçå°éå®¶ããšããŠæãããŠããŸãããCDCãæ°å¹Žåã«æ¿èªããHCQçæ³ãäžå·ããã®ãªã¢ã瀟ã®ã¬ã ãã·ãã«ã«æ£åœæ§ãäžããäžã§éèŠãªåœ¹å²ãæŒããŸããã
ãã¡ãŠãå士ã¯ãã¬ãŒã¬ã³æ¿æš©æä»£ããåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æïŒNIAIDïŒã®æé·ãåããŠããã圌ã¯ãããã°ãã¡ãŒãã®å£å©ã圹ãšããŠç¥ãããŠããã
ãã¡ãŠãå士ã¯6æäžæ¬ã«ã¬ã ãã·ãã«ãçºå£²ãã(詳现ã¯åŸè¿°)ããã¡ãŠãå士ã«ãããšãã¬ã ãã·ãã«ã¯ã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãéçºãããã³ããã»ã¯ã³ããŒã»ãã©ãã°ãã ãšããã16åãã«ã®å€§åœããã ã
ã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã®æŠèŠ æ²¿é©
ã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã¯æ°ååãã«èŠæš¡ã®ãã€ãªè£œè¬äŒç€Ÿã§ãçŸåšã¯ã¬ã ãã·ãã«ã®éçºã»è²©å£²ã«æºãã£ãŠãããã®ãªã¢ãã«ã¯é·ãæŽå²ããããŸããVanguard GroupãCapital Research & Management Coãªã©ã倧ææè³ã³ã³ã°ãããªããã®æ¯æŽãåããŠãããç±³åœæ¿åºãšã®é¢ä¿ãçºå±ããŠããã
1999幎ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã¯ã¿ããã«ïŒå£ç¯æ§ã€ã³ãã«ãšã³ã¶ãé³¥ã€ã³ãã«ãšã³ã¶ã®æ²»çè¬ãšããŠäœ¿çšïŒãéçºãããåœæãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã®ãããã¯ãåŸã«ãžã§ãŒãžã»Wã»ããã·ã¥æ¿æš©ã§åœé²é·å®ïŒ2001ã2006幎ïŒã«å°±ä»»ããããã«ãã»ã©ã ãºãã§ã«ãæ°ïŒ1997ã2001幎ïŒã ã£ããã©ã ãºãã§ã«ãã¯ãã¢ãã¬ãã¹ã¿ã³ïŒ2001幎ïŒãšã€ã©ã¯ïŒ2003幎ïŒã®éæ³ãã€ç¯çœªçãªæŠäºã調æŽãã責任ãè² ã£ãŠããã
ã©ã ãºãã§ã«ãã¯ãåœé²é·å®ãšããŠã®åšä»»æéäžïŒ2001-2006ïŒãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãšã®ã€ãªãããç¶æããŠãããCNNãããŒïŒ2005幎ïŒã«ãããš ãé³¥ã€ã³ãã«ãšã³ã¶ãçºçãããšããèŠéãã¯ãïŒã®ãªã¢ãç€Ÿã®æ ªããŸã ææããŠããïŒããã«ãã»ã©ã ãºãã§ã«ãåœé²é·å®ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºã®ä»ã®æ¿æ²»çã«ã€ãªããã®ããæè³å®¶ã«ãšã£ãŠã¯éåžžã«è¯ããã¥ãŒã¹ã ã£ãã5ã
ã¢ã³ãœããŒã»ãã¡ãŠãã¯1984幎ããNIAIDã®è²¬ä»»è
ãåãããã®ç«å Žãå©çšããŠãç±³åœæ¿åºãšå€§æè£œè¬äŒç€Ÿã®ã仲ç«ã¡ããããŠãããã©ã ãºãã§ã«ãåœé²é·å®æä»£ã«ã¯ããã€ãªãã察çã®äºç®ã倧å¹
ã«å¢å ããã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãå«ã倧æè£œè¬äŒç€Ÿãšã®å¥çŽãè¡ããããã¢ã³ãœããŒã»ãã¡ãŠãã¯ã2002幎åãã«ãã€ãªããã«å²ãåœãŠãããäºç®ã¯ã次ã®ãããªãã®ã§ãããšèããã
ãæ»æã«äœ¿ãããå¯èœæ§ã®ãã埮çç©ã®çç©åŠãšç åæ§ããããŠåŸ®çç©ã®å®¿äž»ã§ãã人éãšãã®å ç«ã·ã¹ãã ã®çç©åŠã«å¯Ÿããæã ã®çè§£ãå éãããããã®çµæãããæ¯æ§ã®å°ãªãããã广çãªã¯ã¯ãã³ãã§ããã¯ãã§ããã(Washington Post, 2æ7æ¥å·)6
2008幎ãã¢ã³ãœããŒã»ãã¡ãŠãå士ã¯ããžã§ãŒãžã»Wã»ããã·ã¥å€§çµ±é ãããä»ã®äººã ãããé·ããããå¥åº·ã«çããããã®æåºãšããç©æ¥µçãªåãçµã¿ãã«å¯ŸããŠã倧統é èªç±å²ç« ãæäžãããŸãã7ã
89

2020幎ã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿ ã¬ã ãã·ãã«ãããžã§ã¯ã
äž»èŠãªããã¥ã¡ã³ãïŒã€ãã³ãïŒãäžå¿ã«ã玹ä»ããŠãããŸãã
幎衚ïŒ2020幎2æïœ6æïŒ
2020幎2æ21æ¥ NIH-NIAIDã®ã¬ã ãã·ãã«ã»ãã©ã»ã詊éšã«é¢ããåæãªãªãŒã¹ 4æ10æ¥ïŒGilead Sciences, Incã®ç ç©¶ãNEJMã«æ²èŒããããCompassionate Use of ã¬ã ãã·ãã«ã
4æ29æ¥ïŒNIHãã¬ã ãã·ãã«ã®ç ç©¶ãçºè¡šïŒå ±åæžçºè¡šæ¥ïŒ
5æ22æ¥ïŒMandeep Mehraå士ãã³ãŒãã£ããŒãããããããã·ã¯ãããã³ã«é¢ããBWH-Harvard StudyãLancelèªã«æ²èŒãããŸããã
MehraãThe Lancetã«æ²èŒãããŸããã
5æ22æ¥ïŒCOVID-19æ²»çã®ããã®ã¬ã ãã·ãã«-äºåå ±åãåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æãåœç«è¡çç ç©¶æãNew England Journal of Medicine (NEJM)ã«å ±åã
6æ5æ¥Â ïŒHCQã«é¢ããïŒåœïŒLancetã¬ããŒãïŒ5æ22æ¥ïŒãæ€åãããã
6æ29æ¥Â ïŒFauciã®çºè¡šãGilead Sciencesãšã®16åãã«ã®remdesivirã®HHSå¥çŽã
Inc
2020幎4æ10æ¥ Gilead Sciences, Incã® ãRemdesivirã®æãããã®ããäœ¿çš ãã«é¢ããç ç©¶ãNEJMã«æ²èŒãããã
ã®ãªã¢ã瀟ãã¹ãã³ãµãŒãšãªã£ãå ±åæžããNew England Journal of Medicineã« ãCompassionate Use of Remdesivir for Patients with Severe COVID-19 ïŒé床ã®COVID-19æ£è ã«å¯Ÿããã¬ã ãã·ãã«ã®æãããã®ãã䜿çšïŒããšããè«æã§çºè¡šãããŸããããã®å ±åæžã¯56人ã®èåãªå»åž«ãç§åŠè ãå ±åå·çããŠããããã®å€ããã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿããã³ã³ãµã«ãã£ã³ã°æãåãåã£ãŠããŸãã
90
Gilead Sciences, Inc.ã¯ãè€æ°ã®ã¹ã¿ãããå ±èè ãšããŠå«ãæ¬è©Šéšã«è³éãæäŸããŸããã
ã詊éšã«ã¯ã2020幎3æ7æ¥ä»¥åã«ã¬ã ãã·ãã«ãå°ãªããšã1åæäžãããåèš61åã®æ£è ãå«ãŸãããã®ãã¡8åã¯ãããŒã¹ã©ã€ã³åŸã®æ å ±ã®æ¬ èœïŒ7åïŒããã³ã¬ã ãã·ãã«éå§æ¥ã®èª€ãïŒ1åïŒã«ããé€å€ããã......ããã®åæã«å«ãŸããæ®ãã®53äººã®æ£è ã®ãã¡ã40人ïŒ75ïŒ ïŒãã¬ã ãã·ãã«ã®10æ¥éã®å šã³ãŒã¹ãåãã10人ïŒ19ïŒ ïŒã5æ¥ãã9æ¥ã®æ²»çãåãã3人ïŒ6ïŒ ïŒã5æ¥æªæºã®æ²»çãåããŸãããã(NEJMã2020幎4æ10æ¥å·)8ã
NEJMã®èšäºã«ã¯ããGilead Sciences, Incã¯2020幎1æ25æ¥ã«ã¬ã ãã·ãã«ã®æãããã®ãã䜿çšã«é¢ããèšåºå»ããã®èŠè«ãåãä»ãå§ãã ããšæžãããŠããŸãã
誰ããã®ãã©ãããã®ïŒWHOïŒ2020幎1æ30æ¥ïŒã«ãããšãäžåœä»¥å€ã®18ã«åœã§86äººã®æ£è
ãçºçãããã®ãã¡ç±³åœã§5人ããã©ã³ã¹ã§5人ãã«ããã§3人ãšãªã£ãŠããã
è€æ°ã®èåãªå»åž«ãç§åŠè
ããã®ãªã¢ã瀟ãè¡ã£ãã¬ã ãã·ãã«ã®Compassionate Use詊éšã«ã€ããŠã詊éšã®èŠæš¡ãå°ããããšã«çç®ããŠçåãæããããŠããŸããç®èãªããšã«ããã®è©Šéšã®æ£è
æ°ã¯å
±èè
ã®æ°ãããå°ãªãã®ã§ããã53äººã®æ£è
ãã«å¯Ÿã㊠ã56人ã®å
±èè
ã
以äžãNEJMè«æ9ã®çºè¡šçŽåŸã«çºè¡šãããã®ãªã¢ãã®NEJMãããžã§ã¯ãã«é¢ããç§åŠç声æïŒãµã€ãšã³ã¹ã¡ãã£ã¢ã»ã³ã¿ãŒïŒã®æç²ã玹ä»ããã
ãæãããã®ããäœ¿çš ããšã¯ãä»ã«æ²»çæ³ããªãããã«æªèªå¯ã®æ²»çæ³ãæ£è
ã®æ²»çã«äœ¿çšããããšã§ãããšèª¬æããã®ãé©åã§ããããã®ãããªäœ¿çšã«åºã¥ãç ç©¶ã¯ãèšåºè©Šéšã®åªãã宿œæ¹æ³ã®ç¹åŸŽã§ãã察ç
§çŸ€ãç¡äœçºåããªããããæ¥µããŠæ
éã«æ±ãããã¹ãã§ããã(ãªãã¯ã¹ãã©ãŒã倧åŠèšåºæ²»çåŠããã³ã«ã³ã»ãªãã£ãŒãææ)
ããã®ç ç©¶ãéå°ã«è§£éããªãããšãéèŠã§ããæãéèŠãªããšã¯ããã®æ¯èŒçå°æ°ã®æ£è
ã°ã«ãŒããã¬ã ãã·ãã«ã®æäžãåããªãã£ãå Žåã®è»¢åž°ãç¥ãããšã¯äžå¯èœã§ãããšããããšã§ããã(Dr. Stephen Griffinããªãã¯ã¹ãã©ãŒã倧åŠèšåºæ²»çåŠ) (ãªãŒãºå€§åŠå»åŠéšåææ Stephen Griffinå士)
ããã®ç ç©¶ã¯è峿·±ããã®ã§ãããçŸæç¹ã§ã¯äœã蚌æããŠããŸãããããã®ããŒã¿ã¯å°èŠæš¡ã§é察ç
§ã®ç ç©¶ããã®ãã®ã§ããã(ãšãžã³ãã©å€§åŠèšåºè¬çåŠã»åŠæ¹åŠææ ãµã€ã¢ã³ã»ãã¯ã¹ãŠã§ã«æ°)
ããã®è«æã®ããŒã¿ã¯ã»ãšãã©è§£éã®ãããããªããã®ã§ããéåžžã«é©ãã¹ãããšã§ããããããããã¥ãŒã€ã³ã°ã©ã³ãã»ãžã£ãŒãã«ã»ãªãã»ã¡ãã£ã·ã³èªã«æ²èŒãããããšã¯ãéåžžã«é©ãã¹ãããšã§ãããå«çã«åããŠãããšããèšããã§ããããç ç©¶ã®ã¹ãã³ãµãŒãšãªã£ã補è¬äŒç€Ÿã®ãŠã§ããµã€ãã«ããŒã¿ãæ²èŒããã®ãããé©åã§ããããå°ãªããšãã®ãªã¢ã瀟ã¯ãããã質ã®é«ãç§åŠè«æã®æžãæ¹ã§è¡ãããŠããªãããšãæããã«ããŠããŸããã(ã¹ãã£ãŒãã³ã»ãšãã³ã¹ææããã³ãã³å€§åŠè¡çç±åž¯å»åŠå€§åŠé¢è¬ç©ç«åŠææ)
ããã®ãããªé察ç
§ã®ç ç©¶ããæçãªçµè«ãå°ãåºãããšã¯éåžžã«å°é£ã§ããç¹ã«ãäœãèµ·ãããããããªãæ°ããç
æ°ããå Žæãæéã«ãã£ãŠçµæã倧ããç°ãªãå Žåã¯ãªãããã§ãããã®ç ç©¶ã¯ãäœãããæ©äŒãéžããããšãæå³ããŠããŸããã(ã¢ãã ã»ãã£ã³ææãããªã¹ãã«å€§åŠå°å
ç§ææïŒ
91
2020幎4æ29æ¥ ã¬ã ãã·ãã«ã«é¢ããç±³åœåœç«è¡çç ç©¶æïŒNIHïŒã®ç ç©¶çµæã«ã€ããŠ
4æ10æ¥ã«Gilead Sciences, Incã®ç ç©¶ãNEJMã«æ²èŒãããããšãåããŠã4æ29æ¥ã«ãã¬ã ãã·ãã«ã«é¢ããç±³åœåœç«è¡çç ç©¶æïŒNIHïŒã®ãã¬ã¹ãªãªãŒã¹ãçºè¡šãããŸããããã®å
šæã¯5æ22æ¥ãNEJMèªã®ã¿ã€ãã«ã§çºè¡šããããCOVID-19ã®æ²»çã«å¯Ÿããã¬ã ãã·ãã«-äºåå ±åæžïŒNEJMïŒã
æ¬è©Šéšã¯2020幎2æ21æ¥ã«éå§ãããŠããã4æ29æ¥ã®ãã¬ã¹ãªãªãŒã¹ã®ã¿ã€ãã«ã¯ã以äžã®éãã
ãCOVID-19ã«å¯Ÿããã¬ã ãã·ãã«ãå埩ãŸã§ã®æéãæ¹åããããšãç€ºãæ»èªæžã¿ããŒã¿Â ãã§ãã
ããã¯ã1,063人ã®å
¥é¢æ£è
ã察象ãšããç¡äœçºå詊éšã®äºåããŒã¿ãå«ããæ¿åºäž»å¬ã®å ±åæžã ãAdaptive COVID-19 Treatment TrialïŒACTTïŒãšåä»ãããããã®è©Šéšã®çµæã¯ããã¡ãŠã·å士ã®åœç«ã¢ã¬ã«ã®ãŒã»ææçç ç©¶æïŒNIAIDïŒã®ææ®äžã§è¡ãããäºåçãªãã®ã§ããã
ãã®è©Šéšãç£ç£ããç¬ç«ããããŒã¿ã»å®å šæ§ã¢ãã¿ãªã³ã°å§å¡äŒïŒDSMBïŒã¯4æ27æ¥ã«äŒåãéããããŒã¿ãæ€èšããäžéè§£æã詊éšããŒã ãšå ±æããŸããããã®çµæãäž»èŠè©äŸ¡é ç®ã§ããã€ã³ãã«ãšã³ã¶ã®èšåºè©Šéšã§ããçšããããææšã§ããå埩ãŸã§ã®æéã®èгç¹ãããremdesivirã¯ãã©ã»ããããåªããŠãããšææãããŸãããæ¬è©Šéšã«ãããå埩ãšã¯ãéé¢ãŸãã¯éåžžã®æŽ»åã¬ãã«ã«æ»ãã®ã«ååãªç¶æ ã§ãããšå®çŸ©ãããŸããã
éå ±å€ã§ã¯ãã¬ã ãã·ãã«ã®æäžãåããæ£è ããã¯ããã©ã»ãã®æäžãåããæ£è ããã«æ¯ã¹ãŠå埩ãŸã§ã®æéã31%æ©ãã£ãããšã瀺ãããŠããŸãïŒp<0.001ïŒãç¹ã«ãå埩ãŸã§ã®æéã®äžå€®å€ã¯ããã©ã»ãæäžçŸ€ã®15æ¥éã«æ¯ã¹ãã¬ã ãã·ãã«æäžçŸ€ã®11æ¥éã«ãªããŸããããŸããæ»äº¡çããã©ã»ã矀11.6ïŒ ã«å¯Ÿããã¬ã ãã·ãã«æäžçŸ€8.0ïŒ ãšãªããçåçã®åäžã瀺åãããŸããïŒp=0.059ïŒã(匷調)10
NIHãå ã«çºè¡šãã2020幎2æ21æ¥ã®å ±åæžïŒè©Šéšéå§æã«çºè¡šïŒã§ã¯ããã®æ¹æ³ã«ã€ããŠæ¬¡ã®ããã«è¿°ã¹ãããŠããŸãã
... ã³ãããŠã€ã«ã¹ææçãšèšºæãããå ¥é¢äžã®æäººã«ãããæ²»éšçšæãŠã€ã«ã¹å€ã¬ã ãã·ãã«ã®å®å šæ§ãšæå¹æ§ãè©äŸ¡ããããã®ç¡äœçºåæ¯èŒèšåºè©Šéš2019ïŒCOVID-19ïŒ ...
æ°ã§ããã©ãã§ïŒãã€ïŒ
2æ21æ¥ã®å ±åã§ã¯ãæåã®æ²»éšåå è
ã¯ã暪æµïŒæ¥æ¬é æµ·ïŒã«åæ³ããããã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ã§æ€ç«ãåããŠééãããç±³åœäººãã§ããããšã確èªãããïŒç¬¬äºç« åç
§ïŒããã¢ã¡ãªã«åœåçããã€ã€ã¢ã³ãã»ããªã³ã»ã¹å·ããééãã13人ããããã©ã»ã詊çšè©Šéšã®æ£è
ãšããŠéžã°ããã
ç®èãªããšã«ãç ç©¶éå§åœåãå
šäžçã®ã確å®çäŸãã®58.7ïŒ
ïŒ924人äž542人ïŒïŒäžåœä»¥å€ïŒããæåã®è©Šéšçšãã©ã»ãæ£è
ãéžãã ãã€ã€ã¢ã³ãã»ããªã³ã»ã¹å®¢è¹ã«ããã®ã§ããã
ã©ãã§ããã€ãéžã°ãã68ã«æã§ã®èšåºè©ŠéšïŒãããåŸæ¥ã«ãªã£ãã®ã¯ã2æ19æ¥ïŒWHOã®ããŒã¿ïŒã®æç¹ã§ã¯ãç±³åœã§ã¯éœæ§äŸã15äŸããèšé²ãããŠããªãã£ãããã§ãïŒäžè¡šåç
§ïŒã
ãæçµçã«åèš68æœèšã詊éšã«åå ããããã¢ã¡ãªã«47ã«æããšãŒããããšã¢ãžã¢ã®åœ21ã«æã§ããã(匷調)
92
Remdesivir for the Treatment of COVID-19 - Preliminary Reportãšé¡ããã5æ22æ¥ã®NEJMèªã®æçµå ±åæžã§ã¯ã次ã®ããã«è¿°ã¹ãããŠããŸãã
ç±³åœïŒ45æœèšïŒããã³ããŒã¯ïŒ8ïŒãè±åœïŒ5ïŒãã®ãªã·ã£ïŒ4ïŒããã€ãïŒ3ïŒãéåœïŒ2ïŒãã¡ãã·ã³ïŒ2ïŒãã¹ãã€ã³ïŒ2ïŒãæ¥æ¬ïŒ1ïŒãã·ã³ã¬ããŒã«ïŒ1ïŒã®60è©Šéšæœèšãš13ãµããµã€ããåå ããŸããã察象æ£è ã¯ãremdesivirãŸãã¯ãã©ã»ãã®ãããããæäžãããããã1察1ã®å²åã§ç¡äœçºã«å²ãä»ããããŸãããç¡äœçºåã¯ã詊éšå®æœæœèšãšç»é²æã®çŸæ£éç床ã«ãã£ãŠå±€å¥åãããŸãã11ã
ã¯ã·ã³ãã³ãã¹ãçŽã¯ãAnthony Fauciæ°ã®çºè¡šãè³è³ããŠããïŒ4æ29æ¥ä»ïŒ12ã
Anthony S. Fauciããã¯ã€ãããŠã¹ã§çºè¡šããäºåçãªçµæã¯ã...éæ³ã®åŒŸäžžãæ²»çæ³ã«ã¯çšé ããã®ã ã£ã...ãããããCovid-19ã«ã¯æ¿èªãããæ²»çæ³ããªãããã[Lie] Fauciã¯ãå ¥é¢æ£è ã®æšæºçãªæ²»çæ³ã«ãªãã ãããšè¿°ã¹ã...ã
ãã®ããŒã¿ã¯ãã¬ã ãã·ãã«ãå埩ãŸã§ã®æéãççž®ãããšãããæç¢ºã§ææãªãã©ã¹ã®å¹æãæã€ããšã瀺ããŠããŸãããšFauciã¯è¿°ã¹ãŠããŸãã
ãã³ãããŠã€ã«ã¹æ²»çè¬ãšããŠã®å®éšè¬ã¬ã ãã·ãã«ã®æ¿åºåã®å³æ Œãªèšåºè©Šéšã¯ãæ°Žææ¥ãå»åŠçã«æ§ã ãªçµæããããããããæ ªåŒåžå Žãäžæãããäžéšã®æ£è ãå©ããåæã®æŠåšãæå ã«ãããšããåžæãé«ããã
ãã®ãã©ã»ãå¯Ÿç §èšåºè©Šéšãäž»å°ããåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æã®ã¢ã³ãœããŒã»ãã¡ãŠãæé·ã¯ããã¯ã€ãããŠã¹ã§ãã®äºåççµæãçºè¡šãããã®è¬ã¯å ¥é¢æ£è ã®ååŸ©ãæ©ããããæ»äº¡çã§ã¯ããããªå¹æãããªãããšãæããã«ããã
... ãã¡ãŠãã®çºèšã¯ãé£åå»è¬åå±ïŒFDAïŒããã®è¬ãå»åž«ã«åŠæ¹ããããšãèš±å¯ããç·æ¥äœ¿çšèªå¯ãæ±ãããšããæ¶æž¬ãåŒãã ã
èšåºè©Šéšã«å ããŠãã¬ã ãã·ãã«ã¯1,000人以äžã®æ£è ã«åæ çãªäœ¿çšã§æäžãããŠããã[NEJMèªã«4æ10æ¥ã«çºè¡šãããã®ãªã¢ã瀟ã®ç ç©¶ã«ãèšåããŠãã]ã
ç±³åœããã³äžçã®68æœèšã§1,000人以äžã®æ£è ãåå ãããã®ç ç©¶ã¯ãCOVID-19ã«å¯Ÿããã¬ã ãã·ãã«ã®æå¹æ§ã«é¢ããå€§èŠæš¡ãª[?]ç¡äœçºèšåºè©Šéšã«ããæåã®èšŒæ [?]ãæäŸããŠããŸããã
NIHã®ãã©ã»ããã¹ã詊éšã¯ "äºåçãªçµæ "ãæäŸããŸããããã©ã»ã詊éšè©Šéšã¯ "ç¡äœçºå "ããããã68æœèšã§ã®æ£è ã®å šäœçãªéžæã¯å®å šãªç¡äœçºåã§ã¯ãªãã£ããå ±åæžå šæãèŠã13
2020幎5æ22æ¥ä»ãããããã·ã¯ãããã³ïŒHCQïŒã«é¢ããè°è«ãåŒãã ïŒæ€åãããïŒLancetã¬ããŒã
泚ç®ãã¹ãã¯ãNIH-NIAIDã®ãRemdesivir for the Treatment of COVID-19 - Preliminary ReportïŒCOVID-19ã®æ²»çã®ããã®ã¬ã ãã·ãã« - äºåå ±åæžïŒããšé¡ããå
šå ±åæžã2020幎5æ22æ¥ã«NEJMã§çºè¡šãããããããã·ã¯ãããã³ã«é¢ããè°è«ãåŒãã ã©ã³ã»ããå ±åãšåãæ¥ã§ãã£ãããšã§ããã
ãã®åºççŽåŸãã¡ãã£ã¢ã¯å€§åã³ã§HCQã®æ²»çæ³ãäžå·ããäžæ¹ã§ãåãæ¥ã«çºè¡šãããã¬ã ãã·ãã«ã®NIH-NIAIDã¬ããŒããè³è³ããŸããã
93
COVID-19ã®æ²»çè¬ãšããŠå¯äžèªå¯ãããŠããRemdesivirã¯ããã®ç
æ°ã®æ£è
ã®å埩æéãæ©ãã ... ãã¹ã¯ãªãã¹ç ç©¶æã®åµèšè
ã§ããæé·ã§ãããšãªãã¯ã»ããã«ã¯ããããã¯éåžžã«å®å
šã§å¹æçãªè¬ã§ãããCovid-19ã®æåã®æå¹ãªè¬å€ã確å®ããããšã¯å€§ããªåé²ã§ãããä»ã®è¬å€ãïŒè¬å€ã®ïŒçµã¿åããã«ãã£ãŠããã«çºå±ããŠããã ããããšè¿°ã¹ãŠãã14ã
ãã³ã¬ã -ããŒããŒãã«ããLancetã®HCQè«æã6æ5æ¥ã«æ€åããããšãã¯ãé
ããããããã¯æå°éã®ã¡ãã£ã¢å ±éãåãããæ€åãããã«ãããããããHCQã®æ²»çæ³ã¯ ãæ®ºãããŠãããã
2020幎6æ29æ¥ã®ããšãFauciã®ã°ãªãŒã³ã©ã€ããã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãšã®16åãã«ã®Remdesivirå¥çŽ
ã¢ã³ãœããŒã»ãã¡ãŠãå士ã¯2020幎6æ29æ¥ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã« ãã°ãªãŒã³ã©ã€ã ããä»äžããã
ç±³åœæ¿åºNIH-NIAIDäž»å¬ã®ãRemdesivir for the Treatment of COVID-19 - Preliminary ReportïŒNEJMïŒããšããåå
¬åŒã¬ããŒãïŒ5æ22æ¥ïŒããã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãšã®å€§åå¥çŽã®æ£åœåã«äœ¿ãããŸããïŒæçµã¬ããŒãã¯2020幎11æ5æ¥ã«çºè¡šãããŸããïŒã
ãã®å ±åæžã¯ãAnthony Fauciå士ãçããåœç«ã¢ã¬ã«ã®ãŒã»ææçç ç©¶æïŒNIAIDïŒãšåœç«è¡çç ç©¶æïŒNIHïŒãäž»ãªè³éãæäŸãããã®ã§ãã
6æ29æ¥ãNEJMã«æ²èŒãããNIH-NIAIDã®å ±åæžã®çµæã«åºã¥ããä¿å¥çŠç¥çïŒHHSïŒã¯ãã©ã³ãæ¿æš©ã代衚ããŠãã¢ã¡ãªã«ã®æ°éç
é¢ã蚺çæã«ãããCOVID-19ã®æ²»çã®ããã«ã®ãªã¢ãã»ãµã€ãšã³ã¹ç€Ÿããã¬ã ãã·ãã«è¬ã®å€§éäŸçµŠã確ä¿ããåæãçºè¡šããŸããã
NEJMèªïŒ4æ10æ¥ïŒã«çºè¡šããã53äŸïŒå
±èè
56åïŒã®ä¹ããæ€æ»çµæã«åºã¥ãã®ãªã¢ã瀟ã®å
è¡ç ç©¶ã¯åãäžããããŸããã§ããããã®ç ç©¶çµæã«ã¯ãè€æ°ã®èåãªå»åž«ãç§åŠè
ããçåã®å£°ãäžãã£ãŠããã
誰ãã¬ã ãã·ãã«ãè²·ããããã«ãªãã®ãïŒã¬ã ãã·ãã«ã®50äžåã®æäžã¯ãæ£è
äžäººåœãã3200ãã«ãããªãã¡16åãã«ã§æ³å®ãããŠããŸãïŒElizabeth Woodworthã«ããç ç©¶ãåç
§ïŒ15ã
ãŸããæ¬§å·é£åã§ã¯ãVekluryããšããåååã§è²©å£²ãæ¿èªãããŠããã
ãã®å¥çŽãäºå®éã宿œãããã°ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã«ãšã£ãŠããæ²»çãåããç±³åœã®æ°éç
é¢ãã¯ãªããã¯ã«ãšã£ãŠãããã®å¥çŽã¯å€§ããªæå³ãæã€ããšã«ãªãã
ãã©ã³ãæ¿æš©ã®HHSé·å®ã¢ã¬ãã¯ã¹ã»ã¢ã¶ãŒã«ããã°ïŒ2020幎6æ29æ¥ïŒ
ãå¯èœãªéããã¬ã ãã·ãã«ãå¿ èŠãšããã¢ã¡ãªã«ã®æ£è ã確å®ã«å ¥æã§ããããã«ããããïŒ3200ãã«ã§ïŒãã©ã³ãæ¿æš©ã¯ãCOVID-19ã®æåœæ²»çè¬ã«ã€ããŠãã£ãšåŠã³ãã¢ã¡ãªã«åœæ°ã®ããã«ãããã®éžæè¢ãžã®ã¢ã¯ã»ã¹ã確ä¿ããããã«ãå šåãå°œãããŠããŸããã
ã¬ã ãã·ãã«å¯Ÿããããã·ã¯ãããã³(HCQ)
æ
éãªã¿ã€ãã³ã°
Lancetã®ç ç©¶ïŒ2020幎5æ22æ¥çºè¡šããã®åŸæ€åïŒã¯ã6æ29æ¥ã®HHSãšGilead Sciences瀟ãšã®16åãã«ã®åæãç¶æããç®çã§ãCOVID-19ã«æå¹ãªæ²»çè¬ãšããŠã®ããããã·ã¯ãããã³ã®æ£åœæ§ãæãªãããããã®ãã®ã ã£ãã
94
ãã®åæã®æ£åœæ§ã¯ã5æ22æ¥ã«NEJMã«æ²èŒãããNIH-NIAIDã®ç ç©¶ã§ããäºåçããšãããŠããããšã«ããã£ãŠãã16ã
Fauciå士ãèªããªãã£ãã®ã¯ãã¯ãããã³ã15幎åã«CDCã«ãã£ãŠã³ãããŠã€ã«ã¹ææçã«äœ¿çšããè¬å€ãšããŠãç ç©¶ãã詊éšããããŠããããšã§ããããããŠãããããã·ã¯ãããã³ã2020å¹Žã«æ°ã«åœã§COVID-19ã®æ²»çã«äœ¿çšãããããšã§ãã
(2005) Virology Journalã«ãããšããã¯ãããã³ã¯SARSã³ãããŠã€ã«ã¹ã®ææã𿡿£ã匷åã«é»å®³ããã17 ãšããã2002幎ã®SARS-1çºçæã«ã䜿çšããããCDCã®ã墚ä»ãã ã£ãã
HCQã¯æå¹ãªã ãã§ãªããã¬ã ãã·ãã«ãšæ¯èŒãããšãæ°éä¿éºã«å å
¥ããŠããç±³åœæ£è
ã®å Žåãæšå®3,120ãã«ããšããå®äŸ¡ãã§ããã
çµã³ã®èšè
Gilead Sciences, Inc.ã®ã¬ã ãã·ãã«ç ç©¶ïŒ50人以äžã®èè
ïŒã¯ã2020幎4æ10æ¥ã«New England Journal of Medicineã«æ²èŒãããŸããã
ç¶ããŠã2020幎5æ22æ¥ã«NIH-NIAID Remdesivir for the Treatment of COVID-19 - Preliminary ReportãNEJMèªã«æ²èŒãããŸããããããŠãåã5æ22æ¥ã«BWH-Harvardã®Mehraå士ãã³ãŒãã£ããŒãããããããã·ã¯ãããã³ã®å ±åãLancetã«æ²èŒãããŸããïŒãã®åŸãæ€åãããŸããïŒã
ããŒããŒã倧åŠå»åŠéšãšBWHã¯ãMandeep Mehraå士ãã³ãŒãã£ããŒãããHCQã«é¢ããLancetã®ã¬ããŒããäž»å¬ããè³éãæäŸãã責任ãè² ã£ãŠããã®ã§ãã
å©ççžåã¯ãããïŒBWHã¯åæã«ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿãšã®å¥çŽã§ãã¬ã ãã·ãã«ã®ç ç©¶ã«ãé¢ãã£ãŠããŸããã
ããŒããŒã倧åŠã®Mehraå士ãã³ãŒãã£ããŒãããLancetã®ã¬ããŒãã¯æ€åãããŸããããããã§ãã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã®å©çã«ã€ãªãããã®ã§ããã
ã®ãªã¢ãã»ãµã€ãšã³ã·ãºç€Ÿã®NEMJïŒNew England Journal of MedicineïŒæ»èªç ç©¶ïŒ2020幎4æ10æ¥ïŒãšãåããNEJMã«æ²èŒãããNIH-NIAIDç ç©¶ïŒ2020幎5æ22æ¥ïŒã«ã€ããŠãããããç¬ç«ããç§åŠã»å»åŠè©äŸ¡ã宿œããããšãéèŠã§ããã
å·»æ«è³æ
1. ããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºã»ãã¹ãã¿ã«ã2020幎5æ22æ¥ãããããã·ã¯ãããã³ãæäžããã COVID-19 æ£è
ã®æ»äº¡çã«æ¹åãªã https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=3592
2. ããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºã»ãã¹ãã¿ã«ã2020 幎 3 æ 30 æ¥ãããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºã»ãã¹ãã¿ã«ã§é²è¡äžã® 2 ã€ã®ã¬ã ãã·ãã«ã®èšåºè©Šéš https://www.brighamhealthonamission.org/2020/03/26/two-remdesivir-clinical-trials-underway-at-brigham-and-womens-hospital/
3. Xavier Azalbert & Eric Gyssler, June 5, 2020. å¶ç¶ããå¶ç¶ãžããã¹ãã³ã®ã³ãã¯ã·ã§ã³ãRemdesivirãæäŸã https://www.francesoir.fr/politique-monde/coincidences-coincidences-boston-connexion-serves-remdesivir
4. Ibid.
5. ãã«ãœã³ã»Dã»ã·ã¥ã¯ã«ãã2005幎10æ31æ¥ãRumsfeld's growing stake in Tamiflu åœé²é·å®ãã€ã³ãã«ãšã³ã¶æ²»çè¬ã®å
äŒé·ãããŒããã©ãªãªã®äŸ¡å€ãé«ãŸããšèŠãŠããã
æš©è
ã§ããåœé²é·å®ã¯ãããŒããã©ãªãªã®äŸ¡å€ãé«ãŸã£ãŠãããšèŠãŠããã https://money.cnn.com/2005/10/31/news/newsmakers/fortune_rumsfeld/
95
6. ãžã§ãŒãžã»Fã»ãŠã£ã«ã2002幎2æ7æ¥ãhttps://www.washingtonpost.com/archive/opinions/2002/02/07/war-and-health/c1e5dfb2-c373-45ef-87d1-eb89f0db557c/
7. ãžã§ãŒãžã»Wã»ããã·ã¥å³æžé€šã2020幎3æ30æ¥ãhttps://twitter.com/gwblibrary/status/1244601539227942914?lang=en
8. ãžã§ããµã³ã»ã°ã¬ãŒã³ã倧æ²çŽå€«ãä»ã2020 幎 6 æ 11 æ¥ãéçæ£è
ã«å¯Ÿããã¬ã ãã·ãã«ã®å¯å®¹ãªäœ¿çšã«ã€ããŠ
ã³ãã-19. https://www.nejm.org/doi/full/10.1056/NEJMoa2007016#article_references
9. Stephen Evans ææ & Adam Finn ææã2020 幎 4 æ 11 æ¥ãhttps://www.sciencemediacentre.org/expert-reaction-to-a-study-about-compassionate-use-of-remdesivir-for-patients-with-severe-covid-19/ãéçã³ãã19ã®æ£è
ã«å¯Ÿããã¬ã ãã·ãã«ã®æããããã䜿çšã«é¢ããç ç©¶ã«å¯Ÿããå°éå®¶ã®åå¿ã
10. åœç«ã¢ã¬ã«ã®ãŒã»ææçç ç©¶æã2020 幎 2 æ 25 æ¥ãCOVID-19 ãæ²»çããããã®ã¬ã ãã·ãã«ã® NIH èšåºè©Šéšãéå§ããã https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins
11. John H. Beigel, Kay M. Tomashek, et al., November 5, 2020. Covid-19 ã®æ²»çã®ããã® Remdesivir - æçµå ±åæžãhttps://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=recirc_mostViewed_railB_article
12. Laurie Mcginley & Christopher Rowland, April 29, 2020. Gilead's remdesivir improves recovery time of coronavirus patients in NIH trial. https://www.seattletimes.com/nation-world/gileads-remdesivir-improves-recovery-time-of-coronavirus-patients-in-nih-trial/
13. Ibid.
14. Matthew Herperã2020幎5æ22æ¥ãCovid-19詊éšã¯ãã¬ã ãã·ãã«ã«ããæ²»çã®å©ç¹ãšããã®éçã«ã€ããŠã詳述ããŠããŸãã
https://www.statnews.com/2020/05/22/covid-19-study-details-benefits-of-treatment-with-remdesivir-and-also-its-limitations/
15. ãšãªã¶ãã¹ã»ãŠããã¯ãŒã¹ã2020 幎 8 æ 27 æ¥ãCovid-19ã®ããã®ã¬ã ãã·ãã«ïŒãããããªæçæ§ãã®è¬ã«16åãã«ïŒhttps://www.globalresearch.ca/remdesivir-covid-19-1-6-billion-modestly-beneficial-drug/5717690
16. Mandeep R. Mehra, Sapan S. Desai, et al., May 29, 2020. COVID-19 ã®æ²»çã«å¯Ÿãããã¯ãã©ã€ãã䜵çšããããããã·ã¯ãããã³ãŸãã¯ã¯ãããã³ïŒå€åœç±ã¬ãžã¹ããªåæ https://www.globalresearch.ca/remdesivir-covid-19-1-6-billion-modestly-beneficial-drug/5717690
17. Martin J. Vincent, Eric Bergeron, et al., August 22, 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/
96
-------------------- 第8ç« ---------------------
ããã°ã»ãã¡ãŒãã®COVID ãã¯ã¯ãã³ã
æã ã®åäŸãã¡ã¯ç ç²è ã§ãã
ãšã¯ã¹ã»ã¢ã³ã»ãããŽã¡ã³ã¹ã®ãªã»ã»ãŽã¡ã©ãã«ã»ãã»ãªã¥ãŒãã»ã¬ã«ããã ã®åŠçã16æ³ã®ãœãã£ã¢ã»ãã³ããªã©ã¯9æ21æ¥ã«äº¡ããªã£ã[2021] ãã®æ²ã¯ãã³ã«ã©ã€ããåœãŠãèŽåœçãªãã¡ã€ã¶ãŒã¯ã¯ãã³ãåãã7æ¥åŸã«æŒå¥ãããã2åã®å¿èçºäœãè¡æ çã圌女ãå®ããã«ç ããããã«ã
***
ãCOVID-19 ãã¯ã¯ãã³ãå«ãã£ã圌女ã®åšã®13æ³ã®åéãã圌女ã®å¿èã¯åæ¢ããã圌女ã¯éäœã§ããããªãã¡ãã¯ã¹ïŒããã¹ã³ã·ã¢å·ïŒã§ä»èµ·ãã£ãŠããããšã§ã 圌女ããµãã«ãŒããããã£ãããã§ã
圌女ã¯ã¯ã¯ãã³ã飲ã¿ãããªãã£ãã®ã§ããããããéŠçžãã¹ããŒããããåäŸãã¡ã« ã¯ã¯ãã³ã®æ¥çš®ãåœãããšãã ....
ãç§ã¯æ¿åºã«ããããããŠããŸããã
(ã«ããã®æ¯èŠªã®å匷ã声)
****
ãæšæ¥ã®å€æ¹ããã©ã³ã¹ãã22æ³ã®é幎ãã¯ã¯ãã³æ¥çš®ãã9æéåŸã«æ»äº¡ãããšãããã¥ãŒã¹ãå
¥ããŸããã圌ã¯ã®ãªã·ã£ã«æ
è¡ããäºå®ã§ããã圌ã¯ãã çããŠãããã£ãã®ã ãšãç¶èŠªã¯èšã£ãŠããŸããäžäººæ¯åã ã£ãã®ã«ãæ€èšŒããã¹ãããããŠããªãã¯ãœã¯ã¯ãã³ã«ããããŠæ»ãã ãã ãã
äž»èŠã¡ãã£ã¢ã¯ããæš©åšããå»åŠçãã®èšèãåŒçšããŠãç¬èªã®è§£éã瀺ããŸããã
ãããã·ã ã»ãã«ãã©ã®æ»å ã¯ã¯ã¯ãã³ã§ã¯ãªãã圌ã¯ã¢ã¬ã«ã®ãŒåå¿ã«ãã£ãŠæ»ãã ã®ã ãå»çé¢ä¿è
ã«ããã°ãé節ãªé£ç©ã¢ã¬ã«ã®ãŒã®å¯èœæ§ãé«ããã
ç
é¢é¢ä¿è
ãåŒçšãããæš©åšãããã§ã€ã¯ãã¥ãŒã¹ã§ã¯ãªããã仿¥ãæã
ã®æãã¯ããã·ã ã»ãã«ãã©ãšåœŒã®å®¶æãšãšãã«ããã
***
ãããããããèš±å¯ããããå®å
šã«å¥åº·ãªåäŸãã¡ã®åé¿å¯èœãªæ»ãšããã®10åã®æ°ã®é節ãªç
æ°ãçºçããããšãä¿èšŒããŸãããããŠãäœã®å©çãåŸãããªããæ¯ç©åŠãçååŠãè¬çåŠã®40幎ã«ãããèšç·Žãšå®è·µããåŸãç¥èããã£ãŠããã°ãç§ãã¡ã®äžè©±ããã眪ã®ãªãåäŸãã¡ãžã®ãã®ç°åžžãªèåŸ
ã«åå ããããšã¯ã殺人以å€ã®äœãã®ã§ããããŸããã-ãã€ã±ã«ã»ã€ã§ãŒãã³å士ãèåãªç§åŠè
ãå
ãã¡ã€ã¶ãŒç€Ÿå¯ç€Ÿé·
ããªã³ã¿ãªãªå·ã®3人ã®å»åž«ãã圌ããå€åããç
é¢ã4åç®ã®ããŒã¹ã¿ãŒã·ã§ãããè·å¡ã«æäžãå§ããåŸãæ»äº¡ããŸãããå¶ç¶ãªã®ãããããšããã®æ¥µæªééãªäžççã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã®ç ç²è
ãªã®ãïŒã-ããŒã¯ã»ã¿ãªãïŒäœå®¶ãã°ããŒãã«åç ç©¶ã»ã³ã¿ãŒç ç©¶å¡
97
ããã®ã¯ã¯ãã³ãã£ã³ããŒã³ã¯ãå»åŠå²äžæå€§ã®ã¹ãã£ã³ãã«ãšããŠèªãç¶ãããã ãããã»ã»ã»ããã«èšãã°ã人é¡ã«ç¯ããæå€§ã®ç¯çœªãšããŠç¥ãããããšã«ãªãã ããã -ã¯ãªã¹ãã£ã³ã»ã¢ã³ããŒãœã³è°å¡ã欧å·è°äŒè°å¡ã2022幎7æ
ããã§ããããã¯æ®ºäººã¯ã¯ãã³ãªã®ã§ãããã®ã¡ãã»ãŒãžã¯ãã¯ã£ãããšäŒããã¹ãã§ããäžçäžã§èµ·ããŠããããšã§ããåã©ããéå¹Žãæ»ãã§ããã®ã§ãã人éã«å¯Ÿãã眪ãåã©ããã¡ã«å¯Ÿãã眪ã
ä¿å¥åœå±ã¯æ¥åžžçã«ãã¯ã¯ãã³é¢é£ã®æ»å·è
ãCOVID-19ã«åé¡ããããæå°ããŠããŸãããã¯ã¯ãã³æ¥çš®è
ãCOVIDã§æ»ãã§ããããããã¯å€§èãªåã§ãã
ã¯ããã«
ãã®ã¯ã¯ãã³ã¯ã2020幎3æ11æ¥ã®å°éãããã£ãšå幎åŸã®11æ9æ¥ã«çºå£²ãããããã®çžäºã«é¢é£ãã2ã€ã®æ¿ççä»»åã¯ãCOVID屿©ã®æŠç¥çæ¯æ±ãæ§æããŠããã
- ããã¯ããŠã³ã¯ãå šäººé¡ã«åããããçµæžçã»ç€ŸäŒçæŠäºè¡çºã§ãã£ãã
- ååã«ææžåãããïŒ2021幎åé ããïŒmRNA COVID-19ã¯ã¯ãã³ã¯ãã¯ã¯ãã³é¢é£ã®æ»äº¡çãšçœ¹æ£çã®æç¶çãªäžæåŸåããããããæ¯ç©ã§ããã
å°éå®¶ã«ããå ±åæžã§ã¯ãç¹ã«è¡æ ãè¡æ çãå¿ççãäžåŠçãªã©ãã¯ã¯ãã³é¢é£ã®æ»å·ã®åå ã確èªãããŠããŸãã
ãŸããã¯ã¯ãã³ã®åœ±é¿ã¯ãæ
å ±ã®èªç±ã®äžã§å
¬éããããã¡ã€ã¶ãŒã®ç§å¯ã¬ããŒãã«ãã£ãŠèšé²ãããŠããŸãïŒäžèšã®åæåç
§ïŒã
åç»ã§èŠã COVIDã¯ã¯ãã³æ¥çš®ã®æ»äº¡çãžã®åœ±é¿ïŒ2020幎12æïœ2021幎4æãç¹å®åœïŒãèŠèŽã¯ãã¡ãã
å·çæç¹ïŒ2022幎4æ3æ¥ïŒã®ææ°ã®å
¬åŒæ°å€ã§ã¯ããããæ¬¡ã®ããã«ææãããŠããŸãã
COVID-19泚å°é¢é£æ»äº¡è æ°69,053人ãè² å·è æ°10,997,126人ïŒEUãç±³åœãè±åœãå«ãïŒãEUãç±³åœãè±åœãåããã人å£ã¯8å3,000äžäººã§ãã1ã
ããããã¯ã¯ãã³é¢é£ã®æ»äº¡ãæå®³äºè±¡ãåœã®ä¿å¥åœå±ã«å ±åãããšããé¢åãªæç¶ããèžãã®ã¯ã被害è
ãéºæã®ããäžéšã«éããªãã
ããã«ãä¿å¥åœå±ã¯ãæªæ¿èªãã§ãå®éšçããªCOVID-19ãã¯ã¯ãã³ãã«èµ·å ããæ»äº¡ãå·å®³ãé£è§£ã«ããããšã«ç©æ¥µçã«é¢äžããŠããã®ã§ãã
éå»ã®ããŒã¿ïŒElectronic Support for Public Health-Vaccine Adverse Event Reporting System (ESPH-VAERS) p.6ïŒã«åºã¥ããšã以äžã®ããã«ãªããŸãã
å»è¬åãã¯ã¯ãã³ã«ããæå®³äºè±¡ã¯ããããããšã ããå ±åãããŠããªãã...é£åå»è¬åå±ïŒFDAïŒã«å ±åãããã®ã¯ãå šè¬å€æå®³äºè±¡ã®0.3ïŒ æªæºãé節ãªäºè±¡ã®1ïœ13ïŒ ã§ããåæ§ã«ãã¯ã¯ãã³ã®æå®³äºè±¡ã®1%æªæºããå ±åãããŠããŸããã(匷調)2
98
ããã¯ãæ»å·è
ã®ç»é²ãšããæ£åŒãªããã»ã¹ã«åºã¥ããå
¬åŒã®çµ±èšã§ããmRNAã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ããããå®éã®æ»å·è
æ°ã¯ããã£ãšå€ãã®ã§ãã
ãã®æ°åã«é¢é£ãããã©ã¡ãŒã¿ãæãããšãæ¬åœã®æ°åãããããŸããç§ãã¡ã¯éåžžã«é«ãæ°åã«ã€ããŠè©±ããŠããã®ã§ãã
mRNAãã¯ã¯ãã³ãé ãããæå³ïŒ
ã¯ã¯ãã³ã¯åœãæããã®ã§ã¯ãªããããã³ãããã¯ãé£ãæ¢ãããã®ã§ããªããããã°ã»ãã¡ãŒãã«ãšã£ãŠæ°åååèŠæš¡ã®éå²ããªã®ã§ãã
ãããã1åéãã®ã¯ã¯ãã³ãžã£ãã§ã¯ãããŸãããæ°å¹Žã«ãããæ°åã®æäžãäŒå³ãããŠããã
äžçäžã§é©çšããã匷åãªéè婿š©ã«ãã£ãŠåŒ·å¶ãããŠããããã«ã³ãžãã¿ã³ã¶ãã¢ããã€ããé€ããŠãmRNAã¯ã¯ãã³ãæåŠããåæ°ãæã£ãåœã¯äžã€ããªãã
確å®ãªèšŒæ ã¯ãªãããã¿ã³ã¶ãã¢ãšãã«ã³ãžã®å€§çµ±é ãäžå¯è§£ãªç¶æ³ã§æ»äº¡ããããšã¯æ³šç®ã«å€ããã
ãã€ãã¯è¥¿åçã§å¯äžãmRNAã¯ã¯ãã³ã®å®æœãæåºãšããŠæåŠããåœã§ããã
ç®èãªããšã«ã2021幎7æ7æ¥ã«ãžã§ããã«ã»ã¢ã€ãŒãºå€§çµ±é ãææ®ºãããçŽåŸããžã§ãŒã»ãã€ãã³å€§çµ±é ã¯ãã¢ã€ãŒãºå€§çµ±é ã®æ»åŸ6æ¥ç®ã«ãã³ããã¯ã¹ç€Ÿããå±ãã50äžäººåã®ã¯ã¯ãã³ïŒãããŠã¢ã³ã¯ã«ãµã ã®å¥œæã§ãããã«å¢ããäºå®ïŒããã«ããŒãã©ã³ã¹ãžéããã«éããŸãã3ã
ãã€ããžã®ãã®æåã®åºè·ã¯ã倿°ã®çºå±éäžåœã«éãããäºå®ã ã£ã5åååã®ã殺人ã¯ã¯ãã³ããããªãç±³åœæŽå©ããã°ã©ã ã®äžéšã§ãã£ãã
倧æè£œè¬äŒç€Ÿã®ããã®å€§é
ç±³åœæ¿åºã¯ã2020幎3æ11æ¥ã®å°éçŽåŸã1åååã®ã¯ã¯ãã³ãçºæ³šãããEUã¯18ååå以äžã賌å
¥ããããã¯EUã®äººå£ã®4åã«çžåœãããããã°ãã¡ãŒãã«ãšã£ãŠã®ããã°ãããŒã§ãããçŽçšè
ã®è² æ
ã§è
æããæ¿æ²»å®¶ãžã®æ°åã®è¯ãèŠè¿ãã§ããã
ãã®ç®çã¯ã79å人ã®å°ç人å
šäœã«SARS-CoV-2ã®ã¯ã¯ãã³ãæ¥çš®ããããšã«ãã£ãŠãæçµçã«ã¯éå²ããããããšã§ããã
COVIDã¯ã¯ãã³ã¯ãå°ãªããšã3åã®æ¥çš®ãå¿
èŠã§ãããããã¯äžçå²äžæå€§ã®ã¯ã¯ãã³ãããžã§ã¯ãã§ãããããã°ãã¡ãŒãã«ãšã£ãп倧ã®éå²ãäœæŠã§ããã
äžçäžã§ã人ã
ã¯ã³ããã¯ã¯ãã³ã解決çã§ãããšä¿¡ã蟌ãŸãããŠããããããŠããæ£åžžãªç¶æ
ããåãæ»ãããã®ã ãšã
mRNAã¯ã¯ãã³ã¯ ãæªæ¿èª ãã〠ãå®éšç ãã§ãã
éåžžã§ããã°éçºã«äœå¹ŽããããSARS-CoV-2ãŠã€ã«ã¹ã®ã¯ã¯ãã³ãã2020幎11æ9æ¥ã«ãã¡æ©ãçºå£²ãããã®ã¯ãªãã§ããããïŒ
ãããããã¡ã€ã¶ãŒãã¢ãã瀟ãã¢ã¹ãã©ãŒãã«ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ïŒJ&JïŒãçºè¡šããã¯ã¯ãã³ã¯ãããã²ãã ã«é¢ããå®éšçãªéºäŒåç·šémRNAæè¡ã«åºã¥ããã®ã§ããã
99
mRNAã¯ã¯ãã³æ§æ³ãšçžãŸã£ãŠãããããããžã¿ã«ãã¹ããŒããéçºãããçŸåšå
šäœæ°ã«èª²ãããŠããŸãïŒäžèšã®åæåç
§ïŒã
ãããŠãWHOãç±³åœçŸç
察çäºé²ã»ã³ã¿ãŒïŒCDCïŒããããŠå€ãã®ç§åŠè
ããCOVID-19ã¯ãå£ç¯æ§ã€ã³ãã«ãšã³ã¶ã«äŒŒãŠããããšæç¢ºã«ç¢ºèªããŠããã®ã«ããªãCOVID-19çšã®ã¯ã¯ãã³ãå¿
èŠãªã®ã ãããïŒ(第IIIç« ã®åæåç
§ïŒ
ãã¡ã€ã¶ãŒãã¢ãããã¢ã¹ãã©ãŒãã«ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ïŒJ&JïŒã®4å€§äŒæ¥ã¯ãååœæ¿åºã®çµ¶å€§ãªæ¯æŽãåãããã®å®éšçãªmRNAã¯ã¯ãã³ã®è²©å£²ã«æºãã£ãŠããŸãã
ç±³åœã§ã¯ãFDAã«ããã°ããã®ã¯ã¯ãã³ã¯ãæªæ¿èªè£œåãã§ããã«ãããããããå®éšçãªmRNAã¯ã¯ãã³ã販売ããããã®ãã°ãªãŒã³ã©ã€ããã2020幎12æã«é¡ãä»äžãããã
FDAã¯ææ§ãªè¡šçŸã§ããã¡ã€ã¶ãŒã»ãã€ãªããã¯ç€Ÿã®ã¯ã¯ãã³ã«ããããç·æ¥äœ¿çšèš±å¯ïŒEUAïŒãäžããããªãã¡ãæªæ¿èªè£œåã®ç·æ¥äœ¿çšãèš±å¯ã...ç©æ¥µçãªå
ç«ã®ããã«...ã4ïŒäžèšåç
§ïŒãšããã

ãã®çºèšã«ã¯ãäœãæªãããšãççŸããããããã¡ã€ã¶ãŒã®å®éšçšmRNAã¯ã¯ãã³ã¯ ãæªæ¿èªãã§ãããšåæã«ãèš±å¯ããããŠããã
ç§ã¯ãã®å£°æãèåãªåŒè·å£«ã«ç¢ºèªããããæªæ¿èªã®è£œåãã販売ããããšã¯ããããããŸã«éæ³ã§ãã
ç±³åœã§ã¯ããã¡ã€ã¶ãŒã»ã¢ãã«ãã¯ã¯ãã³ã¯CDCã«ãã£ãŠãæ²»éšè¬ãã«åé¡ãããããéæ³è¬ç© ããšãèšãããã®ãçºå£²ããããšãæ£åœåããããã«ããç·æ¥äœ¿çš ãã®æ¡é
ãããã®ã§ãã
ææã®ãã£ã³ããŒã³ã¯ç¶ããŠãããããç·æ¥äœ¿çšããæ£åœåãããç·æ¥äºæ
ãã¯ååšããªãããªããïŒ
WHOãCDCããã³ãã19ã¯ãå£ç¯æ§ã€ã³ãã«ãšã³ã¶ã«é¡äŒŒãããŠãããæ®ºäººãŠã€ã«ã¹ã§ã¯ãªãããšã確èªããŠããã
ã 確å®éœæ§äŸãã®æšå®ã«äœ¿çšãããPCRæ€æ»ã«æ¬ é¥ãããã2020幎3æä»¥éãCOVID-19ã®ãæ°åãã¯æäœãããã€ãäžããããŠããã
2020幎1æä»¥éã«é©çšãããPCRãã¹ãïŒããã³æšå®å€ïŒã®å šäœçãªåŠ¥åœæ§ããWHOã«ãã£ãŠçåèŠãããŠããïŒ2021幎1æïŒïŒç¬¬IIIç« ã®åæåç §ïŒã
100
ãã¡ã€ã¶ãŒã«ç¯çœªæŽãããæªæ¿èªè£œåã® ããè©æ¬ºçããŒã±ãã£ã³ã°ã
2009幎ã«ãã©ãã·ã¥ããã¯ããŸãã2009幎9æãç±³åœåžæ³çã®æŽå²çãªæ±ºå®ã«ããããã¡ã€ã¶ãŒç€Ÿã¯åäºè²¬ä»»ãèªããŸãã5ãããã¯ãç±³åœåžæ³çå²äžãæå€§ã®å»çè©æ¬ºã®åè§£ãã§ããã
ç±³åœã®è£œè¬å€§æãã¡ã€ã¶ãŒç€Ÿãšãã®åäŒç€Ÿãã¡ã«ãã·ã¢ïŒã¢ãããžã§ã³ç€Ÿã¯ã...ç¹å®ã®å»è¬åã®éæ³ãªããã¢ãŒã·ã§ã³ã«èµ·å ããåäºããã³æ°äºè²¬ä»»ã解決ããããã«ãåžæ³çå²äžæå€§ã®å»çè©æ¬ºã®åè§£éã§ãã23åãã«ãæ¯æãããšã«åæããã (2009幎9æ2æ¥)6

C-Spanã®ãããªã¯ãã¡ãããã芧ããã ããŸãã
ããžã£ã»ãŽã¥ 2020-2022幎ãžã®ãã©ãã·ã¥ãã©ã¯ãŒã
ç±³åœåžæ³çãããè©æ¬ºçããŒã±ãã£ã³ã°ãããé£åå»è¬ååç²§åæ³éåã®é眪ããªã©ã®åäºåçºãåãã倧æè£œè¬äŒç€Ÿã®ã¯ã¯ãã³ã³ã³ã°ãããªãããäžäœã©ããã£ãŠä¿¡çšããã®ã ããïŒ
ãããã2009幎ããã¡ã€ã¶ãŒã¯ãç±³åœåžæ³çããããã°ãå·è¡ç¶äºã7ãèšãæž¡ãããä¿å¥çŠç¥çïŒDHHSïŒã®ç£å¯å®ãšãäŒæ¥å¥å šæ§åå®ããçµã¶ããšã矩åã¥ããããããšãè¿°ã¹ãŠãããªããã°ãªããªãããã®å¥çŽã§ã¯ããã¡ã€ã¶ãŒç€Ÿã®äžæ£è¡çºããåé¿ããè¿ éã«çºèŠããããã®æé ãšå¯©æ»ããèŠå®ãããŠããŸããã
ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãš "ãªããªã€ãã®èå»¶"
101
2020幎11æåæ¬ã®COVID-19ã¯ã¯ãã³ã®çºå£²ãšæãåããããŠãã¡ãã£ã¢ã§ã»ãšãã©åãäžããããªãã£ãã³ãã屿©ã®æäžããžã§ã³ãœã³ïŒãžã§ã³ãœã³ïŒããã³ãã®è²©å£²äŒç€Ÿ3瀟ïŒïŒåŠæ¹ç®ãªããªã€ãã®è²©å£²ã«é¢äžïŒã¯ãæå®³è³ åãæ±ããŠæèšŽããé¡ãåžãšæ°åååã®æ«å®çåè§£ã«éããã8ã éå£èšŽèšã¯ãã¢ã¡ãªã«å²äžæå€§ã®é£éŠè£å€æè£å€ãã ã£ãïŒè©³çްã¯ãã¡ã³ã¿ã«ãã«ã¹ãžã®åœ±é¿ãã«ä¿ãVIç« ãåç
§ããããïŒã
ãã®ãããªæ³çèæ¯ã¯ãããã°ãã¡ãŒãã®ã¯ã¯ãã³æ§æ³ã®çè§£ã«ã€ãªããã®ã§ããããïŒ
ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã¯çŸåšãéºäŒåæ²»çã䌎ãCOVIDã¢ãããŠã€ã«ã¹ãŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ã®è£œé ã»è²©å£²ã«é¢ãã£ãŠããïŒäžèšã®J&Jéå£èšŽèšã¯ãJ&Jã«å¯Ÿããããã€ãã®èšŽèšã®ãã¡ã®äžã€ã§ããïŒã
ïŒHuman Guinea PigsïŒããã¢ã«ã¢ãã
COVIDã¯ã¯ãã³ãšã®é¢é£ã§ã¯ããäžæ£ãªããŒã±ãã£ã³ã°ãã¯æ§ãããªè¡šçŸã§ããããã¡ã€ã¶ãŒãã¢ããããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãã¢ã¹ãã©ãŒãã«ãçºè¡šããmRNAã¯ã¯ãã³ã¯ãããã²ãã ã«é¢ãããå®éšçããªéºäŒåç·šémRNAæè¡ã«åºã¥ããæªæ¿èªè¬ãã§ãã9ã
ããã«ãããŠã¹ããã§ã¬ããã䜿ã£ãæšæºçãªåç©å®éšãè¡ãããŠããªãããã¡ã€ã¶ãŒã¯ãããã®ãŸãŸäººéã® "ã¢ã«ã¢ãã "ã«ããã10ã
ããã詊éšã¯ã7æäžæ¬ãã8æäžæ¬ã«ãããŠéå§ãããïŒ2020幎ïŒãæ°ããã¯ã¯ãã³ã®ãã¹ãã«3ã¶æãšããã®ã¯å代æªèã§ããæ°å¹Žãæ®éã§ãããã (F. William EngdahlãGlobal Researchã2020幎11æ)11
ãã¡ã€ã¶ãŒã®å å¯ç€Ÿé·ã§ãããã€ã±ã«ã»ã€ã§ãŒãã³å士ã¯ãæåºãšããå§¿å¢ã§èšãã§ããŸãã
ãSARS-COV-2ãŠã€ã«ã¹ã«å¯Ÿãããã¹ãŠã®ã¯ã¯ãã³ã¯ãå®çŸ©äžãæ°èŠã®ãã®ã§ãããã¯ã¯ãã³åè£ã¯æ°ã¶æã§éçºãããŠãããã®ã¯ãããŸãããã
ãããããã®ãããªã¯ã¯ãã³ããæç¢ºã«å®éšçã§ãªããããªãç¶æ³äžã§ã䜿çšãæ¿èªããããªããç§ã¯ãåä¿¡è ãç¯çœªçãªãŸã§ã«èª€è§£ãããŠãããšä¿¡ããŠããŸã ã12ã
2020幎12æåæ¬ãMichael Yeadonå士ã¯Wolfgang Wodargå士ãšãšãã«ãEUå šäœã®å»è¬åæ¿èªãæ åœããæ¬§å·å»è¬ååºïŒEMAïŒã«ããã¹ãŠã®SARS-CoV-2ã¯ã¯ãã³è©Šéšãç¹ã«BNT162bã«é¢ããPfizer-BioNtech詊éšïŒEudraCTçªå·2020-002641-42ïŒã®å³æåæ¢ãç³è«ãã13ã
SARS-CoV-2ã¯ã¯ãã³ãããžã§ã¯ãã®æŽå²
å€ãã®ççŸãããã以äžã®åæã¯ãã¯ã¯ãã³ãããžã§ã¯ãã®åææ®µéãšã2019幎10æ18æ¥ã«ãã¥ãŒãšãŒã¯ã§éå¬ããããžã§ã³ãºã»ãããã³ã¹å»ç§å€§åŠäž»å¬ã®ã³ãããŠã€ã«ã¹ãã³ãããã¯ã®201ã·ãã¥ã¬ãŒã·ã§ã³ã®åœ¹å²ã«ã€ããŠè¿°ã¹ãŠããŸãïŒç¬¬Iç« åç
§ïŒã
COVIDã¯ã¯ãã³ã¯ãæ°ååãã«èŠæš¡ã®ããã°ãã¡ãŒãã®äœæŠã§ããã150以äžã®åœå®¶æ¿åºã®å
¬çåµåå¢å ã«è²¢ç®ããããšã«ãªãã
ææãã£ã³ããŒã³ã«æ¯ããããå
¬è¡è¡çããããããééããã®æ§æ³ã®åååãšãªã£ãŠããã
102
GSKãšãã¡ã€ã¶ãŒã®ããŒãããŒã·ãã
COVID-19屿©ãçºçãã5ã«æåã«ãäžçæå€§ã®ãã¡ãŒãã³ã³ã°ãããªãã2ç€ŸãæŠç¥çé¢ä¿ã§æãçµã¶ããšã決å®ããŸããã2019幎8æãGSKã¯ãã¡ã€ã¶ãŒãšãã³ã³ã·ã¥ãŒããŒãã«ã¹ã»ãžã§ã€ã³ããã³ãã£ãŒããšé¡ããå€§èŠæš¡ãªããŒãããŒã·ããã®åœ¢æã確èªãã14ã
ãã®é¢ä¿ã¯ãä¿¡é Œã§ããã³ã³ã·ã¥ãŒããŒãã«ã¹ãã©ã³ããã«éå®ããããšãããŠããããåæã§ã¯æ°ååãã«ã®å
±åæè³ãããžã§ã¯ããå«ãå
±å財åæç¶ããæ³å®ãããŠãããå䜵ã§ã¯ãªããã®ã®ãGSKãšãã¡ã€ã¶ãŒã®ææºã¯ãã¯ã¯ãã³åžå Žãå«ãäž¡ç€Ÿã®æŽ»åã®å€ãã«ãããŠãéžæççµ±åãšäºå®äžã®å
±è¬ãæå³ããã
ããã¡ã€ã¶ãŒãšã®ååŒäºæ¥ã®å®äºã¯ãGSKã®å€é©ã®æ¬¡ã®æ®µéã®å§ãŸããæå³ããŸããããã¯ã°ã«ãŒãã«ãšã£ãŠéèŠãªç¬éã§ãããå»è¬åã»ã¯ã¯ãã³ãšã³ã³ã·ã¥ãŒããŒãã«ã¹ã®2ã€ã®å倧ãªäŒæ¥ã®åºç€ãç¯ããã®ã§ããã (GSKã2019幎8æ1æ¥ã匷調)15
ãã®GSKãšãã¡ã€ã¶ãŒã®é¢ä¿ã¯ãããŒãããŒã§ãã補è¬äŒç€Ÿãç ç©¶æããŠã€ã«ã¹ç ç©¶æãè»ããã³ãã€ãªãã¯ãããžãŒäºæ¥äœãªã©ã®ãããã¯ãŒã¯ãå
å«ããŠããããã®å€ããçŸåšCOVIDã¯ã¯ãã³æ§æ³ã«é¢äžããŠããã
çŸåšãäžçã®ã¯ã¯ãã³åžå Žã®80%ã¯ãGSKãPfizerãå«ãå°æ°ã®å€åœç±äŒæ¥ã«ãã£ãŠã³ã³ãããŒã«ãããŠããŸãã䞡瀟ã®åæã«ãããGSK-Pfizerã¯COVID-19ã¯ã¯ãã³ã«é¢ããŠæ¯é
çãã€å調çãªåœ¹å²ãæããããšãäºå®ãããŠããŸãã
2019幎10æã®ãã³ãããŠã€ã«ã¹äºä»¶201ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ãã广çãªã¯ã¯ãã³ ãã®éçº
ã³ãããŠã€ã«ã¹ã¯åœåãCEPIãšWHOã«ãã£ãŠnCoV-19ãšåä»ããããããããã¯2019幎10æäžæ¬ã«éå¬ãããã³ãããŠã€ã«ã¹ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã«ä¿ãWEF-Gates-Johns Hopkins Event 201 (2019-nCov) ã§æ¡çšãããåç§°ãšå
šãåãã§ãã£ããCOVID-19ããŠã€ã«ã¹ãšããŠã§ã¯ãªããç
æ°ïŒã³ãããŠã€ã«ã¹ç
ïŒCOVID-19ïŒãšããŠWHOã«ãã£ãŠç¹å®ãããã®ã¯åŸã®ããšã§ããŠã€ã«ã¹ã¯ãéçæ¥æ§åŒåžåšçå矀ãã³ãããŠã€ã«ã¹2ïŒSARS-CoV-2ïŒãšããŠç¹å®ãããŸããã
ã€ãã³ã201ãžã§ã³ãºã»ãããã³ã¹ã®ã·ãã¥ã¬ãŒã·ã§ã³ïŒç¬¬Iç« ã§æ€èšïŒã§ã¯ã2019-nCoVãšåä»ããããæ°åã³ãããŠã€ã«ã¹ã®çºçãæ³å®ãã2019幎10æã®ã·ãã¥ã¬ãŒã·ã§ã³ã§ãæ°çŸäžã®çäŸã«å¯Ÿå¿ããæå¹ãªã¯ã¯ãã³ã®éçºã«åãçµãã ããã®ã·ãã¥ã¬ãŒã·ã§ã³ã§ã¯ãå°çäžã®å
šäººå£ã圱é¿ãåãããšããã·ããªãªãçºè¡šãããã
ãå€§èŠæš¡ãªãŠã€ã«ã¹æ§ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ãè¡ã£ããšãã...ãäžçã§6,500äžäººãæ»äº¡ããã
ããã³ãããã¯ã®åææ°ã¶æã®éãïŒã·ãã¥ã¬ãŒã·ã§ã³ã®ïŒçޝç©çäŸæ°ã¯ææ°é¢æ°çã«å¢å ããæ¯é±2åã«ãªããŸãããããŠãçäŸãšæ»äº¡ãèç©ãããã«ã€ããŠãçµæžçã»ç€ŸäŒç圱é¿ããŸããŸãæ·±å»ã«ãªããŸããã
ã·ããªãªã¯18ã¶æã®æç¹ã§çµäºãã6500äžäººãæ»äº¡ããŠããŸããææè
ãæžå°ããŠããããããã³ãããã¯ã¯æžéãå§ããŠãããæå¹ãªã¯ã¯ãã³ãã§ãããŸã§ããããã¯äžç人å£ã®80ã90%ãææãããŸã§ããã³ãããã¯ã¯ããçšåºŠã®é床ã§ç¶ãã ããããã®æç¹ãããå°å
çŸæ£ã®é¢šåç
ãšãªãå¯èœæ§ãé«ã16ã
äžççµæžãã©ãŒã©ã ã®ãããªã201 Johns Hopkins SimulationããèŠãã«ã¯ããããã¯ãªãã¯ããŠãã ããã
103
ç«ç 察çã€ãããŒã·ã§ã³é£åïŒCEPIïŒã®äžå¿çãªåœ¹å²
æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³æ§æ³ã®äž»äœã¯ãäžççµæžãã©ãŒã©ã ïŒWEFïŒãšãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãåŸæŽã»åºè³ããCEPIïŒCoalition for Epidemic Preparedness InnovationsïŒãšããçµç¹ã§ããã
äžè¯äººæ°å
±ååœã«ãã£ãŠãŠã€ã«ã¹ãæ£åŒã«ç¹å®ããã2é±éåŸïŒ2020幎1æ7æ¥ïŒã2020幎1æ20æ¥ïœ24æ¥ã«éå¬ãããããã¹äžççµæžãã©ãŒã©ã ã§ãCEPIããæ°åã³ãããŠã€ã«ã¹ã®ã¯ã¯ãã³ãçºè¡šãããŸããã
å¹Žè¡šã«æ³šç® 2019-nCoVã¯ã¯ãã³ã®éçºã¯ãäžçïŒäžåœä»¥å€ïŒã®ãç¢ºå®æ£è
æ°ãã83人ãšãªã£ãæç¹ã§ãWHOã«ãããäžçå
¬è¡è¡çç·æ¥äºæ
ãã®æ£åŒçºè¶³ïŒ2020幎1æ30æ¥ïŒã®1é±éåã«ããã¹äžççµæžãã©ãŒã©ã ïŒWEFïŒã§çºè¡šãããŸããïŒç¬¬IIç« åç
§ïŒã
WHOããã³ãããã¯ãéå§ããã®ã¯2020幎3æ11æ¥ããããŠãã®5æ¥åŸãã¡ãã£ã¢ã«ã¯ã»ãšãã©åãäžããããªãã£ããã2020幎3æ16æ¥ã«ã·ã¢ãã«ã®Moderna瀟ã«ãã£ãŠãããã®ãã©ã³ãã£ã¢ã察象ãšããæåã®è©Šéšãè¡ãããã
ãã®èšŒæ ã«ããã®ã¯ã¯ãã³ãããžã§ã¯ãã¯ãã£ãšæ©ã段éã§éå§ãããŠãããCoalition for Epidemic Preparedness InnovationsïŒCEPIïŒã®CEOã§ããRichard Hatchettã«ãããšãã¯ã¯ãã³éçºãããžã§ã¯ãã¯ã³ãããŠã€ã«ã¹ã®çºèŠã»ç¹å®ïŒ2020幎1æ7æ¥ïŒä»¥åã®ã¿ãªããã2019幎10æã®ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã®æ°ã¶æåããéå§ãããŠããïŒäžèšRichard Hatchettã®ã€ã³ã¿ãã¥ãŒåç
§ïŒ17ã
CEPIã¯ãã²ã€ã財å£ãšWEFã代衚ããŠã倿°ã®ãåè£è
ããšææºããŠããäžççãªã¯ã¯ãã³ãããžã§ã¯ãããç®çãšããã¯ã¯ãã³æ¥çš®äºæ¥ã«ããããç¬å çããªåœ¹å²ãæ±ããŠããã®ã§ãã£ãã
ã¢ãã瀟ã®ã¹ããã¡ã³ã»ãã³ã»ã«CEOã¯ãããã¹ã§éãããäžççµæžãã©ãŒã©ã ã®èšè
äŒèŠïŒ2020幎1æïŒã§ãmRNAã¯ã¯ãã³ã®ç¹åŸŽã説æããããæç€ºã泚å
¥ãã......mRNAã¯ãã©ãããã©ãŒã ã§ããã NISãCEPIãšå
±åã§ããã§ã«ç ç©¶ãé²ãã§ããããšã確èªããŸãããåç»ã¯ãã¡ãããã芧ããã ããŸããClick here to view the video.

WHOãäžççãªå ¬è¡è¡çäžã®ç·æ¥äºæ ïŒPHEICïŒãå ¬åŒã«æã¡åºãããã©ã³ã倧統é ãäžåœãšã®èªç©ºè·¯ç·ãæå¶ããããšã決ããç¿æ¥ã®2020幎1æ31æ¥ãCEPIã¯ãã€ãã®ãã€ãªè£œè¬äŒç€ŸCureVac AGãšã®ææºãçºè¡šããã
ãã®æ°æ¥åŸã®2020幎2æäžæ¬ãCEPIã¯ã倧æã¯ã¯ãã³ã¡ãŒã«ãŒã®GSKããå瀟ç¬èªã®ã¢ãžã¥ãã³ãïŒã¯ã¯ãã³ã®å¹æãé«ããååç©ïŒã察å¿ã«äœ¿çšããããšãèªãããšçºè¡šãããïŒãã³ãããã¯ã¯2020幎3æ11æ¥ã«æ£åŒã«éå§ãããïŒ18
COVID-19ã«å¯Ÿããã¯ã¯ãã³ãäœãããšããäžçäžã®æ°åã®ç ç©¶ã°ã«ãŒããç«¶äºããŠãããç¶æ ã§ãå€ãã®ãæœåšçãªã¯ã¯ãã³ããã€ãã©ã€ã³ã«ãããç¶æ ã§ãã£ãã
104
COVID-19äžçäºé²æ¥çš®ããã°ã©ã
CEPIã¯ïŒ201ã®ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã«è³éæäŸããGates-WEFã®ä»£çãšããŠïŒããã€ãªãã¯ãããžãŒäŒæ¥ã倧æè£œè¬äŒç€Ÿãæ¿åºæ©é¢ã倧åŠã®ç 究宀ãšååããŠãå€§èŠæš¡ãªäžçèŠæš¡ã®ã¯ã¯ãã³æ¥çš®ããã°ã©ã ã«ãããŠéèŠãªåœ¹å²ãæ ããŸããã

CEPIã«ããåè¿°ã®å£°æã¯ã2020幎3æ11æ¥ã«å ¬åŒã«ãã³ãããã¯å®£èšãåºãããçŽ2ã«æåã«åºããããã®ã§ããã2020幎1æ30æ¥ã«äžåœä»¥å€ã§ç¢ºèªãããææè æ°ã¯83人ã§ããã
ãæã ã¯å¹ åºãæœåšçãªããŒãããŒãšäŒè©±ãããŠãããããããŠããããã®äŒè©±ã«äžå¯æ¬ ãªã®ã¯ ããããŸã ãã³ãããã¯ãèµ·ãã£ãŠããªãã®ã§ããã°ã人ã ããŸããŸã確信ããŠããããšã«é¢é£ããå¯èœæ§ã®ããæéæ ã®äžã§ãéåžžã«å€§éã®ã¯ã¯ãã³ãäœãèšç»ã¯äœã§ããïŒ[Richard Hatchett, CEPI CEO in interview with stat.news.com] (emphasis added)19
COVIDãã³ãããã¯ã«é¢ããäºåç¥èãmRNAã¯ã¯ãã³ã¯ãã§ã«ãã€ãã©ã€ã³ã«ãã£ã
éèŠãªã®ã¯ãããã§ããæ°ããã³ãããŠã€ã«ã¹ã®çºèŠã»ç¹å®ïŒ2020幎1æ7æ¥ïŒä»¥åã ãã§ãªãã2019幎10æã®201幎ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã®æ°ãæåããã¯ã¯ãã³éçºã®ãããžã§ã¯ããéå§ããŠããããšã確èªããããšã§ãã
105
ç§ãã¡ã¯ãæšå¹ŽãããïŒ2019幎åãïŒã«ãããè¡ããŸãã...ãç§ãã¡ã¯åéããæ å ±ã䜿ãããã®ããŒã ã«ã¯ä»ãããŸããŸãªçš®é¡ã®ã¯ã¯ãã³ãã¹ã±ãŒã«ã¢ããããæ©äŒã«ã€ããŠèããŠããã£ãŠãããšããã§ããããã¯çŸåšé²è¡äžã§ããããã€ãã®æè¡ã«ã€ããŠã¯ãæµè¡ã«é©ããææã«æè¡ç§»è»¢ãã§ããå¯èœæ§ããããŸãã
ãã®ããã«ã¯ãçžåœãªçç£èœåãæã€äººãã¡ãå·»ã蟌ãããšãéèŠã ãšæããŸãã倧æã®çç£è ããã®ããŒãã«ã«ã€ãããšã¯ããã®æ·±ããçµéšãå éšè³æºããããšãŠããšãŠãéèŠãªããšã§ãããã
åè£ãšãªãã¯ã¯ãã³ã¯ãéåžžã«æ©ãéçºãããã§ããããNIAIDã®ãã£ã¬ã¯ã¿ãŒã§ããã¢ã³ãœããŒã»ãã¡ãŠãå士ïŒãããã¯ãŒã¯TVã§ãããã¯ããŸãæ£ãããŠããïŒã¯ãã¢ããã¯ã¯ãã³ã®èšåºè©Šéšã¯æ©ããã°ïŒ»2020幎ã®ïŒœæ¥ã«ãªããšæããšå ¬èšããŠããŸãã(匷調)20
CEPIé·å®ã®ãªãã£ãŒãã»ããã§ãããNIAIDãçããã¢ã³ãœããŒã»ãã¡ãŠãå士ããããŠã¢ããã®ã¹ããã¡ã³ã»ãã³ã»ã«CEOã¯ãCOVID-19ã®ãã³ãããã¯ã®çºçããäºåã«ç¥ã£ãŠãããã®ã ãããïŒ
ããã§ããã®çºèšããã圌ãã¯2019幎åé ã«ã¯ãã§ã«mRNAã¯ã¯ãã³ã®éçºã«åãçµãã§ããããšãããããããããã«ãäžåœã®ä¿å¥åœå±ããããããæ°åã³ãããŠã€ã«ã¹ãã®ååšãå
¬åŒã«ç¢ºèªãã2é±éåã®2019幎12æ12æ¥ãã¢ãã瀟ã¯åœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æïŒNIAIDïŒãšãšãã«ãããŒã¹ã«ãã©ã€ã倧åŠãã£ãã«ãã«æ ¡ã®ç ç©¶å¡ã«ãã§ã«ãmRNAã³ãããŠã€ã«ã¹ã¯ã¯ãã³åè£ãéã£ãŠãããïŒJosephMercolaïŒJuly10ïŒ2021åç
§ïŒ21ã
CEPIãåŸæŽããã¯ã¯ãã³ã³ã³ã°ãããªããã¯ãäžççãªäžçä¿å¥ç·æ¥äºæ
ïŒ2020幎1æ30æ¥ã«WHOã宣èšïŒã«å
ç«ã£ãŠããã§ã«æè³èšç»ãç«ãŠãŠããã®ã§ããã
ã¢ããã¯2020幎2æ24æ¥ããmRNA-1273â²ãšåŒã°ããå®éšçïŒã¡ãã»ã³ãžã£ãŒïŒmRNA COVID-19ã¯ã¯ãã³ãã®éçºãçºè¡šããããã®ã¯ã¯ãã³ã®åæãããã¯ãã¢ã³ãããŒã»ãã¡ãŠãå士ãçãããåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æïŒNIAIDïŒãã®ç±³åœæ¿åºç ç©¶è
ã«æ¢ã«åºè·ãããŠããã
ãã¡ãŠãå士ã®èšèãåããã°
ãSARS-CoV-2ã®ææãäºé²ããå®å šã§å¹æçãªã¯ã¯ãã³ãèŠã€ããããšã¯ãå ¬è¡è¡çäžã®ç·æ¥èª²é¡ã§ããèšé²çãªã¹ããŒãã§éå§ããããã®ç¬¬1çžè©Šéšã¯ããã®ç®æšéæã«åããéèŠãªç¬¬äžæ©ãšãªããŸãã22ã
以äžã¯ã2020幎1æ13æ¥ã®æç¹ã§ãã¢ã³ãœããŒã»ãã¡ãŠãã®NIAIDãšã®ååé¢ä¿ãšåæ§ã«ãäºèŠãã瀺ãã¢ããã®å£°ææããã®æç²ã§ãã23ã
COVID-19ã«å¯Ÿããæœåšçãªã¯ã¯ãã³ã«é¢ããã¢ãã«ãã®åãçµã¿ã«ã€ããŠ
ã¢ããã¯ããã®ç¶ç¶çãªã°ããŒãã«ãã«ã¹ã®ç·æ¥äºæ ã«å¯Ÿå¿ããããã«æŽ»åããŠããå€ãã®ã°ã«ãŒãã®äžå¡ã§ããããšãèªãã«æã£ãŠããŸãããã®ããŒãžã§ã¯ãåœç€Ÿã®ã¯ã¯ãã³åè£ïŒmRNA-1273ïŒã®éçºã«ãããäž»èŠãªãã€ã«ã¹ããŒã³ããŸãšãããããã質åã«ãçãããŠããŸãã
2020幎3æ16æ¥ãŸã§ã®ç§ãã¡ã®å¯Ÿå¿ã«é¢ããã¿ã€ã ã©ã€ã³
2020幎1æ11æ¥ãäžåœåœå±ãæ°åã³ãããŠã€ã«ã¹ã®éºäŒåé åãå ±æã
2020幎1æ13æ¥ãç±³åœåœç«è¡çç ç©¶æïŒNIHïŒãšModernaã®ææçç ç©¶ããŒã ããæ°åã³ãããŠã€ã«ã¹ã«å¯Ÿããåœç€Ÿã®ã¯ã¯ãã³ã§ããmRNA-1273ã®å¡©åºé åã確å®ããŸããã
106
ã³ãããŠã€ã«ã¹ åœæãNIHåäžã®åœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æïŒNIAIDïŒã¯ãã³ãããŠã€ã«ã¹ã®è åšã«å¯ŸããmRNA-1273ã¯ã¯ãã³ãçšãããã§ãŒãº1詊éšã宿œããæåã瀺ããã¢ãã«ãã¯èšåºè£œé ã«åããŠåãåºããŸããããã®ãããã®è£œé ã¯ãCEPIïŒCoalition for Epidemic Preparedness InnovationsïŒã®è³éæŽå©ãåããŠããŸãã
2020幎2æ7æ¥ããã€ã¢ã«ãžã®å å¡«ãšä»äžããå«ãæåã®èšåºããããå®äºããé åã®éžæããã¯ã¯ãã³è£œé ãŸã§åèš25æ¥éãçµéããŸããããã®åŸããã®ãããã¯ãªãªãŒã¹ã«åããåæè©Šéšãžãšé²ã¿ãŸããã
2020幎2æ24æ¥ãèšåºãããã¯ãNIHã®ç¬¬1çžèšåºè©Šéšã«äœ¿çšãããããModernaããNIHã«åºè·ãããŸããã
2020幎3æ4æ¥ãç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ãNIHãæåºããmRNA-1273ã®æ²»éšè¬ïŒINDïŒç³è«ã®å¯©æ»ãå®äºããèšåºè©Šéšéå§ã®ããã®è©Šéšé²è¡ãèš±å¯ããŸããã
2020幎3æ16æ¥ãNIHã¯ãmRNA-1273ã®ãã§ãŒãº1詊éšã®æåã®åå è ãæäžãããããšãçºè¡šããé åéžæããæåã®ãããžã®æäžãŸã§ãåèš63æ¥éãšãªããŸããã
ã¢ãã瀟ã¯åœåãæåã®èšåºè©Šéšã4æäžæ¬ïŒ2020幎ïŒã«éå§ãããšè¿°ã¹ãŠããããããã®ãã©ã³ãã£ã¢ãå«ã詊éšã¯2020幎3æäžæ¬ã«ã·ã¢ãã«ã§å§ãŸã£ãïŒãã³ãããã¯ãå ¬åŒã«å§ãŸã£ãã®ã¯2020幎3æ11æ¥ã§ããããšã念é ã«çœ®ããŠã»ããïŒ24ã
ã·ã¢ãã«ã®ç ç©¶è ã¯ãæææ¥ã«å®éšçãªã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®ãã¹ãã§æåã®äººã«æåã®æ³šå°ããã-ãã³ãããã¯ãæ¥å¢ããŠããã«ãããããããä¿è·ã®ããã®äžççãªç©ããéå§ããã...
ãã®ç ç©¶ã§ã¯ã18æãã55æãŸã§ã®å¥åº·ãªãã©ã³ãã£ã¢ãæ éã«éžã³ãä»ã®äººãããé«ãæäžéãäžããã©ã®çšåºŠã®åŒ·ãã§æ¥çš®ãã¹ããããã¹ãããŠãããç§åŠè ã¯ãå¯äœçšããã§ãã¯ããè¡æ¶²ãµã³ãã«ãæ¡åããŠãã¯ã¯ãã³ãå ç«ç³»ã掻æ§åããŠãããã©ããããã¹ãããNIHãå ã«ã¯ã¯ãã³æ¥çš®ããããŠã¹ã§çºèŠãããããªå¿åŒ·ãæããããæ¢ãããšã«ãªãã
ããã®ã¯ã¯ãã³ãå ç«åå¿ãåŒãèµ·ãããã©ãããå®å šãã©ããã¯ããããŸãããã ãã詊éšãããŠããã®ã§ãããšãžã£ã¯ãœã³ã¯åŒ·èª¿ããããäžè¬åžæ°ã«æäžããããšãå¯èœãªæ®µéã§ããæ éã«ãªãã¹ã段éã§ããããŸãããã(FOXãã¥ãŒã¹ããŒã«ã«)25
COVIDã¯ã¯ãã³ãšID2020ããžã¿ã«ã»ã¢ã€ãã³ãã£ãã£ã»ãã©ãããã©ãŒã
CEPIãããã¹äžççµæžãã©ãŒã©ã ã§äžççãªã¯ã¯ãã³ã®çºå£²ãçºè¡šããäžæ¹ã§ãããäžã€éèŠã§é¢é£ãã詊ã¿ãé²è¡äžã§ãã£ããããã¯ãID2020ã¢ãžã§ã³ãããšåŒã°ãããã®ã§ãããŒã¿ãŒã»ã±ãŒãããã«ããã°ããããžã¿ã«IDã®ãã©ãããã©ãŒã ãšããŠãäžè¬çãªã¯ã¯ãã³æ¥çš®ãçšããé»åIDããã°ã©ã ããæ§æãããã®ã§ããã
ãID2020ã¢ãžã§ã³ãã¯ãæ¢åã®åºçç»é²ãšäºé²æ¥çš®ãå©çšããæ°çå ã«æºåž¯å¯èœã§æ°žç¶çãªãã€ãªã¡ããªãã¯ã«ãªã³ã¯ãããããžã¿ã«IDãæäŸãããã(Peter Koenig, March 12, 2020)26ã
ID2020ã®åµèšããŒãããŒã¯ããã€ã¯ããœãããããã¯ãã§ã©ãŒè²¡å£ãã¯ã¯ãã³ãšäºé²æ¥çš®ã®ããã®ã°ããŒãã«ã¢ã©ã€ã¢ã³ã¹ïŒGAVIïŒïŒã²ã€ã財å£ã®ã€ãã·ã¢ããïŒã§ããã
107
GAVIãšãã®ããŒãããŒïŒWHOãUNICEFãäžçéè¡ãIMFïŒã¯ãCOVAXãšåä»ããããäžçèŠæš¡ã®ã¯ã¯ãã³ãããžã§ã¯ãã®å®æœïŒèè³ïŒã«ç©æ¥µçã«é¢äžããŠããŸããã
COVAXã®èª¿æŽã«é¢ããäž»èŠãªäž»äœã¯ãã¯ã¯ãã³åçïŒGAVIïŒãç«ç 察ç驿°é£åïŒCEPIïŒãäžçä¿å¥æ©é¢ïŒWHOïŒã§ãããã®3å£äœã¯ãããããã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£ããè³éæŽå©ãåããŠããŸãã

ID2020ã¢ã©ã€ã¢ã³ã¹ããã¥ãŒãšãŒã¯ã§ãRising to the Good ID Challengeããšé¡ãããµããããéå¬ããã®ã¯ããã¥ãŒãšãŒã¯ã®ãžã§ã³ãºã»ãããã³ã¹ã§è¡ãããã€ãã³ã201ãšé¡ããnCov-2019ã·ãã¥ã¬ãŒã·ã§ã³æŒç¿ã®ã¡ããã©1ã«æåã2019幎9æ19æ¥ãšããã®ã¯æ³šç®ã«å€ããã§ãããã
WHOããã³ãããã¯ãšåŒã¶ãã®ã®å§ãŸãã«ID2020ãå±éãããã®ã¯ãåãªãå¶ç¶ãªã®ã§ããããïŒ- ãããšããID2020ã®è€æ°ã®ç Žå£çãªããã°ã©ã ããå±éãããããã«ããã³ãããã¯ãå¿ èŠãªã®ã§ããããïŒ(Peter Koenig, March 2020)27
ID2020ã¯ãäžç統治ããããžã§ã¯ãã®äžéšã§ããããããé©çšãããã°ãäžéšã®ã¢ããªã¹ããã¯ã¯ãã³æ¥çš®ïŒãã€ã¯ããããã®åã蟌ã¿ïŒãéããŠäžçäžã®æ°åå人ã®å人æ
å ±ãå
å«ããäžçèŠå¯åœå®¶ãšè¡šçŸãããããªèŒªéãå±éãããããšã«ãªãã
ããŒãããã»ããŒãã³å士ïŒããã¢ã»ããªãŒãã³ããåŒçšïŒã«ããã°ããããã¯ã¯ã¯ãã³ã§ã¯ãªããã
ãããã¯ã¯ã¯ãã³ã§ã¯ãªã......ã¯ã¯ãã³ãšããèšèã䜿ã£ãŠãå ¬è¡è¡çäžã®å 眪笊ãšããŠãã£ãã䜿ããã®ã ......ãããã¯ãèèªå 垯ã«å ãŸããmRNAã现èã«éã蟌ããã®ã ãããã¯ã人éã®çްèãåºæ¿ããŠç åäœãäœãåºãããã«èšèšãããå»çæ©åšã§ãããããã¯ã¯ã¯ãã³ã§ã¯ãããŸãã ã¯ã¯ãã³ã¯ãå ¬è¡è¡çæ³ãCDCãFDAã®åºæºã«ãããæ³çã«å®çŸ©ãããçšèªã§ãããã¯ã¯ãã³ã¯ç¹ã«ããããåãã人ã®å ç«ãåºæ¿ããããã«ææã黿¢ããªããã°ãªããªãã®ã§ãã28
COVID-19ã¯ã¯ãã³ã«ããé ããå·å®³ïŒåŸ®å°ãªè¡æ
ã¯ã¯ãã³æ¥çš®ãåãã人ã®å€ãã¯ããã®å·å®³ã«ããã«ã¯æ°ã¥ããªãã ãããå€ãã®å ŽåãåŸè ã®ãæå®³äºè±¡ãã¯èŠåããã€ãããèšé²ã«ãæ®ããªãã倧ããªè¡æ ã¯ãšããã
108
ã«ããã®ãã£ãŒã«ãºã»ãããã§å士ã«ããéèŠãªç ç©¶ã¯ãmRNAã¯ã¯ãã³ãã埮å°ãªè¡æ ããçæããããšã瀺åããŠããŸãã
ãç§ãã¡ãè³ã«ãããã¡ãã£ã¢ãéåžžã«çšã ãšäž»åŒµããè¡æ ã¯ãè³åäžã®åå ãšãªã倧ããªè¡æ ã§ãCTã¹ãã£ã³ãMRIãªã©ã«æ ãåºããããã®ã§ãã
ç§ãèšã£ãŠããè¡æ ã¯åŸ®çްãªãã®ã§ãå°ããããŠã©ã®ã¹ãã£ã³ã§ãèŠã€ããããšãã§ããŸããããããã£ãŠãDãã€ããŒæ€æ»ã§ããçºèŠã§ããªãã®ã§ãã
ãããã®äººã ã¯ããããã®åŸ®å°ãªè¡æ ãããããšããç¥ããªãã®ã§ããæãå¿é ãªã®ã¯ãè³ãèé«ãå¿èãèºãªã©ãäœã®äžã«ã¯åçã§ããªãéšåãããããšã§ãããããã®çµç¹ãè¡æ ã«ãã£ãŠæå·ãåãããšãæ°žä¹ çãªæå·ãåããããšã«ãªãã®ã§ãã
ããã®æ³šå°ã¯å€§ããªãã¡ãŒãžãäžããŠãããææªã®äºæ ã¯ããããã§ããã29ã
ããŒã©ã»ãªã³ã»ã¿ã€ã©ãŒã»ãã³ããœã³ãšã®ã€ã³ã¿ãã¥ãŒã¯ãã¡ãïŒRumbleãã£ã³ãã«ã§ãèŠèŽå¯èœïŒ
ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ç¶ã®äžèº«ã¯åãã£ãŠããã®ã ãããïŒ
ã¯ã¯ãã³ã«é¢é£ããæ»å·ã®åå ã¯ãä¿å¥åœå±ã«ãã£ãŠå¯ŸåŠãããŠããŸããã
ã¯ã¯ãã³ç¶ã®äžã«ã¯äœãå ¥ã£ãŠããã®ã§ããããïŒåœã®ä¿å¥åœå±ã¯ãæ€æ»çµæãå ¬è¡šããŠããŸãããã¯ã¯ãã³ç¶ã®ãããã®å®éšå®€æ€æ»ãè¡ããããã©ããã«ã€ããŠã¯äžæã§ããã
以äžã¯ãç¬ç«ããã©ã»ãã³ã¿ã»ã³ã«ã ãã¹ãã€ã³ããŒã ã«ãã£ãŠè¡ãããåæãšå®éšå®€ç ç©¶ã®ã¬ãã¥ãŒã§ãã
é žåã°ã©ãã§ã³ã»ããç²å
ã¹ãã€ã³ã®La Quinta ColumnaresearchããŒã ãè¡ã£ãã©ã詊éšã«ãããšããã¡ã€ã¶ãŒç€Ÿã®mRNAã¯ã¯ãã³ã®ãã€ã¢ã«ããé žåã°ã©ãã§ã³ã»ããç²åãæ€åºãããŸãã30ã
109
圌ãã®ç ç©¶ã®äºåçãªçµæïŒé»åé¡åŸ®é¡ãšåå æ³ã«ããåæïŒã¯ãåºç¯å²ã«åãã§ãããé žåã°ã©ãã§ã³ã¯ãè¡æ ãè¡æ¶²ååºãèªçºããæ¯çŽ ã§ããããŸããå ç«ç³»ã«ã圱é¿ãäžãããèºã«èç©ãããé žåã°ã©ãã§ã³ã¯ã壿» çãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ã©ã»ãã³ã¿ã»ã³ã©ã ãã®ãªã«ã«ãã»ãã«ã¬ãã»ãã«ãã£ã³ã®ã€ã³ã¿ãã¥ãŒã¯ãã¡ãã
ã¹ãã€ã³ã®ç ç©¶çµæã¯ããŸã ååã«ç¢ºèªãããŠããŸããããèšé²ãããã¯ã¯ãã³é¢é£ã®æ»äº¡ããæå®³äºè±¡ãã¯ãCOVIDã¯ã¯ãã³ãã€ã¢ã«ã«å«ãŸããé
žåã°ã©ãã§ã³ããç²åã®çµæã§ããå¯èœæ§ã瀺åããŠããŸãã
åæ§ã«ãçŸåšåœæ°ã«ã¯ã¯ãã³ãæ¥çš®ããŠããåœé£å ç193ã«åœã®åœå®¶ä¿å¥åœå±ã«å¯Ÿããã¯ã¯ãã³ç¶ã®ç¬èªã®èª¿æ»ãšåæãè¡ãããèŠè«ããŸãããããŠãããé
žåã°ã©ãã§ã³ãæ€åºãããå Žåã«ã¯ãã¯ã¯ãã³æ¥çš®ããã°ã©ã ãçŽã¡ã«äžæ¢ãã¹ãã§ããã
ãæ°Žæ§æžæ¿æ¶²äžã®é
žåã°ã©ãã§ã³ã®æ€åº, å
åŠããã³é»åé¡åŸ®é¡ã«ãã芳å¯çç ç©¶ããšé¡ãã圌ãã®å ±åæžã®æŠèŠãã芧ãã ãããç ç©¶ã®å
šæãèªãïŒè±èªïŒ31
ãŸãããã§ã€ã¹ãã¹ã¯ã«ãé
žåã°ã©ãã§ã³ã®ããç²åãå«ãŸããŠããããšãéèŠã§ããïŒååœã®ä¿å¥åœå±ãèªããŠããïŒ32ã
mRNA ã¯ã¯ãã³ã®é»ç£æ³¢ç¹æ§
ã¯ã¯ãã³æ¥çš®ãåãã人ã
ã«æ€åºãããé»ç£æ³¢ã®åœ±é¿ã¯ãäœãåŒãéã«ãªã£ãŠããã®ã ãããïŒ
ãããã®åœ±é¿ã¯ãã¯ã¯ãã³æ¥çš®è
ãå«ãç¬ç«ããæ
å ±æºã«ãã£ãŠååã«ææžåãã確èªãããŠãããåœã®ä¿å¥åœå±ã¯ããã®èª¬æãããããšãã§ããªãã§ããã
ã¯ã¯ãã³èŠæã®ããã®æ¬§å·ãã©ãŒã©ã ã宿œããç ç©¶ãåç
§ã
110
以äžã¯ãã©ã»ãã³ã¿ã»ã³ã«ã ãã®ã¹ãã€ã³èªç ç©¶ããŒã ãå¶äœãã2ã€ã®ãããªã§ããäžã®ãããªãèŠãã«ã¯ããããã¯ãªãã¯ããŠãã ããã
äžã®ãããªãèŠãã«ã¯ããããã¯ãªãã¯ããŠãã ããã
ããã°ã»ãã¡ãŒã ãã¡ã€ã¶ãŒã®äžçç¬å ã«è¿ãç¶æ
äœååãã«ãšããéãããã£ãŠãããããã¯äžçå²äžæå€§ãã€æãå±éºã§é«äŸ¡ãªã¯ã¯ãã³èšç»ã§ãããäžçäžã®çšéã§è³ãããäºå®ã§ããããã倿°ã®åœã®å ¬çåµåã«æãããªè² æ ã匷ããŠããã
ãã®ã¯ã¯ãã³èšç»ã«ã¯ã以äžã®ãããªå埩çãªmRNAã®æ¥çš®ãããªããã¿ã€ã ã©ã€ã³ããå«ãŸããŠããã
111
æ°å¹ŽåŸ äžèšã®ããã«ãããã¯äžçäžã®æ»äº¡çãšçœ¹æ£çã«å£æ»
çãªåœ±é¿ãäžããã ããã
屿©ã«çããŠããã®ã¯ããã¡ã€ã¶ãŒç€Ÿãçé ãšãã倧æè£œè¬äŒç€Ÿã®æ°ååãã«ã®ããã°ãããŒäœæŠã§ããã
ãã¡ã€ã¶ãŒã»ãã€ãªããã¯ïŒã¢ããç€ŸãšææºïŒã¯ãã¢ã¹ãã©ãŒãã«ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ïŒJ&JïŒãå«ãäž»èŠãªç«¶äºçžæãæŒãã®ããäžççã«ïŒã»ãŒç¬å çã«ïŒãã®å°äœãåºããããšããŠãããšããã§ããã
ãã¡ã€ã¶ãŒç€Ÿã¯ãèªç€Ÿã®mRNAã¯ã¯ãã³ãæ¯æããããæ¿æ²»å®¶ã«å§åããããŠããããã®æ¿æ²»çãããŒæŽ»åã¯ãããã°ãã¡ãŒãã®ç«¶åä»ç€Ÿã«ãåããããŠãããThe Bureau of Investigative Journalismã®ã¬ããŒãã«ããã°ãã
ç¡åã®åœã®äº€æžã«ç«ã¡äŒã£ãããé¢ä¿è ã¯ããã¡ã€ã¶ãŒã®èŠæ±ãããã€ã¬ãã«ãªãããããšè¡šçŸããæåœã¯ã¯ãã³ãå ¥æããããã«æ¿åºãã身代éãèŠæ±ãããŠãããããã«æãããšè¿°ã¹ã34ã
ç®èãªããšã«ãEUã§ã¯ããã¡ã€ã¶ãŒ-ãã€ãªããã¯ã¯ã¯ãã³ã«é¢é£ããæ»å·è
ã倧å¹
ã«å€ãã£ãã«ãããããããå ±åãããæ»å·è
ã¯ã欧å·å§å¡äŒãã¢ã¹ãã©ãŒãã«ãšã®å¥ç޿޿°ãåãæ¶ãããã«å©çšãããã
2021幎4æãEUå§å¡äŒã¯ãã¢ã¹ãã©ãŒãã«ãšJ&Jã®ã¯ã¯ãã³å¥çŽãæéåãã§çµäºããããããšã確èªãããããã¡ã€ã¶ãŒã®æ³šå°ãåªå
ããã ãããšã«ãªããŸããã¢ã¹ãã©ãŒãã«ã§ã®ãã©ããŒã¢ããæ¥çš®ãæ°ã«ããããšãªããä¿å¥åœå±ã¯2åç®ã3åç®ã®æ¥çš®ããã¡ã€ã¶ãŒãã¢ãã«ãã§åããããæç€ºããŠããïŒããã«ãã£ãŠãç®ã«èŠããŠå»çèŠç¯ã«éåããŠããã®ã§ããïŒã
ãã¡ã€ã¶ãŒãšãã€ãªããã¯ç€Ÿã¯ãç«¶åä»ç€Ÿãæé€ããããã«ãã¯ã¯ãã³ç¶ã®äŸ¡æ Œãé«éš°ãããããã¡ã€ã¶ãŒã¯æåéããEUãšç±³åœã®äž¡æ¹ã®åžå Žã远ãè©°ããŠããã
ç±³åœåžæ³çã«ç¯çœªæŽã®ããäŒç€Ÿã«ãã£ãŠãã»ãŒäžççãªã¯ã¯ãã³ç¬å ãè¡ãããããšããŠããã®ã§ããã
ãã¡ã€ã¶ãŒç€Ÿã®ç§å¯å ±åæž
æ å ±å ¬éïŒFOIïŒæç¶ãã®äžç°ãšããŠå ¬éãããæ¥µç§ãã¡ã€ã¶ãŒã¬ããŒãã¯ã2020幎12æã®ã¯ã¯ãã³ãããžã§ã¯ãéå§ãã2021幎2ææ«ãŸã§ã®ãã€ãŸãéåžžã«çãæéïŒãããã2ã¶æåïŒã«ãã¡ã€ã¶ãŒãèšé²ããæ»äº¡ãšæå®³äºè±¡ã«é¢ããããŒã¿ãæäŸãããã®ã§ããã
ã2021幎2æãŸã§ã«ããã¡ã€ã¶ãŒã¯ãã§ã«ãã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ãããããšãããæ»äº¡ã®1,200件以äžã®å ±åãåãã270ä»¶ã®åŠåš ã®ãã¡23ä»¶ã®èªç¶æµç£ã2,000件以äžã®å¿é害ã®å ±åãªã©ãæ°äžä»¶ã®æå®³äºè±¡ã®å ±åãåããã 35ã
ãã¡ã€ã¶ãŒç€Ÿã®ãã€ãªããã¯ã¯ã¯ãã³ã¯ã2020 幎 12 æ 11 æ¥ã®ç·æ¥äœ¿çšèš±å¯ä»äžåŸã12 æ 14 æ¥ã«ç±³åœã§çºå£²ãããã
å ±åæžäœæè ã¯ãŒã«ãã¯ã€ãã»ãŒãã㣠ãã¡ã€ã¶ãŒ
ãã®ææžã«å«ãŸããæ å ±ã¯ãæææš©ããã³æ©å¯æ å ±ã§ãããã¡ã€ã¶ãŒããã®é¢é£äŒç€Ÿãã©ã€ã»ã³ã·ãŒããŸãã¯èŠå¶åœå±ä»¥å€ã§ã®ãã®æ å ±ã®é瀺ãè€è£œãé åžããŸãã¯ãã®ä»ã®æ®åã¯åºãçŠããããŠããŸããå¥éåæãããå Žåãé€ã
112
ãããã®è³æãåé ãŸãã¯æ€èšããããšã«ãããããªãã¯ãããã®æ å ±ãç§å¯ã«ããä»è ã«é瀺ããïŒé©çšãããæ³åŸã«ãã£ãŠèŠæ±ãããå Žåãé€ãïŒãç¡èš±å¯ã®ç®çã®ããã«äœ¿çšããªãããšã«åæãããã®ãšããŸãã36ã
ç®èãªããšã«ããã®ãã€ã³ãµã€ããŒã»ã¬ããŒããã§æããã«ãããããŒã¿ã¯ãååœæ¿åºãšWHOã売ã蟌ãã§ããå
¬åŒã®ã¯ã¯ãã³ç©èªãåŠå®ãããã®ã ããŸããmRNAãã¯ã¯ãã³ããããããç Žå£çãªçµæãæããã«ããå€ãã®å»åž«ãç§åŠè
ã®åæãè£ä»ããŠããã
ãã¡ã€ã¶ãŒã®ãæ©å¯ãå ±åæžã«å«ãŸããŠããã®ã¯ããã¯ã¯ãã³ããæ»äº¡çã眹æ£çã«äžãã圱é¿ã«ã€ããŠã®è©³çްãªèšŒæ ã§ããããã®ã銬ã®å£ãããçºããããããŒã¿ã¯ãããã°ã»ãã¡ãŒããæ¿åºãWHOãã¡ãã£ã¢ã«å¯Ÿããæ³çæç¶ããšåæ§ã«ã察決ããããã«äœ¿çšããããšãã§ããã®ã§ãã
è£å€ã§ã¯ããã®å€§æè£œè¬äŒç€Ÿã®æ©å¯å ±åæžã«å«ãŸãã蚌æ ïŒEUãè±åœãç±³åœã®ååœåœå±ããŸãšããæ»äº¡ãæå®³äºè±¡ã«é¢ããããŒã¿ãšåãããŠïŒã¯åè«ã®äœå°ããããŸããã

ãã®ããŒã¿ã¯ãå ±åããèšé²ãããçäŸã«åºã¥ããŠãããã¯ã¯ãã³ã«é¢é£ããæ»äº¡ãæå®³äºè±¡ã®å®éã®æ°ã®ããäžéšãæ§æããŠããããšã念é ã«çœ®ããŠããã
ããã¯ãã¡ã€ã¶ãŒç€Ÿã®äºå®äžã®é倱ã§ããïŒãããããã¯æ®ºäººã¯ã¯ãã³ã§ãïŒã
ãã¡ã€ã¶ãŒç€Ÿã¯ãèªç€Ÿãäžççã«è²©å£²ããŠããmRNAã¯ã¯ãã³ãæ»äº¡çã眹æ£çã®æ³¢åãããããããšãååã«èªèããŠããã®ã§ãããããã¯ããã°ã»ãã¡ãŒãã®äººé¡ã«å¯Ÿããç¯çœªã«çããã
ãã¡ã€ã¶ãŒã¯åœåããæ®ºäººã¯ã¯ãã³ã§ããããšãç¥ã£ãŠããã®ã ã37ã
37 ããã¯ãŸããããã°ãã¡ãŒãã«è
ããããè³è³ãããã£ãŠããäžçäžã®è
æããåœå®¶æ¿åºã®çœªæ»
ãŒãã§ãããåé眪ã§ãããã37 ãŸããããã°ãã¡ãŒãã«è
ããããè³è³ãèŽãããŠããäžçäžã®è
æããååœæ¿åºã®çœªæ»
ãŒãã§ãããã
ãã®èšäºãæžããŠããæç¹ã§ã¯ãååœæ¿åºã¯æ®ºäººã¯ã¯ãã³ã®æ€åãæ±ããããšã¯ããŠããªãã
人ã
ã¯ããã®ã¯ã¯ãã³ã¯åœãæãããã®ãã®ã ãšèããããŠããã
ãæ®ºãããšã¯ããžãã¹ã«ãšã£ãŠè¯ãããšã ããšãããã¯äžçäžã§æ°ååãã«èŠæš¡ã®äºæ¥ã§ããããããŠãã¡ã€ã¶ãŒã¯ãã§ã« ç±³åœåžæ³çãããè©æ¬ºçããŒã±ãã£ã³ã°ãã®å®¹çã§2009幎ã«ç¯çœªæŽãããã
çµã³ã®èšè ïŒã¯ã¯ãã³ã»ãã¹ããŒã
ãã¡ã€ã¶ãŒç€Ÿã®å ±åæžã«åŒçšãããŠããããŒã¿ã ãã§ãªããå
¬åŒãªæ
å ±æºããã®ããŒã¿ããCOVID-19ãã¯ã¯ãã³ããã¯ã¯ãã³é¢é£ã®æ»äº¡çããã³çœ¹æ£çã®äžæåŸåããããããããšãæç¢ºã«è£ä»ããŠããã
ãã£ãŒã«ãºã»ãããã§å士ã®ç ç©¶ãã¹ãã€ã³ã®ç ç©¶ããŒã ïŒLa Quinta ColumnaïŒããã¡ã€ã¶ãŒç€Ÿã®æ©å¯å ±åæžããã®ä»å€ãã®ç ç©¶ã«ãããmRNAãã¯ã¯ãã³ãããæ®ºäººã¯ã¯ãã³ãã§ããããšãæç¢ºã«ç¢ºèªãããŠããã®ã§ãã
ã§ã¯ããªãæ¿åºã¯äºé²æ¥çš®ãåããããã«å§åããããŠããã®ã ãããïŒ
113
äžçäžã®åœå®¶å éŠãšæ¿åºéŠè³ã¯ã匷åãªéèå©çå£äœããå§åãåããè³è³ãåãåããå ±è¬ãããããŠïŒãŸãã¯è ãããŠãCOVIDã¯ã¯ãã³ã»ã³ã³ã»ã³ãµã¹ãåãå ¥ããŠããã®ã ã
ã¯ã¯ãã³ã»ãã¹ããŒãã¯ãããžã¿ã«å°å¶æ¿æ²»ãšäººå£æžå°ãžã®ç§»è¡ãæ§æããæçµææ®µã§ããïŒç¬¬XIIIç« ãšç¬¬XIVç« ãåç
§ïŒã
ãšã³ãããŒã
1. Doctors for COVID Ethicsã2022幎6æ22æ¥ãJ'Accuse! éºäŒåã«åºã¥ããã¯ã¯ãã³ããäººãæ®ºããŠãããhttps://www.globalresearch.ca/jaccuse-governments-worldwide-lying-you-people-populations-they-purportedly-serve/5750650
2. The gency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services, 2010. Electronic Support for Public Health-Vaccine Adverse Event Reporting System (ESP:VAERS). https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf
3. ãã£ããã³ãã¬ããã©ã€ã2021 幎 8 æ 26 æ¥ãè€æ°ã®åã³ãã19ã¯ã¯ãã³å€§çµ±é ãææ®ºãããäž»æµã¡ãã£ã¢ã¯æ²é»ãCOVID-19ãžã£ãããå¶ç¶ããããæ°æ¥åŸã«ããŒã«ã¢ãŠãhttps://www.globalresearch.ca/several-anti-covid-19-vaccine-presidents-assassinated-mainstream-media-silent-covid-19-jabs-coincidentally-rolled-out-just-days-later/5754040
4. FDAã2022幎1æ3æ¥ãComirnaty and Pfizer-BioNTech COVID-19 Vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines#additional
5. US Department of Justice, September 2, 2009. åžæ³çãå²äžæå€§ã®å»çè©æ¬ºã«é¢ããåè§£ãçºè¡šãPfizer to Pay 23 Billion for Fraudulent Marketing. https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history
6. åäž
7. åäž
8. KHN ã¢ãŒãã³ã°ããªãŒãã£ã³ã°ã2020 幎 11 æ 6 æ¥ã4 Drug Companies Agree To $26 Billion Opioid Settlement. https://khn.org/morning-breakout/4-drug-companies-agree-to-26-billion-opioid-settlement/ïŒè±èªïŒã
9. F. William Engdahlã2021幎10æ17æ¥ããã¡ã€ã¶ãŒã®ã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã«ã€ããŠèªãããŠããªãããšã"人éã®ã¢ã«ã¢ãã"ïŒ
https://www.globalresearch.ca/what-not-said-pfizer-coronavirus-vaccine/5729461
10. åäž.
11. åäž
12. ãã¡ããã芧ãã ããïŒhttps://threadreaderapp.com/thread/1302725167588798467/error
13. ãŠã©ã«ãã¬ã³ã°ã»ãŠã©ãã«ã°å士ãšãã€ã±ã«ã»ã€ã§ãŒãã³å士ã2020幎12æ1æ¥ãPetition/Motion For Administrative/Regulatory Action Regarding Confirmation Of Efficacy End Points And Use Of Data In Connection With The Following Clinical Trial(S). https://2020news.de/wp-content/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf
14. GSKã2019幎8æ1æ¥ãGSKããã¡ã€ã¶ãŒãšã®ååŒãå®äºããäžçããªãŒãããæ°ããã³ã³ã·ã¥ãŒããŒã»ãã«ã¹ã±ã¢ã»ãžã§ã€ã³ãã»ãã³ãã£ãŒãèšç« https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/
15. åäž.
16. Center for Health Security, n.d. The Event 201 scenario. https://www.centerforhealthsecurity.org/our-work/exercises/event201/scenario.html
17. ãã¬ã³ã»ãã©ã³ãºãŠã§ã«ã2020 幎 2 æ 6 æ¥ãIn effort to develop coronavirus vaccine, outbreak expert sees 'hardest problem' of his career. https://www.statnews.com/2020/02/06/cepi-coronavirus-vaccine-development/
18. GSKã2020 幎 2 æ 3 æ¥ãCEPI ãš GSK ã¯ã2019-nCoV ãŠã€ã«ã¹ã«å¯Ÿããã¯ã¯ãã³éçºã®ããã®äžççãªåãçµã¿ã匷åããããã®ååãçºè¡šãhttps://cepi.net/news_cepi/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/
114
19. ãã¬ã³ã»ãã©ã³ãºãŠã§ã«ã2020幎2æ6æ¥ãã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®éçºåªåã®äžã§ãã¢ãŠããã¬ã€ã¯å°éå®¶ã¯èªåã®ãã£ãªã¢ã®äžã§ãæãé£ããåé¡ããèŠãŠãã https://www.statnews.com/2020/02/06/cepi-coronavirus-vaccine-development/
20. Ibid.
21. ãžã§ã»ãã»ããŒã³ã©ã2021幎7æ11æ¥ãNIAIDãModernaã¯2019幎12æã«COVIDã¯ã¯ãã³åè£ãæã£ãŠããhttps://www.globalresearch.ca/niaid-moderna-covid-vaccine-candidate-december-2019/5749713
22. åœç«è¡çç ç©¶æã2020 幎 3 æ 16 æ¥ãCOVID-19ã®æ²»éšçšã¯ã¯ãã³ã®NIHèšåºè©Šéšéå§ã
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
23. ã¢ãã«ã瀟ã2020 幎ãCOVID-19ã«å¯Ÿããæœåšçãªã¯ã¯ãã³ã«é¢ããModernaã®åãçµã¿ã
https://www.sec.gov/Archives/edgar/data/1682852/000119312520074867/d884510dex991.htm
24. ããŒã¯ã»ãã©ãŽããŽã£ããã2020 幎 2 æ 24 æ¥ãModerna ã®æ°ãã COVID-19 ã¯ã¯ãã³ããã詊éšã®æºåå®äºãæ ªäŸ¡ã¯ 15%äžæ https://www.fool.com/investing/2020/02/24/modernas-new-covid-19-vaccine-ready-for-human-tria.aspx
25. APéä¿¡ã2020幎3æ16æ¥ãã³ãããŠã€ã«ã¹ã»ã¯ã¯ãã³ã®è©Šéšéå§ãã·ã¢ãã«ã®ãã©ã³ãã£ã¢ã1åç®ã®æ¥çš®ãåãã https://www.q13fox.com/news/coronavirus-vaccine-test-opens-as-volunteer-in-seattle-gets-1st-shot
26. ããŒã¿ãŒã»ã±ãŒãããã2020 幎 3 æ 12 æ¥ãã³ãããŠã€ã«ã¹ã¯ã¯ãã³ãæ¬åœã®å±éºã¯ãã¢ãžã§ã³ãID2020ããããžã¿ã«ã»ã¢ã€ãã³ãã£ãã£ãã®ããã®ãã©ãããã©ãŒã ãšããŠã®ã¯ã¯ãã³æ¥çš®https://www.globalresearch.ca/coronavirus-causes-effects-real-danger-agenda-id2020/5706153
27. Ibid.
28. ããã¢ã»ããªãŒãã³ã2021幎11æ13æ¥ãmRNA COVID Vaccine Is Not a Vaccine. https://www.globalresearch.ca/coronavirus-causes-effects-real-danger-agenda-id2020/5706153
29. ãã©ã€ã¢ã³ã»ã·ã«ããŽã£ãŒã2021 幎 7 æ 14 æ¥ãã«ããã®å»åž«ïŒCOVIDã®ã¯ã¯ãã³ãæ¥çš®ããåœŒã®æ£è
ã®62ïŒ
ãæ°žä¹
çãªå¿èã®ãã¡ãŒãžãåããŠããã"埮å°ãªè¡æ "ãhttps://www.globalresearch.ca/canadian-doctor-62-patients-vaccinated-covid-have-permanent-heart-damage/5750198
30. ãªã«ã«ãã»ãã«ã¬ãããã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2021幎7æ17æ¥ããã㪠ã°ã©ãã§ã³ã»ãªããµã€ããCOVID-19 mRNAã¯ã¯ãã³ã®ãã€ã¢ã«ã«å«ãŸããæ¯æ§ç©è³ªïŒ https://www.globalresearch.ca/video-graphene-oxide-a-toxic-substance-in-the-vial-of-the-covid-19-mrna-vaccine/5750340
31. Prof. Dr. Pablo Campra Madrid, June 28, 2021. æ°Žæ§æžæ¿æ¶²äžã®é
žåã°ã©ãã§ã³æ€åºãå
åŠããã³é»åé¡åŸ®é¡ã«ããã芳å¯çç ç©¶ https://www.docdroid.net/Ov1M99x/official-interim-report-in-english-university-of-almeria-pdf
32. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2021幎7æ14æ¥ããã§ã€ã¹ãã¹ã¯ã«ã¯æ¯ç©ã§ããã°ã©ãã§ã³ãå«ãŸããŠãã https:// https://www.globalresearch.ca/face-masks-contain-graphene-a-poisonous-substance/5749855
33. Mamer and Amar Goudjil, January 23, 2022. ã¯ã¯ãã³æ¥çš®è
ã®é»ç£æ°åŠã®ç ç©¶ https://www.globalresearch.ca/study-electromagnetism-vaccinated-persons-luxembourg/5749516
34. ããã¬ã³ã»ãã€ãŽã£ã¹ãããµã»ãã«ããŒãä»ã2021 幎 2 æ 23 æ¥ã身代éãèŠæ±ãããããhttps://www.thebureauinvestigates.com/stories/2021-02-23/held-to-ransom-pfizer-demands-governments-gamble-with-state-assets-to-secure-vaccine-deal
35. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022幎8æ13æ¥ããã¡ã€ã¶ãŒã®ã¯ã¯ãã³ããŒã¿ã«é¢ããçåŒŸææžãã³ããhttps://www.globalresearch.ca/bombshell-document-dump-pfizer-vaccine-data/5763397
36. ãã¡ã€ã¶ãŒã2021幎ã2021幎2æ28æ¥ãŸã§ã«åé ããPF-07302048ïŒBNT162B2ïŒã®æ¿èªåŸæå®³äºè±¡å ±åã®çޝç©åæ https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
37. åäžã
115
-------------------- 第9ç« --------------------
2009幎H1N1è±ã€ã³ãã«ãšã³ã¶ã®ãã³ãããã¯
ããã¯äºè¡æŒç¿ã ã£ãã®ãïŒ
ã¯ããã«
2009幎ã®H1N1 "ãã³ããã㯠"ã«ã€ããŠããªãã倧統é ã®ç§åŠæè¡è«®åå§å¡äŒãH1N1ãã³ãããã¯ã1918幎ã®ã¹ãã€ã³é¢šéªã®ãã³ãããã¯ãšæ¯èŒããåŸè ã®æ¹ãããèŽåœçã ãšåœæ°ã«å®å¿ãããããšãæãåºããŠã»ããïŒCBC: Get get swine flu vaccine ready: U.S. Department of Science and TechnologyïŒè©³çްã¯ãMichel Chossudovsky, August 2009 Study on H1N1 Pandemic.1ïŒãã·ã§ã«ã»ãã§ã¹ããã¹ããŒãæ°åã€ã³ãã«ãšã³ã¶ã«é¢ãã2009幎8æã®ç ç©¶ïŒãåç §ã®ããšã
WHOã®ããŒã¬ã¬ããã»ãã£ã³äºåå±é·ã¯ãäžå®å šã§ä¹ããããŒã¿ã«åºã¥ãããä»åŸ2幎éã§20å人ãã®äººã ãææããå¯èœæ§ããããããã¯äžç人å£ã®ã»ãŒ3åã®1ã«çžåœãã ããšåšä¿¡ããããŠäºèšããã®ã§ãã(2009幎7æã欧米ã¡ãã£ã¢ãå ±ããäžçä¿å¥æ©é¢)
äžççãªå ¬è¡è¡çäžã®ç·æ¥äºæ ããåäŸã®ãªãèŠæš¡ã§å±éãããŠããã®ã§ãããäžçä¿å¥æ©é¢ïŒWHOïŒãæ³å®ãã49åååã®H1N1è±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã
ãªãã倧統é ã®ç§åŠæè¡è«®åå§å¡äŒã®å ±åæžã¯ããH1N1ãã³ãããã¯ãç±³åœã«ãšã£ãŠãæ·±å»ãªå¥åº·äžã®è åšããšã¿ãªãã1918幎ã®ã¹ãã€ã³é¢šéªã®å€§æµè¡ã»ã©ã§ã¯ãªããã1976幎ã®è±ã€ã³ãã«ãšã³ã¶çºçããã¯æ·±å»ã§ãã ããšè¿°ã¹ãŠããã
ãæ°åH1N1ãã³ãããã¯æ ªãããããŸã§ã®ã€ã³ãã«ãšã³ã¶ã®è åšãããèŽæ»çãé«ããšããããšã§ã¯ãªããå ç«ãæã£ãŠãã人ãå°ãªããããéåžžãããå€ãã®äººã«ææããå¯èœæ§ãé«ããšããããšã§ããã (è±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæºåããïŒç±³åœã¢ããã€ã¶ãŒ)

WHOã®ããŒã¬ã¬ããã»ãã£ã³äºåå±é·ãæ¯æŽããããã°ã»ãã¡ãŒãã«ãšã£ãŠãæ°åååã®å€§åœããã ã£ãã®ã§ããã
ãã®åŸã®å£°æã§ããã£ã³åå£«ã¯æ¬¡ã®ããã«ç¢ºèªããã
ãã¯ã¯ãã³ã¡ãŒã«ãŒã¯ãæè¯ã®ã·ããªãªã®å Žåã幎é49åã®ãã³ãããã¯ã€ã³ãã«ãšã³ã¶äºé²æ¥çš®ãè¡ãããšãã§ããããããŒã¬ã¬ããã»ãã£ã³äžçä¿å¥æ©é¢ïŒWHOïŒäºåå±é·ããã€ã¿ãŒéä¿¡ã2009幎7æ21æ¥ããïŒ2
ãè±ã€ã³ãã«ãšã³ã¶ã¯ä»åŸ2幎éã§ã¢ã¡ãªã«äººã®æå€§40ïŒ ãçºçããã¯ã¯ãã³ãã£ã³ããŒã³ãªã©ãæåããªããã°ãæ°åäžäººãã®æ»è ãåºãå¯èœæ§ãããã (ãªããæ¿æš©ã®å ¬åŒå£°æãMSNBCãã¥ãŒã¹ã2009幎7æ24æ¥ïŒ.3
ããžã£ãŽã¥ ããŒã«ã»ãã¡ãŒã¬ãœã³
2009幎4æãH1N1屿©ã®ãŸãã«ãã®æããã³ãã³å€§åŠã€ã³ããªã¢ã«ã«ã¬ããžã®ããŒã«ã»ãã¡ãŒã¬ãœã³ææã¯ããã«ã»ã²ã€ããšWHOã«å©èšãäžããŠããã
116
ããã®ãŠã€ã«ã¹ã«å¯ŸããèŠæãã¬ãã«4ã«åŒãäžããããšã決å®ããäžçä¿å¥æ©é¢ïŒWHOïŒã®ã¿ã¹ã¯ãã©ãŒã¹ã®ã¡ã³ããŒã§ããããŒã«ã»ãã¡ãŒã¬ãœã³ææã¯ãããããããæ¬åœã«ãã³ãããã¯ã«ãªã£ãå Žåãä»åŸ6ã¶æã§äººå£ã®30%ãã40%ãç æ°ã«ãªããšäºæ³ãããããšè¿°ã¹ã4ïŒåŒ·èª¿è¡šç€ºïŒã
ããã¯ãã³ãããŠã€ã«ã¹ã®ããã¯ããŠã³ã¢ãã«ïŒ2020幎3æ11æ¥ã«çºå£²ïŒãèšèšããããŒã«ã»ãã¡ãŒã¬ãœã³ïŒã²ã€ã財å£ã®å¯å€§ãªæ¯æŽãåããŠããïŒãšåã人ç©ã§ãã£ããæãèµ·ããã°ããã®2020幎3æã®æ°åŠã¢ãã«ã¯ãè±åœã§60äžäººãæ»äº¡ãããšãããäºæž¬ãã«åºã¥ãããã®ã ã£ãã
20å人ã«åœ±é¿ãäžããH1N1ãã³ãããã¯ã¯ååšããªãã£ãã®ã§ãã
äœçŸäžååãã®è±ã€ã³ãã«ãšã³ã¶ã»ã¯ã¯ãã³ããååœæ¿åºã«ãã£ãŠããã°ã»ãã¡ãŒãã«çºæ³šãããŠããã®ã§ãã
äœçŸäžãã®ã¯ã¯ãã³ã¯ãã®åŸå»æ£ããã倧æè£œè¬äŒç€Ÿã«ãšã£ãŠã¯å€§åœãããååœæ¿åºã«ãšã£ãŠã¯æ¯åºã®å±æ©ãšãªã£ãã
ãã®æ°ååãã«ã®è©æ¬ºã®èåŸã«èª°ãããã®ãã調æ»ã¯è¡ãããªãã£ããäœäººãã®è©è«å®¶ã¯ãH1N1ãã³ãããã¯ã¯ãåœç©ãã ãšèšã£ãŠããã
人暩ã®çªäººã§ããæ¬§å·è©è°äŒè°äŒïŒPACEïŒã¯ãWHOããã³ãããã¯ã宣èšããåæ©ã«ã€ããŠå
¬ã«èª¿æ»ããŠãããå®éããã®æåãªä¿å¥å§å¡äŒã®å§å¡é·ã§ããç«åŠè
ã®ãŠã©ã«ãã¬ã³ã°ã»ãŠã©ãã«ã°æ°ã¯ããåœã®ãã³ããã㯠ãã ãä»äžç޿倧ã®å»åŠã¹ãã£ã³ãã«ã®äžã€ ããšæããã
WHOã®äžã§ãããã€ãã®ãã¥ã³ã¹ã¿ãŒã«ããWHOç«åŠå
±åã»ã³ã¿ãŒã®ãŠã«ãªããã»ããŒã«æé·ã¯ãåºæ¬çã«ãã³ãããã¯ã¯ããã§ãããšã¬ããã«ã貌ã£ãŠããããç§ãã¡ã¯ãå
¬è¡è¡çã®èгç¹ããã巚倧ãªè³æºã®é
åãã¹ïŒãããŸã§ã«180åãã«ïŒãç®æããŠããã®ã§ãããšã圌ã¯èšã£ãã
ãã®éãã§ãããããã¯åãªãé床ã®èŠæå¿ãåçŽãªèª€å€æã§ã¯ãªãããã³ãããã¯å®£èšãšããã以æ¥é³ŽããããèŠç¬ã¯ãå»åŠçãªåé¡ã§ã¯ãªããæ¿æ²»çãªåé¡ã«ãã£ãŠåæ©ã¥ããããããŸã£ããäžèª å®ãªè¡åãåæ ããŠããã®ã§ããã
è±ã€ã³ãã«ãšã³ã¶ã¯ãéåžžã®å£ç¯æ§ã€ã³ãã«ãšã³ã¶ããã¯ããã«è»œãããšã蚌æãããŠããã®ã¯çãäœå°ããªããç±³åœçŸç
察çäºé²ã»ã³ã¿ãŒã®æšèšã«ããã°ãæ»äº¡çã¯3åã®1ãã10åã®1ã§ããããã©ã³ã¹ãæ¥æ¬ãªã©ã®ä»ã®åœã®ããŒã¿ã§ã¯ãããããã¯ããã«è»œããšããããšã ã
(ãã€ã±ã«ã»ãã©ã¡ã³ãããã©ãŒãã¹ã2010幎2æ10æ¥)5
2009幎H1N1ã¯ã¯ãã³ã§åã©ããã¡ã®è³ã«ãã¡ãŒãž6
NIAIDé·å®ã®ã¢ã³ãœããŒã»ãã¡ãŠãã¯ãããã°ã»ãã¡ãŒãã代衚ããŠ2009幎ã®H1N1ã¯ã¯ãã³ãæšå¥šããŠããã
ãçŽ6000äžäººïŒãã®ã»ãšãã©ãåäŸïŒããã®ã¯ã¯ãã³ã®æ¥çš®ãåãã...ããã®åŸããã®ã¯ã¯ãã³ãGSKã®PandemrixTDããã«ã³ã¬ãã·ãŒãšã«ã¿ãã¬ãã·ãŒãåŒãèµ·ããå¯èœæ§ãããããšãæããã«ãªããŸããããã«ã³ã¬ãã·ãŒã¯ãç¡ç ãµã€ã¯ã«ã«åœ±é¿ãäžããäžåºŠã«90å以äžç ããªããªããæ¥äžã«æèã倱ã£ãŠããŸãç æ°ã§ãããã®çç¶ã¯ç²Ÿç¥æ©èœãšèšæ¶ã«ãã¡ãŒãžãäžããå¹»èŠã粟ç¥çŸæ£ãåŒãèµ·ããå¯èœæ§ããããïŒInternational Business Times, 03 February 2014)
117
ã«ããã«ãããGSK瀟
GSKã®ArepanrixTDïŒPanbremixTDãšåºçŸ©ã®é¡äŒŒåã§åç§°ãç°ãªãïŒãã«ããã§ç³è«ãããïŒãã¡ãïŒ7ã
2009幎6æ11æ¥ã«WHOã®H1N1ãã³ãããã¯ã宣èšããããGSKã¯ã«ããæ¿åºãšå¥çŽããŠãããGSKã®ã¯ã¯ãã³ãArepandrixTMãã¯ã4ã«æè¶³ããã§ã«ããã®ä¿å¥åœå±ã«çŽåãããã
ã«ããäžé¢ã«æãããGSKã®ããŒã«ã»ã«ãŒã«ã¹ç€Ÿé·ã¯ãã45ïŒ
ã®ã«ãã人ãGSKã®ã¢ã¬ãã³ããªã¯ã¹TMãæ¥çš®ããŠH1N1ãŠã€ã«ã¹ããä¿è·ããããïŒã«ããäžé¢ç€ŸäŒã»ç§åŠã»æè¡åžžä»»å§å¡äŒã2009幎10æ9æ¥ïŒãšèªæ
¢ããŠãã8ã
é²è·çã¯ãªãã£ããã«ããã§ã¯ãH1N1ã¢ã¬ãã³ãªãã¯ã¹TDã®ã¯ã¯ãã³ãæ¥çš®ããåŸã«äœèª¿ã厩ã人ãç¶åºãããã€ã®ãªã¹ãšEUã§ã¯ãGSKã®ã¯ã¯ãã³ã®è¢«å®³è
ã«ã¯ããã¡ããšè£åããªããããããã¯ãååã®éããé¡äŒŒãã¯ã¯ãã³ïŒPambremixTDïŒã§ããã
[è±åœãè±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæåããçµæãè³ã«é害ãè² ã£ãæ£è ã¯ãè±åœæ¿åºããæ°çŸäžãã³ãã®æ¯æããåããããšã«ãªã£ãã
æ¿åºã¯çŽ6000äžãã³ãã®è«æ±æžãåãåãã60人ã®è¢«å®³è ã¯ããããçŽ100äžãã³ããåãåãèŠéãã ã(International Business Timesã匷調)9
ç®èãªããšã«ãã¯ã¯ãã³ã«ããåäŸã®è³é害ã®ä»£éãæ¯æã£ãã®ã¯ãïŒGSKã§ã¯ãªãïŒè±åœæ¿åºã§ãã£ãã
ã«ããã§ã¯ãååãªèšŒæ ãããã«ãããããããè£åã¯è¡ãããªãã£ãã
ã¢ããã»ã¢ããã¥ãšããåã®å°å¥³ã®æãåºã®ããã«
GSKã®ã¯ã¯ãã³ã¯ãAmina Abuduãšããåã®å°å¥³ã殺ããŸããã
ã¯ã¯ãã³ã¯åžå Žã«åºåãããã®5æ³ã®å°å¥³ã¯äœçŸäžäººãã®ã«ãã人ã®äžäººãšããŠæ¥çš®ãåããããã®5æ¥åŸãã¢ããŒãã®å ãããã³ãã®ã€ãŒã¹ããšã³ãã«ããäžå®¶ã®å®¶ã®æµŽå®€ã§æèäžæã®ãŸãŸæšªããã£ãŠããã®ãçºèŠãããåœŒå¥³ã¯æ»ãã§ããã®ã ã
䞡芪ã®åŒè·å£«ãžã£ã¹ãã³ã»ãŽãŒã³æ°ã¯ãé£éŠæ¿åºãã«ãã人ã«äºé²æ¥çš®ãåããããã匷ãå§åããããããããæ··ä¹±ããã€ã³ãã«ãšã³ã¶ã®å£ç¯ã«ãäºé²è¬ãé©åãªãã¹ããªãã«è¿ éã«æã¡åºããããšäž»åŒµããã(ãã·ã§ãã«ã»ãã¹ãçŽ 2019 幎 11 æ)10
118

èšé²äžãGSKã¯ãã«ããã§é©çšãããArepanrixTDããè±åœããã³EUã§é©çšãããå°å
ã®è³é害ãåŒãèµ·ãããGSKã®PandemrixTMãšãé¡äŒŒãããŠããããšãèªããŸããã
PandemrixTDïŒ2009幎ïŒã¯ããç¡ç èŠéãµã€ã¯ã«ãå¶åŸ¡ããè³ã®èœåã«åœ±é¿ãåãŒãæ
¢æ§ç¥çµé害 ãã«åé¡ããããã«ã³ã¬ãã·ãŒã®åå è¬ã§ãããã®åŸãPandemrixTMã¯æ€åãããŸããããã«ããã§ç³è«ãããArepanrixTDïŒPandremrixTMãšé¡äŒŒãŸãã¯åäžã®ãã®ïŒã¯å蚎ããŸããã
ãã¹ãŠã®èšŒæ ãããããªãææãããã®ã§ãããã¢ããã®äž¡èŠªã¯ã11幎ã«ãããGSK瀟ã«å¯Ÿãã蚎èšããªã³ã¿ãªãªå·é«çè£å€æã«èµ·ãããããã«æ§èšŽè£å€æã«èšŽããã
ã¢ããŒãã¡ããã®ç¶èŠªã®ã¢ãã ã»ã¢ããã¥ããã«è©±ãèããšã倿±ºæã®ã»ããå€ãã®æ³åŸææžãæäŸããŠãããã
以äžã¯ã2019幎12æã®ãªã³ã¿ãªãªå·é«çè£å€æã®çµè«æã§ããïŒåŒ·èª¿ïŒã
åšã倱ã£ãããã«ãã£ã¯ã»ã³ããããšã¢ãã ããã匷ããããæ²ãã¿ã«ãããåæ
ããŠããGSKã«ããæšæºã±ã¢éåã®èªå®ããæ»å ãã¢ã¬ãã³ãªãã¯ã¹ã¯ã¯ãã³ã§ãããšã®èªå®ã¯ã蚌æ äžãæ¯æãããªãã
åäŸã倱ã£ãçã¿ã¯æ¶ããããšã¯ãã£ãŠãããªããªãããšã¯ãããŸããããã€ãã§ã³ã¹ãããšã¢ãã ãããã¢ããŒãã®æ»ã®åå ç©¶æã«è²»ãããåªåãšãšãã«ã®ãŒãã圌ãã®çã¿ãåãããäžå©ãšãªãããšãå¿ããé¡ã£ãŠããŸããã¢ããŒãã®æ»ãGSKãå
¬è¡è¡çåœå±ãè£å€æã«èŠéããããŠããªãããšãç¥ããå°ãã§ãæ
°ãã«ãªãã°ãšæããŸãã
ãã®ãããªç¶æ³ã«çœ®ããã芪ãªã誰ã§ãå§åãããã§ãããçåãžã®çããæ±ããé·ãéãæžåœã«æŠã£ãŠããããšã¯çè§£ã§ããããªããç§ã®åã©ãã¯æ»ãã§ããŸã£ãã®ãïŒç§ã¯ã10幎éã®èª¿æ»ã®çµæããããããªãããšããçããåºããªããã°ãªããªãããšãæ·±ãæ®å¿µã«æããç§åŠçãå»åŠçç¥èŠã¯äŸç¶ãšããŠéãããŠãããäžå®å
šãªãŸãŸã§ããããããè£å€æã¯ãç®ã®åã«ãã蚌æ ã«åºã¥ããŠå€æãäžããªããã°ãªããŸããããã®èšŒæ ã¯ãã¢ã¬ãã³ãªãã¯ã¹ãAminaããã®éåžžã«äžå¹žãªæ»ãåŒãèµ·ãããããããã¯ãã®äžå ãšãªã£ãããšããèç¶æ§ã®ãã©ã³ã¹ã«ãããŠç«èšŒãããã®ã§ã¯ãããŸããããã®çµæãç§ã¯ååã®èšŽããåŽäžããªããã°ãªããŸããã
ãªã³ã¿ãªãªå·äžçŽè£å€æãJ Koehnenã2019幎12æ10æ¥ 119å·
119
ãFrivolous JusticeïŒè»œèãªæ£çŸ©ïŒã
ããã³ãã®å€§æäŒæ¥æ³åŸäºåæMcMillan LLPã®å 蚎èšããŒãããŒã§ãããè£å€é·ãMarkus Koehnenã®äžèšã®çºèšã®éæªãªå£èª¿ã«æ³šç®ããŠã»ããã
ãç§ã¯ããã€ã»ã³ãããšã¢ãã ãããã¢ããŒãã®æ»ã®åå ãèŠã€ããããã«è²»ãããåªåãšãšãã«ã®ãŒãã圌ãã®èŠçãåãããå©ãã«ãªãããšãå¿ããé¡ã£ãŠããŸããã
ãããã ãFrivolous JusticeïŒè»œèãªæ£çŸ©ïŒããšåŒã¶ã«ãµããããã
äžèšã®å€æ±ºïŒèšŒæ ãèªãããæ¹æ³è«çã«åæããŠããªãïŒã¯ããã®åŸã2020幎12æïŒ2009幎ã«Aminaã亡ããªã£ãŠãã11幎以äžïŒã«æ§èšŽè£å€æã«æåºãããããã«ã«ããã®æé«è£å€æã§ã審çãæåŠãããŸããã
ã¢ããã»ã¢ããã¥ã®éå» - 圌女ã®éºç£ã¯çãç¶ãã
ããã°ãã¡ãŒãã®COVID mRNAãã¯ã¯ãã³ãã«ãã£ãŠçåœãè ããããŠããäžçäžã®äœçŸäžäººãã®åã©ããã¡ã®ããã«ã
åäŸãã¡ã«åããããç¯çœªã®æ ¹åºã«ã¯ãWHOã®ããŒã¬ã¬ããã»ãã£ã³äºåå±é·ãããã»ç§åŠãã«åºã¥ããŠH1N1ã®å€§æµè¡ã宣èšããç»æçãªæ±ºå®ã«é¡ããã®ãããã®ã§ãããã³ãããã¯ã¯èµ·ãããªãã£ãããå±éºãªãåœã¯ã¯ãã³ãã7åååãé
åžããããããã¯æå³çãªãã®ã ã£ãã®ã§ããããïŒ
ãåäŸãã¡ãæ°ã«ããªãã§ã...ããã¯H1N1ã¯ã¯ãã³ã売ã£ãŠæ°ååãã«ã皌ãã ããã°ãã¡ãŒãã®ãå·»ãæ·»ã被害ãã§ãã
è±åœå»åŠéèªã§ç¢ºèªãããããè±ã€ã³ãã«ãšã³ã¶ã®äžççæµè¡ã«å¯Ÿããäžçä¿å¥æ©é¢ã®å¯Ÿå¿ã¯ãç§å¯äž»çŸ©ãšè£œè¬äŒç€Ÿãšã®å©ççžåã«ãã£ãŠæ·±ãé¢ãã£ãŠãããã
ãBMJã¯ãWHOã®æãŠã€ã«ã¹å€äœ¿çšã«é¢ããã¬ã€ãã©ã€ã³ãããããã®è¬ã®ããã2ã¡ãŒã«ãŒã§ãããã·ã¥ãšã°ã©ã¯ãœã»ã¹ãã¹ã¯ã©ã€ã³ïŒGSKïŒããã³ã³ãµã«ã¿ã³ãæãåãåã£ãŠããå°éå®¶ã«ãã£ãŠäœæãããŠããããšãæããã«ããã
ãŸããæšå¹ŽãWHOã«ãã³ãããã¯å®£èšãåºããã©ããããã€åºããã«ã€ããŠå©èšãããããã«çµæããã16人ã®ã¡ã³ããŒãããªãç§å¯ã®ãç·æ¥å§å¡äŒãã®å°ãªããšãäžäººã®å°éå®¶ã2009幎ã«GSKããå ±é ¬ãåããŠããããšãæããã«ãããã
è±ã€ã³ãã«ãšã³ã¶ãäžççãªå€§æµè¡ãšãªã£ãããšãçºè¡šãããšãGSKãå«ã6ã€ã®å€§æè£œè¬äŒç€Ÿãšã¯ã¯ãã³è£œé ã®æœåšçãªå¥çŽãèªåçã«çºçããã®ã§ãããWHOã¯ãå§å¡äŒã®ã¡ã³ããŒãç¹å®ããããšãæåŠããŠãããæ¥çã®å§åããå®ãããªããã°ãªããªããšããŠããããBMJèªã®ç·šéè Fiona Godleeã¯ç€Ÿèª¬ã§ãWHOã®ä¿¡é Œæ§ã¯å€§ããæãªãããããšè¿°ã¹ãŠããã(AFPã2010幎6æ4æ¥ã匷調)
2009幎ã®H1N1ãã³ãããã¯ã¯ãäºè¡æŒç¿ãã ã£ãã®ãïŒ
H1N1è©æ¬ºã®èåŸã«ã¯ãããã°ãã¡ãŒããå«ã匷åãªéèé¢ä¿è
ãšã²ã€ã財å£ãå«ãåäžé·è
ã®æ
åå®¶ãã¡ãããã®ã§ããã
ã圌ãã«ãšã£ãŠã®ãæèšã¯äœã ã£ãã®ã ãããïŒ
120
- ãã³ãããã¯ã¯åœç©ã§ãH1N1ã¯ã¯ãã³ã®å±éºæ§ã¯ã€ã®ãªã¹ãšEUã®è£å€ã§æããã«ãªããŸããã
- 仿¥é²è¡äžã®COVID屿©ãšã¯å¯Ÿç §çã«ãäž»æµã¡ãã£ã¢ã®äžéšãH1N1ã«ã€ããŠå ±éããåœæ°ã«æ å ±ãæäŸãããããäžæ£ã¯æããã«ãªã£ãã
- ãªã³ã©ã€ã³æ€é²ãšçµã³ã€ããçµæåã®ãããããã¬ã³ãè£ çœ®ã¯ååšããªãã£ãã
- çµç¹çãªææãã£ã³ããŒã³ããªãã£ãã
- WHOã®å éšã«ãåè£ããã£ãã
- ç§åŠè ãå»åž«ãWHOã®æ±ºå®ãæ¯æããããäžåœãªå§åãåããããšã¯ãªãã£ãã
H1N1ã®èåŸã«ããäžæ£ãæããã«ããæ¬§å·è°äŒã®æ³šç®ãéãããŠã©ã«ãã¬ã³ã°ã»ãŠã©ãã«ã°å士ã¯ãçŸåšãã€ã±ã«ã»ã€ã§ãã³å士ãšãšãã«COVID-19ã¯ã¯ãã³å察ãã£ã³ããŒã³ã«ç©æ¥µçã«é¢ãã£ãŠããã
å·»æ«è³æ
1. Michel Chossudovskyææã2009幎8æ25æ¥ã2009幎H1N1è±ã€ã³ãã«ãšã³ã¶ãã³ãããã¯ã® "ãã§ã€ã¯ "ãæ³èµ·ãããhttps://www.globalresearch.ca/the-h1n1-swine-flu-pandemic-manipulating-the-data-to-justify-a-worldwide-public-health-emergency/14901
2. Katie Reid and Laura MacInnis, May 19, 2009. WHO ã¯ãæè¯ã®ã±ãŒã¹ã§ 49 åã®ãã³ãããã¯ã€ã³ãã«ãšã³ã¶äºé²æ¥çš®ãèŠãŠãããhttps://www.reuters.com/article/healthNews/idUSTRE54H1XO20090519
3. MSNBC ãã¥ãŒã¹ã2009 幎 7 æ 24 æ¥ãè±ã€ã³ãã«ãšã³ã¶ã¯ 2 幎㧠20 å人以äžãèŠãããå¯èœæ§ããããhttps://www.nbcnews.com/id/wbna32122776
4. NDTVã2009幎4æ28æ¥ãèŽåœçãªã€ã³ãã«ãšã³ã¶ãè±åœã®äººå£ã® 40%ã«ææããå¯èœæ§ãndtv.com/.../deadly-flu-could-infect-40-uk-population: Report.per-cent-of-uk-population-report-392997
5. ãã¡ããã芧ãã ããïŒ https://www.forbes.com/2010/02/05/world-health-organization-swine-flu-pandemic-opinions-contributors-michael-
fumento.html#4fd9f96548e8 ïŒèšäºã¯æªæ²èŒã§ãããïŒ
6. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020幎5æ3æ¥ã2009幎H1N1ã¯ã¯ãã³ã§åäŸã®è³é害ãçºçãã¢ã³ãœããŒã»ãã¡ãŠãå士ã«ãããã¯ã¯ãã³ã®å®å
šæ§ãåé¡ãhttps://www.globalresearch.ca/video-dr-anthony-fauci-on-the-2009-h1n1pandemic-the-2009-h1n1-vaccine-caused-brain-damage-in-children/5711540
7. åäžã
8. ãã¡ããã芧ãã ããïŒ https://sencanada.ca/en/committees/oci/
9. ãã ã»ããŒã¿ãŒã20214幎3æ2æ¥ãè±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã§è³ãæå·ããè±åœã®è¢«å®³è
ã6000äžãã³ãã®è£åãåããããšã«ãªã£ããhttps://www.ibtimes.co.uk/brain-damaged-uk-victims-swine-flu-vaccine-get-60-million-compensation-1438572
10. ãã ã»ãã©ãã¯ãŠã§ã«ã2019 幎 11 æ 5 æ¥ãã¯ã¯ãã³ã®å¯äœçšãçãçããè£å€ã§ã䞡芪ã¯H1N1ã€ã³ãã«ãšã³ã¶ã®äºé²æ¥çš®ã5æ³ã®åšã殺ãããšèšã https://nationalpost.com/news/at-rare-trial-of-alleged-vaccine-side-effects-parents-say-h1n1-flu-shot-killed-5-year-old-daughter
121
---------------------第10ç« ---------------------
æè°éåã ãå瀟äŒçãµã€ã³ãã¹ ãã«
ã«ããŽã©ã€ãºãã
ãå¿çåŠã®éå
·ã¯ãééã£ãäººã®æã«ããããšå±éºã§ãããè¿ä»£çãªæè²æ¹æ³ã¯ã人éã®è³ãåçåãããã®æèãç¹å®ã®ã€ããªãã®ãŒäœç³»ã«é©åããããã«æèŠãå€ããããã«ãã»ã©ããŒã«å¿çšããããšãã§ãããã- Joost A. M. Meerlooãã¶ã»ã¬ã€ãã»ãªãã»ã¶ã»ãã€ã³ãã1956幎
ã匷å¶çãªå¿çã·ã¹ãã ã¯ãã€ããªãã®ãŒãæå®ããã信念ãã¢ã€ãã¢ãæ
床ãè¡åã®ã»ãããåŠç¿ãæ¡çšãããããã«ã匷å¶çãªæ¹æ³ã§å¿çåã䜿çšããè¡åå€å®¹ããã°ã©ã ã§ããã- æ
ããŒã¬ã¬ããã»ã·ã³ã¬ãŒå士
ãé©åããããã«ãšãã匷ãå§åã¯ãä¿¡è
ã®å
±åäœãåºããããšãã詊ã¿ã§ãããæå±ããããã®å³æ Œãªã«ãŒã«ã課ãããç°ãå±ããè
ã¯æé€ãããããã®å
±åäœã¯ç¬èªã®ééå瀌ãçºæãããããã¯æŽç€Œã®äžçš®ã§ãæãã®åã®ããšã«æµåããããã¯ã¯ãã³ããæäžäž»ãšããŠåŽæããããã-ããã·ããªã¢ã³ã»ãã©ã«ãææã2022幎7æå·
ã¯ããã«
MRNAã¯ã¯ãã³ã®æŒãã€ãã¯ãã¡ãã£ã¢ã®ãããã¬ã³ããææãã£ã³ããŒã³ãšçžãŸã£ãŠã匷å¶çãªèª¬åŸãšæŽè³æŠè¡ã«äŸåããŠãããåœå®¶æ¿åºã®ç®çã¯ããå容ãã確ä¿ããããšã§ãããäžèšã®ããŒã¬ã¬ããã»ã·ã³ã¬ãŒå士ã¯ãã匷å¶çãªåœ±é¿åãäžå®ãã¹ãã¬ã¹ãäžããæŠè¡ãç¶ç¶çã«è¡ãããšãã«èšåããŠããã
ãã³ãããã¯çºçåœåãããæ¿åºã®ã³ãããŠã€ã«ã¹å¯Ÿçã«å察ãã人ã
ããç¹å®ããããåé¡ãããæ¥µæªééãªããã»ã¹ãè¡ãããŠããã®ã§ããã
ãããããå°éå®¶ã«ããå¿çåŠçç ç©¶ãïŒã°ããŒããªã¹ããšãªãŒãã®ããã«äŒæ¥è²¡å£ãäŸé ŒããïŒã«ãããšãã³ããã³ã³ã»ã³ãµã¹ã«å察ãã人ã
ã¯ãå瀟äŒçãµã€ã³ãã¹ãã«åé¡ãããŠããŸãã
äºé²æ¥çš®ãåããŠããªã人ã¯ãæ
è¡ã劚ããããä»äºãã¯ãã«ãããåŠæ ¡ã倧åŠã«éããªããããŠããŸãã圌ãã¯ãïŒãç§åŠçæèŠãã«åŸã£ãŠïŒéæ¿æŽŸã粟ç¥ç
質è
ãšåé¡ãããéé£ãããŠããŸãã
å±éãããŠããã®ã¯ãã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®éã®ç€ŸäŒçåè£ã§ãã
ãããã瀟äŒçåè£ã¯ãå®¶æãå°å瀟äŒã®äžã§å¯Ÿç«ãçã¿ãæåéã瀟äŒç掻ã®åŽ©å£ãæããŠããŸãã
瀟äŒç掻ã®åŽ©å£ã«ã€ãªãããçµæžæŽ»åã«ã壿»
çãªåœ±é¿ãåãŒããŠããŸãã
ã¡ãã£ã¢ã®ãããã¬ã³ãã«æ¯ãããããã£ã³ããŒã³ã¯çµ¶ãéãªãé²è¡ããŠãããæ®ºäººçãªãã¯ã¯ãã³ããæåŠãã人ã
ã¯ããå瀟äŒçãªç²Ÿç¥ç
質è
ãã«åé¡ãããŸãã
åªå¢ãªã®ã¯ãåå²çµ±æ²»ãã®ã·ããªãªã§ãããå€ãã®åœã§åæã«å®æœãããŠããã
ãã®ç« ã§ã¯ãCOVID-19ã®çŸ©ååãšã¯ã¯ãã³ã«å¯Ÿããæè°éåã匱äœåãããç®çã§å®æœãããããã€ãã®å¿çåŠçç ç©¶ãã¬ãã¥ãŒããã
122
ãç§åŠçãªç ç©¶ãïŒCOVIDå察掟ã ãå瀟äŒçãµã€ã³ãã¹ ãã«ã«ããŽã©ã€ãºãã
ãããã® ãç§åŠçç ç©¶ ãã®æ§è³ªãšç®çã¯äœã§ããããïŒ
ãå
¬åŒã®çå®ãã«æè°ããæ¿åºã®åœä»€ãæ¹å€ããç£çŠã瀟äŒçè·é¢ããã¹ã¯ççšãã¯ã¯ãã³ãªã©ã«é£è²ã瀺ãã°ãïŒãç§åŠçèŠè§£ãã«ããã°ïŒãå·é
·ã§æ¬ºçã«æºã¡ããµã€ã³ãã¹ããšããã¿ã°ãä»ããããã
ãå
¬åŒã®ç©èªããšã¯ã¯ãã³ã®çŸ©åä»ããåãå
¥ãããšãããªãã¯ä»äººã®æ°æã¡ãçè§£ãããå
±æåããæã£ããè¯ã人ããšããã¿ã°ãä»ããããŸãã
ããããå°éå®¶ã«ãããå®èšŒçå ±åæžãã§ã¯ããã§ã€ã¹ãã¹ã¯ã®ççšã瀟äŒçè·é¢ã眮ãããšãæåŠãã人ã
ã¯ãå瀟äŒçäººæ Œé害ãã§ãããšèšè¿°ãããŠããŸãã
ãCOVID-19ã®æ¡æ£ãé²ãããã®æªçœ®ãå®ããªãã人ãã¡ã¯ããå瀟äŒçããšã¿ã°ä»ããããŠããã®ã§ããã
1,578äººã®æäººãããµã³ãã«ããšããŠè¡ã£ããã©ãžã«ã®ç ç©¶çµæã¯ããPersonality and Individual Differencesãèªã«ãCOVID-19 pandemic over timeããšããã¿ã€ãã«ã§çºè¡šãããŠããŸããDo antisocial traits matter?1

ãå ±ææ§ ããš ãå瀟äŒçç¹åŸŽ ãã®æ¯èŒ
ãã®ç ç©¶ã®çµ±èšç㪠"æ¹æ³è« "ã¯åçŽæå¿«ã§ãããããã¯ã¢ãã«ãšããŠæ©èœããããšãæå³ããŠããããã©ãžã«ã®å šäž»èŠå°åã®æäººãããªããããããµã³ãã«ãã2ã€ã®ç°ãªãã°ã«ãŒãã«åé¡ããããšã§ããããããæ€èšŒããã
123
å瀟äŒçç¹æ§ãšCOVID-19ã«ããå°ãèŸŒãæªçœ®ã®éµå®ã®é¢ä¿ãæ€èšããããµã³ãã«ã¯18-73æ³ã®ãã©ãžã«ã®æäºº1578人2ã§ãããå°ã蟌ã察çãžã®ã³ã³ãã©ã€ã¢ã³ã¹ã«é¢ãã質å祚ã宿œããã
æœåšãããã¡ã€ã«åæã®çµæã2ã€ã®ãããã¡ã€ã«ã®è§£ã瀺ãããã
ãå瀟äŒçãã¿ãŒã³ã»ãããã¡ã€ã«ã¯ãå·æ·¡ããæ¬ºçæ§ãæµæãè¡åæ§ãç¡è²¬ä»»ãæäœæ§ããªã¹ã¯ãã€ãã³ã°ã§é«ãã¹ã³ã¢ã瀺ããã广çãªå
±é³ŽãïŒç€ŸäŒççžäºäœçšã®ããã»ã¹ïŒã§äœãã¹ã³ã¢ã瀺ããŠããã
å瀟äŒçã°ã«ãŒããšå
±æã°ã«ãŒãã¯ãææãªå·®ã瀺ããã... æã
ã®çºèŠã¯ãå瀟äŒçç¹æ§ãç¹ã«å
±æåºŠã®äœããå·æ·¡ããæ¬ºçããªã¹ã¯ãã€ã¯ãã®é«ãããå°ã蟌ã察çãžã®ã³ã³ãã©ã€ã¢ã³ã¹ã®äœããšçŽæ¥é¢é£ããŠããããšã瀺ããŠããããããã®ç¹æ§ã¯ãå°ãªããšãéšåçã«ã¯ãææè
æ°ãæ»äº¡è
æ°ãå¢å ããŠãã人ã
ãå°ã蟌ã察çãéµå®ããªãçç±ã説æãããã®ã§ããã(匷調)3
èª¿æ»æ¹æ³ã¯ã3ã€ã®äž»èŠãªè³ªåãäžå¿ã«çµã¿ç«ãŠãããŠãã4ã
- ã³ãããŠã€ã«ã¹ã®ç¶æ³ãåãŸããŸã§ãã§ããã ã人ã«è¿ã¥ããªãããã«ããå¿ èŠããããšæããŸããïŒ(瀟äŒçè·é¢æ)
- ã³ãããŠã€ã«ã¹ã®ç¶æ³ãèœã¡çããŸã§ã1æ¥ã«äœåºŠã§ãææŽããã¢ã«ã³ãŒã«ãžã§ã«ã䜿çšããå¿ èŠããããšæããŸããïŒ(è¡ç)
- ãã©ãžã«ã§ãã§ã€ã¹ãã¹ã¯ïŒéŒ»ãšå£ãä¿è·ãããã®ïŒã䜿çšããå¿ èŠããããšæããŸããïŒïŒãã§ã€ã¹ãã¹ã¯ïŒ
Yes/Noã®åé¡
ãã®3ã€ã®è³ªåã«Yesãšçããå ŽåïŒããªãã¯ãå
±æåãïŒïŒçžæã®æ°æã¡ãçè§£ããå
±æããåïŒãæã£ãŠãããšåé¡ãããŸãã3ã€ã®è³ªåã«ãããããã§çããïŒããªãã¯ãå·æ·¡ããæ¬ºçæ§ãæµæãè¡åæ§ãç¡è²¬ä»»ãæäœæ§ããªã¹ã¯ãã€ã¯ã®ã¬ãã«ãé«ãããšåé¡ãããŸãïŒäžèšåŒçšè
泚ïŒã
ãšãŠãç§åŠçã«èãããããããã®å¿çç ç©¶ã®æé»ã®ç®çã¯ãå
¬åŒã®ç©èªã«åŸãããšãæåŠãããµã€ã³ãã¹ãšããã人ã
ãäžå·ããªãããã³ã³ãã©ã€ã¢ã³ã¹ã匷å¶ãããšåæã«ãæ¿åºã«åšåããããã®æä»€ãæäŸããããšã§ãããããã¯å
šãã®åã§ããã
ãéã®äžæ¥µããšãéå£çãã«ã·ã·ãºã ã
ãšãªãã¯ã»Wã»ãã©ã³ïŒPsyPostïŒã«ãããšãäžèšã®ç ç©¶ã¯ãããã尺床ããç¹å®ããããšããæã£ãŠããŸããã察çäžé©å¿ãªæ§æ Œç¹æ§ã®...ããã©ã³ã¯ãŸããé¢é£ããç ç©¶ã«ãèšåããŠããŸãã
ããã«ã·ã·ãºã ããµã€ã³ãã¹ãããã£ããªãºã ã® "ããŒã¯ãã©ã€ã¢ã "ã¯ã
COVID-19ã®äºé²æªçœ®ã®ç¡èŠãšé¢é£ããã
ããŒã©ã³ãã§è¡ãããç ç©¶ã®ã¿ã€ãã«ã¯
124
ãã®ç ç©¶ã¯ããéå£çãã«ã·ã·ãºã ããããªãã¡ã³ãããŠã€ã«ã¹ã®ãçå®ãïŒå¥åã倧åãïŒã«å¯Ÿãããããããã€ã³ã°ã«ãŒããïŒå¥åæè°éåãåäœå¶çå»åž«ãç§åŠè ã®éå£ïŒã«ããå ±éã®ä¿¡å¿µãšå®è·µã«ã€ããŠèšåããŠãããéå£çãã«ã·ã·ãºã ã¯ãå¿çåŠè ããéã®äžæ®µè«æ³ããšåŒã¶ãã®ã«çµã¿èŸŒãŸããŠããã

ãã®ç ç©¶ã¯ããããŒã©ã³ãã®å šåœä»£è¡šãµã³ãã«ïŒN = 755ïŒãã«åºã¥ããŠããŸãããã®ç ç©¶ã§ã¯ããããŒã¯ãã©ã€ã¢ãã®ç¹æ§ïŒããªãã¡ããµã€ã³ãã¹ãããã£ããªãºã ããã«ã·ãºã ïŒãšéåçãã«ã·ã·ãºã ïŒããªãã¡ããšãŒãžã§ã³ãçãå ±åäœçïŒã®é¢ä¿ããæ€èšŒããŠãã...ãããŒã¯ãã©ã€ã¢ãã®ç¹åŸŽãæã€åå è ã¯ãäºé²ãžã®åãçµã¿ãå°ãªãã£ãã
ããã®çµæã¯ããã³ãããã¯æã®è¡åäºæž¬ã«ãããå¥åº·ä¿¡å¿µã®æçšæ§ãææããæãæ§æ ŒïŒããªãã¡ãããŒã¯ãã©ã€ã¢ããéå£çãã«ã·ã·ãºã ïŒã«é¢é£ããåé¡è¡åãïŒå°ãªããšãéšåçã«ïŒèª¬æãããã®ã§ãã£ã...
ããŒã¯ãã©ã€ã¢ãïŒããªãã¡ããã«ã·ã·ãºã ãããã£ããªãºã ããµã€ã³ãã¹ïŒãéå£çãã«ã·ã·ãºã ãªã©ã®ç¹æ§ã¯ã...人ããŠã€ã«ã¹ã«ã©ã®ããã«å¯ŸåŠãããã«åœ±é¿ãäžãããããããªã...ãäŸãã°ãããŒã¯ãã©ã€ã¢ãã®ç¹åŸŽãæã€å人ã¯ãCOVID-19ã«é¢é£ããŠæ¿åºã宿œããå¶éã«åŸãå¯èœæ§ãäœããããããªã7ã
äžã§åŒçšããããšãŒãžã§ã³ãããšããçšèªã¯ãç®æšéæãã®ããšã§ããã
ãããŠããã®æ¹æ³è«ã¯ä»¥äžã®éãã§ãã
ãããŒã¯ãã©ã€ã¢ãã®ç¹æ§ïŒWave 2ïŒã枬å®ãã...ããŒã¯ãã©ã€ã¢ãã»ããŒãã£ããŒã¹ã»ã¹ã±ãŒã«ïŒJonason & Webster, 2010ïŒãåèã«ããããã®å°ºåºŠã¯ããµã€ã³ãã¹ïŒäŸïŒãåçããªãåŸåããããïŒããã«ã·ãºã ïŒäŸïŒãå声ãå°äœãæ±ããåŸåããããïŒãããã£ããªãºã ïŒäŸïŒãèªåã®æãéãã«ããããã«ä»äººãæãåŸåããããïŒã®å人差ãè©äŸ¡ãã4é ç®ããæ§æãããŠãããåå è ã¯ãåé ç®ãžã®è³æã瀺ããïŒ1ïŒåŒ·ãå察ã5ïŒåŒ·ãè³æïŒãåé ç®ã®åçãå¹³åããåç¹åŸŽã®ææ°ãäœæããã
125
ç§åŠçãªé¿ããçµè«ã¯ïŒ
ãå人ã«çŠç¹ãåœãŠãïŒïŒããŒã¯ãã©ã€ã¢ãã®ç¹æ§ïŒãéå£ã«çŠç¹ãåœãŠãïŒïŒéå£ãã«ã·ã·ãºã ïŒæ§æ Œç¹æ§ã«ãã£ãŠããã³ãããã¯ã«å¯Ÿå¿ããé©å¿çè¡åãšäžé©å¿çè¡åã®äž¡æ¹ãäºæž¬ããäžã§ãããŒã¯æ§æ Œç¹æ§ã®é¢é£æ§ã瀺ãããšã«ãã£ãŠãã¢ãã«ã®ç¯å²ãåºãã ããšãããŸãã
å ±åæžã®å šæã¯ãã¡ããã芧ãã ãã9 (匷調)
ããŒã¯ãã©ã€ã¢ãã®å¿çåŠçå®çŸ©ã¯ããã«ã·ã·ãºã ãããã£ããªãºã ããµã€ã³ãã·ãŒã®è€åçãªæ§æ Œç¹æ§ããæ§æãããŠããŸãããæªæã®ããæ§è³ª ããã ãããŒã¯ ããšåŒã°ããŠããŸãã
ããŒã¯ã»ãã©ã€ã¢ããã»ããŒãã£ã»ããºã³ïŒDTDDïŒã¯ãããŒã¯ã»ãã©ã€ã¢ããã®3ã€ã®äººæ Œæ§æèŠçŽ ãè©äŸ¡ã»æž¬å®ãããããåºããäººæ Œç®é²ãã§æ§æãããŠããŸãã
å®è³ªçã«ããã®ãç§åŠçå ±åæžãã確èªããã®ã¯ãã¯ã¯ãã³ã®çŸ©åä»ããå«ãCOVID-19ã®å
¬åŒã·ããªãªã«çåãæã€äººã
ããæªæããäººæ Œé害ããæã€ãšããããšã§ããã圌ãã¯ããŒãã£ã»ããºã³ãããŒã¯ã»ãã©ã€ã¢ãç¹æ§ãïŒDTDDïŒã«èŠããã§ãããšèšãããŠããŸãã

ã¢ã³ãCOVIDã®æè°éå㯠ãéå£çãã«ã·ã·ãºã ããšããŠèªèããã
ã€ã³ã°ã«ãŒãããããã¹ãéåã®äžã§é£ç¶çã«è¡åãããšãã圌ãã¯ãéå£çãã«ã·ã·ãºã ããé©çšãããšã¿ã°ä»ããããã
äžèšã®ç ç©¶ã®æ çµã¿ã¯ãã¯ã«ã·ã£ã¯ã®ã°ã«ãŒããšé£æºããŠä»ã®åœã§ãæ³å®ãããŠããããŸããé¢é£ããç ç©¶ãšããŠããCOVID-19ã®æ¡æ£ãæããããã®å¶éãéµå®ããŠããã®ã¯èª°ãªã®ãïŒCOVID-19ã®ç¶æ³ã«å¯ŸããããŒãœããªãã£ãšèªèãã§ãã10ã
匷ãèšèã ã"æ»èªä»ã"ïŒ
審åç°å¢ãžãããžã¿ã«é女ç©ã
å¿çåŠã¯ãèŠå¯åœå®¶ã®æœçã«æ£åœæ§ãäžããããã«ãæªè³ªãªæ¹æ³ã§å©çšãããŠããããã®æä»€ã¯ããæªæããäººæ Œé害ããæã€ãšããã人ã
ãã远ãããããããšã§ããã
ããã¯ç°ç«¯å¯©åã®æçŸ©ã§ãããæçµçã«ã¯ããžã¿ã«é女ç©ãã«çºå±ããå¯èœæ§ããããã¹ãã€ã³ã®ç°ç«¯å¯©åãšã¯å¯Ÿç
§çã«ãçŸä»£ã®å¯©åã·ã¹ãã ã¯ãCOVID-19ã®ã³ã³ã»ã³ãµã¹ã«å察ããå人ãã¹ãã€ããåé¡ããèœåãã»ãŒç¡å¶éã«åããŠããã
人ã
ã¯ã¿ã°ãä»ããããã©ãã«ã貌ãããé»åã¡ãŒã«ãæºåž¯é»è©±ã¯ç£èŠããã詳现ãªå人ããŒã¿ã¯WHOã®æ¯æŽã®äžã79å人ã®å·šå€§ãªããã°ãã©ã¶ãŒããŒã¿ãã³ã¯ã«å
¥åãããäºå®ã§ããã
åã¯ã¯ãã³æŽŸã®ç§åŠè
ãå»åž«ã¯ãåé¡ãããŠããŸãã圌ãã¯æ€é²ã®å¯Ÿè±¡ãšãªããå Žåã«ãã£ãŠã¯é®æããã粟ç¥ç§ã®ç
æ£ã§æ²»çããããã«éãããŸãã
ãã®ããžã¿ã«ã»ã«ã¿ãã°åãå®äºãããšã人ã
ã¯å¯éãããåºç»ã«éã蟌ããããŸãã圌ãã®ãããã¡ã€ã«ã¯ç¢ºç«ãããã³ã³ãã¥ãŒã¿åãããããŒã¿ãã³ã¯ã«å
¥åãããã
126
äžæ¹ãåžæ°ã¯ãã°ããŒãã«ã»ã¬ããã³ã¹ãã®çå¿µãæ¯æããããã«æŽ»æ°ã¥ããããŠããã

åäžé·è ã¯ç²Ÿç¥ã«ç°åžžãããããŠããã®ãïŒ
ãããã®å®èšŒçãªå¿çåŠç ç©¶ã¯ãæ¿åºã宿œããCOVID-19æ¿çåœä»€ã«å察ããåžæ°ã«å¯ŸããŠäœ¿çšãããããšãæå³ããŠããããã®çµæããããã®æ¿åºã¯äžå±€éšã®åœä»€ã«åŸãããšã«ãªãã
ç§ãã¡ã¯çåãæãããããããããªããåäžé·è ããæ åå®¶ããè æããæ¿æ²»å®¶ãªã©ãã³ãã19ã¯ã¯ãã³ãšç£çŠæ¿çã®æé»ã®ç«åœ¹è ã¯ã粟ç¥çã«ãããããªã£ãŠããã®ã ãããïŒ
圌ãã®æ§æ Œç¹æ§ã¯ãç§åŠç調æ»ã®åæ©ã«ã¯ãªããŸããã圌ãã¯ãµã€ã³ãã¹ãªã®ã ãéãšå¯ãåååã§ãã
127
å·»æ«è³æ
1. Fabiano Koich Miguel, Gisele Magarotto Machado, et al., January 1, 2021. COVID-19 ãã³ãããã¯ã«å¯Ÿããå°ãèŸŒãæªçœ®ã®çµæçã³ã³ãã©ã€ã¢ã³ã¹ãDo antisocial traits matter? https://www.sciencedirect.com/science/article/pii/
2.åäž
3. åäž
4. åäž
5. BartÅomiej Nowak, PaweÅ Brzóska, et al., December 1, 2020. COVID-19ãã³ãããã¯æã®é©å¿çè¡åãšäžé©å¿çè¡åãThe roles of Dark Triad traits, collective narcissism, and health beliefs. https://www.sciencedirect.com/
6. åäžã
7. åäžã
8. åäž
9. åäž
10. Marcin Zajenkowski, Peter K. Jonason, et al., November 1, 2020. COVID-19ã®æ¡æ£ãæããããã®å¶éãéµå®ããŠããã®ã¯èª°ãïŒããŒãœããªãã£ãš COVID-19 ã®ç¶æ³ã«å¯Ÿããèªè https://www.sciencedirect.com/science/article/pii/S0191886920303883
128
------------------第11ç« ------------------
äžççãªCOVAXäœæŠãšãã¥ã«ã³ãã«ã¯ã»ã³ãŒã
人éã«å¯Ÿãã眪ããžã§ããµã€ã
ãç¬¬äºæ¬¡äžç倧æŠäžã«äººé¡ã«å¯ŸããŠè¡ãããæ®èè¡çºã®çåè
ã§ããç§ãã¡ã¯ãèªåã®è¯å¿ã«åŸããªããã°ãªããªããšæã£ãŠãã...
ç§ãã¡ã®ç®ã®åã§ãããã«å€§èŠæš¡ãªããã³ãŒã¹ããè¡ãããŠãããç§ãã¡ã¯ã人é¡ã«å¯Ÿãããã®äžé埳ãªå»åŠå®éšãçŽã¡ã«äžæ¢ããããæ±ããŸããããã¯ãã¥ã«ã³ãã«ã¯ã»ã³ãŒããé©çšããªããã°ãªããªãå»çå®éšã§ãããã -ã©ãã»ãã¬ã«ã»ãã³ãã©ãŒããã¬ãŒã»ã·ã£ããªãŒã«ããœãªã³ã»ã·ã£ãã©ãããã·ã£ã»ãªã¬ã«ãã¢ãªãŒã»ã¯ãªã¹ããŒã³ä»ãå
šæã¯ãã¡ãã
mRNAãã¯ã¯ãã³ã察ãã¥ã«ã³ãã«ã¯äºä»¶
ãã®ã¯ã¯ãã³ã¯äžçäžã§é©çšããã課ããããŠããã察象人å£ã¯79åäººãæ°åã®æäžãäºå®ãããŠãããäžçå²äžæå€§ã®ã¯ã¯ãã³æ¥çš®èšç»ã§ããïŒç¬¬VIIIç« åç
§ïŒã
ãåæmRNAã人äœã«éã蟌ãããšã«ãã£ãŠãå°çå
šäœã®äºé²æ¥çš®ãéæãããããšã¯ããã€ãŠãªãã£ãããšã ã(1)

ãããããCOVID-19ã®ããžã¿ã«èšŒææžããçºè¡ããããã®Worldwide Digital Informations Systemãæ§ç¯ããããã®WHOã®ãã¬ã€ãã©ã€ã³ãã¯ãããã¯ãã§ã©ãŒè²¡å£ãšãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ããå¯å€§ãªè³éæäŸãåããŠããã. (第XIIIç« åç §)2
mRNAã¯ã¯ãã³ã®å®éšçæ§è³ªãšãã®ç Žå£çãªå¥åº·ãžã®åœ±é¿ã«çç®ããŠãæ³åŸã¢ããªã¹ãã¯ãããã¹ã®å»åž«ãæŠäºç¯çœªãç¹ã«åŒ·å¶å容æã®åäººãšæ°é人ã®äž¡æ¹ã«å¯Ÿããå»åŠå®éšã®å®æœã§èµ·èšŽãããæŽå²çãªãã¥ã«ã³ãã«ã°ã®ãããã¹ã®å»åž«è£å€ãïŒ1946-47ïŒã®åé¡ãæèµ·ããŠããã
å»åŠäºä»¶ãU.S.A. vs. Karl Brandt, et al.
1946幎ãã47幎ã«ãããŠã23人ã®ã¢ã¡ãªã«äººå»åž«ã起蚎ãããã
æŠäºç¯çœªã人éã«å¯Ÿãã眪ãçµç¹ããããã«å æ ããŠãæèãæ°éäººã«æœãããå»åŠçå®éšãå»çè¡çºã§åçºãããå»åž«ã管çè ãã¡ã§ãã3ã
äž»ç¯æ Œã®ã«ãŒã«ã»ãã©ã³ãã¯ç¬¬äºæ¬¡äžç倧æŠäžã®ãã€ãæ¿åºã®é«å®ã§ãä»ã®è¢«åã«ã¯è»éãSSã®äžçŽå»åž«ã管çè ãå«ãŸããŠããïŒããŒããŒãè³æåç §ïŒ4ã
129

ãã®çµæã1947幎8æ19æ¥ã«ãã¥ã«ã³ãã«ã¯ã»ã³ãŒããå¶å®ãããŸããããã®ãã¡ããã€ãã®ååã¯ãmRNAã¯ã¯ãã³ãšã¯ã¯ãã³ã»ãã¹ããŒãã«é¢é£ããŠããããããŸã«éåãããŠããã
ãã¥ã«ã³ãã«ã¯ã»ã³ãŒããã®ç¬¬äžååã¯ãã被éšè
ã®èªçºçãªåæã絶察ã«å¿
èŠã§ããããšããŠãããããã¯ã¯ãã³ããšã®é¢ä¿ã§ã¯ããŸãã«ãããåŠå®ãããŠããïŒä»¥äžã®å€ªåã®æç« ãåç
§ïŒ6ã
1. 被éšè ã®èªçºçãªåæã絶察çã«å¿ èŠã§ããã
ãã®ããšã¯ãé¢ä¿è ãåæãäžããæ³çèœåãæãã匷å¶ãè©æ¬ºã欺çã匷迫ãéå°ãªèŠæ±ããã®ä»ã®äžå¿ã®ããææã匷å¶ã®èŠçŽ ãä»å ¥ããããšãªããèªç±ãªéžææš©ãè¡äœ¿ã§ããç¶æ³ã«ãããçè§£ãè³¢æãªæ±ºå®ãäžãããšãã§ãããããªé¢ä¿äºé ã®èŠçŽ ã«ã€ããŠååãªç¥èãšçè§£ãæããŠããªããã°ãªããªãããšãæå³ããŠããŸãããã®åŸè ã®èŠçŽ ã¯ãå®éšå¯Ÿè±¡è ãè¯å®çãªæ±ºå®ãåãå ¥ããåã«ãå®éšã®æ§è³ªãæéãç®çã宿œãããæ¹æ³ãšææ®µãåççã«äºæ³ããããã¹ãŠã®äžäŸ¿ãšå±éºãå®éšãžã®åå ããçããå¯èœæ§ã®ããå¥åº·ã人ãžã®åœ±é¿ã«ã€ããŠãå®éšå¯Ÿè±¡è ã«ç¥ããããå¿ èŠãããããšã瀺ããŠããã
130
2. å®éšã¯ã瀟äŒã®ããã«å®ãããçµæããããããããªãã®ã§ãªããã°ãªãããä»ã®æ¹æ³ãç ç©¶ææ®µã§ã¯ãªãåŸãªããã®ã§ãããç¡äœçºã§äžå¿ èŠãªæ§è³ªã®ãã®ã§ãã£ãŠã¯ãªããªãã
3. å®éšã¯ãåç©å®éšã®çµæåã³ç ç©¶äžã®çŸç åã¯ä»ã®åé¡ã®èªç¶å²ã«é¢ããç¥èã«åºã¥ããŠãäºæ³ãããçµæãå®éšã®å®æœãæ£åœåããããã«èšèšãããªããã°ãªããªãã
4. å®éšã¯ãäžå¿ èŠãªèäœçã»ç²Ÿç¥çèŠçãå·å®³ãé¿ããããã«å®æœãããªããã°ãªããªãã
5. ãããªãå®éšããæ»ãŸãã¯é害ãããããæå·ãèµ·ãããšä¿¡ããå éšçãªçç±ãããå Žåã«ã¯ãè¡ã£ãŠã¯ãªããªãããã ããããããå®éšå»åž«ã被éšè ãšãªããããªå®éšã¯é€ãã
6. ãªã¹ã¯ã®çšåºŠã¯ããã®å®éšã解決ããããšããåé¡ã®äººéçéèŠæ§ã«ãã£ãŠæ±ºå®ãããçšåºŠã決ããŠè¶ ããŠã¯ãªããªãã
7. å·å®³ãéå®³ãæ»äº¡ã®å¯èœæ§ããå®éšè ãä¿è·ããããã«ãé©åãªæºåãšé©åãªæœèšãæäŸãããªããã°ãªããªãã
8. å®éšã¯ãç§åŠçãªè³æ Œãæããè ã®ã¿ãè¡ããã®ãšãããå®éšãè¡ãè åã¯å®éšã«åŸäºããè ã«ã¯ãå®éšã®å 𿮵éãéããŠæé«åºŠã®æéãšæ³šæåãèŠæ±ãããã
9. å®éšäžã«ã被éšè ãå®éšã®ç¶ç¶ãäžå¯èœãšæããã身äœçåã¯ç²Ÿç¥çç¶æ ã«ãªã£ãå Žåã«ã¯ãèªç±ã«å®éšãçµäºãããããšãã§ããããšã
10.å®éšäžãæ åœç§åŠè ã¯ãèª å®ããåªããæè¡ãæ éãªå€æåãçºæ®ããŠãå®éšã®ç¶ç¶ãå®éšå¯Ÿè±¡è ã®å·å®³ãéå®³ãæ»äº¡ã«ã€ãªããå¯èœæ§ãé«ããšä¿¡ããã«è¶³ãçç±ãããããããå Žåãã©ã®æ®µéã§ãå®éšãçµäºããçšæãããŠãããªããã°ãªããªãã
(匷調)
ãã¥ã«ã³ãã«ã¯ãšCOVIDã®å±æ©
2020幎12æãããå€ãã®åœã®åœæ°å
šäœããæºæ ããŠäºé²æ¥çš®ãåããããè
ããããŠããã
ãã¥ã«ã³ãã«ã¯ç¶±é ãåç
§ãããšã圌ãã¯ä»¥äžã®ããšãã§ããªãã
ãå§åãè©æ¬ºã欺çã匷èŠãé床ãªèŠæ±ããŸãã¯ä»ã®äžå¿ã«åºã¥ãå¶çŽã匷å¶ã®èŠçŽ ãä»åšããããšãªããèªç±ãªéžææš©ãè¡äœ¿ããããšãïŒäžèšãã¥ã«ã³ãã«ã¯åå1ïŒã§ãã
ååã«ç«èšŒãããŠããããã«ãmRNAã¯ã¯ãã³ã®æ»å·è ã¯äžçäžã§å¢å åŸåã«ãããä¿å¥åœå±ã¯ãå¥åº·è¢«å®³ããååã«èªèããŠããã«ãããããããåœæ°ã«ã¯ç¥ãããŠããªããã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãããªãããããŠãã¡ãã£ã¢ã¯æ¯ã«è¡£çãã¬åãèšã£ãŠããã
131
ãæ»ãé害ãèµ·ãããšä¿¡ããå éšçãªçç±ãããå Žåã¯ããããªãå®éšãè¡ã£ãŠã¯ãªããªããïŒäžèšãã¥ã«ã³ãã«ã¯åå5ïŒ
ãã¥ã«ã³ãã«ã¯åå5ã«æŠèª¬ãããŠããäžèšã®ãå éšççç±ãã¯ãååã«ç«èšŒãããŠãããæ»ãé害ãããããå·å®³ã¯ãå°çå šäœã®ã¬ãã«ã§é²è¡ããŠããŸãããããã¯mRNAã¯ã¯ãã³ã®æ»äº¡çãšçœ¹æ£çã®å ¬åŒçµ±èšïŒEUãç±³åœãè±åœïŒã«ãã確èªãããŠããã
ããã¹ã® ãå»åŠå®éšã
匷å¶å容æã®å人ã«å¯ŸããŠè¡ãããããã¹ã®ãå»åŠå®éšãã«é¢ããå
·äœçãªç¯çœªã®åé¡ãæãèµ·ãããŠã¿ãããããã«ã¯ããè§£ååŠçç ç©¶ã®ããã®ãŠãã€äººã®æ®ºå®³ãçµæ žã«ããã£ãããŒã©ã³ãäººã®æ®ºå®³ããã€ããšå é å°ã«ãããç
æ°ãé害ãæã£ãæ°é人ã®å®æ¥œæ»ããå«ãŸããŠããŸãã... ã7
ã«ãŒã«ã»ãã©ã³ããšä»ã®6人ã®è¢«åã¯æçœªå€æ±ºãåãæ»åã宣åããã9人ã®è¢«åã¯æçœªå€æ±ºãåãçŠåºåã宣åããã7人ã®è¢«åã¯ç¡çœªãèšãæž¡ãããã
è£å€ã®æžé¡ãšèšŒæ ã¯ãã¹ãŠä¿ç®¡ãããŠããã被åã¯ãæŠäºç¯çœªãšäººéã«å¯Ÿãã眪ã§èµ·èšŽãããã

äžççãªCOVID-19ã¯ã¯ãã³äœæŠã®èŠæš¡ãšå€§ãã
ãã¥ã«ã³ãã«ã¯ã®ååã¯COVID-19ã¯ã¯ãã³ã»ãããžã§ã¯ããšæãé¢é£æ§ãé«ãã®ã§ãããåçŽãªæ¯èŒã¯é¿ããã¹ãã§ããããmRNAãã¯ã¯ãã³ãã«é¢é£ããæèãæŽå²ãéµå®ã®ã¡ã«ããºã ã¯æ ¹æ¬çã«ç°ãªã£ãŠããã®ã§ãã
äžççãªCOVAXäœæŠã®èŠæš¡ãšå€§ããããããŠãã®è€éãªçµç¹æ§é ã
132
(WHOãGAVIãã²ã€ã財å£ãããã°ãã¡ãŒãïŒã¯ãåäŸããªãã
人é¡å
šäœããŽã¡ããã¯ã¹ã»ãããžã§ã¯ãã®å¯Ÿè±¡ã§ãããCOVID-19ã¯ã¯ãã³ã®å®éšå¯Ÿè±¡è
ã¯ãå°çäžã®å
šäººå£ã§ããã
çŽ80åäººãæ°åã®æ¥çš®ã䌎ãã
äžç人å£ã«4ååãæãããšïŒãã¡ã€ã¶ãŒç€Ÿã®ææ¡ïŒïŒæ¡éãã®300åååãå šäžçã§æ¥çš®ãããã
ãã®æ°ã¯æ°ååã«ã®ãŒããæ»äº¡çã眹æ£çã«äžãã圱é¿ã¯ãèšèã§ã¯èšã衚ããªãã»ã©å€§ããã
ãã®å®æ°ããŒãããŒã·ããã®ãããžã§ã¯ãã®èåŸã«ã¯ãããã°ãããŒãããã
ç§ãã¡ã¯ã人é¡ã«å¯Ÿããç¯çœªã®äžççãªéçšãæ±ã£ãŠããã®ã§ããåœé£ã®å€æ°ã®å çåœã®åœæ°å
šäœããïŒæ³ã®æ¯é
ãªãã«ïŒé å®ãšåŒ·å¶ã®å¯Ÿè±¡ãšãªãã
ãã圌ããã¯ã¯ãã³ãæåŠããã°ã瀟äŒçã«çå€ãããç£çŠãããéçšäž»ããæçµ¶ããã瀟äŒããæçµ¶ãããæè²ãåããããããã£ãªã¢ããªãã人çããŸãŸãªããªãã®ã§ãã圌ãã®äººçã¯ç Žå£ãããã
ãã圌ããã¯ã¯ãã³ãåãå
¥ããã°ã圌ãã®å¥åº·ãšçåœã¯æœåšçã«å±éºã«ãããããŸãã
çŸåšïŒå
¬åŒããŒã¿ïŒãšå°æ¥ïŒäŸïŒæªæ€åºã®åŸ®å°è¡æ ïŒã®äž¡æ¹ã§ãã¯ã¯ãã³æ¥çš®ã«ããæ»äº¡çãšçœ¹æ£çã®èšŒæ ã¯å§åçã§ããïŒç¬¬VIIIç« åç
§ïŒã
ãããŠãããã¯ã»ãã®å§ãŸãã«éããªãã
äžçäžã§äººéã«å¯Ÿããåºç¯ãªç¯çœªãè¡ãããŠããã
mRNAãã¯ã¯ãã³ãã¯ãå°çå
šäœã®ã¬ãã«ã§ããã²ãã ãæ¹å€ãããããã¯å€§éèæ®ºã ã
ç§ãã¡ã®ç®ã®åã§èµ·ãã£ãŠãããããã倧ããªããã³ãŒã¹ãããªã®ã ã
å·»æ«è³æ
1. ã©ãã»ãã¬ã«ã»ãã³ãã©ãŒããã¬ãŒã»ã·ã£ããªãŒã«ãä»ã2021幎9æ16æ¥ãã³ããã»ããã³ãŒã¹ãã黿¢ãã! å
¬éæžç°¡ãhttps://www.globalresearch.ca/stop-the-covid-holocaust-open-letter/5755902
2. WHOã2021 幎 8 æ 27 æ¥ãCOVID-19èšŒææžã®ããžã¿ã«ææžïŒã¯ã¯ãã³æ¥çš®ç¶æ³ïŒãŠã§ãä»å±æžAïŒDDCC:VSã³ã¢ããŒã¿èŸæžã2021幎8æ27æ¥. https://www.who.int/publications/i/item/WHO-2019-nCoV-Digital_certificates-vaccination-data_dictionary-2021.1
3. Harvard Law School, n.d. NMT Case 1: U.S.A. v. Karl Brandt et al.ã§ããThe Doctors' https://nuremberg.law.harvard.edu/nmt_1_intro
4. åäž.
5. US Holocaust Memorial Museum, n.d. Nuremberg Code. https://www.ushmm.org/information/exhibitions/online-exhibitions/special-focus/doctors-trial/nuremberg-codeïŒã¹ãã·ã£ã«ã»ãã©ãŒã«ã¹/ãã¯ã¿ãŒãºã»ãã©ã€ã¢ã«/ãã¥ã«ã³ãã«ã¯ã»ã³ãŒã
6. åäžã
7. Harvard Law School, n.d. NMT Case 1: U.S.A. v. Karl Brandt et al.ïŒããŒããŒãå€§åŠæ³ç§å€§åŠé¢ãn.d. NMT Case 1: U.S.A. v. Karl Brandt et al: The Doctors' Trial. https://nuremberg.law.harvard.edu/nmt_1_intro
133
--------------------第12ç« -------------------
äžççãªã¯ãŒãã¿ãŒãšã倧ãªã»ãã äžççãªåµåãš
æ°èªç±äž»çŸ©ç㪠ãã·ã§ãã¯çæ³ã
ãIMFãäžçéè¡ããããŠäžçã®æå°è
ãã¡ã¯ãCOVIDé¢é£ã®ããã¯ããŠã³ã«ãã£ãŠäžççµæžãééããããšããäžçã®è²§å°å±€ã«ã©ã®ãããªåœ±é¿ãäžããããååæ¿ç¥ããŠããã
ãããã圌ãã¯ãããèªå¯ããããããŠä»ã2022幎ã ãã§ããäžçäžã§ããã«2å5000äžäººä»¥äžã®äººã
ãæ¥µåºŠã®è²§å°ã«é¥ããšããèŠéããç«ã£ãŠãããã(ã³ãªã³ã»ããããã³ã¿ãŒã2022幎7æå·)
çµæžãã·ã§ãã¯çæ³ãã®æŽå² æ§é 調æŽããã°ã©ã ïŒSAPïŒãã ãã°ããŒãã«ã»ã¢ãžã£ã¹ãã¡ã³ãïŒGAïŒããž
2020幎3æ11æ¥ïŒåæïŒãåœé£å çåœçŽ193ã«åœã®åœå®¶çµæžãééããããšã¯ã極æªééã§å代æªèã®ããšã§ããäœçŸäžäººãã®äººã
ãè·ã倱ããçæ¶¯ã®è²¯èã倱ã£ãŠãããçºå±éäžåœã§ã¯ãè²§å°ã飢é€ãçµ¶æãèå»¶ããŠãããåœå®¶çµæžã®ééã¯ãäžççãªåµåã®èšåŒµãæããããŸããŸãååœæ¿åºã¯åµæš©è
ã«æ¯é
ããã瀟äŒçã»ãŒããã£ããããäŒæ¥ææžãæåœãŠã«è³éãäŸçµŠããŠããã®ãçŸç¶ã ã
ãã®ãããªãã°ããŒãã«ãªä»å
¥ãã¢ãã«ã¯åäŸããªãããIMFã«ãã匷åãªãçµæžè¬ãã®æŒãä»ããªã©ãåœã¬ãã«ã®ãã¯ãçµæžæ¹é©ãæãããç¹åŸŽãããããã®åé¡ã解決ããããã«ããããããçµæžçã·ã§ãã¯çæ³ãïŒ1970幎代ã«åããŠäœ¿ãããèšèïŒã®æŽå²ãæ€èšŒããŠã¿ãã1ã
1973幎9æ11æ¥ãããªãžãã©ãã·ã¥ããã¯
ç§ã¯ãããªã»ã«ããªãã¯å€§åŠã®å®¢å¡ææãšããŠãæ°äž»çã«éžåºãããã¢ãžã§ã³ãæ¿æš©ã«å¯Ÿããè»äºã¯ãŒãã¿ãŒãçµéšãããããã¯ãããã·ã³ãžã£ãŒåœåé·å®ãçããCIAã®äœæŠã§ãããç Žå£çãªãã¯ãçµæžæ¹é©ãè¡ãããã
ã¯ãŒãã¿ãŒã®ç¿æããã³ã®äŸ¡æ Œã¯äžå€ã«ããŠ11ãšã¹ã¯ãŒããã40ãšã¹ã¯ãŒãã«äžæããã2ã ãããã§ãç¬è£æ¿æš©äžã§å®è³ªè³éãšéçšãèšç»çã«åŽ©å£ããå
šåœçã«è²§å°åãé²è¡ããã
134

é£ç³§äŸ¡æ Œãé«éš°ããäžæ¹ã§ããçµæžã®å®å®ãšã€ã³ãã¬æå¶ãã®ããã«è³éã¯åçµãããã1幎足ããã®éã«ãããªã®ãã³ã®å€æ®µã¯36åã«ãªããããªã®äººå£ã®85ïŒ ãè²§å°ç·ä»¥äžã«è¿œãããããã®ã§ãããããã1973幎ã®ããªã®ããªã»ãããã§ããã
ãã®äºå¹ŽååŸã®1976幎ãç§ã¯ç£æ¥ã®äžå¿å°ã§ããã¢ã«ãŒã³ãã³åéšã«ããã³ã«ããåœç«å€§åŠã®å®¢å¡ææãšããŠã©ãã³ã¢ã¡ãªã«ã«æ»ã£ããç§ã®æ»åšã¯1976幎3æã®è»äºã¯ãŒãã¿ãŒãšéãªã£ãã
èæ®ºãšäººæš©äŸµå®³ã®èåŸã«ã¯ã ãèªç±åžå Žã ãã¯ãçµæžæ¹é©ãèŠå®ãããŠãã-ä»åã¯ã¢ã«ãŒã³ãã³ã®ãã¥ãŒãšãŒã¯åµæš©è ã®ç£ç£ã®äžã§-ãã®äžã«ã¯ãè»äºæ¿æš©ã®çµæžå€§è£ãã»ã»ã¢ã«ãã¬ãã»ãã«ãã£ãã¹ã»ãã»ããºã®å人ã§ãã£ããã€ãŽã£ããã»ããã¯ãã§ã©ãŒãå«ãŸããŠãã3ã

ããªãšã¢ã«ãŒã³ãã³ã¯ãæ¥ãã¹ããã®ã®ããã®ããã¬ã¹ãªããŒãµã«ãã§ãã£ããIMFã»äžçéè¡ã®æ§é 調æŽããã°ã©ã ïŒSAPïŒã®æŒãã€ãã¯ã1980幎代åé ãã100ã«åœä»¥äžã«åãã ïŒMichel Chossudovsky, The Globalization of Poverty and the New World Order, Global Research, 2003åç §ïŒ4ã
ãèªç±åžå Žãã®æªåé«ãäŸã§ããã1990幎8æã®ãã«ãŒã¯ãIMFã®æç€ºã«åŸããªãã£ãããã«åŠçœ°ããããçæäŸ¡æ Œã¯31åããã³ã®äŸ¡æ Œã¯1æ¥ã§12å以äžã«è·³ãäžãã£ã5 ããããã®æ¹é©ã¯ãæ°äž»äž»çŸ©ãã®åã®äžã«è¡ãããããè»äºæ¯é ã®æ³ã®äžã§ããªãšã¢ã«ãŒã³ãã³ã«é©çšããããã®ããã¯ããã«ç Žå£çã§ãã£ãã
2020幎3æã®ããã¯ããŠã³ ãçµæžæŠäºã
ãããŠä»ã2020幎3æ11æ¥ãæã ã¯ãã¯ãçµæžã®äžå®å®åãšããæ°ããªå±é¢ãè¿ããããã¯40幎ã«ããããã·ã§ãã¯çæ³ããšç·çž®è²¡æ¿ã®æŒãã€ããããç Žå£çã§ãã
135
IMFã¯éèçã®æ¯é
çãªå©çã代åŒããŠããã
ããã«ã¯æçµ¶ããããæŽå²çæçµ¶ããããšåæã«ãé£ç¶æ§ããããããã¯ ãæ°èªç±äž»çŸ© ãã®æ¥µèŽã§ããã
äžççµæžã®ééãå°çå
šäœã®ã¬ãã«ã§ã®çµæžçã»ç€ŸäŒç圱é¿
仿¥ãäžççµæžã«èµ·ããŠããããšããæ§é 調æŽããã°ã©ã ïŒSAPïŒã®äžã§åµæš©è
ã課ããåœããšã®ã亀æžã«ããããã¯ãçµæžæªçœ®ãšæ¯èŒããŠã¿ããã2020幎3æ11æ¥ã®ãäžç調æŽãã¯ãååœæ¿åºãšäº€æžããããã®ã§ã¯ãªããããã¯ãåœã®ç§åŠã«æ¯ããããã¡ãã£ã¢ã®ãããã¬ã³ãã«æ¯ããããå
±è¬ããŠè
æããæ¿æ²»å®¶ã«åãå
¥ããããã宿°ããŒãããŒã·ãããã«ãã£ãŠæŒãã€ãããããã®ã§ããã
瀟äŒçäžå¹³çãšè²§å°åããä»çµãã ãè²§å°ã®ã°ããŒãã«å
å°çå
šäœã«åœ±é¿ãåãŒã2020幎3æ11æ¥ã®ãäžç調æŽããã¬ã€ãã©ã€ã³ããã1973幎9æ11æ¥ã®ããªãšæ¯ã¹ãŠã¿ããã
ç®èãªããšã«ã2020幎ã®ãäžç調æŽãã®èåŸã«ããåã倧éæã¡ããããªïŒ1973幎ïŒãšã¢ã«ãŒã³ãã³ïŒ1976幎ïŒã«ç©æ¥µçã«é¢äžããŠããã®ã§ããããã³ã³ãã«äœæŠããšãããŒãã£ãŠã©ãŒïŒGuerra SuciaïŒããæãåºããŠã»ããã
é£ç¶æ§ããããé£éŠæºåå¶åºŠçäºäŒããŠã©ãŒã«è¡ãåœé決æžéè¡ïŒBISïŒãäžççµæžãã©ãŒã©ã ïŒWEFïŒãšé£æºããŠããIMFãšäžçéè¡å®åãå«ãåã匷åãªéèå©çå£äœã¯ãçŸåšãã°ã¬ãŒããªã»ããã®äžã§ïŒåµæš©è
ã®ããã«ïŒãã¹ããã³ãããã¯ãæ°åãåµååŠçã®æºåãšç®¡çã«é¢äžããŠããã
ãã³ãªãŒã»ããã·ã³ãžã£ãŒã¯ã1973幎9æ11æ¥ã®ããªã®ããªã»ãããã®èª¿æŽã«æºãã£ãã
ç¿1974幎ã«ã¯ããåœå®¶æŠç¥å®å
šä¿éã¡ã¢ã©ã³ãã 200ïŒNSSM200ïŒãã®èµ·èãæ
åœããäººå£æžå°ãã第äžäžçã«å¯Ÿããç±³åœã®å€äº€æ¿çã®æåªå
äºé
ããšäœçœ®ã¥ãã6ã
ã°ã¬ãŒãã»ãªã»ããã®ããšã§ã®ãéçåãæšãé²ããïŒ

仿¥ããã³ãªãŒã»ããã·ã³ãžã£ãŒã¯ãã²ã€ã財å£ïŒã²ã€ã財å£ãäººå£æžå°ã匷ãæãã§ããïŒãšå ±ã«ãäžççµæžãã©ãŒã©ã ïŒWEFïŒã®åŸæŽã®äžãã°ã¬ãŒãã»ãªã»ããã匷åºã«æ¯æããŠããïŒç¬¬XIIIç« åç §ïŒã
ååœæ¿åºãšã®äº€æžããæ¿æš©äº€ä»£ãã®å®è¡ãå¿ èŠãªãã2020幎3æ11æ¥ã®å°éèšç»ã¯ã150ã«åœä»¥äžã®åœæ°çµæžã«äžæã«åœ±é¿ãäžãããããå€§èŠæš¡ãªç Žç£ã倱æ¥ãæ°å¶åãèªçºãããäžç調æŽãã§ããã
ãããŠããã®äžé£ã®ããã»ã¹ã¯ãCDCãšWHOã«ããã°å£ç¯æ§ã€ã³ãã«ãšã³ã¶ã«äŒŒããæ®ºäººãŠã€ã«ã¹ãã«å¯Ÿæããææ®µãšããŠäžè«ã«æç€ºãããïŒç¬¬IIIç« åç §ïŒã
136
ã°ããŒãã«è³æ¬äž»çŸ©ã®èп𩿧é
åäžé·è
ã®è²¡å£ãå«ãããã°ãããŒãåååã§ããããŠã©ãŒã«è¡ãšéè¡ãç³æ²¹ã»ãšãã«ã®ãŒè€åäŒæ¥ããããããé²è¡è«è² æ¥è
ãã倧æè£œè¬äŒç€Ÿããã€ãªãã¯ãããžãŒè€åäŒæ¥ãäŒæ¥ã¡ãã£ã¢ãéä¿¡ã»ããžã¿ã«æè¡å€§æãããã«ã·ã³ã¯ã¿ã³ã¯ããããŒå£äœãç ç©¶æãªã©ã®ãããã¯ãŒã¯ãè€éã«çµ¡ã¿åã£ãŠãããç¥ç財ç£ã®æææš©ãäžå¿çãªåœ¹å²ãæ
ã£ãŠããã
ãã®åŒ·åãªããžã¿ã«éèæææ±ºå®ãããã¯ãŒã¯ã«ã¯ãäž»èŠãªåµæš©è
ã»éè¡æ©é¢ã§ããé£éŠæºåéè¡ã欧å·äžå€®éè¡ïŒECBïŒãIMFãäžçéè¡ãå°åéçºéè¡ãããŒãŒã«åœé決æžéè¡ïŒBISïŒãªã©ãåå ããŠãããéèŠãªæŠç¥ç圹å²ãæ
ã£ãŠããã
æã匷åãªéèæ©é¢ã¯ã以äžã®ãããªå·šå€§ãªæè³ããŒããã©ãªãªã³ã³ã°ãããªããã§ããã
ãã©ãã¯ããã¯ããã³ã¬ãŒããã¹ããŒãã¹ããªãŒãããã£ããªãã£ãªã©ã§ããã圌ããæ¯é
ããŠããã
ã...éçšè³ç£ã¯åãããŠ20å ãã«....æ§ããã«æ°ããŠã4åãã5åã®ã¬ãã¬ããžå(ããªãã¡ã80ç±³ãã«ãã100å ç±³ãã«çšåºŠ)ããããã®åŒ·åãªéèã³ã³ã°ãããªããã¯ãäžçã®GDPãäžåãçŽ82å ãã«ã®ã¬ãã¬ããžãæã£ãŠãããã7
ããã«ããã³ã¿ãŽã³ãç±³åœæ å ±æ©é¢ïŒããã³ãã®ç ç©¶æïŒãä¿å¥åœå±ãåœåå®å šä¿éçãç±³åœåœåçïŒ150ã«åœä»¥äžã®ç±³åœå€§äœ¿é€šãå«ãïŒãªã©ãç±³åœã®åœå®¶æ©æ§ã®äžå±€éšïŒããã³ç±³åœã®è¥¿åŽåçåœïŒãçŽæ¥çã鿥çã«é¢äžããŠããã
ãå®äœçµæž ããš ãããã°ãããŒã
ãªãããã®ãããªCOVIDããã¯ããŠã³æ¿çããç Žç£ãè²§å°ã倱æ¥ã®å
é£ãåã£ãŠããã®ãïŒ
ã°ããŒãã«è³æ¬äž»çŸ©ã¯äžæå²©ã§ã¯ãªãã確ãã«ãè¶
å¯è£å±€ãšäžç人å£ã®å€§å€æ°ãšã®éã«ããéçŽéäºãããã
ãããã°ãããŒè³æ¬ããšãåœãå°åã¬ãã«ã®ããŸããŸãªçç£æŽ»ååéã®äŒæ¥ã§æ§æããããçã®è³æ¬äž»çŸ©ããšãèšãã¹ããã®ãšã®éã®å¯Ÿç«ã§ããããã®äžã«ã¯ãäžå°äŒæ¥ãå«ãŸããã
ä»ãäžçå²äžé¡ãèŠãªãå¯ã®éäžïŒãšå
端æè¡ã®æ¯é
ïŒãé²è¡äžã§ãããéèæ©é¢ïŒæ°ååãã«ã®åµæš©è
ïŒãç Žç¶»äŒæ¥ãåœå®¶è³ç£ã®å®ç©è³ç£ãå奪ããäºå®ã§ããã
ãå®äœçµæžããšã¯ãçç£è³ç£ã蟲æ¥ãå·¥æ¥ããµãŒãã¹æ¥ãçµæžç€ŸäŒåºç€ãæè³ãéçšãªã©ãå®éã®çµæžæŽ»åã®ãçµæžç颚æ¯ããæ§æãããã®ã§ãããäžçã¬ãã«ãåœå®¶ã¬ãã«ã®å®äœçµæžããçµæžæŽ»åã®å°éã»ééã®å¯Ÿè±¡ã«ãªã£ãŠãããã°ããŒãã«ãããŒã®éèæ©é¢ã¯ãå®äœçµæžã®ã嵿š©è
ãã§ããã
ã°ããŒãã«ã»ã¬ããã³ã¹ å šäœäž»çŸ©åœå®¶ãž
2019幎10æ18æ¥ã®201ã·ãã¥ã¬ãŒã·ã§ã³ã«é¢ãã£ãå人ãçµç¹ã¯ã2020幎1æ30æ¥ã«WHOã®åœéçã«æžå¿µãããå ¬è¡è¡çäžã®ç·æ¥äºæ ïŒPHEICïŒã®äžã§æ¬çšŒåãããšãå®éã®å±æ©ç®¡çã«é¢ããããšã«ãªãããã®çµæãèå°ã¯
137
2020幎2æã®éè屿©ãš3æã®éåœïŒç¬¬â
ç« åç
§ïŒã
åœæ°çµæžã®ééãšéå¡ã¯ãäžå°äŒæ¥ã®èšç»åç£ïŒäžçäžã§é©çšïŒãšçžãŸã£ãŠã倧éã®å€±æ¥ã®æ³¢ãåŒãèµ·ãããïŒç¬¬IVç« åç
§ïŒã
ããããã¹ãŠã¯ãããããæè°ãæµæã®åœ¢ã厩ãããšããã°ããŒãã«ãªå
šäœäž»çŸ©åœå®¶ã®èšçœ®ã«ãã£ãŠå
å°ãããŠããã
COVIDã¯ã¯ãã³æ¥çš®ããã°ã©ã ïŒåã蟌ãŸããããžã¿ã«ãã¹ããŒããšQRã³ãŒããå«ãïŒã¯ãã°ããŒãã«å
šäœäž»çŸ©äœå¶ã®äžå¯æ¬ ãªéšåã§ããïŒç¬¬VIIIç« ãšç¬¬XIIIç« ãåç
§ïŒã
æªåé«ãID2020ãšã¯äœã ããããåœé£æ©é¢ãåžæ°ç€ŸäŒãªã©ã宿°ã®ããŒãããŒã«ããåçã§ãããäžè¬çãªã¯ã¯ãã³æ¥çš®ãããžã¿ã«IDã®ãã©ãããã©ãŒã ãšããé»åIDããã°ã©ã ã ããã®ããã°ã©ã ã¯ãæ¢åã®åºçç»é²ãšäºé²æ¥çš®ã®æ¥åãå©çšããŠãæ°çå ã«æºåž¯å¯èœã§æ°žç¶çãªãã€ãªã¡ããªãã¯ã«ãªã³ã¯ããããžã¿ã«IDãæäŸããŸããã¬ãããŸãŒã³ããã§ã€ã¹ãã¹ã¯ã瀟äŒçè·é¢ãããã¯ããŠã³ã(ããŒã¿ãŒã»ã±ãŒãããã2020幎3æ12æ¥)8
ãã°ã¬ãŒã ãªã»ããã
COVIDäžçåµå屿©ãåŒãèµ·ãããã®ãšåã匷åãªåµæš©è ããçŸåšãäžççµæžãã©ãŒã©ã ããã°ã¬ãŒãã»ãªã»ããããšè¡šçŸãããã®ã課ãããšã§æ¬è³ªçã«æãç«ã€ãæ°åžžæ ãã確ç«ããŠããã
ãã®å€é©ãæšãé²ããããã«COVID-19ã®ããã¯ããŠã³ãå¶éãå©çšãããã°ã¬ãŒããªã»ãããã¯ã第4æ¬¡ç£æ¥é©åœããè£ ã£ãŠå±éãããŠãããå€ãäŒæ¥ã¯åç£ã«è¿œã蟌ãŸãããç¬å äŒæ¥ã«åžåãããCOVID以åã®çµæžã®å·šå€§ãªéšåãäºå®äžééããŠããã®ã§ãããçµæžã¯ããªã¹ãã©ããããå€ãã®ä»äºãAIé§åã®æ©æ¢°ã«ãã£ãŠæ ãããããšã«ãªãã
è·ã倱ã£ã人ãã¡ïŒãããŠãã®å€ãã¯ãããªãã ããïŒã¯ãããçš®ã®ãŠãããŒãµã«ã»ããŒã·ãã¯ã€ã³ã«ã ã«é ããããè³ç£ãåœå®¶ãããæ£ç¢ºã«ã¯ãã®ã°ã¬ãŒããªã»ãããåŸæŒãããéèæ©é¢ã«æž¡ã代ããã«ãè² åµïŒå€§èŠæš¡ãªè² åµãšç Žç£ã¯ãããã¯ããŠã³ãšèŠå¶ã®æå³çãªçµæã§ããïŒãåž³æ¶ãã«ãããããšã«ãªãã®ã ãããWEFã¯ãåœæ°ãå¿ èŠãšãããã®ã¯ãã¹ãŠãã¬ã³ã¿ã«ããããšèšã£ãŠããããæç¶å¯èœãªæ¶è²»ããšãå°çãæãããšããåç®ã®ããšãæææš©ãå¥å¥ªããã®ã§ããããã¡ããããã®ã°ã¬ãŒããªã»ãããå±éããæ¥µå°ã®ãšãªãŒãããã¹ãŠãææããããšã«ãªãã(ã³ãªã³ã»ããããã³ã¿ãŒããã£ã¹ããã¢å€§ãªã»ããã2020幎11æ9æ¥)9
ãªã»ãããã¿ã³ãæŒã
äžççµæžãã©ãŒã©ã ã®ã°ã¬ãŒãã»ãªã»ããã¯ãé·ãæéããããŠè¡ãããŠãããäžççµæžãæãããšãèŠéã«å ¥ãã ãPush the reset button"ãã¯ãCOVID-19ãã³ãããã¯ã®çåšãæ¯ãã6幎åã®2014幎1æã«WEFäŒé·ã¯ã©ãŠã¹ã»ã·ã¥ã¯ãã«ãã£ãŠçºè¡šãããŸããã
ãä»å¹ŽïŒ2014幎ïŒã®ããã¹äŒè°ã§ããããããšã¯ããªã»ãããã¿ã³ãæŒãããšã ãäžçã¯ããŸãã«ã屿©çç¶æ³ã«é¥ã£ãŠãããã
2幎åŸã®2016幎ãã¹ã€ã¹ã®ãã©ã³ã¹èªãã¬ãå±ïŒRTSïŒã®ã€ã³ã¿ãã¥ãŒã§ãã¯ã©ãŠã¹ã»ã·ã¥ã¯ãã¯äººäœã«ãã€ã¯ãããããåã蟌ãããšã«ã€ããŠè©±ããããã¯èŠããã«ãå®éšçãCOVID mRNA ã¯ã¯ãã³ã®åºç€ãšãªããã®ã§ããã
138
ã¯ã©ãŠã¹ã»ã·ã¥ã¯ãæ°ã¯ãããããããèŠãŠããã®ã¯ãç©ççäžçãšããžã¿ã«äžçãšçç©åŠçäžçã®èåã§ããããšèªã£ãã
ã·ã¥ã¯ãæ°ã¯ã人éã¯è¿ãå°æ¥ãããžã¿ã«äžçãšèåããããã«ãäœå ã«ããããåã蟌ãããšã«ãªããšèª¬æããã
RTSïŒãããã¯ãã€ããã«ãªãã®ã§ããããïŒã
KSïŒãééããªããä»åŸ10幎以å ã§ããããã
ãè³ãç®èã«åã蟌ããšããããšãæ³åã§ããŸããã
ããããŠãè³ãšããžã¿ã«ã¯ãŒã«ãã®éã«çŽæ¥çãªéä¿¡ãè¡ãããããšãæ³åã§ããŸããã
ããŒã¿ãŒã»ã±ãŒãããã®ã€ã³ã¿ãã¥ãŒãTowards Digital Tyrannyãã¯ãã¡ãããã芧ãã ãããBitchuteçã¯ãã¡ãã
2020幎6æ WEFããã°ã¬ãŒãã»ãªã»ããããæ£åŒçºè¡š
ããã³ãããã¯ã¯ãããå¥åº·ã§ãããå ¬å¹³ã§ãããè±ããªæªæ¥ãåµé ããããã«ãç§ãã¡ã®äžçãæ¯ãè¿ããåæ³åãããªã»ãããããçšã§ãããªããçãæ©äŒã®çªã瀺ããŠããŸããã - ã¯ã©ãŠã¹ã»ã·ã¥ã¯ããWEFïŒ2020幎6æïŒ
ã°ã¬ãŒãã»ãªã»ãããã§æ³å®ãããŠããã®ã¯ã2030幎ãŸã§ã«äžçã®åµæš©è ãäžçã®å¯ãå奪ããäžæ¹ã§ãäžçã®äººå£ã®å€§éšåãè²§å°åããããšããã·ããªãªã§ããã
2030幎ã«ã¯ããããªãã¯äœãæããªããªãã幞ãã«ãªãããã(ãããªãèŠãã«ã¯ãããã¯ãªãã¯ããŠãã ãã)
åœé£ ïŒéžæã§éžã°ããªã宿°ããŒãããŒã·ããã®ããã®ã°ããŒãã«ã»ã¬ããã³ã¹ã®éå ·
139
åœé£ã·ã¹ãã ãå æ ããŠãããåœé£ã¯ãã°ããŒãã«ã»ã¬ããã³ã¹ããšãã°ã¬ãŒãã»ãªã»ããããæ¿èªããŠãããããã«ã³ãããã ã

ã¢ã³ãããªã»ã°ããŒã¬ã¹åœé£äºåç·é·ã¯ããã³ãããã¯ããå¥åº·å±æ©ä»¥äžã®ãã®ãã§ããããšãæ£ããèªèããŠãããããã®å±æ©ã®çã®åå ã«ã€ããŠãåœé£ã®åŸæŽã®äžãææçŸ©ãªåæãè°è«ãè¡ãããŠããªãã
2020幎9æã®åœé£å ±åæžã«ãããš
ãäœåäžäººãã®åœã倱ããããæ°ååã®äººã ã®ç掻ãç Žå£ããããå¥åº·ãžã®åœ±é¿ã«å ããCOVID-19ã¯æ·±ãäžå¹³çãé²åããæªåããã......ãå人ãšããŠãå®¶æãšããŠãå°å瀟äŒãšããŠããããŠç€ŸäŒãšããŠåœ±é¿ãåãŒããŠããããŸã çãŸããŠããªã人ãå«ããããããäžä»£ã«åœ±é¿ãåãŒããŠããŸãããã®å±æ©ã¯ãåœå ããã³åœå®¶éã®è匱æ§ããããŠå ±éã®è åšã«å¯ŸããŠã°ããŒãã«ã«å調ããŠå¯Ÿå¿ããããã®ã·ã¹ã ã ã®è匱æ§ãæµ®ã圫ãã«ããŸããã(åœé£å ±åæž)10
äžçäžã®ç€ŸäŒçã»çµæžçç Žå£ã®åŒãéãšãªã£ãé å€§ãªæ±ºå®ã«ã¯èšåããªããåœé£å®ä¿çã§è°è«ãããªããåœé£å®ä¿çã®5ã€ã®åžžä»»çäºåœãã¹ãŠã®åæã
V the Virusã¯ããããªãçµæžç Žå£ã®ããã»ã¹ã®è²¬ä»»ãè² ããããŠããã
äžççµæžãã©ãŒã©ã ã® ãReimagine and Reset Our World ïŒäžçãåæ§ç¯ãããªã»ããããïŒããšé¡ãã宿°ããŒãããŒã·ããã®ãããžã§ã¯ãã¯ãåœé£ã«ãã£ãŠæ¿èªãããã

1940幎代åŸåã®ãžã§ãŒãžã»ã±ãã³ãšãã«ãŒãã³ã»ãã¯ããªã³ã«æãã銳ããŠã¿ãããã±ãã³ã¯ãåœé£ããæš©åãšé埳ãçµã³ã€ãããããã®æå¹ãªææ®µã§ãããã¢ã¡ãªã«ã®ã人éçæŠäºãã«ãŽã å°ãæŒãããã®ææ®µãšããŠé埳ãå©çšãããã®ã ãšèããŠããã
ã³ãã屿©ãããã¯ããŠã³æªçœ®ãmRNAã¯ã¯ãã³ã¯ãæŽå²çããã»ã¹ã®é倧æã§ããã
äžççµæžã®ããã¯ããŠã³ãšééã¯ãæ¬åœã®æå³ã§ã人ã ã®ç掻ãç Žå£ãããã倧éç Žå£å µåšããªã®ã§ããååã«èšŒæãããŠããããã«ãCOVID-19 mRNAã¯ã¯ãã³ã¯ã殺人ã¯ã¯ãã³ããšè¡šçŸããã®ãæããµããããã
ç§ãã¡ãæ±ã£ãŠããã®ã¯ãåºç¯ãªã人éã«å¯Ÿãã眪ããªã®ã§ãã
ãžã§ãŒã»ãã€ãã³å€§çµ±é ãš ãã°ã¬ãŒãã»ãªã»ããã
ãžã§ãŒã»ãã€ãã³ã¯ãéèæ©é¢ã®å©çã«å¥ä»ãããä¿¡é Œã§ãã代ç人ãšããŠãè²ãŠãããæ¿æ²»å®¶ã§ããã
140
ãžã§ãŒã»ãã€ãã³ã¯ããµãã ã»ãã»ã€ã³ãã倧éç Žå£å
µåšãä¿æããŠããããšããçç±ã§ãã€ã©ã¯äŸµæ»ãæåºæ¯æããããšãå¿ããŠã¯ãªããªãããã¢ã¡ãªã«åœæ°ã¯ãã®æŠäºã«éšãããããšããã£ãã¯ã»ããŒãã³äžé¢è°å¡ã¯èšã£ãããžã§ãŒã»ãã€ãã³ã«åã³ã ãŸãããŠã¯ãªããªãã11
é²åããé åèªïŒ9/11ãGWOTãWMDããããŠä»COVIDããã€ãã³ã¯ãã€ã©ã¯äŸµæ»ãæ¯æããããšã§å ±ããåããã
éžææŠã®éãFox Newsã¯ãã€ãã³ãè³æ¬äž»çŸ©ãè
ããã瀟äŒäž»çŸ©è
ããšè¡šçŸãããããžã§ãŒã»ãã€ãã³ã¯ç€ŸäŒäž»çŸ©è
ã®ãã°ã¬ãŒãã»ãªã»ãããéåãšäžç©ãªã€ãªãããããããšããã
ããã¯ãŸã£ãããã³ã»ã³ã¹ã ããå€ãã®ã鲿©çããªäººã
ãåæŠæŽ»åå®¶ã¯ããã€ãã³å€§çµ±é ã®å°±ä»»ãããããåºç¯ãªåœ±é¿ãåæããããšãªãããžã§ãŒã»ãã€ãã³ãæ¯æããŠããã
ãã°ã¬ãŒãã»ãªã»ãã ãã¯ç€ŸäŒçåè£ã§ããã人皮差å¥çã ãããã¯ãã°ããŒãã«è³æ¬äž»çŸ©ã®æ¥µæªééãªãããžã§ã¯ãã§ãããããã¯ã倧倿°ã®ã¢ã¡ãªã«äººåŽåè
ãäžå°äŒæ¥ã«å¯Ÿããè
åšã§ããããŸããè³æ¬äž»çŸ©çµæžã®ããã€ãã®éèŠãªéšéã匱äœåãããã
ãã€ãã³å€§çµ±é ãšããã¯ããŠã³
COVIDã«é¢ããŠããã€ãã³æ°ã¯ããæ®ºäººãŠã€ã«ã¹ãšã®æŠããã®ææ®µãšããŠãç±³åœçµæžãšäžççµæžã®äž¡æ¹ã®éšåçãªééãç¶æããããšã«åºãã³ãããããŠããã
ãã€ãã³å€§çµ±é ã¯ãã³ããã®ããã¯ããŠã³ãæåºãšããŠæ¯æããã圌ã¯ã確åºããCOVID-19ããã¯ããŠã³æ¿çã®æ¡çšãæ¯æããã ãã§ãªããåœŒã®æ¿æš©ã¯ãäžççµæžãã©ãŒã©ã ã®ãã°ã¬ãŒãã»ãªã»ããããšãã¯ã¯ãã³ã»ãã¹ããŒãããç±³åœã®å€äº€æ¿çã®äžå¯æ¬ ãªéšåãšããŠãäžçäžã§å®æœãããæ£ç¢ºã«ãæŒãä»ãããããšã«ã³ãããããŠããã®ã§ããã
ãã€ãã³ïŒããªã¹æ¿æš©ã¯ãã³ãããŠã€ã«ã¹ã®å°ã蟌ãã«å¯Ÿããããããæ°è¡ã®æµæéåãç¡å¹ã«ããããšããã ããã
å±éãããŠããã®ã¯ãã¢ã¡ãªã«åžåœäž»çŸ©ã®æ°ããªç Žå£ç段éã§ãããããã¯çµæžçã»ç€ŸäŒçãšã³ãžãã¢ãªã³ã°ã®å
šäœäž»çŸ©çãããžã§ã¯ãã§ãããæçµçã«ã¯äžçäžã®äººã
ã®ç掻ãç Žå£ãããã®ã ã瀟äŒçæå§ã®éå
·ãšããŠã³ããã»ããã¯ããŠã³ãçšãããã®ãæ¬æ°ãªãæ°èªç±äž»çŸ©çã¢ãžã§ã³ãã¯ããã€ãã³å€§çµ±é ãšæ°äž»å
ã®æå°è
ã«ãã£ãŠæ¯æãããŠããã
ãã€ãã³ãã¯ã€ãããŠã¹ã¯ããã€ãŽã£ããã»ããã¯ãã§ã©ãŒããã°ããŒãã«ã»ã¬ããã³ã¹ããšåŒã¶ãã®ã®å°å
¥ã«åãçµãã§ããã
æè°éå
ç±³åœã«ãããããã¯ããŠã³ã«å¯Ÿããæè°éåã¯åŒ±ããšããããšã«æ³šæããªããã°ãªããªããå®éãéŠå°Ÿäžè²«ããèã®æ ¹ã®å
šåœçãªæè°éåã¯ååšããªãããªããïŒå·Šç¿Œç¥è人ãNGOãªãŒããŒãåŽåçµåã»åŽåè
ãªãŒããŒãªã©ã®ã鲿©çå¢åã-ãã®å€ãã¯æ°äž»å
ãšé£æºããŠãã-ã¯ãåœåããç£çŠãæ¯æããŠããããã§ããããããŠã圌ãã¯ãžã§ãŒã»ãã€ãã³ã«ãæ¯æçã§ããã
èŠãç®èã«ããåæŠæŽ»åå®¶ã ãã§ãªããæ°èªç±äž»çŸ©ãæ¹å€ãã人ãã¡ããžã§ãŒã»ãã€ãã³ãæ¯æããŠããã
åœå
å€ã§ã®å€§ããªæè°ãšçµç¹çæµæããªãéããã°ã¬ãŒãã»ãªã»ããã¯ããžã§ãŒã»ãã€ãã³ïŒã«ãã©ã»ããªã¹æ¿æš©ã®åœå
æ¿çãšç±³åœå€äº€æ¿çã®äž¡æ¹ã®ã¢ãžã§ã³ãã«çµã¿èŸŒãŸããããšã«ãªãã ããã
141
ããããã人éã®é¡ããããåžåœäž»çŸ©ã ã
éžæã§éžã°ããªãã£ãã³ããã«æè°ãã ã宿°ããŒãããŒã·ããã ã¯ã©ãã«ããã®ã?
ã°ã¬ãŒãã»ãªã»ããããšãã°ããŒãã«ã»ã¬ããã³ã¹ãã®æé»ã®ç«åœ¹è
ã§ããåãæ
å財å£ïŒããã¯ãã§ã©ãŒããã©ãŒãããœãã¹ãªã©ïŒã¯ãæ°åå€å掻åãçµ¶æ»
ã®åä¹±ãäžç瀟äŒãã©ãŒã©ã ããã©ãã¯ã©ã€ãã¹ãã¿ãŒãLGBTãªã©ã«ãïŒæãã¿ãªãïŒè³éæŽå©ããŠããã
ãããæå³ããã®ã¯ããããã®ç€ŸäŒéåã®èã®æ ¹ã¯ãæ¥åžžçã«äžæ¡ãã®äŒæ¥è²¡å£ã«åã蟌ãŸããå¯å€§ãªå ±é
¬ãäžããããŠããæå°è
ã«ãã£ãŠããã°ãã°èª€è§£ãããè£åããããšããããšã§ããã
äžç瀟äŒãã©ãŒã©ã ïŒWSFïŒã¯ããã®21åšå¹Žãèšå¿µããŠãäžçäžããåã°ããŒããªãºã ã®æŽ»åå®¶ãéãŸã£ãŠããããããã誰ãWSFãæ¯é
ããŠããã®ã ãããã2001幎1æã®çºè¶³åœåãããïŒåœåã¯ïŒãã©ãŒã財å£ã®è³éæäŸãåããŠããã
ãããã ã人工çãªå察æèŠã ã§ãã (ããŒãã³ã»ãã§ã ã¹ããŒã® ã人工çåæã ãããã¯ããã«é°éºã§ãã) ã
éèãšãªãŒãã®ç®çã¯ãã人ã
ã®éåãæçåããåºå€§ãª ãdo it yourself ãã®ã¢ã¶ã€ã¯ã«ããããšã§ãã£ãããæŽ»åã¯æççã«ãªããã¡ã§ãããçµ±åãããåã°ããŒããªãºã åæŠéåã¯ååšããªããïŒãã·ã§ã«ã»ãã§ã¹ããã¹ããŒÂ Manufacturing Dissent, Global Research, 2010)12ã
ãã©ãŒã財å£çäºé·ïŒ1966-1979ïŒã®McGeorge Bundyã®èšèã§ããã
ããã©ãŒãã財å£ãè¡ã£ãããšã¯ãã¹ãŠãè³æ¬äž»çŸ©ã«ãšã£ãŠäžçãå®å šã«ãããããšã§ãããèŠããã§ãã人ã ãæ °ããæã£ãŠãã人ã ã«å®å šåŒãæäŸããæ¿åºã®æ©èœãæ¹åããããšã«ãã£ãŠç€ŸäŒã®ç·åŒµãç·©åããããšã§ãã£ããšèãããã13ã
ã°ããŒãã«ã»ã¯ãŒãã¿ãŒãã§ãããã°ã¬ãŒãã»ãªã»ãããã«å¯Ÿããæè°éåã¯ãäžççãªåå¡ã®ããã»ã¹ãå¿ èŠãšããã
ãå察æèŠããæè°éåã®ã¿ãŒã²ããã§ããåãäŒæ¥å©çå£äœïŒWEFãã²ã€ãããã©ãŒããªã©ïŒããæœ€æ²¢ãªè³éæäŸãåããŠããå Žåãæå³ã®ãã倧è¡éåã¯ããããªãã14ã

142
å·»æ«è³æ
1. Michel Chossudovsky, April-June 1975. Hacia El Newvo Económico Chileno Inflación Y Redistribución Del Ingreso. https://www.jstor.org/stable/20856482?refreqid=excelsior%3A9228243fa26a81bb3c2b0c2d58094922&seq=1
2. åäžãIbid.
3. Michel Chossudovsky, April 16, 1977. Legitimised Violence and Economic Policy in Argentina.https://www.jstor.org/stable/4365500?seq=1
4. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2020 幎 6 æ 3 æ¥ãè²§å°ã®ã°ããŒãã«åãšæ°äžçç§©åºãçè§£ãããhttps://www.globalresearch.ca/own-nothing-happy-being-human-2030/5728960
5. åäžã
6. åœå®¶å®å
šä¿éäŒè°ã1974幎12æ10æ¥ãäžççãªäººå£å¢å ã®ç±³åœå®å
šä¿éãšæµ·å€å©çãžã®åœ±é¿ïŒTHE KISSINGER REPORTïŒã
https://pdf.usaid.gov/pdf_docs/PCAAB500.pdf
7. ããŒã¿ãŒã»ã±ãŒãããã2022 幎 1 æ 22 æ¥ãã³ããã»ãªãã¯ãã³ã»ã¯ã©ã€ã·ã¹ãäžççãªéè屿©ãã€ã³ãã¬ãããžã¿ã«åãžã®ããŒãããããhttps://www.globalresearch.ca/covid-omicron-is-killing-christmas-and-beyond-financial-crash-inflation-digitization/5765170
8. ããŒã¿ãŒã»ã±ãŒãããã2020幎3æ12æ¥ãã³ãããŠã€ã«ã¹ã¯ã¯ãã³ããæ¬åœã®å±éºã¯ãã¢ãžã§ã³ãID2020ããããžã¿ã«ã»ã¢ã€ãã³ãã£ãã£ãã®ããã®ãã©ãããã©ãŒã ãšããŠã®ã¯ã¯ãã³æ¥çš® https://www.globalresearch.ca/coronavirus-causes-effects-real-danger-agenda-id2020/5706153
9. ã³ãªã³ã»ããããã³ã¿ãŒã2020幎11æ9æ¥ããã£ã¹ããã¢çã倧ãªã»ãããã"äœãææããã幞ãã«ãªã "2030幎ã®äººéã§ããããš https://www.globalresearch.ca/own-nothing-happy-being-human-2030/5728960
10. åœé£ã2020 幎 9 æãCOVID-19 ã«å¯Ÿããåœé£ã®å
æ¬ç察å¿ãhttps://www.un.org/sites/un2.un.org/files/un-comprehensive-response-to-covid-19.pdf
11. ããŒã¯ã»ã¯ã€ãºãããŒã2020 幎 2 æ 17 æ¥ãworth the price? Joe Biden and the Launch of the Iraq War (narrated by Danny Glover).https://www.youtube.com/watch?v=vhcuei8_UJM
12. Michel Chossudovskyææã2010幎9æ20æ¥ã"Manufacturing Dissent": åã°ããŒããªãºã éåã¯äŒæ¥ãšãªãŒãã«ãã£ãŠè³éæäŸãããŠãã https://www.globalresearch.ca/manufacturing-dissent-the-anti-globalization-movement-is-funded-by-th.e-corporate-elites/21110
13. åäž.
14. åäžã
143
----------------- 第13ç« ---------------
ãããžã¿ã«å°å¶æ¿æ²»ããšQRã³ãŒã
ãQRã³ãŒãã®äžççãªäŸµç¥ã§ããããªãã®æã芪å¯ãªããŒã¿ãå¥åº·ãå人ã®è¡åãç¿æ £ãç§ãã¡ãã©ãã«è¡ã£ãŠãã©ãã«è¡ãããšããŠãããã®èšé²ãªã©ããã¹ãŠãQRã³ãŒãåããã®ã§ããQRã³ãŒãããéãããããã®ã¯äœããªãã誰ãããã«ã€ããŠè©±ããŸãããã-ããŒã¿ãŒã»ã±ãŒããããå äžçéè¡ã¢ããªã¹ããã°ããŒãã«åç ç©¶ã»ã³ã¿ãŒã»ãªãµãŒãã¢ãœã·ãšã€ã
ããžã¿ã«åãããäžçã®èŠå¯åœå®¶ã«åããŠ
äžççãªQRèªèšŒã³ãŒããããžã§ã¯ãã¯ãéèæ©é¢ãæ¯é ãããããžã¿ã«åãããäžçèŠå¯åœå®¶ãã®æš¹ç«ã«åããäžå°äœãã«ãªã£ãŠãããããã¯ãæ ããŽã£ããã»ããã¯ãã§ã©ãŒãéè¡å®¶ãšç¥è人ã®åçã«åºã¥ããäžçæ¿åºãžã®è¡é²ããšåä»ããããšã®äžéšã§ããïŒç¬¬12ç« åç §ïŒãããŒã¿ãŒã»ã±ãŒãããã¯QRã³ãŒãããã衚çŸããŠããã
ãå šé»åID-åå人ã®ãããããã®ïŒå¥åº·ãéè¡ãå人ããã©ã€ããŒããªã©ã®èšé²ïŒã«ãªã³ã¯ããã
äžççãªããžã¿ã«é貚ã·ã¹ãã ïŒCBDCïŒã«åããŠ
äžççµæžãã©ãŒã©ã ïŒWEFïŒãšäžå€®éè¡ãšã®éã§ããããããäžå€®éè¡ããžã¿ã«é貚ïŒCBDCïŒãããã¯ãŒã¯ã®å®çŸã«åããåè°ãé²ããããŠãããDavid Skripacæ°ã«ãããš
ãäžççãªããžã¿ã«IDã·ã¹ãã ã®æ§ç¯ãé²ãã§ããã... WEFãšãã¹ãŠã®äžå€®éè¡ã®ç®çã¯ããã¹ãŠã®äººã®å人ããŒã¿ãäžå€®éè¡ããžã¿ã«é貚ïŒCBDCïŒãããã¯ãŒã¯ã«çµã¿èŸŒãŸããã°ããŒãã«ãªã·ã¹ãã ãå®çŸããããšã ãã1
QRèªèšŒã³ãŒããœãããŠã§ã¢
2022幎åé ãWHOã¯ãã€ããã¬ã³ã Tã·ã¹ãã ãºãšå€§èŠæš¡ãªå¥çŽãçµã³ãäžçäžã§é©çšãããQRèªèšŒã¢ããªãšãœãããŠã§ã¢ãéçºããŸããã
QRã³ãŒãããŒã¹ã®ãœãããŠã§ã¢ãœãªã¥ãŒã·ã§ã³ã¯ã次ã®ããã«äœ¿çšãããäºå®ã§ãã
ãããªãªãé»ç±ç ãªã©ãä»ã®äºé²æ¥çš®ã«ã䜿çšãããäºå®ã§ãããšT-Systemsã¯å£°æã§è¿°ã¹ãŠããŸã...ããã«ãWHOã¯194ã®å çåœã«å¯Ÿããåœãå°åã®æ€èšŒæè¡ã®æ§ç¯ãæ¯æŽãããšããŠããŸãã(匷調)
ãã€ããã¬ã³ã I-Tã·ã¹ãã ãºã®ã³ãã¥ãã±ã«ãããšããWHOã®ã²ãŒããŠã§ã€ã»ãµãŒãã¹ã¯ãå°åã·ã¹ãã éã®æ©æž¡ãã®åœ¹å²ãæããããšãããããã¯æ¬è³ªçã«ãå°çã®å
šäººå£ãç£ç£ããQRç£èŠã®ã°ããŒãã«ãªèª¿æŽæ§é ãæå³ããŠããŸã2ã
ãããŠãäžåºŠç¢ºç«ãããã°ãã©ãã«ããŠããçæŽ»ã®ããããé¢ããç£èŠããããšã«ãªãã®ã§ããããŸããå°æ¥ã®äºé²æ¥çš®ãã£ã³ããŒã³ãå®¶åºå
èšé²ã®äžéšãšããŠãå©çšã§ããã
144
ãã€ãã»ãã¬ã³ã Tã·ã¹ãã ãºã®CEOã«ãããš
ãã³ãããäžçãææ¡ããŠãããããžã¿ã«åãäžçãåãããŠããã3ã
ãã«ã»ã²ã€ãã¯ããã€ããã¬ã³ã ã®åCEOã§ãããã³ã»ãŸããŒãš1990幎代åŸåããé·ãã«ããã£ãŠé¢ä¿ãç¯ããŠãã4ã
ãã¬ãŒã¹ãšãã©ããã³ã°
T-Systemsã¯ä»¥åãEuropean Federation Gateway ServiceïŒæ¬§å·é£åã²ãŒããŠã§ã€ãµãŒãã¹ïŒ(EFGS)ãç«ã¡äžããŠããããã®ãµãŒãã¹ã¯ãå çåœã®ã³ããã®ãã¬ãŒã¹ã¢ããªãåœå¢ãè¶ããŠæ©èœããããšãä¿èšŒãããã®ã§ããã
ãã¬ã³ã ã®ã¢ããªã¯ããäžçã§æãæåãããã¬ãŒã¹ã¢ããªã®1ã€ãã«åé¡ããããäžçãææ¡ããŠããã®ã¯èª°ãªã®ãïŒçŽ80å人ã«é¢ãã巚倧ãªããŒã¿ãã³ã¯ã¯ããããã°ãããŒãã«ãã£ãŠã³ã³ãããŒã«ãããŠãã5ã
人ã
ã¯ã¿ã°ãä»ããããã©ãã«ã貌ãããé»åã¡ãŒã«ãæºåž¯é»è©±ã¯ç£èŠããã詳现ãªå人ããŒã¿ã¯å·šå€§ãªããã°ãã©ã¶ãŒã»ããŒã¿ãã³ã¯ã«å
¥åãããã
ãããžã¿ã«å°å¶æ¿æ²» ãã¯ãããããæ¿æ²»çã»ç€ŸäŒçæµæãæé€ããå¿
èŠãããã
åã
ã®äººéã¯ ãæ°å ããšããŠåé¡ãããããã®ãæ°åããã°ããŒãã«ãªããžã¿ã«ããŒã¿ãã³ã¯ã«å
¥ãããããšã人é¡å
šäœãã°ããŒããªã¹ããããªãã¡éèãšã¹ã¿ããªãã·ã¥ã¡ã³ãã®æ¯é
äžã«çœ®ãããããšã«ãªãã
åœæ°åœå®¶ã®æŽå²ãæåãã¢ã€ãã³ãã£ãã£ã¯å°å°ãããã人ã
ã¯ãã°ããŒãã«ãªããŒã¿ãã³ã¯ã«æ¿å
¥ãããçªå·ãšãªãããã®çµæãåœå®¶ãå°æ¹ãå°åã¬ãã«ã§ã®ç€ŸäŒçãããžã§ã¯ãïŒprojet de sociétéïŒã®çå®ã¯æ¹æ®ºãããã
ç€ŸäŒæ°äž»äž»çŸ©ã瀟äŒäž»çŸ©ããªãã¿ãªã¢ããºã ãªã©ãã°ããŒãã«ã»ã¬ããã³ã¹ã®ããšã§ã¯ããããã圢æ
ã®ä»£è¡šçæ°äž»äž»çŸ©ãšéçŽéäºãæŽå²ã®ãŽãç®±ã«æ²ããããã®ã§ããã
鲿©çãªäººã
ã¯ããã®èŠæš©äž»çŸ©çãªãããžã§ã¯ãã®èåŸã«ããã®ã誰ãªã®ããããã¯æ°èªç±äž»çŸ©ã®ã¢ãžã§ã³ãã®äžéšã§ããã人éã®ã¢ã€ãã³ãã£ãã£ãç Žå£ããäººéæ§ãç Žå£ããçµæ«çãªãã®ã§ããããšãçè§£ããã¹ãã§ããã
äžççµæžãã©ãŒã©ã ïŒWEFïŒãšã²ã€ã財å£ãåŸæŽããWHOã®ãã³ãããã¯æ¡çŽã«çµã¿èŸŒãŸããŠãããã®æ¥µæªééãªã¢ãžã§ã³ããå®å
šã«è§£äœããããã«ãå¹
åºãæµæéåãçµç¹ããããšãéèŠãªã®ã§ããã
ã°ããŒããªã¹ãã®ãããžã§ã¯ãã®æ§åŒã¯ãWEFãšã²ã€ã財å£ã®ã€ãã·ã¢ããã§ããWHOã®ãã³ãããã¯æ¡çŽã«åã蟌ãŸããŠããã
æªåé«ãWHOã® ããã³ãããã¯æ¡çŽã
2022幎3æãWHO㯠ããã³ãããã¯æ¡çŽãããªãã¡WHOå çåœã®æš©åšãèŠãã°ããŒãã«ãã«ã¹çµ±æ²»æ©é¢ãåµèšããããšãå§ä»»ãããæ¿åºéäº€æžæ©é¢ïŒINBïŒãçºè¶³ãããã
ããã³ãããã¯å¯Ÿçã«é¢ããã°ããŒãã«ã»ãã³ãããã¯æ¡çŽ ãã¯ãããžã¿ã«IDïŒã¯ã¯ãã³ãã¹ããŒããã¯ã¯ãã³æ¥çš®ã®çŸ©ååãæž¡èªå¶éãããã¯ããŠã³ãæšæºåå»çãªã©ã宿œããæš©éãªã©ãäžçã®ãã€ãªã»ãã¥ãªãã£ã«é¢ãã絶察çãªæš©éãWHOã«äžããããšã«ãªãã®ã§ããã
145

ãã®ãã³ãããã¯æ¡çŽã宿œãããã°ãäžçã®æ å¢ã¯äžå€ããããªããç§ã®æãåºæ¬çãªæš©å©ãšèªç±ã奪ãããããšã«ãªãã
ééããªããWHOãã³ãããã¯æ¡çŽã¯ãå çåœã®äž»æš©ã«å¯ŸããçŽæ¥çãªæ»æã§ãããããªãã®èº«äœã®èªåŸæ§ã«å¯ŸããçŽæ¥çãªæ»æã§ãããã®ã§ããã (ããŒã¿ãŒã»ã±ãŒãããã2022幎6æ)6
ãã³ãããã¯æ¡çŽã¯ãWHOã®QRæ€èšŒã³ãŒããããžã§ã¯ããšCOVID-19 mRNAã¯ã¯ãã³ã«çµã³ã€ããŠããã
WHOã®æ¯æŽã®äžã§ã®ããã³ãããã¯ã«é¢ããæ¡çŽããšãQRæ€èšŒã³ãŒããã®äž¡æ¹ã®æ£åœæ§ã¯ããCOVID-19ãã³ãããã¯ã¯å®åšããããšãããmRNAã¯ã¯ãã³ããŠã€ã«ã¹ã®æ¡æ£ãæå¶ãã解決çãæ§æãããšããæšå®ã«åºã¥ããŠããã
ãã®æ¥µæªééãªãããžã§ã¯ãã®èåŸã«ããç§åŠãšåæ§ã«æ£åœæ§ã¯äœã§ããããïŒãããŸãããååã«ç¢ºèªãããŠããŸãããã³ãããã¯ã¯ååšããªãã®ã§ããCOVID-19ã®ãã³ãããã¯çæã¯ããã»ç§åŠãã«åºã¥ããŠããïŒç¬¬IIIç« åç §ïŒã
EUã®ããžã¿ã«COVIDèšŒææžãã¬ãŒã ã¯ãŒã¯ããWHOã®QRæ€èšŒã³ãŒããããŸã£ããã®åãšã§ã£ã¡äžãã«åºã¥ããŠããã

ç»åïŒæ¬§å·é£åçäºäŒãã
ãã³ãããã¯æ¡çŽã¯ããã°ããŒãã«ã»ã¬ããã³ã¹ããšããžã¿ã«å°å¶æ¿æ²»ã«åãããè£å£ãã§ãããããã¯ã倧æéèæ©é¢ãåäžé·è ããããŠåœŒãã®æ å財å£ãããªããè¶ åœå®¶ç䞻暩ãïŒäžçæ¿åºïŒãæ¯é ãã代çäººæ¿æš©ã®äžççãªãã¯ãµã¹ãæ§ç¯ããããšã«ããïŒç¬¬åäºç« åç §ïŒã
WHOã®èšç»ã¯10幎åŸã®ãã³ãããã¯ïŒ2020-2030幎ïŒã§ããã
WHOã¯ã²ã€ã財å£ã®æ¯æŽãåããŠãå°æ¥ã®äžé£ã®ãã³ãããã¯ãæ³å®ããŠãããæ¬§å·çäºäŒã®ã·ã£ã«ã«ã»ãã·ã§ã«è°é·ãWHOã®ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹äºåå±é·ã«ãããšã
ããã³ãããã¯ããã®ä»ã®å€§èŠæš¡ãªå¥åº·äžã®ç·æ¥äºæ ã¯ãä»åŸãçºçããå¯èœæ§ããããŸãã
åé¡ã¯ãããããã§ã¯ãªãããã€ãããšããããšã§ãã...ç§ãã¡ã¯ãé«åºŠã«é£æºãã圢ã§ãã³ãããã¯ãäºæž¬ãäºé²ãæ€åºãè©äŸ¡ãã广çã«å¯Ÿå¿ããæºåãæŽããªããã°ãªããŸããã
ãã®ããã«ãæã ã¯ååœããã³ãããã¯ãžã®æºåãšå¯Ÿå¿ã«é¢ããæ°ããåœéæ¡çŽã«åããŠååãã¹ãã§ãããšèãããã
-åœéãã³ãããã¯æ¡çŽã®ããã®å ±ååŒã³ãã7
146
ãã«ã»ã²ã€ãã®ããã³ãããã¯ã»ãã³ããŒ2ã:ãµã«çïŒ
ãæã ã¯ãŸããã³ãããã¯ãèµ·ããã ãããæ¬¡ã¯éãç åäœã«ãªãã ãããïŒ2022幎2æ18æ¥ãCNBCïŒ
ãæ¬¡ã«åããããã«ã¯...
ããã³ãããã¯2 "ã«åããããã«ã...ãç§ã¯ããããã³ãããã¯ã»ã¯ã³ãšåŒãã§ãããïŒãã«ã»ã²ã€ãããããªåç §ããã芧ãã ãããWHOã¯10幎åŸã®ãã³ãããã¯ãèšç»ããŠãã)8
ãžã§ãŒã»ãã€ãã³å€§çµ±é ã¯ãã¢ã¡ãªã«ã¯ã次ã®ãã³ãããã¯ã«åããããã«è³é調éãéå§ããå¿
èŠãããããšè¿°ã¹ãŠããã
ãã€ãã³ã®ææ¡ã®èåŸã«ã¯ããã«ã»ã²ã€ããæ¯æŽããããã°ãããŒãããã
ããã¯ã€ãããŠã¹ã¯ããã³ãããã¯å¯Ÿå¿ã®èšç»ã«åããŠ820åãã«ãå²ãåœãŠãããšãææ¡ããŠãããã(ããžãã¹ã€ã³ãµã€ããŒã2022幎6æ23æ¥)9
ãµã«çã®PHEIC
2022幎7æ23æ¥ãåœéä¿å¥èŠåïŒIHRïŒç·æ¥å§å¡äŒã®å€æ°æ±ºïŒå察9ãè³æ6ïŒã«åããŠãWHOäºåå±é·ãããã¹ã»ã¢ããã ã»ã²ãã¬ã€ãšã¹ã¹å士ãäžæ¹çã«ãåœéçã«æžå¿µããããµã«çå ¬è¡è¡çç·æ¥äºæ ïŒPHEICïŒãã宣èšãã10ã
ãç§ãã¡ã¯ãæ°ããæææ§åŒã«ãã£ãŠäžçäžã«æ¥éã«åºãã£ãŠããã¢ãŠããã¬ã€ã¯ãæã£ãŠããŸã...ç§ïŒãããã¹ïŒã¯ãäžççãªãµã«ããã¯ã¹ã®çºçã¯ãåœéçã«æžå¿µãããå ¬è¡è¡çäžã®ç·æ¥äºæ ã衚ããŠãããšå€æããŸãããã..11
ãç§ïŒãããã¹ïŒã¯åœéçã«æžå¿µãããå ¬è¡è¡çäžã®ç·æ¥äºæ ã宣èšããŠããããçŸæç¹ã§ã¯ãããã¯ç·æ§ãšã»ãã¯ã¹ããç·æ§ãç¹ã«è€æ°ã®æ§çããŒãããŒãæã€ç·æ§ã«éäžããŠããã¢ãŠããã¬ã€ã¯ã§ããã...
ãããã£ãŠããã¹ãŠã®åœãç·æ§ãšã»ãã¯ã¹ãããç·æ§ã®ã³ãã¥ããã£ãšå¯æ¥ã«ååãã广çãªæ å ±ãšãµãŒãã¹ãèšèšããŠæäŸããææããã³ãã¥ããã£ã®å¥åº·ã人暩ãå°å³ãä¿è·ããæªçœ®ãæ¡çšããããšãäžå¯æ¬ ã§ããã
(匷調)
ãç§ã¯æ±ºãã... ã
ãããã¹æ°ã®çºèšã¯ãå²ç¬ã«è¿ããç§åŠçæ ¹æ ã¯ã©ãã«ããã®ã ããïŒãã®æå³ã¯ïŒWHOã®å£°æãèŠçŽããšããç§åŠçåèŠããšæçœãªæäœãããããšããããã
ãããŠãCDCãSARS- CoV-2ã®æ€åºã«ã¯ç¡å¹ã§ãããšå®£èšããïŒ2021幎12æ31æ¥æå¹ïŒãªã¢ã«ã¿ã€ã PCRæ€æ»ããçŸåšããµã«çç
åäœã®æ€åºãã«äœ¿çšãããŠããããšã ããšæšæž¬ããã12ã
147

ãµã«çãæ§ææçã§ããããšã瀺ã蚌æ ã¯ãªãã(ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒåç
§ãã°ããŒãã«ã»ãªãµãŒãã2022幎8æ1æ¥ïŒ13
ãããã¹æ°ã®çºèšã¯ãçŸåšç·æ¥æªçœ®ã®å¯Ÿè±¡ã§ããLGBTã³ãã¥ããã£ã®åºæ¬çæš©å©ã®äŸµå®³ã«ãããã®ã ããããäžã«åŒçšãã IHR ç·æ¥å§å¡äŒã®å ±åæžã®èšèãåããã° ãä»å
¥ã¯ããã®å±€ïŒLGBTïŒã察象ãšããŠããã
WHOã¯ã²ã€ã財å£ããè³éæäŸãåããŠããããããŠããã«ã»ã²ã€ãã¯äžå¿äººç©ã ã2017幎ããç¿çã®ã·ããªãªãæšãé²ããŠããã
ããã«2021幎3æã«ã¯ãæ°ååã®å¯è±ªã®f o u n d a t i o n s ãæãã¿ãªãåºè³ããåäžã·ãã¥ã¬ãŒã·ã§ã³ïŒ2019幎10æã®ã€ãã³ã201ã·ãã¥ã¬ãŒã·ã§ã³ãšåæ§ïŒãããçããæ ªã®ãµã«çãŠã€ã«ã¹ãé¢ããèŽåœçã§ã°ããŒãã«ãªãã³ãããã¯ã®æ¶ç©ºã®æŒç¿ã·ããªãªããæããŠããããã®ã·ãã¥ã¬ãŒã·ã§ã³ã¯ããã¥ã³ãã³å®å
šä¿éäŒè°ã§çºè¡šãããã
ã·ãã¥ã¬ãŒã·ã§ã³ãš ãçŸå®ã® ããµã«çã®å€§æµè¡
2022幎5æ15æ¥ããã·ãã¥ã¬ãŒã·ã§ã³ã·ããªãªãã§ã¯ããµã«çã®æµè¡ãå§ãŸãïŒäžå³åç
§ïŒã2023幎1æïŒè¢«å®³åœ83ã«åœïŒã7000äžäººã®æ£è
ã確èªããã130äžäººãæ»äº¡ããïŒäžå³åç
§ïŒ14ã
å¶ç¶ã®äžèŽïŒ2022幎5æ15æ¥ãã·ãã¥ã¬ãŒã·ã§ã³ã®150äŸã¯ããREAL ãã®å ±éãšWHOã®å§åã«é
·äŒŒããŠããããšãç®ã«èŠããã
ã2022幎5æ13æ¥ä»¥éãWHOã®3ã€ã®å°åã«ããã£ãŠããµã«çãŠã€ã«ã¹ã®é¢šåç ã§ãªã12ã®å çåœãããµã«çã®çäŸãå ±åãããŠããŸããç«åŠç調æ»ãé²è¡äžã§ããã...ã(WHOã¢ããã€ã¶ãªãŒ)15
148

PHEIC2.0ããããã³ãããã¯ã»ãã³ããŒ2ããžã®ç§»è¡ïŒ
ãããã¹å士ã®2022幎7æã®ç¿çPHEICã¯ãWHOã®COVID-19ã®2020幎1æ30æ¥ã®PHEICãã¢ãã«ã«ããŠããïŒç¬¬IIç« åç
§ïŒã
次ã¯äœãããã®ãïŒPHEICã¯èå°ãèšå®ãããããã¯ããã®åŸã®ãã³ãããã¯ã«åããååšæŠã§ããã
2022幎7æ23æ¥ã®æŽå²çãªãµã«çPHEIC2.0ã¯ãããã³ãããã¯ã»ãã³ããŒ2ããããªãã¡å°æ¥ã®ããããŒã¿ã§WHOãå
¬åŒã«å¶å®ãããµã«çäžç倧æµè¡ãžã®éãéãã ãããã
2022幎5æã®çºçã«å
ç«ã¡ïŒãµã«ããã¯ã¹ã¯ã¯ãã³ãéçºãããŸããã2022幎5æ18æ¥ã«çºè¡šããã16ã
å·»æ«è³æ
1. ãã€ãŽã£ããã»ã¹ã¯ãªããã¯ã2022幎3æ26æ¥ããããã«ãã! ç§ãã¡ã®æ
é·ãšå
äœæ°ã®....... ç¬è£è
ã ! WEFã¯ãæã
ã®èªç±ãèžã¿ã«ãããhttps://www.globalresearch.ca/canada-our-home-native-dictatorship/5772052
2. ã¢ã«ããŒãã»ããŒã«ãã2022幎2æ23æ¥ãCovid 19ã®èšŒææžã確èªãããäžçä¿å¥æ©é¢ãT-Systemsãç£æ¥ããŒãããŒã«éžå®https://www.telekom.com/en/media/media-information/archive/covid-19-who-commissions-t-systems-648634
3.åäž
4. Dow Jones Newswires, September 4, 1998. Deutsche Telekom Won't Comment On Reports of Talks With MicrosoftïŒãã€ããã¬ã³ã ããã€ã¯ããœãããšã®äº€æžå ±éã«ã€ããŠã³ã¡ã³ãããªãïŒã
Microsoft.https://www.wsj.com/articles/SB904923633645893500
5. Worldometer, n.d. Current World Population. https://www.worldometers.info/world-population/
6. Peter Koenig & Prof. Michel Chossudovsky, June 2, 2022. ãããªãDigital Tyranny and the QR Code. WHO ãã³ãããã¯æ¡çŽã¯ãã°ããŒãã«ã»ã¬ããã³ã¹ããžã®è£å£ https://www.globalresearch.ca/digital-tyranny-and-the-qr-code-the-who-pandemic-treaty-is-a-back-door-to-global-governance/5782245
149
7. Council of the European Union, n.d. A international treaty on the pandemic prevention and preparednessïŒæ¬§å·é£åçäºäŒããã³ãããã¯ã®äºé²ãšæºåã«é¢ããåœéæ¡çŽïŒã
https://www.consilium.europa.eu/en/policies/coronavirus/pandemic-treaty/
8. Stopworldcontrolã2022 幎 5 æ 4 æ¥ãTHE PLAN - WHOã¯2020幎ãã2030幎ãŸã§ã®10幎éã®ãã³ãããã¯ãèšç»ããŠãããhttps://rumble.com/v13kefy-must-see-the-plan-who-plans-for-10-years-of-pandemics-from-2020-to-2030.html
9. ãã·ã¥ãŒã»ããŒã2022幎6æ23æ¥ããã€ãã³ã¯ãå¥ã®ãã³ãããã¯ãæ¥ãã®ã§ãç±³åœã¯ãã®æºåãå§ããå¿
èŠããããšè¿°ã¹ãŠãããhttps://www.businessinsider.com/biden-second-pandemic-funding-us-preparing-2022-6
10. Michel Chossudovsky ææã2022 幎 5 æ 25 æ¥ãäžççãªç¿çå¥åº·å±æ©ïŒPHEICïŒããã«ã»ã²ã€ãã«ãšã£ãŠã¯ããããŒããã¯ã¹ãã2021幎3æã«æ¶ç©ºã®ãµã«çãŠã€ã«ã¹ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ã2022幎5æã«æ¬çšŒå https://www.globalresearch.ca/bill-gates-warns-smallpox-terror-attacks-urges-leaders-use-germ-games-prepare/5781195
11. WHOã2022 幎 7 æ 23 æ¥ãWHO, 2022幎7æ23æ¥. WHO Director-General's statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox - 23 July 2022. https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022
12. CDCã2022 幎 6 æ 6 æ¥ãæ€æ»æé Monkeypox virus Generic Real-Time PCR Test. https://www.cdc.gov/poxvirus/monkeypox/pdf/pcr-diagnostic-protocol-508.pdf
13. ãã·ã§ã«ã»ãã§ã¹ããã¹ããŒææã2022幎8æ1æ¥ãWHOã® "äºå®äžã®ã«ãªã¹"ïŒDr. Tedros: Monkeypox Outbreak Is "Among Men Who Have Sex with Men". https://www.globalresearch.ca/factual-chaos-at-the-who-dr-tedros-monkeypox-outbreak-is-among-men-who-have-sex-with-men/5788349
14. NTIã2021 幎 11 æ 23 æ¥ã髿žå¿µçç©åŠçè
åšãäºé²ã察å¿ããããã®ã°ããŒãã«ã·ã¹ãã ã®åŒ·å https://www.nti.org/analysis/articles/strengthening-global-systems-to-prevent-and-respond-to-high-consequence-biological-threats/
15. WHOã2022 幎 5 æ 21 æ¥ãéãšã³ãããã¯åœã«ããããµã«çã®è€æ°åœã§ã®çºçhttps://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385
16. Michel Chossudovsky ææã2022 幎 5 æ 25 æ¥ãäžççãªãµã«çå¥åº·å±æ©ïŒPHEICïŒããã«ã»ã²ã€ãã«ãšã£ãŠã¯ "Moneypox "ã§ããã2021幎3æã«æ¶ç©ºã®ãµã«çãŠã€ã«ã¹ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ãè¡ãã2022幎5æã«æ¬çšŒåãhttps://www.globalresearch.ca/bill-gates-warns-smallpox-terror-attacks-urges-leaders-use-germ-games-prepare/5781195
150
----------第14ç« Zend_Love --------
COVID-19ã®çµç€æŠïŒ
åªçåŠãšéçåã¢ãžã§ã³ã
ãç§ãã¡ã¯ä»ãåœéçã»åœå®¶çã¬ãã«ã§éåžžã«åŒ·åãªçµç¹ããšãªãŒãããåºæ¬çã«èªæ®ºè¡çºã§ããæ¿çãåŒã³ãããŠããç¶æ³ã«çŽé¢ããŠããã®ã§ãããåºæ¬çã«ããçš®ã®æ»ã®é¡æã§ãããã-ãããªãã¯ã»ã ãŒã¢ãã°ãªãŒã³ããŒã¹åäŒé·
ãã® ãDo Goodie ãåäžé·è
ãã¡ã¯ãèªåãã¡ã®éå£äºé²æ¥çš®ãã£ã³ããŒã³ãçã¿åºãã§ãããæ®ºæ®ãšèŠçã«ã€ããŠãäœãèããŠããã®ã ãããïŒãããšãã人å£ã®å°ãªãäžçãç®æšãªã®ã ãããïŒ-ãã€ã±ã«ã»ãã€ããããŒïŒèåãªäœå®¶ãå°æ¿åŠçåæå®¶
ã¯ããã«
åç« ã§æ€èšããCOVIDã¢ãžã§ã³ãã®2ã€ã®æŠç¥çæ¯æ±ã¯æ¬¡ã®ãšããã§ããã
- ããã¯ããŠã³ïŒè²§å°åã瀟äŒççå€ãçµ¶æã®äžççããã»ã¹ãåŒãèµ·ããããçµæžã»ç€ŸäŒæŠäºè¡çºã
- mRNA COVIDãã¯ã¯ãã³ãã¯ãæ»äº¡çãšçœ¹æ£çãäžççã«äžæãããçµæãšãªã£ãã
äžçå²äžåäŸã®ãªãããšã ãããã®2ã€ã®æŠç¥çæ¯æ±ã¯ã人é¡ã«å¯Ÿããåºç¯ãªç¯çœªãæç¢ºã«ææããéçåã®ããã»ã¹ãåŒãèµ·ããã®ã«åœ¹ç«ã£ãŠããã®ã§ããã
äººå£æžå°æ¿çã®å®æœã«ã¯ãéèæ©é¢ãæ¯é
ãã瀟äŒçã«æå§çãªãã°ããŒãã«ã»ã¬ããã³ã¹ãæ§é ãå¿
èŠã§ããã
ãŸããäžçäžã§ç€ŸäŒçå容ã匷å¶ããããã®ãçµæåã®ãããããã¬ã³ãè£
眮ãå¿
èŠã§ããããããŠããã®ããã»ã¹ã«ã¯ãåžæ³å¶åºŠã®ç¯çœªåãšçžãŸã£ãŠã代衚çãªæ¿åºæ©é¢ã®åŽ©å£ãå¿
èŠã§ããã
éçåãšåªçåŠã®æŽå²
ã°ããŒãã«ã»ã¬ããã³ã¹ã®ã·ããªãªã¯ã瀟äŒå·¥åŠãšçµæžçã³ã³ãã©ã€ã¢ã³ã¹ãšããã¢ãžã§ã³ããæŒãä»ããããšãããã®ã§ããã
ã°ããŒããªã¹ãã«ãã£ãŠæ§æ³ãããäžçæ¿åºã¯ãæåŸãšå容ãåæã«ããŠããŸãããã®äž»èŠãªç®çã®äžã€ã¯ãäžççãªäººå£æžå°ã®ã¢ãžã§ã³ããå®è¡ããããšã§ããã
äžççµæžãã©ãŒã©ã ïŒWEFïŒãšåäžé·è
ã®æ
åå®¶ãåŸæŽããçŸä»£ã®åªçåŠéåã¯ãäžç人å£åæžã®éå
·ã§ããã³ããã»ããã¯ããŠã³ãšmRNAã¯ã¯ãã³ãšããäºã€ã®æŠç¥çæ¯æ±ã«æãã£ãŠããã
ç±³åœã»NATOäž»å°ã®æŠäºããŸã人å£åæžã®éå
·ã§ããã
151
ç§ãã¡ãä»çããŠããããšã¯ãå代æªèã®ããšã§ããã仿¥ã®äººå£æžå°æ¿çã¯ã20äžçŽåé ã«ç±³åœã§å±éãããåªçåŠéåãšã¯å šãæ¯èŒã«ãªããªããåœåãåªçåŠã¯ãããããåŠç¿é害ããã身äœé害ããæã€ç¹å®ã®äººå£éå£ã«åããããæ³åŸã«åºã¥ããŠããïŒ
1907å¹Žã®æ³åŸã§ã¯ãã粟ç¥çãèäœçã«æ¬ é¥ãããããã®æ¬ é¥ãçèšãç«ãŠãèœåã«åœ±é¿ãäžããå¯èœæ§ãããããšå€æãããè ã®å ¥åœãæåŠããŠããããã®ãªã¹ãã« ãimbeciles ïŒæãè ïŒããš ãfleble-minded personsïŒåŒ±ã人ïŒãã远å ãããã...
1938幎ãŸã§ã«ãã¢ã¡ãªã«ã®33ã®å·ã§åŠç¿é害ãæã€å¥³æ§ã®åŒ·å¶äžåŠæè¡ãèªãããã29ã®å·ã§éºäŒççŸæ£ãæã€ãšæããã人ã ã察象ãšãã匷å¶äžåŠæè¡æ³ã坿±ºããããã¢ã¡ãªã«ã®æ³åŸã§ã¯ãç¹å®ã®é害è ãçµå©ããæš©å©ãå¶éãããŠããŸããããã®æ³åŸã1940幎代ã«å»æ¢ããããŸã§ã3äž6å人以äžã®ã¢ã¡ãªã«äººã匷å¶äžåŠæè¡ãåããŠããŸããã(ãã¯ããªã¢ã»ããªã°ãã«)1
第äžäžçã«å¯Ÿããéçåã®æç€º
åªçææ³ã«è§Šçºãããç¬¬äºæ¬¡äžç倧æŠåŸã®æä»£ã«ã¯ãäººå£æžå°ãæ°æ€æ°å°æ¿çã®éèŠãªäžéšãšãªã£ããããã¯ããããããçºå±éäžåœãã«å¯Ÿããã¢ã¡ãªã«ã®å€äº€æ¿çã®æçŸ©ã«ãæ³šææ·±ãçµã¿èŸŒãŸããŠããã
ç§ãã¡ã¯ããã³ãªãŒã»ããã·ã³ãžã£ãŒç±³åœåé·å®ã®ãåœå®¶å®å
šä¿éç ç©¶ã¡ã¢ã©ã³ãã 200ãïŒImplications of Worldwide Population Growth For U.S. Security and Overseas Interests 米åœã«å¯Ÿããäžççãªäººå£å¢å ã®åœ±é¿ã»ãã¥ãªãã£ãšæµ·å€ã®å©çïŒãšé¡ããææžãæãåºãã

ããã·ã³ãžã£ãŒã«ããã°ïŒNSSM200ã1974幎ïŒ:
ãéçåã¯ç¬¬äžäžçã«å¯Ÿããå€äº€æ¿çã®æåªå äºé ã§ããã¹ãã ããªããªããç±³åœçµæžã¯æµ·å€ãç¹ã«åŸé²åœãã倧éã®ããããå¢å€§ããé±ç©ãå¿ èŠãšããããã ãã
152

第äžäžçã«å¯Ÿããã¯ã¯ãã³ã»ãã£ã³ããŒã³
第äžäžçã®åœã ã«å¯ŸããŠã¯ãã¯ã¯ãã³ã«ãã人å£åæžãæ éã«è¡ããããWHOãšãŠãã»ãã®æŽå©ã§å®æœããããç Žå·é¢šã¯ã¯ãã³ããããžã§ã¯ãã¯ããå°çäžã®è²§ããåœã ã®å¥³æ§ãã¡ãå¯ãã«äžåŠåãããããšãç®çãšããŠããã®ã§ãã
ãã±ãã¢ã®ã«ããªãã¯åžæã¯ãã±ãã¢æ¿åºã«ãã£ãŠåŸæŽãããç Žå·é¢šäºé²æ¥çš®ããã°ã©ã ã«é ããŠãäœçŸäžäººãã®å°å¥³ã女æ§ã«äžåŠæè¡ãè¡ã£ããšããŠãäºã€ã®åœé£çµç¹ãåçºããŠããã2ã
çŸåšãã°ããŒããªã¹ãã®mRNAãã¯ã¯ãã³ãããã°ã©ã ã®æåç·ã«ãããã«ã»ã²ã€ãããè€éã«é¢äžããŠããããã²ã€ã財å£ã¯ãäžçäžã®æ¿åºãã±ãã¢ãã€ã³ãããã£ãªãã³-ãªã©ãã蚎ãããããã (ããŒã¿ãŒã»ã±ãŒãããã2020幎4æå·)3
ã°ããŒããªã¹ãã®éçåã¢ãžã§ã³ãããWhat to Do with All These Useless People?ãïŒãã®åœ¹ç«ãããã©ããããïŒïŒ
ã°ããŒããªã¹ãã¯å°çã人å£éå°ã§ãããšèããŠããããã¯ã¯ãã³ãå«ãCOVID-19ã®çŸ©åä»ããäžç人å£ãæžããææ®µã§ããããšã¯æ£åŒã«ã¯èªããŠããªããã¯ã¯ãã³ã¯ãåœãæããããã®ææ®µãšããŠæ¯æãããŠããã
ã¯ã©ãŠã¹ã»ã·ã¥ã¯ãã®åŒåã§ãããŠãŽã¡ã«ã»ãã¢ã»ãã©ãªææã¯ãããã§ããªããããã®åœ¹ã«ç«ããªã人ã
ãã©ããããããã®ãïŒããšããçåãæããããŠããã
ãã©ãªã¯äžççµæžãã©ãŒã©ã ïŒWEFïŒã®æåã¡ã³ããŒã§ãå°çäžã®ãã¹ãŠã®äººéãçãŸãããšãããæ¯é ããäžæ¡ãã®ã°ããŒããªã¹ãã«ãã£ãŠç®¡çããããã£ã¹ããã¢ç€ŸäŒãäœããšããèããæ¯æããŠããã(ãã£ã¢ã·ãŒã»ã¢ã¬ã¯ãµã³ããŒã»ã°ãºãã³ã2022幎7æ)4
153
2009幎ãåãå¶æ¥œéšãç§å¯äŒè°ããåäžé·è ãäžçã®äººå£ãæžããããšããã
2009幎4æ25æ¥ã«ãã©ãã·ã¥ããã¯ãããããŒã¬ã¬ããã»ãã£ã³çããäžçä¿å¥æ©é¢ïŒWHOïŒã¯ãH1N1è±ã€ã³ãã«ãšã³ã¶ã®å€§æµè¡ã«é¢ããåœéä¿å¥äžã®ç·æ¥äºæ
ïŒPHEICïŒã宣èšããããããã¯å€ãã®ç¹ã§COVIDãã³ãããã¯ã®ããã¬ã¹ãªããŒãµã«ãã ã£ãïŒIXç« ãåç
§ïŒãããããããã2é±éåŸã®2009幎5æåæ¬ãH1N1ããã³ãããã¯ãã®çã£åªäžãåäžé·è
ã®æ
åå®¶ãã¡ã¯ãã³ããã¿ã³ã®ããã¯ãã§ã©ãŒå€§åŠåŠé·å®
ã§éå
¬éã®äŒåãæã£ãã
ãã®ç§å¯ã®éãŸãã¯ãã«ã»ã²ã€ããäž»å¬ããŠããŸããã圌ãã¯èªåãã¡ããã°ããã¯ã©ãããšåŒãã§ãããåå è
ã®äžã«ã¯æ
ããŽã£ããã»ããã¯ãã§ã©ãŒããŠã©ãŒã¬ã³ã»ããã§ããããžã§ãŒãžã»ãœãã¹ããã€ã±ã«ã»ãã«ãŒã ããŒã°ããããã»ã¿ãŒããŒããªãã©ã»ãŠã£ã³ããªãŒãªã©ãããããããã¡ã³ããŒãããŸããã
ãã¢ã¡ãªã«ã代衚ããåäžé·è ãã¡ãå¯ãã«éãŸããèªåãã¡ã®å¯ãäžçã®äººå£å¢å ãé ãããå¥åº·ãæè²ã®æ¹åãæ©ããããã«ã©ã䜿ãããæ€èšããŠãããã(Sunday Times, 2009幎5æå·) (Sunday Times, May 2009)5
ãã®äŒè°ã§åŒ·èª¿ãããã®ã¯ã人å£å¢å ïŒã€ãŸãèšç»çãªåè²ãŠïŒã§ã¯ãªãããäººå£æžå°ããã€ãŸãäžç人å£ã®çµ¶å¯ŸèŠæš¡ã®çž®å°ã§ãã£ããWSJã®èšäºå šæã¯ãã¡ããã芧ãã ããã
ãµã³ããŒã»ã¿ã€ã ãºçŽã®å ±éã«ããã°
ãã€ã¯ããœããã®å ±åèšç«è ã§ãããã«ã»ã²ã€ãã®ã€ãã·ã¢ãã£ãã§éå¬ããããµãããã«åºåžããæ åå®¶ãã¡ã¯ãå€åãé»ãæ¿æ²»çã»å®æçãªé害ãå æããããã«åãåãããããšã話ãåã£ãã
...
ã¯ããã¯ã«ã»ãªãã»ãã£ã©ã³ãœãããŒèªã®ã¹ãã€ã·ãŒã»ããŒããŒç·šéé·ã¯ããã®ãµãããã¯å代æªèã®ãã®ã§ãããšèªã£ãããç§ãã¡ã¯ããã®ãµãããã®ããšãåŸã«ãªã£ãŠãããå¶ç¶ã«ç¥ããŸããããã€ããªãããã®äººãã¡ã¯åãã§å€§çŸ©ååãèªãã®ã«ãä»åã¯éãããããããäžççãªé°è¬ãšèŠãããããªãããã ããããšèªã£ãã
å¥ã®ã²ã¹ãã«ããã°ããæç¥šã»ã©ç²éãªãã®ã¯ãªãããã人å£å¢å ãç°å¢ã瀟äŒãç£æ¥ã®ç Žå£çè åšãšããŠåãçµããšããæŠç¥ãæ¯æãããšããã³ã³ã»ã³ãµã¹ãçãŸããã
ãããã¯ãããŸãã«ãæªå€¢ã®ãããªããšãªã®ã§ããã®ã°ã«ãŒãã®å šå¡ãã倧ããªé è³ã§çããåºãå¿ èŠããããšåæããã®ã§ãããšããã®ã²ã¹ãã¯èšã£ãã...
ãªãç§å¯ã«ããŠããã®ãïŒã圌ãã¯ãèªåãã¡ãèšã£ãããšãæ°èã«èŒãããšãå¿é ããããšãªããéæã¡ãšéæã¡ã®éã§è©±ããããã£ãã®ã ãã(ãµã³ããŒã»ã¿ã€ã ãº)6
æææ±ºå®ã¯è€éæªå¥ã§ããã2009幎5æã«è¡ããããã®ç§å¯äŒè°ã®å ±åæžã¯ãäººå£æžå°ã«é¢ããã·ããªãªãã»ãŒæããã«ããŠããããã®äŒè°ã¯ãæ°å€ãã®é¡äŒŒããäŒè°ïŒã¡ãã£ã¢ã§å ±éãããããšã¯ã»ãšãã©ãªãïŒã®ãã¡ã®äžã€ã§ããã
éèŠãªã®ã¯ããããã®åäžé·è
ã®ãæ
åå®¶ããå°çãéçåããããšããç¯çœªçæå³ãæ±ããŠããããšã§ããã
154

ãã«ã»ã²ã€ã 2010幎éçå声æããæ°åã¯ã¯ãã³ ãã®åœ¹å²
2009幎5æã®ç§å¯äŒè°ã§ã¯ãäžç人å£ã®çµ¶å¯ŸçãªãåæžããèããããŠããã®ã ãããïŒãã®æ°ã¶æåŸããã«ã»ã²ã€ãã¯ã¯ã¯ãã³æ¥çš®ã«é¢ããTEDã®ãã¬ãŒã³ããŒã·ã§ã³ïŒ2010幎2æïŒã®äžã§ã次ã®ããã«ç¢ºèªããŠããã
ãæ°ããã¯ã¯ãã³ããã«ã¹ã±ã¢ãçæ®å»çãµãŒãã¹ã«ãããŠæ¬åœã«çŽ æŽãããä»äºãããã°ãç§ãã¡ã¯ïŒäžç人å£ãïŒ10ïŒ ã15ïŒ æžãããã ããã7ã
ãã®ãããªã®04:21ããåŒçšããèããã ããããŸããåŒçšæã®ã¹ã¯ãªãŒã³ã·ã§ããã¯ä»¥äžãã芧ãã ããã

ãã«ã»ã²ã€ããæå±ããäžç人å£ã® ã絶察æžå° ãèšç»
ãã«ã»ã²ã€ããææ¡ãããã¯ã¯ãã³æ¥çš®ãææ®µãšããäžç人å£ã®ã絶察æžå°ãã¯æ¬¡ã®ãããªãã®ã§ããã
äžç人å£ïŒ2022幎11ææšèšïŒã¯80åäººèŠæš¡ã§ããã
2022幎ã®10%ã®çµ¶å¯Ÿåæžã¯8åæ¡ã«ãªãã
2022幎ã«äžç人å£ã®15%ã絶察çã«æžå°ããããšããã®èŠæš¡ã¯
12åã§ãã
2009幎5æã®ãç§å¯ã®å Žæãã«éãŸã£ãåãåäžé·è ã°ã«ãŒãããã³ãã屿©ã®åœåãããäžçäžã§é©çšãããŠããããã¯ããŠã³æ¿çãmRNAã¯ã¯ãã³ããããŠãã°ã¬ãŒãã»ãªã»ãããã®èšèšã«ç©æ¥µçã«é¢äžããŠããããã®æçµç®çã¯å€§èŠæš¡ãªäººå£æžå°ïŒéçåïŒã§ããã
人é¡ã«å¯Ÿããç¯çœªã¯çèã«å°œãããããã
ç§ãã¡ã¯ãç«ã¡åãããªããã°ãªããªãç¯çœªéå£ã«å¯ŸåŠããŠããã®ã§ãã
155
å·»æ«è³æ
1. Victoria Brignell, December 10, 2010. https://www.globalresearch.ca/when-america-believed-eugenics/5743548?utm_campaign=magnet&utm_source=article_page&utm_medium=related_articles
2. ãã€ã±ã«ã»ã¹ãã€ããŒã2014幎11æ11æ¥ãWHOã¯äžçåå°ã®å¥³æ§ãå¯ãã«äžåŠåããããã«ã¯ã¯ãã³ã䜿ã£ãŠããã®ãïŒ
https://www.globalresearch.ca/is-the-un-using-vaccines-to-secretly-sterilize-women-all-over-the-globe/5413599
3. ããŒã¿ãŒã»ã±ãŒãããã2021 幎 3 æ 4 æ¥ããã«ã»ã²ã€ããšéçåã¢ãžã§ã³ãããããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢ã調æ»ãåŒã³ãã https://www.globalresearch.ca/bill-gates-and-the-depopulation-agenda-robert-f-kennedy-junior-calls-for-an-investigation/5710021
4. ãã£ã¢ã·ãŒã»ã¢ã¬ã¯ãµã³ããŒã»ã°ãºãã³ã2022幎8æ6æ¥ãã°ããŒããªãºã ã®ã«ã«ããã°ã¬ãŒãã»ãªã»ãããšãã圹ã«ç«ããªã人ã
ãã®ããã®ãã®ãæçµçãªè§£æ±ºçã https://www.globalresearch.ca/cult-globalism-great-reset-final-solution-useless-people/5784969
5. John Harlow, May 24, 2009. https://www.thetimes.co.uk/article/billionaire-club-in-bid-to-curb-overpopulation-d2fl22qhl02
6. åäžã
7. ãã«ã»ã²ã€ãã2010幎ãInnovating to zero! https://www.ted.com/talks/bill_gates_innovating_to_zero/transcript
156
------------------- 第15ç« -------------------
The Road Ahead (åé)ïŒ
ãã³ããã®å°å¶æ¿æ²»ãã«å察ããäžççãªéåã®æ§ç¯
ãã¹ãã£ãŒãŠã®åµã¯1789幎7æ14æ¥ã®ååŸãããªã§èµ·ãã£ãããã¹ãã£ãŒãŠã¯äžäžã®æŠåšåº«ã§ãããèŠå¡ã§ãããæ¿æ²»çãªç¢çã§ãã£ããã«ã€16äžæ²»äžäžã®çæš©ã象城ãããã®ã§ãã£ãã
ãã©ã³ã¹çæ¿ã¯ãæ°ãã«å®£èšãããåœæ°è°äŒã®æš©åšãåãå
¥ãããšåæã«ã1789幎8æåãã«çå®ãããã人éãšåžæ°ã®æš©å©ã®å®£èšãïŒDeclaration des Droits de l'Homme et du CitoyenïŒã«å«ãŸããåºæ¬æš©ãæ¯æããããšã矩åã¥ããããŠãã1ã
ãããã230幎以äžçµã£ãä»ããããã®åºæ¬çæš©å©ïŒLiberté, Ãgalité, FraternitéïŒ(èªç±ãå¹³çãåæ)ãã¯ãå
šäœäž»çŸ©çã§æãã©ããã®ãªãéèçµç¹ã«ä»£ãã£ãŠãäžçäžã®è
æããæ¿åºã«ãã£ãŠåæ
ã«ããã€ã€ããã

ãã¹ãã£ãŒãŠ2022
ããã¹ãã£ãŒãŠ2022ãã¯ããããã®åºæ¬çæš©å©ãå埩ããããšã ããç®çãšããŠããã®ã§ã¯ãããŸãããããã¯ã2幎å以äžã®éã«ã193ã®åœé£å çåœã«ãããŠãç Žç£ã倱æ¥ã倧éã®è²§å°ãçµ¶æãšçžãŸã£ãŠãäžçäžã§çµæžçã瀟äŒçãæ¿æ²»çæ··ä¹±ãåŒãèµ·ãããç¯çœªçãªCOVID-19ã¢ãžã§ã³ããèŠããç¡ååããããšãç®æããã®ã§ããã25ã«åœä»¥äžã§é£¢é¥ãå ±åãããŠããã
157
2020幎11æãããç§ãã¡ã®æ¿åºãçºå£²ããå®éšçãªmRNAã¯ã¯ãã³ïŒãŠã€ã«ã¹ã®æ¡æ£ã«å¯ŸæãããããšèšãããŠããïŒã¯ãã¯ã¯ãã³é¢é£ã®æ»å·è
ãäžççã«å¢å ãããçµæãšãªã£ããããã¯æ®ºäººã¯ã¯ãã³ã ã人é¡ã«å¯Ÿããç¯çœªã§ãã
ãã¹ãã£ãŒãŠ2022ã¯ãç矩ã®ãæè°ãéåã§ã¯ãããŸããã
ç§ãã¡ã¯è
æããæ¿åºé«å®ãšäº€æžããããšãæ±ããŠã¯ããŸããã圌ãã®æ£çµ±æ§ãçãã®ã§ãã圌ãã¯åã€ãã§ãã
ç§ãã¡ã®æå³ã¯ãæåéãäžçäžã§äººã
ã®ç掻ãç Žå£ãã瀟äŒã®äžã«åè£ãçã¿åºããŠããããã®ç¯çœªçãªè©Šã¿ã®èåŸã«ãã匷åãªé¢ä¿è
ã«ç«ã¡åããããšãªã®ã§ããäžçäžã®äººã
ã®ç²Ÿç¥è¡çã«äžãã圱é¿ã¯å£æ»
çã§ããã
åã®ç« ã§èšé²ããæ°ã
ã®ããã¯ããŠã³ïŒåŽååã®èªå®
åŸ
æ©ïŒãææãã£ã³ããŒã³ãåœé£ã®ããã193ã®å çåœã«èª²ããããCOVID-19æ¿çæä»€ãã匱äœåãšäžå®å®åã«å¯äžããŠããã
æè²ãæåãèžè¡ã瀟亀ãã¹ããŒãã嚯楜ãªã©ãåžæ°ç€ŸäŒãšãã®çµç¹ã®æ§é ãã®ãã®ã
ç©ççã»ç€ŸäŒçã€ã³ãã©ã瀟äŒãµãŒãã¹ãæ³å·è¡ãªã©ãããããå ¬å ±éšéã®æŽ»åã
äžå°ã»å€§äŒæ¥ãå®¶æçµå¶èŸ²å Žãå·¥æ¥ãåžå£²ã»å°å£²æ¥ãéœåžãµãŒãã¹çµæžãé茞äŒç€Ÿãèªç©ºäŒç€Ÿãããã«ãã§ãŒã³ãªã©ãåœã»å°åã»å°æ¹çµæžãç¹åŸŽã¥ããäž»èŠãªæ°éã»ã¯ã¿ãŒã®å šæŽ»å
åœéåå貿æãæè³ãåœå®¶éã®èŒžåºå ¥é¢ä¿ãªã©ã®äžççµæžã®æ§é ãäžççµæžã®å šäœåã厩ããŠããŸã£ãã®ã§ãã
ãããŠã瀟äŒçäžå¹³çã®æ¡å€§ãšãšãã«ããšãªãŒãåäžé·è
ã«ããå¯è£åã®éçšãå±éãããŠããïŒç¬¬Vç« åç
§ïŒã
åœæ°åœå®¶ã¯ãè
æãšè²¡æ¿ç Žç¶»ã®çµæãèšå€§ãªåµåãæ±ããããšã«ãªã£ããåœå®¶æ¿åºã¯ãŸããŸã匷åãªåµæš©è
ã®ç¢é¢ã«ç«ãããã窮å°ã«ç«ããããŠããã瀟äŒã®ããããã¬ãã«ã§ã®åµåã®å¢å€§ãããã®åååãšãªã£ãŠããïŒç¬¬4ç« åç
§ïŒã
倧è¡éåã®åµé
åé¡ã¯ããã®é°æ¹¿ãªãããžã§ã¯ãã®ç«åœ¹è
ã®æ£åœæ§ãšæš©åšãåã倧è¡éåïŒåœå
ããã³äžçïŒãäœãåºãããšã§ããããã®ç«åœ¹è
ã¯ã倧ãŸãã«èšãã°ãããã°ãããŒãããã°ãã¡ãŒããæ
å ±æè¡è€åäœãå®å
šä¿éæ©æ§ãæ
å ±æ©é¢ãè»ç£è€åäœãããã°ãšãã«ã®ãŒãäŒæ¥ã¡ãã£ã¢ãªã©ããçºããããŠããã
ç®èãªããšã«ãCOVID-19ããã³ãããã¯ãã®ç«åœ¹è
ã¯ãçŸåšã解決çãã®çå®ã«ç©æ¥µçã«é¢äžããŠãããäžççµæžãã©ãŒã©ã ã®ã°ã¬ãŒãã»ãªã»ããã¯ãäžççãªå
šäœäž»çŸ©äœå¶ã確ç«ããããšã§ãããäŒå³ãããŠããã®ã¯ãäººå£æžå°ãåæãšãããã°ããŒãã«ã»ã¬ããã³ã¹ãã®ã·ã¹ãã ã§ããïŒç¬¬12ç« ãšç¬¬13ç« åç
§ïŒã
ããã193ã®åœé£å çåœã匱äœåãã匱äœåããããšãäºå®ãããŠããã圌ãã¯ãäžçå²äžæãæ·±å»ãªåµå屿©ã®æ¯é
äžã«ãããã°ã¬ãŒãã»ãªã»ããã®ããšã§ã¯ããã®å¶åºŠã¯
158
è°äŒå¶æ°äž»äž»çŸ©ãšçŠç¥åœå®¶ã¯ãéèæ©é¢ã®äžå±€éšãæ¯é ããéžæã«ãããªãã宿°ããŒãããŒã·ãããã«åã£ãŠä»£ããããããšã«ãªãã
çã®æ°äž»äž»çŸ©ãåãæ»ã
ç§ãã¡ã¯ããã®å
šäœäž»çŸ©çãªãããžã§ã¯ããç¡ååãã匱äœåãããããã«ãå¹³åçãªææ®µã§ããããéãæš¡çŽ¢ãããããã«ã¯ãå
¬çæ©é¢ãç§çæ©é¢ïŒåŠçãæåž«ãèŠå¯å®ãè»ãåžæ³ã®ã¡ã³ããŒãªã©ïŒãšã®å¯Ÿè©±ãå«ãŸããã
å¿
èŠãªã®ã¯ãè
æãéå±€ãæš©åšã®ä¹±çšã®æ§é ãæç Žããããšãããªãã¡ã次ã®ãããªããšã远æ±ããããšã§ããã
ã€ãŸãããçµç¹å ã®æææ±ºå®ã®æ°äž»åãã§ããã
欺çã®æè¡
ãšã¯ãããåœå®¶æ¿åºã«å¯ŸããŠå¹æçãªåžæ³æç¶ããè¡ãã«ã¯éçãããããšãçè§£ããªããã°ãªããªããè£å€å®ã¯ããã°ãã°å§åãåããè
ããããè
æããæ¯é
çãªéèå©çãšæ¿æ²»å®¶ã®äž¡æ¹ãšé£æºããŠããã
ããã«ããã®é°æ¹¿ãªãããžã§ã¯ããäžçäžã®ååœæ¿åºã«ãã£ãŠå®æœãããŠããéããåœé£å®å
šä¿éçäºäŒã«é¢ããŠå
¬åŒã«ãç¬ç«ãããŠããåœéåäºè£å€æïŒICCïŒã¯ãç±³åœãšNATOã®æŠäºç¯çœªã暪åãããŠããé·å¹Žã®å®çžŸãããã®ã ãICCã¯ãååœæ¿åºãæ¯é
ããŠããã®ãšåãéèãšãªãŒãã«ãã£ãŠã³ã³ãããŒã«ãããŠããã
ãã®æ
éã«èšç»ããã調æŽãããå
šäœäž»çŸ©ãããžã§ã¯ãã®è€éããçè§£ããå¿
èŠããããŸããã€ãŸããæ§ã
ãªè©æ¬ºçéèæ©é¢ãäŒæ¥ã®é¡§åããããŒå£äœãã³ã³ãµã«ã¿ã³ãããç§åŠçã¢ããã€ã¶ãŒããªã©ããããã°ãã¡ãŒããéèãšãªãŒãã®ããã«ä»²ä»åœ¹ãšããŠåããŠããã®ã§ãã
æš©åšã®æ§é ã«ã¯ããšã©ã«ããŒãååšããããã®è€éã§å
¥ãçµãã æææ±ºå®ããã»ã¹ã¯ãæ¿åºé«å®ãåã蟌ã¿ãè³è³ãèŽããæãããã«å©çšããããã»ãŒåãæ¿çåœä»€ïŒããé«ãæš©åšããçºããããïŒã倿°ã®åœã§åæã«å®æœãããæŽ»çºãªèª¿æŽãå¿
èŠãšãããåã匷åãªãããŒäŒæ¥ããç°ãªãåœïŒäŸãã°åç±³ãšæ¬§å·é£åïŒã§äžåºŠã«è¡åããŠããã
å€§èŠæš¡ãªè¡é æè°è¡åã¯ããã®è
æããæææ±ºå®ããã»ã¹ã广çã«ç¡ååããããšã«çŠç¹ãåœãŠãªãéããåã€ããšã¯ãªãã ããã
159


160
ç§ãã¡ã®åªå é äœã¯ïŒã«ãŠã³ã¿ãŒã»ãããã¬ã³ã
äžçäžã§70å人以äžã®äººã
ããã³ãã屿©ã®åœ±é¿ãçŽæ¥ãŸãã¯éæ¥çã«åããŠããããã§ã«æ°åå人ããæªæ¿èªãã®å®éšçãªmRNAãã¯ã¯ãã³ããæ¥çš®ããããã®çµæãäžççã«æ»äº¡çãšçœ¹æ£çãäžæããŠããã
ãã®åŸåã¯ãã¯ã¯ãã³é¢é£ã®æ»äº¡ãæå®³äºè±¡ã«é¢ããå
¬åŒã®æ°åã§ç¢ºèªãããŠããããäž»æµã¡ãã£ã¢ãšæ¿åºã¯åŠå®çãªç«å Žã«ããã
COVID-19ã¯ã¯ãã³ãå¥åº·ã«åãŒã壿»
çãªåœ±é¿ã¯ãã»ãšãã©èªããããŠããªããããŠã€ã«ã¹ã¯ã¯ã¯ãã³ããã¯ããã«å±éºã§ããã ãšããåããã£ãããã¬ãŒãº (ããã¯å®å
šãªåã§ãã) ãç¹°ãè¿ãããåãæ°ãå¬ãã
ãå®éã«ã¯ããŠã€ã«ã¹ãããã¯ã¯ãã³ã®å®å šæ§ã«é¢ããããŒã¿ã®æ¹ãå€ãããã§ã«ãŠã€ã«ã¹ãã¯ã¯ãã³ãããã¯ããã«å±éºã§ããããšãããã£ãŠããŸãã(ã€ã³ã¿ãŒã±ã¢) 2
ã¢ã©ã³ã»ã·ã¥ããŒããŒå士ã¯ã芪ãå¿é ããã®ã¯ããèªç¶ãªããšã ãšèããŠãããã10代ã®è¥è ã«ãšã£ãŠã¯ãã¯ã¯ãã³ããããŠã€ã«ã¹ã®æ¹ãå±éºã ãšè¿°ã¹ãŠããã(NBC)3
å»åž«ãã¡ã¯ãåäŸãã¡ã®ããã«èŠæããŠããããèå¿ã®ãŠã€ã«ã¹ã¯ã¯ã¯ãã³ããã¯ããã«å±éºã§ããããšã«å€ããã¯ãªãã
ããªãã¯ãã³å€ç°äœã®çªç¶å€ç°ã¯ãããïŒãŠã€ã«ã¹ïŒããã墿®ãããå±éºã§ãæãã©ããã®ãªããã®ã«ããŠãããçãšèšãããŠããŸãã
ãã®ãããã¬ã³ãã®ã³ã³ã»ã³ãµã¹ãæã¡ç Žããªããã°ãªããªããã¯ã¯ãã³ã«é¢ããŠã¯ãæ»äº¡äŸãæå®³äºè±¡ã«é¢ããããŒã¿ãå
šåœã®äººã
ã«ç¥ãããããšãæåã®ã¹ãããã§ãã
2020幎1æã«å§ãŸã£ãCOVID屿©ã¯ãäžçå²äžå代æªèã®åºæ¥äºã§ãããã¥ã«ã³ãã«ã¯äœå¶äžã§ã®ãããã¬ã³ãã¯ç¯çœªã§ããïŒç¬¬åäžç« åç
§ïŒã
ãããã¬ã³ãè£
眮ãè§£äœããããšãéèŠã§ãããã«ãŠã³ã¿ãŒã»ãããã¬ã³ãã¯ãæ¿çåœä»€ãæ£åœåããããã«äœ¿ãããåãæããã«ããäžã§éèŠãªåœ¹å²ãæãããã¡ãã£ã¢ã®æ ¹åŒ·ãåœæ
å ±ããªããã°ãCOVIDã®å
¬åŒã·ããªãªã¯å¹³æ¿ãªãã®ã«ãªã£ãŠããŸãã
äœããããŸããç§ãã¡ã¯äž»æµã¡ãã£ã¢ã«åŒ·ãåããããªããã°ãªããªãããã ããå
¬åŒã®ã·ããªãªã«åŸãããæç€ºãããŠããäž»æµãžã£ãŒããªã¹ããç¹ã«ã¿ãŒã²ããã«ããå¿
èŠã¯ãªãããã®ç¹ã§ãç§ãã¡ã¯åã
ã®ïŒç¬ç«ããïŒãžã£ãŒããªã¹ããšã®å¯Ÿè©±ãéèŠãã¹ãã§ãã
ç§ãã¡ã¯ãäžçäžã®äººã
ããç§åŠçæŠå¿µãåæã蚌èšãããŒã¿ã«è£ä»ããããCOVID屿©ã®æŽå²ãšç Žå£çãªåœ±é¿ã«ã€ããŠçè§£ã§ããããã«ããªããã°ãªããŸããããã®åªåã¯ãèã®æ ¹ã¬ãã«ã§ãåžæ°ãæåããçæã®ãã³ãããã¯ã®æ¬è³ªãmRNAã¯ã¯ãã³ãRT-PCRãã¹ããããã«ããã¯ããŠã³ã®ç Žå£çãªçµæžçã»ç€ŸäŒç圱é¿ã«ã€ããŠå¯Ÿè©±ã確ç«ããããã»ã¹ã䞊è¡ããŠè¡ãå¿
èŠããããŸãã
ææã®ãã£ã³ããŒã³ã«çµæ¢ç¬Šãæã€äžæ¹ã§ãmRNAã¯ã¯ãã³ã®å±éºæ§ããåžæ°ç€ŸäŒã®æ§é ãã®ãã®ã«å¯Ÿãããã°ããŒãã«ã»ã¬ããã³ã¹ããšããå
šäœäž»çŸ©çãªã¢ãžã§ã³ããåŒãèµ·ããæ··ä¹±ã«ã€ããŠãåèåžæ°ã«æ
å ±ãæäŸããªããã°ãªããŸããã
ãææã®ãã£ã³ããŒã³ãã¯ããæ
å ±ãã³ã³ã»ãããåæãããŒã¿ãããããŠããã°ãã¡ãŒããè
æããé«å®ãããã°ãããŒã®ã¹ãã³ãµãŒãšå¯Ÿæ±ºãããæŠç¥ãã«çœ®ãæããããã¹ããã®ãªã®ã§ãã
161
ãŸãã瀟äŒã®èã®æ ¹ã§å¯Ÿè©±ãšè°è«ãè¡ãããããã«ããªããã°ãªããŸããã
ãæ®ºäººã¯ã¯ãã³ ãã«çµæ¢ç¬Šãæã€ããš
ç§ãã¡ã®æåã®ä»äºã¯ãäžçäžã§æ»äº¡çãšç
çç¶æ
ã®æ³¢ãåŒãèµ·ãããŠãããããããCOVID-19ãã¯ã¯ãã³ããçŽã¡ã«åæ¢ããäžæ¢ããããšã§ãã
ããŒãã¹ã»ãã€ã³ããŒå士ã«ããã°
ãéºäŒå泚å°ã¯å®å šã§ã¯ãããŸãããã¢ããã£ã©ãã·ãŒåå¿ãè¡æ 塿 çãè¡å°æ¿æžå°çãåŒãèµ·ããå¯èœæ§ããããçæçã«ã¯è¡æ 塿 çãè¡å°æ¿æžå°çãæç𮿧è¡ç®¡å ååºçå矀ãå¿ççãåŒãèµ·ããå¯èœæ§ããã4ã
äžæçã«ã¯å ç«æå¶ãšæäœäŸåæ§å¢åŒ·ãADEã®å¯èœæ§ããããŸãã
ãããŠé·æçã«ã¯èªå·±å ç«çŸæ£ããããäžåŠçã®å¯èœæ§ãããããã®ãªã¹ã¯ã¯ãŸã åŠå®ãããŠããªããã
COVIDå«çã®å»åž«ã«ãããšãEUãè±åœãç±³åœã§ã¯ãEudraVigilanceãMHRAïŒè±åœïŒãVAERSïŒç±³åœïŒãããããéèšããããŒã¿ã§ãçŸåšãå€ãã®æ»äº¡è æ°ãèšé²ãããŠããã
ãCOVID-19ãã¯ã¯ãã³ãã®å±éã«ããæ»å·è æ°ã¯ãèšé²éå§ä»¥æ¥ããããŸã§ã®ãã¹ãŠã®ã¯ã¯ãã³ãåãããæ°ãããå€ãèšé²ãããŠãããã
mRNAãã¯ã¯ãã³ãã«é¢ããŠã¯ãå ¬åŒã®æ°åãå ¬éãããŠããã«ãããããããæ³šå°ã«é¢é£ããæ»äº¡ã®å£æ» çãªæ°ã¯ãäž»èŠã¡ãã£ã¢ã«ãã£ãŠå ±åãããŠããªãã
ãæå®³æ§ã®ã·ã°ãã«ã¯ä»ãè°è«ã®äœå°ãªãå§åçã§ãããèšåºè©Šéšã«é¢ããæ®éçã«åãå ¥ããããå«çåºæºã«æ²¿ã£ãŠãæã ã¯COVID-19ãã¯ã¯ãã³ãããã°ã©ã ãäžçäžã§çŽã¡ã«åæ¢ããããšãèŠæ±ããã
倧人ãšåã©ãã®äž¡æ¹ã«æ·±å»ãªè¢«å®³ãšæ»ãç¶ããŠããããšãç¥ããªããããã®ããã°ã©ã ãç¶ç¶ããããšã¯ã人éã«å¯Ÿãã眪ïŒãžã§ããµã€ããæ§æãããã®è²¬ä»»è ãå æ è ãæçµçã«å人ç責任ãåãããããšã«ãªãã5ã
第VIIIç« ã§æŠèª¬ããããã«ããã¡ã€ã¶ãŒã¯ããäžæ£ããŒã±ãã£ã³ã°ãã®å®¹çã§ç±³åœåžæ³çã«åäºèšé²ãæ®ããŠããŸãïŒ2009幎ïŒ6ã
2009幎ã®åžæ³çã®åè§£ã®äžç°ãšããŠããã¡ã€ã¶ãŒã¯ä»®éæŸãšãªããŸããã
ããã¡ã€ã¶ãŒã¯ãŸãããã®åé¡ã®åå ãšãªã£ãè¡çºãšåæ§ã®è¡çºãåé¿ããè¿ éã«æ€åºããããã«å®æœãã¹ãæç¶ããšã¬ãã¥ãŒãèŠå®ãã...ã®åºç¯ãªäŒæ¥çµ±åå¥çŽãç· çµããããšã«åæãããã 7
ããããç§ãã¡ã¯ãã¯ããäžæ£ãªããŒã±ãã£ã³ã°ããæ±ã£ãŠããã®ã§ã¯ãªãã
ãæ®ºãããšã¯å売ã«ãªãã :ã¯ã¯ãã³ã¯äžçäžã§æ°ååãã«èŠæš¡ã®äºæ¥ã ãããã¯éå€±èŽæ»ã
162
ãã¯ã¯ãã³ãã忢ãããã°ãããã°ã»ãã¡ãŒãã®ç¯çœªæ§ãå®å
šã«æããã«ãªããçè§£ãããã§ããããã²ããŠã¯ãåãšãã»ç§åŠã«åºã¥ãCOVIDå
¬åŒã·ããªãªã®æ£åœæ§ãæãªãããããšã¯å¿
è³ã§ããããã¯ããå
¬åŒãCOVIDã·ããªãªãç Žãããã®ç¬¬äžæ©ãªã®ã§ãã
çå®ã¯éèŠãªå¹³åçæŠåšã§ãããããã¬ã³ããšã¡ãã£ã¢ã®åœæ
å ±ãªãããŠããã®ãããžã§ã¯ãã®ç«åœ¹è
ã¯è¶³å
ã«ãåã°ãªãã
COVID-19ã®ãå
¬åŒãã³ã³ã»ã³ãµã¹ãšãç¯çœªçãªã¢ãžã§ã³ãã«ãæ£åœæ§ããäžãããããã¬ã³ãè£
眮ãå£ããã§ã¯ãããŸãããã
ãã£ããããã厩ããã°ãéå»2幎åã®éã«çããçµæžçã瀟äŒçãæ¿æ²»çãªæ··æ²ã®åºç¯ãªéçšãé転ãããéãéãããã§ãããã
å°æ¿åŠçãªåŽé¢
å±éãããŠããã®ã¯ãã¢ã¡ãªã«åžåœäž»çŸ©ã®æ°ããªç Žå£çãªå±é¢ã§ãããããã¯ãçµæžçã瀟äŒçãšã³ãžãã¢ãªã³ã°ã®å
šäœäž»çŸ©çãããžã§ã¯ãã§ããã
çµæžã»ç€ŸäŒå·¥åŠçãããžã§ã¯ãã§ããã
ãã€ãã³æ¿æš©ã¯ãåœå®¶çµæžãäžå®å®ã«ãã匱äœåãããããã«å©çšãããŠããCOVIDã¢ãžã§ã³ããæ¯æããŠããïŒç®èã«ããç±³åœã ãã§ãªãããã®åçåœããã®ãæµãããå«ãïŒã
COVIDã®å±æ©ããã¢ã¡ãªã«ã®å€äº€æ¿çãšã¢ã¡ãªã«ã®èŠæš©äž»çŸ©çã¢ãžã§ã³ãïŒãŠã¯ã©ã€ãæŠäºãç±³é²é¢ä¿ãNATOã®æ¡å€§ãšæ¡åŒµãäžåœã«åããåã·ãæµ·ã®è»äºåãã€ã©ã³ãšäžæ±ã®å°æ¿åŠããããºãšã©ãšãã¥ãŒãã«å¯Ÿããé²è¡äžã®å¶è£ã¬ãžãŒã ãªã©ïŒããåãé¢ããŠçè§£ããããã«ã¯ãããŸããã
瀟äŒã®ããããã»ã¯ã¿ãŒãçµ±åãã
å€ãã®è¥¿åŽè«žåœã§ã¯ãçµç¹çãªå察éåã匱ãããšã«çæãã¹ãã§ããããªããïŒè¥¿ãšãŒããããšåç±³ã®å·ŠæŽŸç¥è人ãNGOãªãŒããŒãåŽåçµåã»åŽåè
ãªãŒããŒãå«ãã鲿©çå¢åãããæåããCOVIDã®å
¬åŒã·ããªãªãæ¯æããŠããããã§ããããããã鲿©çãªéåã®å€ãã¯ãäŒæ¥ã®è²¡å£ã«ãã£ãŠæ¯æŽãããŠããŸãã
ãã°ã¬ãŒãã»ãªã»ããããšãã°ããŒãã«ã»ã¬ããã³ã¹ãã®æé»ã®ç«åœ¹è
ã§ããåãåäžé·è
ã®è²¡å£ã¯ãããŸããŸãªç€ŸäŒéåãžã®ïŒæãã¿ãªãïŒè³éæäŸã«ãé¢äžããŠããã®ã§ããã圌ãã¯éå
ãæ¯é
ããŠãããã
ãã®ããšãæå³ããã®ã¯ãèã®æ ¹ã®æŽ»åå®¶ã¯ãåäžé·è
ã®ã¹ãã³ãµãŒã«æ¥åžžçã«ååãããããŠããæå°è
ã«ãã°ãã°æããããè£åããããšããããšã§ããã
ããããèã®æ ¹ã®æŽ»åå®¶ããCOVID-19ã³ã³ã»ã³ãµã¹ã«å察ããéåã®äž»è»žã«çµã¿èŸŒãããšãèèŠã§ããã
ããããã®é
å¿ èŠãªã®ã¯ããã®å±æ©ã®ç«åœ¹è ãšãã¯ã¯ãã³ã®æäžãçµæžæŽ»åã®å°éã»ééã«é¢äžããããããã¬ãã«ã®æ¿åºïŒåœãå·ãçãåžãªã©ïŒã®äž¡æ¹ã«ç«ã¡åãããå¹ åºãèã®æ ¹ãããã¯ãŒã¯ã®çºå±ã§ããã
163
ãã®ãããã¯ãŒã¯ã¯ã瀟äŒã®ããããã¬ãã«ãçºãæãè·å Žãå°æåºãåŽåçµåã蟲æ°çµç¹ãè·æ¥å£äœãäŒæ¥å£äœãåŠççµåãé圹è»äººäŒãªã©ã§ïŒåœå
å€ã«ïŒç¢ºç«ãããã§ãããããã®éåãçµ±åããããã«ãæäŒã®ã°ã«ãŒããèŠè«ãããã§ãããã
ãœãŒã·ã£ã«ã¡ãã£ã¢ãç¬ç«ãããªã³ã©ã€ã³ã¡ãã£ã¢ãéããŠãèšèãåºãããããšã¯ãGoogleãFacebookãæ€é²ã®éå
·ã§ããããšã念é ã«çœ®ããŠè¡ãããã§ãããã
äžçã®äž»èŠãªå°åã§ãæ³çæç¶ããšæè°è¡åãå±éãããŠããŸããäžççãªã€ãã·ã¢ããã®ãããã¯ãŒã¯ã®äžéšãšããŠãåœå
ããã³åœå®¶éã®ã³ãã¥ãã±ãŒã·ã§ã³ã察話ã亀æµã®ã¡ã«ããºã ã確ç«ããããšãéèŠã§ããã
éèãšãªãŒãã倧æè£œè¬äŒç€Ÿãªã©ã®æ£åœæ§ããåœå®¶ã¬ãã«ã®æ¿æ²»çæš©åšã®æ§é ã«ååŒ·ãææŠããããã®ãããªéåã®åµé ã¯ç°¡åãªããšã§ã¯ãããŸãããäžçå²ã«äŸãèŠãªãã»ã©ã®é£åž¯ãšå£çµãšã³ãããã¡ã³ããå¿
èŠã§ãã
å¿
èŠãªã®ã¯ã瀟äŒã®äžã®æ¿æ²»çãã€ããªãã®ãŒçãªå£ïŒïŒæ¿å
éïŒãåãæããå°å¶æ¿æ²»ã«å察ããäžççãªã³ã³ã»ã³ãµã¹ã®æ§ç¯ã«åããŠãäžã€ã®å£°ã§è¡åããããšã§ãã
äžççãªé£åž¯ãšäººéã®å°å³ããã®åååã§ãã
å·»æ«è³æ
1. Encyclopaedia Britannica, July 20, 1998.https://www.britannica.com/topic/Declaration-of-the-Rights-of-Man-and-of-the-CitizenïŒäººããã³åžæ°ã®æš©å©å®£èšïŒã
2. Intercare, n.d. Part 10: COVID-19 vaccines and long-term side-effects/ https://healthhub.intercare.co.za/2021/09/15/part-10-covid-19-vaccines-and-long-term-side-effects/
3. Anoushah Rasta, May 5, 2021. FDAã¯åäŸã®ã¯ã¯ãã³æ¥çš®ãæ¿èªããèŠèŸŒã¿ã ãã芪ã¯åé²ããæºåãã§ããŠãããïŒ https://www.nbcbayarea.com/news/coronavirus/fda-expected-to-approve-vaccinations-for-kids-but-are-parents-ready-to-move-forward/2537309/
4. Doctors for COVID Ethics, August 3, 2021. COVIDã¯ã¯ãã³ã®å¿
èŠæ§ãæå¹æ§ãå®å
šæ§ãhttps://doctors4covidethics.org/covid-vaccine-necessity-efficacy-and-safety-3/
5. Doctors for COVID Ethics, October 22, 2021. J'Accuse! éºäŒåã«åºã¥ããã¯ã¯ãã³ããäººãæ®ºããŠãããhttps://www.globalresearch.ca/jaccuse-governments-worldwide-lying-you-people-populations-they-purportedly-serve/5750650
6. US Department of Justice, September 2, 2009ïŒç±³åœåžæ³çã2009 幎 9 æ 2 æ¥ïŒãPfizer Inc. "Fraudulent Marketing": ãå²äžæå€§ã®å»çè©æ¬ºã«é¢ããåè§£ã(2009 幎). US Department of Justice. https://www.globalresearch.ca/justice-department-announces-largest-health-care-fraud-settlement/5738792
7. åäžã
164